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Preface 
The manipulation of the genetic chemical, DNA, for scientific study of how it 
governs the operations of normal and abnormal cells, seems unable to proceed 
without intense controversy. 
The very birth of a convincing double-helical model of the structure of 
DNA in 1953, emerging dramatically in such a way as to capture the attention of 
briUiant workers, intensified struggles between old and new approaches to bio-
logical science, even as it opened enormous new fields of research. 
In the early 1970's, scientists involved in studying DNA themselves un-
leashed an increasingly passionate public debate on what then seemed to be 
possibihties of risks to humans from work on recombinant DNA. This debate 
brought molecular biology to the brink of regulations that might have stifled 
research of vast potential value, for such purposes as the elucidation of human 
cancer induction, in its cradle. But by its very intensity, and extensiveness, the 
debate sharpened popular consciousness of the practical potential of such re-
search in fundamental biology and genetics. 
In a few years, attention shifted, once again with drama, to attempts to 
speed the commercial application of the new biology, in the development of new 
food-plant varieties, the management of diseases in commercially important 
animals, microbe-assisted manufacture of pharmaceuticals, or even in reducing 
the internal energy tax that must be paid by such energy industries as oil 
refining. 
The dark colors of earlier debate on risks and the roseate glow of antici-
pated commercial benefits both spread over the 1980 decision of the United 
States Supreme Court that microorganisms themselves, created by genetic 
manipulation techniques, could be patented along with processes for making or 
using such microorganisms. 
The decision that the genetically engineered organism itself would be 
patentable is likely to have its greatest immediate effect in making the life of 
patent lawyers somewhat less complicated. The organism itself can be used in 
disputes over whether a patent has been infringed. Enforcement of patents of 
genetically engineered microorganisms should be simpler. 
iX 
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But such practical utility of a court decision does not explain the extra-
ordinary public interest that surrounded the decision that a microorganism de-
veloped by Ananda Chakrabarty, then of General Electric Company and now of 
the University of Illinois, should obtain a patent from the U.S. Patent and Trade-
mark Office. For many, the decision took on a wider, if largely emotional signifi-
cance. To an imperfectly informed public, the decision seemed to say that 
"life," whatever that term might mean, could be patented, and thus, that some 
kind of permission had been granted for genetic manipulations that people had 
become accustomed—if largely by science fiction—to consider menacing. 
For scientists, the decision also was a shock. The notion that fundamental 
biological discoveries could be turned into intellectual property through the 
patent system forced many biologists to consider what the rapid elaboration of 
such property would do to the organization of the university laboratories. For 
many biologists, the situation was new and apparently challenging to cherished 
beliefs and practices. It seemed of little help to reflect that chemists had been 
wrestling with similar problems for a century, and physicists for almost as long. 
Even for patent attorneys, the practical helpfulness and technical narrow-
ness of the 1980 Chakrabarty decision was overshadowed by unease about the 
vast unexplored legal territory represented by the forest of work on DNA. 
So, in the summer of 1980, there seemed to be a strong need for a meeting 
between biologists and patent lawyers, at which the two groups could explore 
the disparate traditions of advanced genetics and patent law. 
The hope was that the lawyers and scientists would each come away 
understanding the other's environment and culture a little better. 
The idea came up in conversations among Phillip Sharp, an alumnus of 
Cold Spring Harbor Laboratory, now at the Massachusetts Institute of Tech-
nology, and Joseph Sambrook and J.D. Watson, both of Cold Spring Harbor 
Laboratory. I received the assignment of trying to organize a meeting that would 
take the Banbury Center from its dominant focus on environmental health risk 
assessment into a broader realm of the social implications of advances in molecu-
lar biology. 
Over the next few months, we were fortunate in recruiting three organizers 
of very different backgrounds who could recruit in turn the participants needed 
to carry the meeting beyond the reutterance of pious generalities. With the help 
of David W. Plant of the patent law firm of Fish and Neave, Niels J. Reimers of 
the technology licensing office at Stanford University, and Norton D. Zinder of 
Rockefeller University, we were able to aim at a meeting that could explore the 
practical impact of the Chakrabarty decision on both biological science and 
patent law. 
Of particular assistance in keeping the feet of the meeting firmly planted 
on the ground was the participation of Judge Giles Rich of the U.S. Court of 
Customs and Patent Appeals (since reorganized into the U.S. Court of Appeals 
for the Federal Circuit). Before going on the bench in 1956 by appointment of 
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President Eisenhower, Judge Rich had helped in the drafting of the 1952 
revisions of the U.S. Patent Code. He wrote the lower court opinion in the 
Chakrabarty case that was upheld by the Supreme Court. Judge Rich enlivened 
the sessions of the conference with penetrating questions. 
We also were aided by the participation of Alvin Tanenholtz, the chief ex-
aminer in the Patent and Trademark Office in the biotechnology field, and of 
Alan MacPherson, former chief counsel of National Semiconductor Corporation, 
who gave us a lively and very detailed review of a branch of the electronics 
industry whose use of patents is very different from that of the pharmaceutical 
industry. 
Evidence of the strong interest in the meeting was provided by the fact 
that no less than 15 industrial companies agreed to cosponsor it: Baxter-
Travenol Laboratories, Inc., Chevron Research Company, The Dow Chemical 
Company, E.I. duPont de Nemours and Company Inc., Exxon Research and 
Engineering Company, Hoffmann-LaRoche Inc., Johnson and Johnson, Eli Lilly 
and Company, Merck Sharp and Dohme Research Laboratories, Monsanto 
Company, National Distillers and Chemical Corporation, Pfizer Inc., Schering-
Plough Corporation, Smith Kline and French Laboratories and The Upjohn 
Company. It is a pleasure to thank them all for their splendid help toward both 
the conference and the publication of this report, and for sending strong repre-
sentatives to the conference. 
A number of the companies contributing to the conference on Patenting 
of Life Forms had been long-time contributors to Cold Spring Harbor Labora-
tory, or recent contributors to other Banbury conferences, but others assisted 
us for the first time. The conference represented an important step forward in 
intellectual as well as financial support from industry to Cold Spring Harbor 
Laboratory and its Banbury Center. 
Lawyers attending the meeting were able to gain some idea of the extra-
ordinary richness and complexity of the work in the exploding field of molecu-
lar biology. The scientists were able to see somewhat better why the emergent 
technologies of recombinant DNA seem absorbable in the tradition of patent 
law. Both sides realized that the true impact of the Chakrabarty decision will 
become apparent only gradually, as the result of a slow, case-by-case building of 
a body of patents, and decisions in suits over those patents. It may be that 
participants in the Banbury meeting of 18 to 21 October 1981 will wish to 
reassemble in future to assess what has happened by them. 
Such an intellectual enterprise as the Patenting conference aind this report 
of its proceedings is impossible without the cooperation of scores of people. 
I wish to thank not only the organizers but each of the participants, 
including those who went on to provide us with detailed manuscripts. As in 
each Banbury Report, it is my pleasure to thank my administrative assistant, 
Beatrice Toliver, and the Banbury editor, Lynda Moran, for their devoted work 
at every stage of the conference and its report. I wish also to thank J.D. Watson, 
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Director of Cold Spring Harbor Laboratory, for his continuing refusal to be 
checked by difficulties. This is the central quality for success in entrepreneurial 
enterprises like Cold Spring Harbor Laboratory or its Banbury Center. 
Victor K. McElheny 
Cambridge, Massachusetts 
21 May 1982 
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SESSION 1: 
Scientific Issues 

Background to Issues in the 
Patenting of Life Forms 
The following two selections, assembled by the Banbury Center staff, present 
background material to both the scientific and legal questions which shall be 
more extensively considered in the succeeding chapters. The first is a synopsis 
based upon the introductory remarks made to the opening session of the 
Banbury conference by Dr. James Hicks of Cold Spring Harbor Laboratory. The 
second selection is a brief excerpt from the 1981 publication of the U.S. Con-
gressional Office of Technology Assessment on the Impacts of Applied Genetics 
and delineates Congressional options regarding the patentability of life forms. 
Synopsis of Dr. James Hicks's Opening Remarks 
The purpose of this session, as I see it, is to present some of the relevant con-
cepts of molecular biology as they relate to the patenting of life, and to assess 
how such patenting, in turn, may affect the dynamics of doing molecular 
biology. This essentially becomes the question of enabling industry to com-
mercially safeguard its discoveries without unduly restricting the flow of infor-
mation between academic and commercial spheres. The potential interference 
of this flow could become a rate-limiting step in the continuing progress of this 
field. 
The basic technology involved is essentially standard fermentation pro-
cedures only as now applied to newly-developed genetically altered bacteria and 
yeast. The organisms most commonly employed are the common gut bacterium 
Escherichia coli, various species of the Bacillus soil bacteria and the yeast species 
Saccharomyces cerevisiae and Schizosaccharomyces pombe. The major 
attraction of yeasi in this realm, despite its larger size and hence reduced yield 
per volume in batch fermentation procedures, is that historically the fermenta-
tive handling of yeast is far better developed than is that of bacteria. 
In either instance, however, the basic genetic goal is the same. This is the 
expression of a single protein product from a specific piece of DNA carried on a 
self-perpetuating unit called a "plasmid carrier" within the chosen host 
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organism. Which piece of DNA the plasmid may be engineered to carry will no 
longer be determined by the organism's own evolutionary pressures, but by the 
experimenter's autonomous selection of which product it is now deemed 
desirous for this particular organism to make. Part of the business here is to 
make as many plasmids as possible in as large a number of cells as possible, for 
the least amount of money. Also included in this equation must be additional 
procedures for isolating and purifying the final gene product of interest. 
To achieve this a plasmid has to have several components, the most im-
portant being the origin of replication. The DNA double helix has to open up at 
some point to allow new DNA synthesis to occur and to allow the eventual 
duplicating of that whole sequence into two copies. This can happen either co-
ordinately with the replication of the chromosomal DNA of the cell, in which 
case it is stringently controlled, or it can replicate at will, essentially, and give 
rise to many more copies of plasmid than there are copies of genomic DNA, up 
to hundreds of copies per cell. An additional plasmid component is a marker 
which can be used to indicate which cells actually harbor the plasmid. This often 
is a drug resistance marker, thereby additionally enabling one to select a popu-
lation of cells all of which must contain the plasmid; as once inserted, it will 
make the recipient bacterium resistant to that particular drug. A combination 
frequently used is a plasmid called pBR322, carrying the ampicilUn-resistance 
gene and tetracycline-resistance gene. 
There is still one further essential step beyond selecting a gene and in-
serting it into a replicating plasmid containing a drug-resistance marker. It is 
also necessary to build something into the system to ensure that the gene in 
question will be expressed—that is, that it will be transcribed into a messenger 
RNA for translation into the ultimate protein product. The coding sequence will 
get you a protein no matter where it is, but you have to supply the appropriate 
signal sequences in most cases. Vectors, (i.e.. something that will transport a 
sequence from one cell to another, or from a test tube into a cell) can now be 
designed not only with a site in which to put the gene, but also along with a 
site that is a so-called RNA promoter. One example of such a *patchwork' 
plasmid built up in this way is the bacterial molecule pBR322. which was 
isolated to be ampicillin-resistant and tetracycline-resistant and replicate in E. 
coli and further modified to contain a yeast gene coding for an enzyme in the 
biosynthetic pathway of uracil. There is also an existing yeast plasmid, called the 
2-micron circle. One thing that is commonly done is to additionally insert a 
piece of DNA from that plasmid which has a yeast origin in it. The resultant 
•patchwork' plasmid thus has an origin from bacteria and an origin from yeast, 
plus selectable markers and will replicate extensively in either yeast or bacteria. 
Other bits and pieces of DNA can also be added to this for other purposes. 
For instance, one of the things currently being done in my lab is to introduce 
bits of DNA from a plant into a plasmid very much like this, looking for a 
plant sequence that can lead to expression of the bacterial gene inside of yeast. 
So a few questions I would like to leave with you are . . . which parts of this 
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organism may be patentable? Is the entire concept patentable? The idea of using 
2-micron circle origin in yeast was patented earlier. Is that different from using 
the chromosomal origin, which has also been patented? What if someone else 
makes a similar plasmid, but with a different piece of plant DNA? And, finally, 
what if you make a silent mutation—i.e., it doesn't change anything as far as the 
plasmid's overall use is concerned—but is now one base pair different. Is that a 
unique organism or a unique plasmid compared with the starting one that 
someone else has patented? I certainly do not know the answers, and I doubt 
if any of us really do here, but I think it is just a sample of the sort of things we 
are going to have to figure out very soon. 
6 / Background to Issues In the Patenting of Life Forms 
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I s s u e and O p t i o n s 
ISSUE: To what extent could Congress 
provide for or prohibit the pat-
entability of l iving organisms? 
In its Chakrabarty opinion, the Supreme 
Court stated that it was undertaking only the 
narrow task of determining whether or not 
Congress, in enacting the patent statutes, had 
intended a manmade micro-organism to be ex-
cluded from patentability solely because it was 
alive. Moreover, the opinion specifically invited 
Congress to overrule the decision if it disagreed 
with the Court's interpretation. 
Congress has several options. It can act to re-
solve the questions left unanswered by the 
Court, overrule the decision, or develop a com-
prehensive statutory approach. Most important-
ly, Congress can draw lines; it can decide which 
organisms, if any, should be patentable. 
OPTIONS 
A: Congress could maintain the status quo. 
Congress could choose not to address the 
issue of patentability and allow the law to be 
developed by the courts. The advantage of this 
option is that issues will be addressed as they 
arise in the context of a tangible, nonhypo-
thetical case. Some of the issues raised in the 
debate on patenting may turn out to be irrel-
evant as the technology and the law develop. 
Moreover, many of the uncertainties raised by 
the Chakrabarty decision regarding provisions 
of the patent law other than section 101 may be 
incapable of statutory resolution. The complexi-
ty of living organisms and the increase in knowl-
edge of molecular genetics will raise such broad 
and varied questions that legal interpretations 
of whether a particular biological invention 
meets the requirements of novelty, nonobvious-
ness, and enablement will best be done on a 
case-by-case basis by the Patent Office and the 
Federal courts. 
There are two disadvantages to Ihis option. 
First, a uniform body of law may take time to 
develop, since judicial decisions about new legal 
questions by different Federal courts may ini-
tially conflict. Second, the Federal judiciary is 
not designed to take sufficient account of the 
broader political and social interests involved. 
B: Congress could pass legislation dealing with 
the specific legal issues raised by the Court's 
decision. 
Many of the legal questions do not readily 
lend themselves to statutory resolution. How-
ever, three questions are fairly narrow and 
well-defined and may therefore be better re-
•solved by statute: 1) Is there a continuing need 
for the plant protection Acts if plants can be 
patented under section 101? 2) If there is a con-
tinuing need for these Acts, could they be ad-
ministered better by one agency? 3) Should the 
definition of infringement be clarified by 
amending section 271 of the Federal Patent 
Statutes (title 35 U.S.C.) to include reprcxluction 
of a patented organism for the purpose of sell-
ing it? 
Congressional action to clarify these issues 
would provide direction for industry and the 
Patent Office, and it would obviate the need for 
a resolution through costly, time-consuming lit-
igation. Lessening the chances of litigation or 
the chances of a patent being declared invalid 
will provide some stimulation for innov ation by 
lessening the risks in commercial development. 
In addition, Congress could determine that the 
plant protection Acts could l>e tjetter admin-
istered by one agency or should be incorporated 
under the more general provisions of the patent 
law; if so, some administrative expenses prob-
ably could be saved. 
C; Congress could mandate a study of the plant 
protection Acts. 
T\%o statutes, the Plant Patent Act of 1930 
and the Plant Variety Protection ,Ac-t of 1970, 
grant ownership rights to plant breeders who 
develop new and distinct varieties of plants. 
They could serve as a mcxlel for studying the 
broader, long-term potential impacts of patent-
ing living organisms. An empirical study of the 
impacts of the plant protection laws has not 
been done. Such a studv would be timely, not 
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only because of the Chakrabarty decision, but 
also because of allegations that the Acts have en-
couraged the planting of uniform varieties, loss 
of germplasm resources, and increased concen-
tration in the plant breeding industry. In addi-
tion, information about the Acts' affect on in-
novation and competition in the breeding in-
dustry would be relevant to this aspect of the 
biotechnology industry. However, it may be ex-
tremely difficult to isolate the effects of these 
laws from the effects of other factors. 
D: Congress could prohibit patents on any living 
organism or on organisms other than those 
already subject to the plant protection Acts. 
By prohibiting patents on any living orga-
nisms. Congress would be accepting the 
arguments of those who consider ownership 
rights in living organisms to be immoral, or who 
are concerned about other potentially adverse 
impacts of such patents. Some of the claimed 
impacts are: 1) patents would stimulate the de-
velopment of molecular genetic techniques, 
which wil l eventually lead to human genetic en-
gineering; 2) patents contribute to an atmos-
phere of increasing interest in commercializa-
tion, which wil l discourage the open exchange 
of information crucial to scientific research; and 
3) plant patents and protection certificates have 
encouraged the planting of uniform varieties, 
loss of germplasm resources, and increasing 
concentration in the plant breeding industry. 
Also, by repealing the plant Acts, Congress 
would be reversing the policy determination it 
made in 1930 and in 1970 that ownership rights 
in novel varieties of plants would stimulate 
plant breeding and agricultural innovation. 
A prohibitory statute would have to deal with 
those organisms at the edge of life, such as 
viruses. Although there are uncertainties and 
disagreements in classifying some entities as 
living or nonliving. Congress could be arbitrary 
in its inclusions and exclusions, so long as it 
clearly dealt with all of the difficult cases. 
This statute by itself would slow but not stop 
the development of molecular genetic tech-
niques and the biotechnology industry because 
there are several good alternatives for maintain-
ing exclusive control of biological inventions: 
maintaining organisms as trade secrets; patent-
ing microbiological processes and their prod-
ucts; and patenting the inanimate components 
of a genetically engineered micro-organism, 
such as plasmids, which are the crucial ele-
ments of the technique anyway. The develop-
ment would be slowed primarily because infor-
mation that might otherwise become public 
would be kept as trade secrets. A major conse-
quence would be that desirable products would 
take longer to reach the market. Also, certain 
organisms or products that might be marginally 
profitable yet beneficial to society, such as some 
vaccines, would be less likely to be developed. 
In such cases, the recovery of development 
costs would be less likely without a patent to 
assure exclusive marketing rights. 
Alternatively, Congress could overrule the 
Chakrabarty decision by amending the patent 
law to prohibit patents on organisms other than 
the plants covered by the two statutes men-
tioned in option C. This would demonstrate 
congressional intent that living organisms could 
be patented only by specific statute and alleviate 
concerns of those who fear the "slippery slope." 
E: Congress could pass a comprehensive law 
covering any or all organisms (ejccept 
humans). 
This option recognizes the fact that Congress 
can draw lines where it sees fit in this area. It 
could specifically limit patenting to micro-orga-
nisms or encourage the breeding of agricul-
turally important animals by granting patent 
I'ights to breeders of new and distinct breeds. 
Any fears that such patents would eventually 
lead to patents on human beings would be un-
founded, since the 13th amendment to the Con-
stitution, which abolished slavery, prohibits 
ownership of human life. 
The statute would have to define included or 
excluded species with precision. Although there 
are taxonomic uncertainties in classifying or-
ganisms. Congress could arbitrarily inclucie or 
exclude borderline cases. 
A statute that permitted patents on several 
types of organisms could be modeled after the 
Plant Variety Protection Act—e.g., it should 
cover organisms that are novel, distinct, and 
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uniform in reproduction; such terms would 
have to be defined. Infringement should include 
the unauthorized reproduction of the orga-
nism—although reproduction for research 
should be excluded to allow the development of 
new varieties. In fact, consideration should be 
given to covering in one statute plants and all 
other organisms that Congress desires to be pat-
entable. This would provide the advantage of 
comprehensiveness and uniform treatment; it 
could also address the problems discussed 
under option B. 
The impact of this law cannot be assessed 
precisely. A comprehensive statute would stim-
ulate the development of new organisms and 
their products and would encourage dis-
semination of technical information; however, 
such a statute is not essential to the de-
velopment of the biotechnology industry, since 
incentives and alternative means for protection 
already exist. The secondary impacts on society 
of the legislation are even harder to assess 
because of the scarcity of data from which to 
draw conclusions. The policy judgments will 
have to be made by Congress after it weighs the 
opinions of the various interest groups. 
Through legislation. Congress has the chance to 
balance completing views on this controversial 
issue and, if necessary, to alleviate the primary 
concerns about the long-term impacts of the 
decision—that higher organisms will inevitably 
be patented. 
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Discussion of Hic1<s's Opening Remarlcs 
SCANLON: What is the frequency of these silent mutations in a typical 
plasmid? 
HICKS: You mean naturally occurring? 
SCANLON: Yes. 
HICKS: If you looked at a million organisms in detail over a certain sequence, 
you would be likely to find one that had a different sequence in at least 
one base pair. Under other conditions, you can change that in the labora-
*tory at will. You can just take that piece of DNA, change it chemically, 
and put it back in. 
CARLSON: Are these plasmids exchanged frequently among scientists at vari-
ous stages of their evolution? 
HICKS: Actually, still very frequently. It is a matter of trust and mutual bene-
fit. The standard thing has been-there is no rule—that you are considered 
in bad form if, after a plasmid has been published, you don't send it out. 
Lots of people send things out long before they are published if they 
don't feel threatened. 
JOHNSON: That is one of the things that keeps the science, as well as the 
technology moving. If we didn't do it, it would be static. 
HICKS: Exactly, and that was my earlier point: How can we make sure, since 
we are getting such a large number of people who are doing incredibly 
sophisticated directed things in companies, that we are going to get the 
byproducts of that back out into the research community, so that people 
don't have to repeat that? Otherwise it is a waste of time. 
BRENNER: If it is SO easy, why not? 
HICKS: A lot of it isn't easy. 
BRENNER: The first time it is difficult. 
HICKS: Every 2 or 3 months, we are finding a new important sequence or 
somebody is fusing one thing to another that allows various sophisticated 
and more subtle manipulations of the genes. For example, if you wanted 
to make a huge amount of one protein that might be deleterious to the 
cell as it likes to grow normally, one idea is to have one of these signal 
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sequences, a promoter which is under control, so that you grow up these 
organisms to a huge volume where they are fairly happy and then add a 
chemical that turns on one gene. It doesn't matter if they are dead, be-
cause you are going to harvest them anyway. But just at that point, for the 
next several hours, they will now start pumping out 50% of their protein 
with that one gene. Then they will suicide in a way that you like. 
Now, developing that to the nth degree is probably clearly under the 
purview of making something for commercial purposes. It is easier to 
understand doing that than it is what we normally do—we just want to 
study genes as they are normally controlled, not under some aberrant 
situation. On the other hand, if you wanted to purify a protein for re-
search purposes, you would want to hook it up to that kind of a vector 
so that you could make it more easily. And that should be available. The 
most sophisticated plasmid should be available to the research com-
munity. 
But under certain circumstances, you can imagine that the industrial 
community could not afford to send it out, because just having it out 
there means that somebody could get it from that research person, even 
without his knowledge. If there is no way of finding out that somebody 
is using that, then the molecule itself becomes important, and not just 
the principle that it is protected. That molecule out there, which is repli-
cating alone, could be grown up by somebody else and used and save them 
years of work, which in company competion would be disastrous. 
DELLENBAUGH: You talked about putting in drug-resistance markers. Could 
you put in a marker that would identify a plasmid as being your plasmid? 
HICKS: I think that is a key. 
DE ROSNAY: Yes, that was the question I wanted to ask, a sort of silent 
sequence which can be in a code that you could refine by hybridizing 
with a probe of your own. 
HICKS: Sure, if that became an organized way of doing things. I think that is 
the one people have talked about a lot, and I think it is perfectly logical. 
DE ROSNAY: If you do that, then you might be able to build a patchwork 
plasmid in the sense that you would be bringing together tilings that are 
already known but in an original manner, which is a patentable construc-
tion. Therefore, a patchwork plasmid like this with a sequence that will 
allow you to recognize it if it is being used improperly could be a pro-
prietary information program. 
HICKS: That could amount to your copyright notice. 
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DELLENBAUGH: In copyright, people will make mistakes in their books 
deliberately, so that if you copy it, then you copy their mistake, and 
the inference is you copied their book. 
HEYNEKER: It looks like a nice idea, but especially since, these days, plasmids 
are really built up by building blocks, what people will do will be to 
try to avoid having any of these sequences occurring in their plasmid 
collection. You just take out only that piece or fragment of interest 
and put it in a plasmid you have. I think it sounds nice, but it won't work 
in practice, I am afraid. 
JOHNSON: Yes, I agree. 1 hate to use the word "guidelines," because I have 
spent several years trying to destroy them, but I really think we have to 
come up with a set of guidelines or rules that people can live by that will 
allow the science to proceed and will protect people. 

Monoclonal Antibodies 
DONALD J. ZACK AND MATTHEW D. SCHARFF 
Department of Cell Biology 
Albert Einstein College of Medicine 
Bronx, New York 10461 
The production of antibodies, primarily for diagnostic purposes but also for 
research and therapy, is a $300 million business aimually (Business Week 1981). 
Despite this significant market, commercial interest in the licensing and 
patenting of antibodies has been limited due to the fact that conventional im-
munization is as old as Pasteur and because it is a relatively expensive and 
complex process. Recently, however, a new approach, called the hybridoma 
technology, has been developed for producing homop;eneous (monoclonal) anti-
bodies (Kohler and Milstein 1975). This technolc^ promises to increase the 
diagnostic and therapeutic uses of antibodies as \/ell as the quality and quantity 
of reagents that can be produced while at the same time decreasing the expense 
and complexity of their production. It also provides the potential of producing 
large amounts of human antibodies for therapy. This dramatic change in the 
mode of production along with the courts' decision on the patenting of life 
forms and the issuance of NIH guidelines indicating that hybridomas and their 
products should be considered as inventions (NIH Guide 1980) has generated a 
great deal of discussion about the licensing and patenting of antibodies. In order 
to appreciate the issues involved, it is necessary to understand some of the 
structural features of the antibody molecule, the basic characteristics of the 
normal immune response which give rise to antibodies, and the manipulations 
that are required to produce monoclonal antibodies through the hybridoma 
technology. 
Antibodies (immunoglobulins) are proteins made by a type of blood cell 
called a B-lymphocyte. They contain two larger and two smaller polypeptides, 
called the heavy (H) and light (L) chains, respectively, which are joined together 
by covalent disulfide (—S—S—) bonds (Fig. 1). The molecule consists of two 
functionally distinct portions, the variable and constant regions. The amino 
terminal (NHj) or variable region (See Fig. 1) binds to the antigen through non-
covalent chemical interactions with parts of the variable region, called the 
hypervariable regions as seen in Figure 1. Once the antigen and the antibody 
have formed a complex, the COOH terminal or constant region of the antibody 
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Schematic representation of a typical antibody mutagen. (•), (•) constant regions; (o) 
variable regions; (VL), (VH), (CH') . (CH') . (CHO specific domains; (-S—S-) interchain 
disulfide bonds. 
associates with receptors on phagocytic cells, activates proteolytic enzymes 
(complement) or carries out other functions to eliminate the antigen. Since these 
different effector functions require different antibody structures, antibody 
molecules may have any of several different constant regions which define the 
classes and subclasses of immunoglobulins (IgM, IgA, IgG|, etc.). 
By both binding to antigen and mediating its elimination, antibodies play 
a major role in protecting animals, including man, from the environment. It is 
estimated that an individual makes as many as a billion different antibodies, each 
with a different set of chemical sequences in its hypervariable regions. The 
antigens against which antibody responses are commonly generated include 
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microorganisms such as viruses and bacteria; substances which are inhaled, in-
gested, or enter the body through wounds; and even an individual's own cells 
when they acquire new antigenic determinants as a result of viral infection or 
malignant transformation. Each of these antigens in tum has on its surface many 
different chemical determinants, each of which elicits the production of a differ-
ent set of antibody molecules. Because of the need for so many antibody 
molecules, animals appear to have been forced to evolve a unique genetic system 
in order to produce a large enough repertoire of chemically different antibodies 
to react to the many different antigens to which they are exposed (Leder et al. 
1981). 
The commercial preparation of antibodies generally involves the injection 
of the foreign substance (antigen) into a recipient animal. After repeated 
boostings, the immunized animal, or man in some cases, is bled and the anti-
bodies of interest are obtained. However, the enormous degree of antibody 
diversity sometimes makes it difficult to use the normal immune response to 
generate reagents that are reproducible and homogeneous enough for diagnosis 
and therapy. Even under the most controlled conditions with the simplest anti-
gens, an animal responds to conventional immunization by producing hundreds 
to thousands of different antibodies, each of which will react with the im-
munizing antigen. In practice, this means that even the best conventional 
antiserum is a mixture of antibodies that vary in the tightness with which they 
bind antigen (avidity) and their specificity or abiUty to react with related 
antigens (cross reactivity). In addition, even amongst those antibodies with the 
same hypervariable regions are some which contain different constant regions: 
some which allow them to bind to receptors on phagocytic cells and others 
which activate complement; some which can pass the placenta and enter the 
fetal circulation and others which cannot; and some which disappear quickly 
from the circulation while others persist for longer periods of time. The relative 
proportions of these different types of antibodies vary from one immunized 
animal to the next and even from time to time in the same animal. This means 
that each bleeding of an immunized animal may generate a unique reagent with 
properties that must be evaluated and compared to other bleedings before it can 
be used with confidence. It also means that any individual bleeding with its 
particular mixture of antibodies may have special properties that caimot be 
duplicated by other bleedings. While this is unusual, it does result in investigators 
being reluctant to part with useful antisera and has discouraged researchers from 
trying to make antibodies against weak or rare antigens such as those that 
distinguish tumor cells from normal cells. 
Many of these difficulties have been overcome by the hybridoma 
technology which was described by Kohler and Milstein (1975). These investi-
gators were studying the expression of inununoglobulin genes by fusing tissue-
culture adapted mouse myeloma cells (malignantly transformed antibody pro-
ducing cells) that were synthesizing one type of antibody molecule to another 
line of mouse myeloma cells which was synthesizing another type of 
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immunoglobulin molecule. In the course of these studies, they also did the 
crucial experiment of fusing cultured mouse myeloma cells to the normal spleen 
cells from a mouse immunized with sheep red blood cells. Since the spleen con-
tains many antibody forming B-lymphocytes, this fusion yielded several cell 
lines which were producing both the myeloma immunoglobulin and antibody 
specific for sheep red blood cells. These hybrids not only produced the antibody 
that was the product of a normal spleen cell but retained many of the properties 
of the malignant myeloma cell, i.e. they grew continuously in culture; could be 
frozen and recovered from the freezer with maintenance of antibody produc-
tion; and when injected into animals formed tumors that grew in an uncon-
trolled fashion and resulted in the accumulation of large amounts of antisheep 
red blood cell antibody in the blood and ascites fluid of the tumor bearing 
animal. As they noted, Kohler and Milstein had immortalized and cloned single 
antibody forming cells which could now generate large numbers of progeny all 
making the exact same antibody molecule. They had in fact developed a 
technology for producing very large amounts of homogeneous antibody and of 
renewing the supply of this antibody whenever it was needed. 
To understand how the hybridoma technology accomplishes all of these 
goals, it is useful to understand a Uttle about the cellular basis of antibody pro-
duction and then to be able to visualize the technique itself. We have aheady 
discussed the large number of chemically different antibodies an individual 
makes in a lifetime. However, each B-lymphocyte makes only a single species of 
antibody that bears a single heavy chain and a single light chain variable region. 
Furthermore, with some possible exceptions that are not discussed here, the cells 
making any antibody preexist in the system prior to the introduction of a 
specific antigen. Each of these B cells has on its surface a small amount of the 
particular antibody which it is preprogrammed to produce. Upon contact with 
an antigen, those antibody-forming cells with a surface antibody that can bind 
that antigen are stimulated to replicate and differentiate, thereby increasing the 
amounts of that antibody made and secreted into the bloodstream. 
In order to form hybridomas, these antibody-forming cells are removed 
from the spleen of the immunized animal and mixed with a tissue-culture line 
of mouse myeloma cells (Fig. 2). Fusion between these cells is promoted by 
adding polyethylene glycol (PEG) (Gefter et al. 1977). This leads to the forma-
tion of spleen X spleen, myeloma X myeloma, and spleen X myeloma hybrids. 
A drug selection technique is used to specifically obtain the spleen X myeloma 
hybrids (Szybalski et al. 1962; Uttlefield 1964). The myeloma cells used contain 
an enzyme defect (hypoxantiiine phosphorybosil transferase or HPRT-) which 
makes them die in the presence of aminopterin. In the presence of aminopterin 
containing medium (hypoxanthine, aminopterin, and thymidine or HAT 
medium), the unfused myeloma and myeloma X myeloma hybrids die. Because 
they cannot grow in tissue culture, the normal spleen cells and spleen X spleen 
hybrids die spontaneously. The normal spleen HPRT enzyme protects the 
spleen X myeloma hybrids from the aminopterin, allowing these hybrids to 
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Production of monoclonal antibodies (hybridomas). (Reprinted, with permission, from 
Diamond etal. 1981). 
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survive and grow out from amongst the mixture of cells in the ftision as seen in 
Figure 2. 
Since only a few percent of the spleen cells are making antibody against 
the immunizing antigen, only a few percent of the surviving hybridomas pro-
duce the desired antibodies. These are identified by distributing the ftised cells 
into small tissue culture wells so that one out of every three wells will contain a 
growing hybridoma. As only one out of every 2 X 10^ spleen cells forms a viable 
hybrid, on the average of 500 hybridomas are generated from each spleen. Of 
these, only a fraction are making the desired antibodies. Because each 
hybridoma is the clonal product of a single antibody forming cell which has 
fused with a myeloma, each hybridoma makes a monoclonal antibody molecule 
which is a homogeneous chemical reagent, i.e. all molecules contain the same 
variable, hypervariable, and constant region sequences. As mentioned above, 
a hybridoma retains the malignant properties of its myeloma parent. It can be 
injected back into animals to form a timior and, as already noted, produce very 
large amounts of antibody in the recipient animal. In fact, the amounts of anti-
body formed in tissue culture fluid are similar to those found in a well im-
munized animal and amounts that can be generated from a single tumor bearing 
mouse are 100-1000 times higher than is usually found in a well immunized 
animal. Since the cells can be frozen away and recovered from the freezer, the 
exact same antibody can be generated in large amounts whenever it is needed. 
Table 1 shows monoclonal antibodies made against many antigens and 
used widely in research and diagnosis (Yelton and Scharff 1981). It is already 
clear that new diagnostic tests will become available as a result of the technol-
ogy. It has proved especially powerful for generating pure antibodies from 
impure antigens such as whole cells and has stimulated researchers to look for 
antigens whose presence was suspected but not proven. Improvements in the 
technology will no doubt be made and result in antibodies against antigens that 
we had not even dreamed of. 
It is, however, still difficult to obtain large numbers of hybridomas from 
species other than rats and mice. The following paper (Croce) discusses the 
generation of human monoclonal antibodies which will be crucial for the in vivo 
diagnosis and therapy of human disease. In spite of this and other problems, the 
hybridoma technology is a major advance in the production of antibodies for re-
search, diagnosis and therapy. Once a hybridoma making a useful monoclonal 
antibody has been obtained, the antibody can be generated in large amounts, 
replenished when needed, and is a defined chemical reagent. Batteries of hy-
bridomas can be screened for monoclonals that are potentially useful for differ-
ent tasks and if necessary, monoclonal antibodies can be further tailormade by 
selecting for class switches (Neuberger and Rajewsky 1981; Thammana and 
Scharff, unpubl. results) or by introducing somatic mutations into the immuno-
globulin genes (Kohler and Schubnan 1980; Yelton et al. 1980). 
From the point of view of patenting, there are some obvious consequences 
of the technology as described above. First, the hybridoma is a normal antibody 
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Table 1 
Application of Monoclonal Antibodies 
APPLICATIONS ALREADY REPORTED 
Tools for research 
Routine serology 
levels of serum proteins, drugs 
Tissue and blood typing 
Diagnosis and epidemiology of infectious agents 
viruses: influenza, rabies 
bacteria 
parasites 
Identification of differentiation antigens 
lymphocyte subsets 
classification of leukemias and lymphomas 
Identification of onco-fetal antigens 
tumor antigens 
Purification of macromolecules 
APPLICATIONS ANTICIPATED IN MAN 
Passive immunization against 
infectious agents 
drug toxicity 
Potentiation of tumor rejection 
Protection against graft rejection 
Manipulation of the immune response 
Treatment of autoimmune diseases 
Diagnostic detection of metastases in vivo 
Specific delivery of cytotoxic agents to tumor cells in vivo 
forming cell that has been changed so that it will have malignant properties. 
The antibody it forms preexisted in the animal; it is not new. Second, since an 
animal can produce hundreds to thousands of chemically different antibodies 
that will react with a particular antigen, the chances of any two investigators 
making a hybridoma which is producing exactly the same antibody molecule is 
very small. It is likely that any two monoclonal antibodies will be distinguishable 
by their electrophoretic mobility, specificity, biological activities, affinity for 
antigen, or, if all of these are identical, by their amino acid sequence. Even if 
two independent hybridomas are producing the same antibody, they are likely 
to have lost different chromosomes and the cells might be distinguishable on 
that basis. In any case, if novelty is the crucial criteria and it is to be defined by 
chemical structure, then most monoclonal antibodies could be considered novel. 
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The technology described above is essentially the same as that described 
by Kohler and Milstein (1975). The crucial manipulations are unchanged, al-
though many laboratories have made minor modifications. There are currently a 
number of different myeloma cell lines that are being used as fusion partners for 
hybridoma production. The Wistar patents (Koprowski and Croce 1979; 
Koprowski et al. 1980) mention one particular line. Could one avoid patent 
infringement simply by using a new cell line or varying an old one? For example, 
it is now common to use myeloma mutants that no longer produce their own 
immunoglobulin (Ig~), so that the resulting hybridomas will only make anti-
bodies of spleen cell origin (Schulman et al. 1978; Kearney et al. 1979). There 
are, in addition, areas where improvements are needed. For example, it is still 
difficult to obtain hybridomas making monoclonal antibodies against weak im-
munogens. If inmiunization does not result in many antibody forming cells in 
the spleen, then the chance of one of those cells forming a viable hybrid is small 
and many fusions and thousands of hybrids will have to be examined to find one 
producing the desired antibody. Even for antigens that induce many antibody 
forming cells, the technology is labor intensive. Methods for enriching for 
antibody forming cells and for increasing the fiision frequency would overcome 
these problems. 
The role of patents in this technology is unclear. WiU every monoclonal 
antibody be patentable? Will distinct cells making the same antibody be 
considered unique? Since anyone can probably make a chemically different 
monoclonal that can carry out the same task, does it matter whether a 
monoclonal is patented? Is it the antigen rather than the antibody which will be 
most often patented? Will the Wistar patents on monoclonals against tumor and 
viral antigens be challenged in the United States and if so, will they hold up? 
Will government regulatory agencies ultimately require that diagnostic immuno-
assays be done with monoclonal antibodies and will they approve monoclonal 
antibodies which are the product of malignant cells to be administered routinely 
to patients? The answers to these questions will obviously have an impact on the 
commercial uses of monoclonal antibodies. However, no matter how they are 
resolved, the scientific community will continue to generate and use mono-
clonals because they are such powerful tools. 
ACKNOWLEDGMENT 
The authors wish to thank Ann Gorgoglione for her expert assistance in the 
preparation of this manuscript. D.J.Z. is a medical scientist trainee supported by 
NIHMS grant 5T32GM7288. M.D.S. receives research support from the NIH 
(grants AI10702 and AI5231). NSF (grant PCM77-25635). and ACS (grant 
NP.317). ^^ 
Monoclonal Antibodies / 23 
REFERENCES 
Business Week. 1981. Biotechnologies. New trust in antibodies. 147. 
Diamond, B.A., D.E. Yelton, and M.D. Scharff. 1981. Monoclonal antibodies: A 
new technology for producing serologic reagents. N. Engl. J. Med. 304: 
1344. 
Gefter, M.L., D.H. Margulies, and M.D. Scharff. 1977. A simple method for 
polyethylene glycol-promoted hybridizatrion of mouse myeloma cells. 
Somatic Cell Genet. 3:231. 
Kearney, J.F., A. Radbruck, B. Liesegang, and K. Rajewsky. 1979. A new mouse 
myeloma cell line that as lost immunoglobulin expression but permits the 
construction of antibody secreting hybrid cell lines. / . Immunol. 123: 
1548. 
Kohler, G. and C. Milstein. 1975. Continuous cultures of fused cells secreting 
antibody of predefined specificity. Nature 256:495. 
Kohler, G. and M. Schulman. 1980. Immunoglobulin M mutants. Eur. J. Im-
munol. 10:467. 
Koprowski, H. and CM. Croce. Oct. 23, 1979. Method of producing tumor anti-
bodies. United States Patent No. 4, 172, 124. 
Koprowski, H., W.V. Gerhard, and CM. Croce. April 1, 1980. Method of pro-
ducing antibodies, United States Patent No. 4,196, 265. 
Leder, P., E.E. Max, J.G. Seidman, S.-P. Kwan, M.D. Scharff, M. Nau, and B. 
Norman. 1981. Recombination events that activate, diversify, and delete 
immunoglobulin genes. Cold Spring Harbor Symp. Quant. Biol. 45:859. 
Littlefield, J.W. 1964. Selection of hybrids from matings of fibroblasts in vitro 
and their presumed recombinants. Science 145:709. 
Neuberger, M.S. and K. Rajewsky. 1981. Switch from hapten-specific immuno-
globulin M to immunoglobulin D secretion in a hybrid mouse cell line. 
Proc. Natl. Acad. Sci. USA 78:1138. 
NIH Guide for Grants and Contracts (supplement, special announcement). May 
1, 1980. NIH policy relating to reporting and distribution of hybridomas 
produced under grants and contracts. 
Schulman, M., CD. Wilde, and G. Kohler. 1978. A better cell line for making 
hybridomas secreting specific antibodies. Nature 276:269. 
Szybalski, W., E.H. Szybalska, and G. Ragni. 1962. Genetic studies with human 
cell lines. / . Natl. Cancer Inst. Monograph 7:75. 
Yelton, D.E., W.D. Cook, and M.D. Scharff. 1980. Somatic variants in mouse 
myeloma and hybridoma cell lines. Transplant Proc. 12:439. 
Yelton, D.E. and M.D. Scharff. 1981. Monoclonal antibodies: A powerful new 
tool in biology and medicine. Ann. Rev. Biochem. 50:657. 
24 / D. J. Zack and M. D. Scharff 
COMMENTS 
BRENNER: You can take a strain of an animal and make monoclonal anti-
bodies to a given chemical in such a way that 14 out of 15 are identical. 
SCHARFF: That is correct. If you happen to immunize BALB/c mice—and this 
is an unusual situation-with the hapten phosphocholine, most of the 
antibodies made will have the same amino acid sequence in that particular 
strain of mice. In this unusual case you make the same monoclonal re-
peatedly. On the other hand, if you did not want to do that, you could go 
to another strain of mouse, immunize with the same antigen, and make an 
antibody with a different chemical structure. 
BRENNER: Or Wait another week before fusing. 
SCHARFF: I think there will be examples where two antibodies may have the 
same structure, but if you wanted to avoid it, it is easy to avoid. 
DELLENBAUGH: You said that you doubted that it would be possible to 
make—or if you wanted to get around it, you could make different mono-
clonal antibodies for the same antigen. How would you distinguish those 
from each other? 
SCHARFF: The amino acid sequence, the chemical composition, of each 
monoclonal antibody that is made is going to be different. So I could 
distinguish it by determining the chemical composition—not a trivial task. 
In addition, and more easily, you could make antivariable region anti-
bodies against antibodies and, distinguish different monoclonals. You 
could also look at its electrophoretic mobility and especially its isoelectric 
point and would probably see a difference. 
Now, it is a httle complicated by the fact that, for reasons that 
probably relate to the mechanism of generating antibody diversity, 
hybridoma and mouse myeloma cells undergo both deletions and point 
mutations at a very high frequency. The spontaneous mutation rate in all 
hybridomas and myelomas is that one in 1000 cells has in it a mutation 
in the genes coding for the immunoglobulin molecules. In fact, I could 
use this technique to improve my antibody reagents by changing the 
structure of the monoclonal so it will be more useful for certain tasks. 
It is the same thing we were talkng about. If I obtained someone's 
hybridoma that was making a particular monoclonal antibody, I could 
rather easily induce a mutation in it that would cause it to have a single 
amino acid different. But I don't think I would ever have to do that, be-
cause, I think it is very unlikely that two monoclonal antibodies against 
the average antigen-with the exceptions noted-are going to be the same. 
I think it is relatively simple to distinguish them. 
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JOHNSON: I have a conmient, just in a matter of accuracy. Both you and Jim 
Hicks alluded to antibiotic resistance as if we were going to be back in the 
dim dark ages of antimicrobial chemotherapy. I would like to point out 
that the first antibiotic with any clinical utility, penicillin, is still with us. 
It is true that these resistance factors can be detected in hospitals. They 
can also be detected in the wilds of New Guinea, where antibiotics were 
never used. In actuality, as scientists, by chemical modification we have 
been able to keep up with the various modes of resistance to antibiotics. I 
don't think they are going to die out and I seriously doubt if they are 
going to be replaced by monoclonal antibodies or by passive transfer of 
immunity. 
SCHARFF: I suspect you are right, but I am not certain, because I think that 
passive immunization will be used for certain organisms. Human mono-
clonal antibody make passive immunization especially attractive. People 
are treating pneumococcal pneumonia again with antibodies. This is to say 
nothing of the fact that there are viral and parasite diseases for which there 
are no chemotherapeutic agents and no vaccines. 
ZINDER: Well, many of these involve cellular immunity. 
SHARP: Let me just point out the diversity of biological systems. Hybridomas 
are now made by fusion. But I see no reason, though it can't be done at 
the moment, that cell biology wouldn't develop to a stage where you 
could introduce a virus into a direct.. . 
SCHARFF: It is done. There is a standard way of making monoclonal anti-
bodies by that technology, described originally by Steinitz and colleagues 
(Steinitz et al. 1977; Koskiemes 1980). In fact, many of the serological 
reagents used in the typing lab in Helsinki are made by the transformation 
of human peripheral blood cells making specific antibodies with the EV 
virus. It is available but I don't think it is quite as useful at the moment, 
but it is available. 
O'NEILL: I would like to suggest, not to contradict your statement that 
nothing has changed since Kohler and Milstein with respect to the pro-
duction of monoclonal antibodies. It is part of the wave of this technology 
that the Jrni Hick's subject of genetic engineering is going to be com-
bined with the monoclonal antibody technology so that one can mass 
produce the important portions of antibody. Anybody who has been 
through the arithmetic and handled a lot of mice can appreciate the limi-
tations to the current monoclonal antibody technology. 
We feel that there will be important patents in that field. I will 
greatly appreciate the comments of this audience as to the patent ability 
of that kind of merging of two technological paths. 
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ZINDER: This is a discussion that is going to go on for the next couple of 
days, what to patent. In a certain sense, you can say that the Boyer-Cohen 
patent subsumes everything—you can't patent anything because you can't 
make anything from the principle of recombinant DNA. 
HOSCHEIT: Could I just ask one question, and perhaps keep some of this in 
context? You talked about the variability of the various antibodies and the 
various hybridomas that you are producing. I take it, however, you are not 
saying that with each variation you have a new antigenic site which you 
have identified. 
SCHARFF: No. Antibodies with different chemical structures can recognize 
the same antigen or they may recognize different antigens. 
PTASHNE: Can't you, for legal purposes, define a class of monoclonal anti-
bodies or antibodies that will recognize, within a certain affinity range, a 
given antigen? Differences within that class become trivial. That is a legal 
question, but isn't that the obvious thing? 
SCHARFF: I am only saying that each one will have a different chemical 
sequence. 
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One of the elements that made hybridoma technology quite useful and im-
portant is the fact that the hybridization event between a myeloma cell and a 
lymphocyte is highly selective. If, for example, we immunize a mouse with 
influenza virus (Koprowski et al. 1977), take the spleen of this mouse and fuse 
the spleen lymphocytes with mouse myeloma cells, we find that about 80% of 
the independent hybridomas are making antibodies against influenza virus 
(Gerhard et al. 1978), whereas if you count how many spleen cells make anti-
bodies against influenza virus, you will find that only one cell out of 3,000 is 
making antiviral antibodies. The reason we obtain 80% of hybridomas making 
influenza antibody is the fact that the myeloma cells preferentially hybridize 
with the lymphocytes that have been stimulated to divide. 
This selective process makes the technique very useful. Otherwise, it would 
be quite difficult to be able to select for the hybridomas that are needed. 
Thousands and thousands of hybridomas would have to be screened all the time, 
which is quite impractical. 
HYBRIDOMA PRODUCTION OF 
MONOCLONAL ANTIBODIES 
One of the uses of this technology in the study of human diseases is to try to 
determine whether it is possible to produce reagents, specific monoclonal 
reagents, against antigens which are associated with specific human malignancies. 
Different groups at the Wistar Institute and other institutions are producing 
monoclonal antibodies (MAB) against different cancer cells, and they have 
found that some of these hybridomas produce MAB which are specific for 
antigens which are associated with specific types of cancer cells (Koprowski 
et al. 1978;Steplewski et al. 1981). 
There is a question of whether these antibodies recognize tumor-specific 
antigens or whether they recognize tumor-associated antigens. Until now, there 
is no definite evidence for the expression of human tumor-specific antigens. 
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Certainly there is evidence for expression of antigens which are associated with 
a specific tumor phenotype, but are also expressed in other cell types. 
Dr. Hilary Koprowski has produced a large variety of human MAB against 
human melanomas. He has found that the great majority of the antimelanoma 
MAB he obtained are divided into groups and react also against a large variety 
of other tumor cell types and normal cells. A very small minority reacted only 
against melanoma. We still cannot call them melanoma-specific because if they 
are tested against a large variety of normal cell types, and possibly, different 
human embryonal cells, we will probably find that these MAB will recognize 
some of them. 
These antibodies, however, can be extremely useful from the practical 
point of view for diagnostic purposes. For example, if a pathologist needs to 
determine whether in a given specimen there are melanoma cells, this can be 
determined by using antimelanoma MAB. 
Because of, the availability of antimelanoma MAB we can now character-
ize the antigens against which these MAB are directed. A large number of MAB 
react, however, against antigens which are also expressed by other cell types. 
More recently, investigators at the Wistar Institute have tried to produce 
MAB against tumor cells of the gastrointestinal tract (Koprowski et al. 1900, 
1979). They were successful in producing a large variety of hybridomas directed 
against carcinoma of the colon, rectal carcinoma, gastric carcinoma, and 
pancreatic carcinoma. A large number of these hybridomas are producing anti-
bodies that do not react against proteins, but react against glycoUpids expressed 
on the cancer cells (Herlyn et al. 1980; Magnani et al. 1981). 
If the antibodies of these hybridomas secreting antibodies against the 
human colon carcinoma-derived cell line 1116 NS-19 (NS-19) are tested against 
the different colon carcinoma cell lines, we find that these antibodies react very 
strongly-the original monoclonal was directed against the NS-19 cell line-
against most of the human colon carcinoma cell lines. It does not react, however, 
against a large variety of other human cancer cells. Of the non-colon-derived 
cell lines it reacts only against one human melanoma cell Une and against one 
astrocytoma cell line. 
These antibodies are quite interesting since they stain specifically tumor 
cells in gastric tumor specimens. They react against a glycolipid that has not 
been described before that migrates in thin-layer chromatography between 
GM-1 and GD-IA (Magnani et al. 1981). More importantly, it can detect the 
presence of an antigen in patients with colon cancer (Heriyn et al. 1980; 
Magnani etal. 1981). 
If we set up a competition radioimmunoassay by competing the reaction 
between this MAB and the colon antigen with sera derived from different 
patients, we can observe that normal individuals and patients with other bowel 
diseases, such as ulcerative coUtis or Crohn disease, do not express in their sera 
this antigen. On the contrary, people with advanced colorectal carcinoma 
express this antigen in their sera. 
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More recently, Koprowski and his associates (Koprowski et al. 1978,1979, 
1981) have carried out numerous experiments using sera derived from patients 
with colon carcinoma, gastric carcinoma, and pancreatic carcinoma. They have 
found that these antibodies can pick up about 60% of the patients with colon 
carcinoma, 85% of the patients with gastric carcinoma, and 98% of the people 
with pancreatic carcinoma. Therefore, these antibodies are extremely useful 
since they allow us to detect practically all patients with pancreatic cancer. 
Possibly antibodies like these would be useful not only for diagnostic purposes, 
but to screen normal individuals for the expression of this tumor associated 
antigen in the sera. 
Even if these MAB are directed against a colon carcinoma specific gangho-
side and do not react with any other cells, they have been found to react with 
meconium, therefore they probably detect some embryonal antigen. From the 
practical point of view, however, these MAB are enormously useful because they 
allow us to diagnose certain human malignancies. Probably many MAB similar to 
these can be produced. 
PRODUCTION OF HUMAN MONOCLONAL ANTIBODIES 
Monoclonal antibodies can be used not only for research purposes and diagnostic 
purposes, but also in immunotherapy. It is necessary to produce human MAB to 
make a MAB useful for therapeutic purposes. It is certainly possible to produce 
somatic cell hybrids between mouse myeloma cells and human lymphocytes. 
Unfortunately, mouse X human hybrids segregate human chromosomes and 
most of the human chromosomes are lost by this type of hybrid cell. In order to 
have expression of a human antibody, a hybrid has to retain the two chromo-
somes coding for the light chain and the heavy chain for a given human 
antibody, and since the majority of the hybridomas might lose one of these 
chromosomes, the majority of the hybridomas might lose the ability to produce 
the desired human antibodies. 
Some time ago, we started selecting for mutant human myeloma cells 
deficient in hypoxanthine-guanine phosphoribosyltransferase (HGPRT). We 
took a human myeloma-derived cell line, called GM-1500, secreting IgG (72 ;K) 
and we have hybridized this human B cell line with peripheral lymphocytes 
from a young girl with a disease called subacute sclerosing encephalitis (SSPE). 
This disease is due to a measles virus infection of the brain. This young woman 
had very high titers of antibodies against measles virus in her sera. In fact, 
her serum could be diluted 1:10^ and still react against measles virus-infected 
cells. 
One of the hybrid cells we obtained is producing the immunoglobulin 
chains of the human parental myeloma cell and a new chain derived from the 
patient (see Fig. 1). The two K chains, the one of the patient and the one of 
the myeloma cell, could not be distinguished in this gel. 
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Figure 1 
Immunoprecipitation and 10% SDS-polyacrylamide gel electrophoresis of secreted human 
immunoglobulin chains produced by human hybridomas. Hybridoma cultures were labelled 
with 100 /iCi'H-leucine (70 Ci/mmol)/ml for 12 hr. The human immunoglobulin chains 
were unmunoprecipitated with rabbit anti4iuman heavy chain antigen using established 
procedures, then separated by 10% SDS-polyacrylamide gel electrophoresis as described 
elsewhere. Lane 1, immunoprecipitates of the immunoglobulin produced by GM1500 
6TG-A12 cells after reaction with an anti-human y antiserum; lanes 2-6, immunoprecipi-
tates of immunoglobulin chains secreted by human X human hybridomas after reaction 
with anti-human ju antiserum; lane 7, immunoprecipitate of immunoglobulin chains secreted 
by hybridoma D3 after reaction with anti-human M and 7 antiserum. 
We tested these antibodies against measles virus, and we found that, in 
fact, two independent hybridomas were producing MAB against the major 
nucleocapsid protein of the virus and against its cleavage product (Fig. 2). 
One interesting aspect of this type of study is that, contrary to the mouse 
X human hybridoma, human X human hybridomas tend to be much more 
stable. It is known that intraspecific hybrids are more stable than interspecific 
hybrid cells. In particular, human X human hybrids seem to be more stable 
than intraspecific mouse hybrids. In fact, when we cloned one of our human 
hybridomas secreting antibodies against measles virus and nucleocapsid protein, 
we found that all subclones derived from this clone were producing anti-measles 
virus antibodies, indicating that these hybrids are stable (Croce et al. 1980). 
Therefore, we can conclude that by using the human hybridoma 
technology it is possible to clone human lymphocytes that are producing specific 
antibodies. 
The amount of antibody that hybridomas produce is very large. For ex-
ample, in the case of the mouse, a good hybridoma in culture, can produce 
something like 50 to 100 jug of a specific antibody per ml culture fluid. If we 
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Figure 2 
Polyacrylamide gel electrophoretic analysis of the measles virus polypeptides precipitated 
by the various monoclonal antibodies, (a) Virus polypeptides precipitated by convalescent 
serum of a patient with atypical measles were used as markers. The polypeptides are as 
follows: H, the virus haemagglutinin; P, a polypeptide associated with the internal nucleo-
capsid structure; NP, the major structural polypeptide of the nucleocapsid; F, the poly-
peptide responsible for cell fusion and haemolytic activities; M, the non-glycosylated mem-
brane polypeptide. Bands 1, 2 and 3 are not unique virus polypeptides, but represent 
proteolytic cleavage fragments of the NP polypeptide, (b) Virus polypeptides precipitated 
by antibody D3. (c) Polypeptides precipitated by antibody C5. (d) Culture fluid from the 
human GM 1500 6TG-A12 cell line. Culture fluids of b. c and d were concentrated 20-fold 
by freeze-drying before use. The procedures used in immunoprecipitation, were as follows: 
lysates of virus-infected CVl cells labelled with " S-methionine were used as antigen. 
Aliquots (25 pi) were mixed with 100 jul concentrated culture fluid and incubated at 37°C 
for 90 min. then at 4*C for 4 hr. Rabbit total anti-human antibody (25 lA) was then added 
and the incubation period repeated. Precipitated polypeptides were collected by centrifu-
gation in an Eppendorf centrifuge for 20 min at 10,000 rpm. The visible pellet was resus-
pended and washed three times. After the final washing, the pellet was suspended in lysis 
buffer, boiled for 3 min and electrophoresed on a 10% SDS-polyacrylamide gel in condi-
tions described elsewhere. After fluorography, dried gels were exposed to Cronex X-ray 
film. 
inject this hybridoma, in the peritoneal cavity of a mouse to obtain an ascitic 
tumor, we find that the concentration of antibody in the ascitic fluid is about 
100-1000-fold higher, approximately 50 mg of a specific antibody per ml of 
ascites. Since it is easy to obtain 10 ml of ascites from each mouse, from a few 
mice it is possible to obtain gram quantities of a specific MAB. This is the reason 
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why recombinant DNA technologies at present are not very useful in this area, 
since it is possible to get much more material from hybridoma cells, which are 
programmed to produce enormous quantities of antibody, than by using other 
technologies. 
In the case of the human, we can also take some of these human myeloma 
cell hybrids and inject them in the peritoneum of athymic nude mice, and 
obtain ascites. We can then detect very large quantities of human antibodies in 
the mouse ascites. In this case, approximately 10 to 30 mg human antibody per 
ml ascites can be obtained. We can use this technology not only to produce 
human MAB against viral agents, but also to produce human MAB against tumor-
associated antigens. 
This technology has been applied to the study of human autoimmune 
diseases—a large variety of diseases which are caused by auto-antibodies against 
specific self-antigens. Some of these diseases are rather restricted, in the sense 
that they are due to specific antibodies directed against one or very few antigens. 
For example, in the case of myasthenia gravis, the auto-antibodies are directed 
against the acetylcholine receptor, and the presence of these antibodies blocks 
neuromuscular transmission. In the case of juvenile diabetes type 1, the patients 
have antibodies directed against the islet cells of the pancreas. In the case of 
Graves disease, for example, the auto-antibodies are directed against the thyroid-
stimulating hormone (TSH) receptor. 
One of the most interesting appUcations of the human hybridoma 
technology is in the study of human autoimmune diseases since this technique 
offers the possibility to clone the human lymphocytes that are producing the 
auto-antibodies. If we clone these auto-antibodies, we should be able to generate 
anti-idiotype antibodies (antibodies directed against these auto-antibodies) and 
using this anti-idiotypic reagents, we should be able to study the disease within 
the patient and among patients with the same disease. Specific questions can be 
answered: whether the disease is monoclonal, oligoclonal, or polyclonal in 
origin, and also which antigens are involved. 
Therefore, we think that this technology has an enormous potential in the 
study of human autoimmune diseases. If we can determine that some of these 
diseases have a monoclonal origin or an oHgoclonal origin, it should be possible 
to produce anti-idiotype antibodies specific for these auto-antibodies that could 
be used for immunotherapeutic purposes. 
In this study the serum of this patient, who had insulin-independent 
diabetes type 1, contained antibodies that reacted against islet cells of normal 
pancreas. This study was carried out in collaboration with Dr. George Eisen-
barth, Duke University (Linnenbach et al. 1981). We took the blood lympho-
cytes derived from the patient. In this case we used a very small quantity of 
lymphocytes from 10 ml of the blood of this young giri. The duration of the 
disease was approximately 11 months. She had antibodies that reacted against 
the surface of islet cells and others that reacted against the cytoplasm of islet 
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cells of the pancreas. Some of these antibodies reacted against the cell surface of 
a rat insulinoma cell line. We purified the lymphocytes derived from the 10 ml 
of blood of this patient through a Ficoll gradient and fused them with our 
human myeloma cell line. 
During this experiment, we wanted to answer specific questions: 
1. whether these antibodies reacted against a single or multiple antigen, 
2. whether the response against the islet cells of the pancreas in this patient was 
polyclonal or oligoclonal, 
3. whether these antibodies were pathogenic or a secondary phenomenon, and 
4. whether we could predict the development of diabetes using these mono-
clonal antibodies. 
Of the 22 hybrids obtained, 21 were absolutely negative and only one gave 
positive immunofluorescence with pancreas sections. In fact, it stained a cyto-
plasmic antigen expressed in the islet cells of the pancreas. 
The human cell line used for this experiment was a subclone of our human 
myeloma cell line that was selected for its inability to produce human immuno-
globulin (Ig) chains. The only chains that were produced by the positive hybrid 
cells were the Ig chains produced by the lymphocyte derived from the patient. 
We subcloned this hybrid clone that produces the only antiislet cell MAB we ob-
tained from this experiment, and looked at the different subclones for the 
expression of human Ig chains. The Ig chains produced by the original human 
myeloma parents, were IgG (72 j*^ )- All the subclones of the positive clone (B6) 
are secreting IgM. In fact, the antibodies against the islet cells are IgM antibodies. 
We tested these antibodies against sections of the pancreas and we competed the 
reaction with insulin in order to determine whether these antibodies were 
directed with insulin. The results of this study indicated that the antibodies re-
acted against islets and were not competed out by insulin. 
In sunmiary, by fusing lymphocytes from a patient with diabetes type 1, 
we have been able to produce a hybridoma producing MAB against the islet cells. 
We are presently using these MAB to determine against which antigen the anti-
bodies are directed. 
In addition, we have been able to produce an anti-idiotype antibody 
specific for these B6 antibodies. We plan to use these anti-idiotype antibodies in 
order to determine whether the same idiotype is expressed in different patients 
with juvenile diabetes type 1, and to follow these patients during the develop-
ment of the disease. In this case, unfortunately, we obtained only one 
hybridoma producing MAB. It should be possible however, by making a major 
effort, to clone many of the lymphocytes producing anti-islet cell antibodies in 
these patients and in other patients. So we should be able to use this approach to 
study this autoimmune disease in great detail. Possibly soon we will be able to 
use some of these anti-idiotype antibodies in immunotherapy of autoimmune 
diseases. 
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COMMENTS 
DE ROSNAY: Could you comment on the technique for in vitro immunization 
for producing human MAB? 
CROCE: I know of several labs all around the country trying to do that. We 
have also some labs at Wistar, with Dr. DeFreitas, trying to do that (pers. 
conmi.). We have tried to make a human hybridoma using lymphocytes 
that have been stimulated in vitro, without any success. I don't think that 
at the present time the technology is such to allow this experiment suc-
cessfully. But, hopefully, it will be possible in the future to improve the 
conditions of immunization in vitro, and it will be possible to be success-
ful. I think that is when the breakthrough will come and will be possible 
to inmiunize human lymphocytes in vitro quite efficiently. At that point 
it will be possible to produce all the human MAB we desire. 
SHARP: If I heard you correctly, you said that insulin did not block binding. 
Do you know what the monoclonal activity is to and what protein? 
CROCE: Yes, it reacts against a glycoprotein of the cytoplasm of beta cells. 
I don't know what the function of this protein is. 
SHARP: Is that the same protein that the autoimmune response to is in the 
patient? 
CROCE: There are antibodies also present in the patient, but that patient also 
has antibodies against other antigens which are expressed in the beta cells 
of the pancreas. So there are several antibodies against different antigens 
within the beta cells of the pancreas. 

Transfer of the Human Insulin Gene 
into the Germ Line of Mice 
AXEL ULLRICH 
Genentech, Inc. 
South San Francisco, California 94080 
Recombinant DNA technology has enabled the isolation and study of genes 
coding for specific proteins from higher animal cells. These techniques also 
permit large scale production of the nucleic acid sequences which code for a 
particular protein. This feature has recently been taken advantage of in the 
construction of bacteria which can function as factories to produce large 
amounts of proteins of medical or academic interest. Recently, the ease of ob-
taining specific gene sequences has also been put to another use: introduction 
of a particular, purified gene into a recipient animal lacking that gene. The 
potential of this type of experiment is extremely widespread;however, much is 
yet to be leamed before this approach can be applied in any medical setting. 
This paper describes recent experiments involving the introduction of the 
human insulin gene into mice carried out in collaboration with Drs.Kurt Burki 
and Karl Illmensee of the University of Geneva. 
Several techniques have been successfully employed to introduce DNA 
into animal cells in culture, including calcium precipitation (Bachetti and 
Graham 1977; Wigler et al. 1977), filling membrane vesicles with DNA and 
fusing these vesicles with the cells (Fraley et al. 1979), by incorporating a piece 
of DNA of interest into a virus and utihzing the virus for intracellular delivery 
(Mantel et al. 1979; Mulligan et al. 1979) or by actual physical microinjection 
of the DNA into cells (Anderson et al. 1980; Capecchi 1980). Many investigators 
are using such DNA introduction procedures in conjunction with specific, 
characterized, pure genes, to explore the regulation of expression of particular 
genes in animal cells. These procedures can be efficient at introducing DNA 
molecules into cells, however the stable association of this DNA with the cell 
is much less probable. When it does occur, stably associated DNA is often 
found actually integrated into the DNA of the recipient cell; how or why this 
occurs is not yet understood. The fact that stable association occurs, even at a 
low frequency, facilitates the study of introduced genes because they remain 
in the cell(s) of interest for prolonged periods. 
37 
3 8 / A . Ullrich 
Insertion of specific genes into the genome of a higher eukaryotic 
organism at an early stage in development could be a promising experimental 
approach to the problem of how the expression of specific genes is regulated 
during mammalian embryonic development. By monitoring the location in the 
DNA of recipient cells into which the foreign DNA inserted, the resulting 
integrity of the foreign DNA after integration has occurred, and any resulting 
expression of the foreign gene in the cells or tissue, one might gain important 
clues towards an understanding of gene regulation during development. Further-
more, this type of effort could lead to the generation of commercially im-
portant animal strains that would be "improved" in their genetic characteristics. 
We were interested in exploring the effect of introduction of the gene for 
a hormone of major physiological importance, the insulin gene, into fertiUzed 
mouse eggs. The human insuHn gene employed in our gene transfer experiments 
had been isolated as described in detail elsewhere (Ullrich et al. 1977; Sures et al. 
1980; Ullrich et al. 1980). Starting with messenger RNA(mRNA) isolated from 
the tissue that produces large amounts of insulin in mammalian organisms (the 
islets of Langerhans), we prepared complementary DNA (cDNA) copies in an 
enzymatic in vitro reaction which were subsequently combined with a bacterial 
plasmid (pBR322) and cloned in Escherichia coli (E. coli) bacterial cells. The 
cloned rat insulin sequences allowed us to then isolate the corresponding human 
cDNA sequences due to the high degree of evolutionary sequence conservation 
between these proteins. Briefly, under certain conditions DNA will bind tightiy 
to other DNA molecules whose sequences are homologous, in a process called 
hybridization. Thus an isolated gene can be radiolabelled and used as a probe 
to detect the presence of other molecules of DNA which are very similar or 
homologous to its own sequence. In this manner, a radioactively labelled human 
insuUn cDNA clone was used to select the corresponding human chromosomal 
gene sequences from a genomic library as described by Maniatis et al. (1978). 
Thus the human insulin gene was isolated, and its nucleotide sequence was 
determined (Fig. 1). 
Restriction endonucleases which cleave DNA at specific sequences 
generate discrete sized fragments after incubation with a particular DNA 
molecule. A procedure called Southern blotting (Southern 1975) enables detec-
tion of fragments of interest in a mixture of fragments generated by restriction 
enzyme DNA cleavage. The fragments are separated on the basis of size, and 
then hybridized with a radiolabelled piece of DNA containing a particular gene. 
Because the fragments are immobilized during the procedure, one can identify 
fragments of a particular size which contain sequences homologous to the radio-
labelled probe. An example of a Southern blot is shown in Figure 2. The dark 
bands represent the binding of a radioactively labelled probe to specific frag-
ments of DNA which contain insulin gene sequences. The lower two bands 
correspond to fragments of mouse DNA containing the mouse insulin gene. 
The upper dark band in lane 5 represents the fragment which corresponds 
precisely in size to that of the injected human DNA fragment containing the 
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Figure 1 
Nucleotide sequence of the human insulin gene and its flanking regions. The sequence con-
taining coding information is translated into the amino acid sequence of preproinsulin 
(upper line). The part of the gene that contains preproinsulin mRNA sequences is inter-
rupted by 2 intervening sequences (boxed areas). Initiation (ATG) and termination (TAG) 
codons are underlined. 
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insulin gene. However, this particular human insuUn gene is quite unique in that 
it was actually carried by the cells of a mouse, throughout development until 
just before birth. After injection of 753 isolated, fertilized mouse eggs with 
about 50,000 molecules of human insuHn gene DNA per egg, culturing the eggs 
in the laboratory, and then reimplanting them for fetal development into the 
uteri of foster mothers, only 60 term fetuses were obtained which had survived 
manipulation and any possible harm this foreign gene might have caused them. 
All 60 fetuses were screened by Southern blotting to identify the presence of 
the human insulin gene. Figure 2, lane 5, shows an example of DNA from 1 of 
2 out of 60 fetuses which could be shown to contain the human insulin gene by 
this procedure. 
We carried out other experiments using a variety of restriction enzymes 
and hybridization probes in conjunction with Southern blotting. These allowed 
us to conclude that the human insulin gene had integrated into the mouse 
genome and had remained intact with regard to its size. We could not detect any 
alterations in the DNA of this gene. Recently others (Constantini and Lacy 
1981; Gordon and Ruddle 1981) demonstrated that an injected, integrated gene 
could be transmitted to second generation mice through normal reproductive 
routes. 
Other workers have successfully carried out similar experiments using 
other genes from higher cells, including those for hemoglobin (Wagner et al. 
1981; Constantini and Lacy 1981), and thymidine kinase (Gordon et al. 1980; 
Wagner et al. 1981; Brinster et al. 1981). We have much to learn about the 
events surroundmg the integration of such foreign genes into recipient cells and 
about the way in which cells control these newly assimilated genes, if at all, 
during embryonic development. However, it is hoped that such experiments will 
shed new l i ^ t on the problems of higher cell gene regulation and development 
and perhaps be beneficial to the needs of our society. 
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Recombinants that are the Same 
But Different 
SYDNEY BRENNER 
Laboratory of Molecular Biology 
Medical Research Council Centre 
University Medical School 
Cambridge CB2 20H, England 
I would like to raise two very general topics before the panel discussion on 
the scientific issues. First, there is a very general point, that there are no 
problems in a purely industrial environment. Here, whether or not things are 
patented is not a scientific decision, but a business decision. This issue has been 
clearly understood in that environment in other fields, and our field will not be 
different from anything that has gone before. 
The new aspect of the situation concerns the potential inventors, who are 
working in institutions that are not in the classic environment of industrial 
activity. These people are in very peculiar situations with regard to that activity; 
they are assuming responsibiUties, or perhaps irresponsibilities, in these matters, 
that are very hard to define. It is important to make that statement very clearly, 
because there is a wide range of institutions that do not conform to the classic 
industrial environment and in which there will be different practices of patenting 
with different consequences for people in that environment. 
This is the issue that I think bothers most people who work in a university 
environment or in a research institution, with or without connections to an 
industry, and who are advised or contractually obligated by their employers to 
patent their inventions, in order to protect them and exploit them. 
In addition, there is the difficulty of activities in different countries. For 
such people, who are not in an industrial environment, conditions in Europe as 
opposed to conditions in America are more stringent. In Europe, prior dis-
closure automatically invalidates any patent. Thus, the inventor must immedi-
ately take up the procedure required to estabhsh the patent at the inception of 
the idea. That will often generate conflicts and difficulties in a nonindustrial 
environment. Scientists want to publish, and they want to talk. In Britain, if 
this concerns a potential patent, pubHcation must be held up because that act 
will destroy the patent's validity. And, if the process of acquiring the patent is 
rather slow, and at the same time, someone in America publishes the same or 
similar data, that will automatically invalidate the patent in Britain. Of course, 
it would not invalidate that person acquiring a patent because of this difference 
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of 1 year, and I think cases have been mentioned. For those of us who have to 
administer this kind of activity, there can be enormous difficulties, and one 
sometimes begins to wonder whether it is worth it in the end. 
The second point, which will bring me back to the scientific issues; is. 
What should one patent? If we are enjoined by our employers, contractually or 
otherwise, to protect inventions that emerge from our laboratories, we need to 
know the answer to this question. I am very reheved to hear that most practi-
tioners in the field don't believe that in this field there will be many differences. 
As far as I understand it, one has to patent either the process or the object by 
its composition and so on. However I should point out that scientific develop-
ments, especially over the last few years, now permit one to make very accurate 
descriptions of materials in the biological field that were not possible even as 
little as 3 years ago. In other words, the sequences of nucleic acid and protein 
molecules can be completely defined, so that one can make a total description of 
the material to distinguish it from all other things. 
Of course, most scientists in the field of biotechnology think that if 
anything is thought up by them, then it is patentable, it is valuable, and it is 
going to earn a lot of money. But the discovery, as you have heard, not only has 
to be new, it needs to be useful. Many things that will be produced will be 
totally useless. In fact, I am often encouraged by the hope that this field will be 
saved for science, because everything that is useful will be unpublishable, since 
journals will not be interested in yet another clone. Perhaps the inverse will 
also be true, namely that everything that is pubUshed in scientific journals will 
be totally useless. I have high hopes. 
Let me begin with chemicals. There are many useful chemicals that many 
people in different areas of biotechnology are interested in producing and using. 
In the last 100 years the whole chemical industry has depended on generating 
these chemicals, which may consist of about 100 atoms. They have been de-
fined very cleariy by formulae, and have been produced in a variety of ways. 
Of course, a large number of these and especially those of high value such 
as antibiotics come from nature. However, even though the methods of produc-
tion are natural these bear no resemblance to the mode of existence in nature, 
because the strains have been improved. A technology has been added. 
Let us just see how the construction of a chemical is done in nature. The 
desirable product, a small molecule, is produced by a chain of intermediates with 
many steps. Ultimately the chain begins with common substances, like sugar or 
ammonia or even hydrogen, carbon dioxide, and nitrogen. Each of the synthetic 
steps is catalyzed by a very specific catalyst, called an enzyme. Thus tiie ele-
mentary constituents are progressively transformed, step by step, by a series of 
enzymes into the final product. The formula of the product is more constrained 
than for an enzyme that has to work on a column or in another microorganism. 
A slight digression-I just had the opportunity of reading the Cohen-
Boyer patent for the first time. I was very interested in it from the point of view 
of one particular important step in tiie process of gene spHcing, and tiiat 
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concerns the reintroduction of the product into the bacterial cell. Note you can 
splice in vitro as much as you like, but the DNA is totally useless; it is as useless 
as a computer program without a computer to put it into. One must have a 
method for loading the bacterium and the patent describes such a method of 
transformation and I was amazed to discover that it did not reference the 
method which was published long ago and which is used here. This is an im-
portant matter. Apart from the intrinsic validity of this step, one could ask 
whether there are valid exceptions which might depend on novel ways of intro-
ducing the DNA into a host cell. Does a better way of doing this give one a valid 
claim on novelty? It is possible, although it may be difficult and expensive, to 
break open the cell an4 reconstruct this pathway in a test tube or a vat simply 
by isolating the enzymes and applying them to the intermediates. The whole 
of biochemistry has depended on the in vitro reconstruction of such a molecular 
plant in the test tube. 
However it should be noted that many of these products are not made this 
way. We either use the whole cell or, we generate these compounds by totally 
man-made pathways. These are organic syntheses that bear no resemblances to 
the natural order because they may exploit other more convenient steps or 
intermediates. We might now ask the following question: Would it be possible 
to mimic the natural pathway by a completely man-made system? The answer 
is yes because, in principle, we could determine the structure of each of the en-
zymes and specify them in the form of an amino acid sequence. With some 
effort, we could actually synthesize the enzymes from amino acids by organic 
chemical methods. It would be very expensive, but the point is we can give an 
exact specification of each of the catalysts. 
Given these steps in this reaction we might now ask how many different 
enzymes are there for a one step? How many compounds can we define that 
would be guaranteed to have the function of converting X to A? There are an 
incredibly enormous number of these. First there are some that may be trivial 
and obvious, different from the enzyme by one or more components. There 
will be others that are totally nonobvious-structurally very different, but still 
guaranteed to perform the same function, and which one could design and 
construct by chemical synthesis. 
Thus, given the function that needs to be performed we can now define a 
set of equivalent elements that would do this. In nature, as you have heard, these 
enzymes are not made by the methods an organic chemist would use, but are 
made by translating a template of nucleic acid, which is an intermediate copy or 
messenger RNA of a gene that carries the specifying information. 
The correspondences between this and the protein chain of the enzyme are 
such that again there is a degeneracy of specification, in the sense that one may 
define yet a greater number of nucleic acid sequences, each of which would 
make exactly the same amino acid sequence, and therefore produce exactly the 
same final function. Some of tiiese variants are trivial but some are not. The 
upshot of tills is that tiie design of a function in biotechnology is implemented 
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through elements each of which can be defined by a sequence, either nucleic 
acid or protein, which can be exactly ascertained in each case, but the numbers 
of instances are absolutely enormous. This is not the end of possibilities. 
Suppose for a function we have defined the gene sequence. We then have to 
load it, so to speak, into an element which has generalized functions for main-
tenance and expression. Again, these can be defined exactly, and again, there are 
probably many alternative structures, some better, some worse, but probably a 
large number, exactly equivalent. 
Then the recombinant itself needs to be enclosed in an organism. It is 
quite conceivable to have an elaborate pathway, each step controlled by an ele-
ment all kept separately in different bacteria and all brought together only at 
the instant of manufacture, by being introduced into a common host, which, 
itself, could be chosen from a wide range of potential microorganisms. 
You may notice that, in principle, everything could be done through the 
medium of chemical synthesis. We have the situation that all we need to have to 
the sequence of the protein, and it could be manufactured by generating a 
plasmid, essentially by a chemical synthesis of a nucleic acid sequence. This has 
been recentiy accompUshed, as sone of you know, by ICI. They did not isolate a 
clone of interferon from nature. They went to the journal Nature and got the 
sequence of the protein interferon, which itself had been deduced from a nucleic 
acid sequence, and then simply synthesized the sequence by chemical methods, 
and generated the same interferon. 
Many scientists have asked whether, given this instance, it is sequences that 
have to be patented or possibly preserved as trade secrets. If you know the 
sequence of a desirable compound and you want to retain control over it, then 
you might do it by never pubUshing the sequence. Publishing that information 
might help others to construct something non-trivially different from yours, 
because of the degeneracy that I have discussed. 
Exactiy how one writes a patent may become crucial. There are so many 
possibihties, which patent writers might have to think about precluding if they 
wish their claims to be compeUing. If you were to claim a method of producing, 
say, human insulin, in bacteria, and you wished to claim all variants of this, 
there is probably not enough paper even in Washington to write down all the 
sequences that you could guarantee would give you insuUn. All would be 
different, by composition, although of course many of them would have trivial 
differences. 
Finally I want to raise a slightiy different view of the new technology and 
its consequences. Using both new and old methods it should be possible to speed 
up evolution in tiie test tube and go through in a few years what might have 
taken 10 billion years to accompUsh in nature, and so produce something that is 
totally new. For example, there may be a desirable enzyme, but it exists only in 
one organism that has a certain habitat. The situation of evolving that particular 
enzyme in anotiier organism with a different habitat has just not arisen in 
nature. However, there is no basic reason why we could not transplant the gene 
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from the existing strain into another, and then let it evolve to adapt to the new 
environment under appropriate selection so that the function is conserved but 
with completely new properties. 
Now, one doesn't have to design this, in fact, it may be difficult to do so. 
We are using a generalized Darwinian process and it is likely that if you did that 
experiment repeatedly it would follow a different path. It is not certain that you 
will always end up with precisely the same composition or sequence, although 
the functional end results might be very similar. Thus it might be very difficult 
to give an accurate prescription of how to make things like this, except by a very 
general outline, although any given end result could be very accurately described 
by sequence. 
I fijid it extremely difficult to know how one would treat a case like this. 
However, you should note that there are constraints beyond function for many 
products which may have to be given to people; in these cases the sequence must 
not only work, but also should not generate an immunological reaction. 
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ZINDER: Today, the scientists have displayed their wares to you, because we 
would like to know, very seriously, what can and what cannot be 
patented. 
The wares in the hybridoma system are primarily two components: 
(1) the myeloma cell line, which produces antibody, and (2) the hyper-
immunized cells from animals that have been immunized with a particu-
lar antigen to which the myeloma line is fused. Cell lines are isolated 
looking for the production of particular antibodies. There are a few special 
procedures and a few different cell lines. But, basically, as Matty Scharff 
already explained that is the hybridoma system. The uses for hybridomas 
are very broad potentially for diagnostics and therapeutics. 
The recombinant DNA system is a bit more complicated. The hosts 
that are commonly used now are our friends E. coli, Bacillus subtilis, 
yeast, and some mammalian cell lines. There are also the vectors which are 
of two kinds: they are either derived from viruses, which can be packaged 
into protein shells so they can be infective, or from smaU-ring plasmids, 
which are self-replicating entities about 1000-fold smaller than the bac-
terial chromosomes, into which you can insert foreign DNA. 
In addition to the vectors, which propagate the DNA, there is the 
foreign gene, the gene that you are interested in propagating or from 
which you want to make a gene product. To make this all go even better, 
there are the regulatory elements, the promoters, from which RNA is 
transcribed, and the ribosome binding sites, which bind the ribosome and 
specify the initiation of protein synthesis. There are also a variety of fancy 
schemes to isolate the particular clones that you are interested in. 
In a sense, these are our wares. Which parts of these procedures and 
components are patentable still completely escapes me . . . for example, if 
you take the protein insulin, which is about 50 amino acids, it turns out 
that the number of DNA sequences that can code for insulin is somewhat 
larger than Avogadro's number (7 X 10^^). That is, you could make that 
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many different DNAs that, because of the degeneracy of the code, could 
make insulin. 
I think one question remains. Of those 7 X 10^ sequences, you 
can't just say they are all equal. What seems obvious to me is that there 
are probably sequences that would work even better than those sequences 
that are currently in use, in man or in E. coli. In years there might be 
some other useful sequences. From these sequences we make a messenger 
RNA, which lives in an environment and has a variety of half-lives and a 
variety of affinities to ribosomes. So I think one of the questions Sydney 
Brenner was raising is that it would certainly be novel and non-obvious 
if one picked out a sequence of insulin which worked several times better 
than the one they now use, for example, at Genentech. What would the 
attitude of the Patent Office be? 
Sydney was absolutely right when he pointed out the potential mess 
there is because the numbers of combinations of things that we can make 
are astronomical, even within a single gene not to mention combina-
tions of genes. 
SCHLICHER: I think Dr. Brenner referred to computer programs and com-
puters at one or two points in his discussion. I think these sequences of 
nucleotides, be they plasmids or otherwise, might be copyrightable as 
computer programs. Computer programs are clearly copyrightable now, 
after the amendments to the Copyright Act in 1980. If they are copy-
rightable, some of the problems that the patent law presents, for example, 
the need to file before you pubUsh, might be obviated. In particular under 
U.S. copyright law, the copyright vests as soon as the work is written 
down, or in this case the computer program is made. Now, it could be 
made on a piece of paper by drawing out the sequence. It could be made 
in the test tube. 
BRENNER: Yes, but you couldn't realize it at that time. 
SCHLICHER: Well, you don't need to realize it. The key to tiie copyright-
ability may well be the fact that more than one sequence of nucleotides 
can end up in the same result, that is, a given protein. 
ZINDER: But is that the same as the problem that we are dealing with? We 
can easily envisage vastiy different syntiieses from different messenger 
RNAs specifying the same protein. That is not the same, just because you 
get the same end product. At least in my head it is not the same. 
SHARP: I don't see a striking difference between that and improvement of a 
process tiiat gives an end chemical product. If you have compound A and 
you make it one way, 2nd tiien anotiier organic chemist makes compound 
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A another way, that is a problem that these patent lawyers have dealt with 
for a long period of time. You file a patent, and then you have to ne-
gotiate with the other people who own the previous patent. I don't see the 
striking difference. I think the striking problem is the diversity of bio-
logical systems. There is going to have to be a lot of Htigation and patent 
law developed to deal with it. But I don't think this example is over-
whelming. 
BRENNER: There is one particular thing in biological systems that differs from 
chemistry, namely that these things are self-copying. If you get a gram of 
insulin, that is it. Then you have to start at the beginning and manufacture 
it. If you have just one molecule of this, that is enough. It can be put 
anywhere, more or less, and it can be fired up as much as you Uke. So in 
that funny sense, it has the feeling of computer software. It can be copied 
using IBM software and loaded into the computer and copied. It may be 
illegal, but it is possible to do. 
I think there is a particular problem about DNA sequences and 
access to them, as there is about cell lines as well, because they are self-
reproducing. That makes it different from an ordinary chemical. 
SHARP: One of the things that David Plant will discuss is the idea of trade 
secrets. My concern about this whole field is not that we are going to get 
into trouble patenting. It is a problem that the development of the science 
in the field is going to be significantiy retarded, because everyone will 
go into the mode of trade secrets. As each of you differ from one another, 
each organism you choose in the laboratory differs from another. If you 
keep doing it frequentiy enough, you are going to have a very specialized 
system that, for some reason or other, some random mutation, is just ideal. 
Now, what do you do? Do you patent it? Or do you just keep it in 
the vat and turn it over? If you keep it in the vat and tum it over, then the 
information that could come from that mutation and advances in other 
people's hands will never be recognized by society at large. 
I think the biggest problem, and the reason patenting biological 
systems and molecular biology has to occur, is that to have this field 
develop rapidly and to realize the benefits of DNA recombinant tech-
nology is going to require protection for commercial development, and not 
what is now stated as the trade-secret mode of dealing with microor-
ganisms. I think it is very important that some workable system develops, 
and I think we should view it in that perspective. 
BRENNER: Can anyone comment on a situation that must have existed 
when the antibiotic companies went into enormous screening programs 
and generated enormous numbers of antibiotics, of which perhaps a 
minute fraction were useful in a commercial sense, and which one 
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knows now, a posteriori, that a large number of them were very im-
portant research tools. What were the guidelines for getting access to 
those compounds? 
DAVIES: They were not patented. 
BRENNER: They were not patented, but how did you find out? 
DAVIES: In general, they were published as biologically interesting material 
that one could work with. In that particular case, since there was no point 
in maintaining them as a trade secret or as a patent, they were just made 
available. 
LASKIN: Is that the concept of publishing useless material? 
DAVIES: Yes, exactly. 
PTASHNE: If that is true, why are big firms so secretive about their strains? 
DAVIES: My sense of that is that they are only secretive about the strains 
that make lots of material for them. You can always get a prototype or-
ganism for any antibiotic. It has to be deposited at the time that a patent 
application is filed. You can get that organism, but you carmot get the 
organism that is currently being used in commercial production. 
PTASHNE: Even though it is protected by a patent. 
UDRY: Yes, for research purposes. 
PTASHNE: Aren't they worried about it going to Europe and being used? 
DAHLING: Usually the ultimate strain used for production purposes is not 
patented. It is usually the first strain, the parent strain, that is patented. 
DAVIES: Everything after that is a trade secret. 
DAHLING: It is a trade secret because if a company has a strain in production, 
the company is concerned about competition. If you make the production 
strain freely available, you are essentially giving your competitors the 
strain on which to base a competitive act against you. It is then kept as 
proprietary information. 
TANENHOLTZ: That would not exclude, tiiough, tiie otiier firm from dis-
covering that new strain by tiiemselves and getting a patent on it, perhaps. 
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SHARP: But when you are dealing with 1000-10,000 different genes, the mu-
tational pathway to get to a high-yielding strain of one form or another 
may not occur in the next 20 years. That is the nature of mutations, which 
are chance occurrences in biological systems; that isn't true in organic 
chemistry or anywhere else. That is why developing patent protection is 
important. 
What are the rights one has under trade secrets? 
PLANT: The remedy for misappropriation is tailored to the situation and is not 
as clear-cut as in the patent law, which is statutorily provided. One of the 
problems with trade secret misappropriation is that frequentiy as a result 
of the misappropriation, there is no longer a trade secret, because it has 
been made public. It may not be made public if the misappropriator keeps 
the trade secret within his four walls, in which case the likely relief would 
be injunctive relief against his using it in perpetuity or so long as the trade 
secret remains such. Coupled with that may be damages for past use, that 
is, the gain or the benefit he enjoyed from the misappropriation. 
If the trade secret has become pubUcly available as a result of the 
misappropriation, there still may be injunctive rehef, but typically it 
would be measured by the so-called headstart period: What advantage did 
he get from taking the trade secret? And how much more rapidly did he 
get into business by having done so than if he had had to do the work 
himself? Or how long would it have taken him to reverse engineer, for 
instance? Also in that case there would be damages. Then if you work 
out some relationship in the future, you may have royalties for the 
future. 
DAVIES: I would like to come back to a question that Sydney raised, re-
garding whether sequences should be patented or whether they should be 
kept as trade secrets. Even if you have a sequence of a viral antigen and 
you patent it, unless you are very careful, somebody can take a part of 
that sequence and not necessarily synthesize it as a form of an oligo-
nucleotide, but synthesize it in the form of a protein, a polypeptide. They 
can then make an antigen, and you can't do anything with it afterwards. 
I think a lot of people are going to be very concerned about what 
they say and perhaps would prefer to keep things as trade secrets in these 
cases, and not pubHsh them in the form of a patent. 
DELLENBAUGH: One of the serious considerations, thinking for a minute 
about monoclonal antibodies, is whether someone can duplicate your 
work by independent research and obtain the same functional material. 
If you make a monoclonal antibody to a certain kind of cell, a T cell, for 
example, and then someone else makes one a littie bit later, the trade 
secret is absolutely no use to you, unless you have the best one. 
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On the other hand, if the patent protection you get is on the very 
monoclonal antibody that you made and the hybridoma that you deposit, 
that is not going to be too much use to you either. But if you can get a 
patent on a class of materials, say, one reactive with an antigen on all 
T cells -
BRENNER: But can you? That is the question. 
DELLENBAUGH: Well, that is the whole thing that has to be answered. 
GOULD: I would just like to point out that these problems were met many 
years ago in the antibody field by use of fimctional language—that is, 
antibodies to a whole variety of different haptenes were successfully 
patented. By successful, I mean that patents were issued. I don't know of 
too many that were actually litigated, put to the ultimate test. But the 
methodology was fairly widespread, used a number of times to get patents 
on antibodies to compound X, compound Y, and so on, and probably 
would also be available to most of the things we are talking about here 
today. 
HOSCHEIT: I think I can answer that in a littie more updated fashion and 
say that, at least in some instances, the U.S. Patent Office is willing to 
consider a claim to an antibody that at least is blocked by your type 
antibody. In other words, the concept would be that you have identified 
a unique antigenic site and that that is your contribution. You have identi-
fied a unique antigenic site on this molecule, and therefore you have led 
the art, so to speak, to this site. Now, whether they use a particular 
hybridoma that you are using to get that antibody or whether they use 
another antibody that would be blocked by it, nevertheless they are 
usurping your discovery and your teaching. At least at the moment, I 
know of an instance in which the Patent Office has accepted that as the 
scope of a viable claim. 
PTASHNE: That can only be tested by experiment. 
HOSCHEIT: By reasonable experiment, that is true. 
ROWLAND: I think that there is not that much difference in a patented ap-
proach and research, in a sense that the first claims we are going to see in 
the next few years are very broad. The person who finds a gene is going 
to express that as a function for making a structural protein. As you nar-
row down, as you find improvements, you will claim those as well. Then 
you have to define the sequence. So we are going from function to se-
quence, from broad definition to very narrow composition. That is pretty 
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much the way chemistry has followed, too. You began by claiming 
relatively broad classes of antibiotics. Then as you modified them and 
showed improvements, you s^ tarted having to detail the structure much 
more closely. So I think we will see the same evolution here. 
But what the surprise is is how broad a claim might be in the initial 
instance. One recent case is antibodies to colorectal tumors. You will 
be defining either the surface antigen or a specific site on that antigen. 
We will see this development going on in the next 5 or 10 years. 
MacPHERSON: I would like to comment just for a moment on the question 
that was asked earlier as to whether or not trade secret protection or 
patent protection would be appropriate. There is one concern that I have 
about trade secret protection and that derives from a pecuhar provision 
in the U.S. patent law, known as 102(g), which provides that any person 
shall be entitled to a patent who has not abandoned, suppressed, or 
concealed the invention. If .a party maintains as a trade secret a particular 
process for developing an antibody or some useful chemical composition, 
and another party, who under the law would have been a subsequent 
inventor, obtains a patent claim covering the process and (or) the product, 
the first party, who has maintained that particular process and (or) pro-
duct as a trade secret, may, in fact—and I don't know the answer to this— 
find himself having to pay royalties to the second inventor. I think that is 
an issue that might be open for discussion. 
EISEN: On the question of trade secrets versus patents on microorganisms and 
related inventions: I think the tide of the new technology may be shifting 
in favor of patents. One of the big problems with microorganisms is that, 
no matter how well you draft the claims there is the big problem of 
proving infringement, forgetting even about the technical. You claim it as 
Streptomyces X; your competitors that are making this are using 5/repto-
myces Y. How do you show that it is different? It is an evidentiary ques-
tion and a very, very tough one. The burden of proof is always on the 
patentee to prove infringement. In the new technology, presumably, you 
will be able to define it structurally. The genes could be sequenced and 
presumably the answer will come out. 
BRENNER: That should be the sentence for patent infringement, that you 
have to go and sequence these. 
PHILLIPS: I would like to ask a very basic question. We keep talking about 
the end product. Not being a microbiologist, I am sort of interested in 
the tools of the trade, so to speak. Are you all looking just at the end 
product? Or are you practicing just old techniques, but in a new environ-
ment? 
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DAVIES: One answer to this is that you are using microorganisms as factories 
to make a product, and this product can be an old product, like an anti-
biotic, or it can be an entirely new product, Uke interferon or human 
growth hormone being made in these microorganisms. 
PHILLIPS: Yes, but I am concerned about all the various steps. There is an area 
of possible patent protection on the techniques for doing each of these 
steps. 
ZINDER: That is covered by the Boyer-Cohen patent. 
PHILLIPS: That is debatable. 
BRENNER: There are many more things than that. 
SHARP: In terms of ongoing research, there are, every day, new methodologies 
for isolating genes and new enzymes being discovered. 
Does every basic laboratory contact a patent lawyer each time 
they discover a new enzyme that might be useful in DNA recombinant 
techniques and the procedures? 
PHILLIPS: It would be nice. 
VOSSIUS: What bothers us is the question. Are your processes for preparing 
new chimeras really reproducible? This, then, answers the question, do 
you have to deposit those things? If you have to deposit these things in a 
public depository and then, after the issuance of the U.S. patent or after 
the German or European publication you have to release it, either under 
the unconditional way or under the expert way, then you are giving away 
something. At this moment, an inventor has no possibility to stop any-
body else from using his invention, only at the stage where the patent is 
granted. The crucial question is, are these processes really repro-
ducible? 
PHILLIPS: When a deposit is made, it is only of the organism. But we also have 
the problem of best mode, right up to the point of the application. If in 
this period you have now got a subsequent strain of this organism that you 
are actually going to put in commercial practice, I question the value of 
your patent, if you ever got it based upon that initial deposit. It seems to 
me you have an element of fraud there. 
DAHLING: The law states you must deposit, in the sense of an antibiotic 
patent, your best producing strain known to Uie inventor at the time of 
filing. At that time, a determination is made as to what is the best strain. 
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and that is the one that must be deposited. After the apphcation is filed, 
assuming there are no additional applications covering the same subject 
matter, there is no obligation to update your deposit. That is, 6 months 
or 1 year after filing, if your inventors derive a better strain, you don't 
have to deposit the better strain. But you always must deposit the best 
strain known to the inventor at the time of filing the U.S. patent applica-
tion. 
PHILLIPS: But wouldn't you logically seek a second apphcation on this next 
strain? 
DAHLING: I would say you wouldn't, because once you deposit the organism, 
anyone can obtain that organism and presumably use it. 
RICH: Not until after the patent issues in this country. 
JOHNSON: You are also patenting a compound, of course, at the same time. 
SCHLICHER: The question is one of enablement. If you can, in your patent 
application, describe how to get to the organism of interest starting from 
a naturally occurring organism, like E. coli K12, and you can describe the 
steps, and the steps are reproducible, and you can end up with the same 
thing, the same end organism, you don't have to deposit anything, because 
you enable the public to practice the invention. The question of repro-
ducibility arises. 
VOSSIUS: I think your aim should be to describe the manufacture of a new 
vector and transformation in such a way that no deposition is neces-
sary, especially in the case of a new gene product. Then you get the 
best protection. Everybody who likes to infringe has to do the job, that is, 
start from pBR322 and complete all the steps. Perhaps eventually he ends 
up with the same system, or an equivalent system. Here we can only hope 
for the help of the courts. If an invention is an important contribution, 
then the scope of protection should be broader. Of course, I am all for the 
doctrine of equivalency, as we have it in West Germany, where the in-
ventor obtains the reward according to the disclosure and according to the 
contribution he made to the pubHc. Then I think your obvious circum-
ventions—your backward engineering, finding other sequences in view of 
the degeneration of the genetic code, these all, in my opinion, are covered 
by the claim, although you gave only one solution. 
ZINDER: From the point of view of the research scientist, can someone tell 
me when, during the patent application process, if it isn't deposited, a 
particular clone becomes available for research purposes? 
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HOSCHEIT: The answer to your question is, not until the U.S. patent issues or 
until the European counterpart apphcation is pubhshed, which would be 
18 months after the filing date. Until then, it is entirely up to the owner 
of the clone. 
LASKIN: Frequently, the owner of the clone, after the filing of the patent 
application, will pubUsh in the scientific Uterature and will make these 
things available to scientists. 
ZINDER: Well, that is what we hope is the case. 
BRENNER: After the application is filed. 
SHARP: We have been talking primarily about the pharmaceutical industry 
making insulin or growth hormone or interferon in bacteria. When you 
start talking about.chemical processes, though I am not an expert on it, 
you deal with metaboHc pathways that might have 50 enzymes involved in 
them; 50 steps, all interacting and feedback regulating. The number of 
possible mutations in that pathway that over-produce, produce a differ-
ent metaboUc state, and produce a different intermediate is just enormous. 
You begin to go through the biology of overproduction and regulation, 
and you isolate strain A, strain B, and strain C, and at the end of 5 or 
10 years of research, you have a collection of strains that allow you 
to ask questions that you can't even conceive of before you start the 
journey. 
Now, if you are an industrial firm and you really are out to pro-
tect your commercial interests, you just hold on to all that. No one 
can duphcate your pathway because it depends on luck and intuition 
and everything else. 
This area of science is important. I think there are going to be 
a lot of commercial appUcations of it and production potential in it. 
To get that out into the pubUc domain as rapidly as possible and yet offer 
protection to the firm that is developing it, I think is going to be very 
difficult. We are thinking much too simply in terms of just taking growth 
hormone and insuUn and making it in bacteria. The biology tends to grow 
on other microorganisms. Once you have one mutant, you isolate a second 
mutant, a third mutant, and you can't go to the fifth mutant unless you 
have the first one. That is the way the field grows-it is inherent. 
BRENNER: I would just like to raise one other point, which refers back to the 
environment under which people are working. I think the issues are very 
different. I cannot conceive of any reasonable way in which someone 
working in a university can keep a trade secret. It is meaningless in that 
conception. 
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WATSON: I can teU you of a university where there are such things. 
BRENNER: If you think of the researcher at the one extreme—if he does 
discover anything that is of potential commercial value—I can only see 
that the most reasonable way for him to do it is to seek patent pro-
tection through his institution or through whatever devices, or quit 
and form four walls in which he can practice trade secrets. 
Then there are people with a foot in both camps, in which there are 
ambiguities about what one does in the university, because I think the two 
extreme environments are very clear to me. 
DAVIES: But don't you think there are a lot of trade secrets in academic 
research anyway? You never teU your hottest competitor what your 
latest mutant is going to do. The point is, I think trade secrets are a com-
mon part of academic Ufe. 
VOSSIUS: But sometimes they are not recognized as such. 
DAVIES: The thing is that there is not a commercial motive behind them; 
there is an academic or scientific motive behind them. 
VOSSIUS: You think your method is trivial to you, but it may, in fact, be a 
trade secret. 
DAVIES: Of course. 
GAYTHWAITE: Sydney, can I answer what you said? You implied that you 
have a choice in a university atmosphere of trade secrets or patents. You 
are doubtful about trade secrets, because you don't think they can be kept 
in a university. I am doubtful whether valid patents can be obtained in 
universities, because I am sure they are being disclosed with no obligation 
of confidence before fiUng. 
PTASHNE: Can we just expand upon this, for those of us who don't under-
stand it in detail? As I understand it, in America you have to disclose 
publicly, and it is open to definition—giving a pubUc talk, etc. But certain-
ly people in your lab can know and they can talk, and you can still apply. 
GAYTHWAITE: Under U.S. law, possibly. Under most other systems of patent 
law, no. If any disclosure is not made in confidence it wiU destroy 
novelty. 
PTASHNE: What does "in confidence" mean? 
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GAYTHWAITE: WeU, if you go up to your mates in the coffee room and say, 
"I have made a wonderful new discovery, but I am not going to teU you 
about it unless you keep it secret," and they say yes, then you have given 
them the secret under confidential conditions, and there is no disclosure 
that would destroy novelty. If, on the other hand, you come racing into 
the coffee room and say, "I found it! I found it," that means it could be 
aU over the country. 
WILLIAMS: That is not true for the United States. 
BRENNER: No, but that is a big difference. 
O'NEILL: I have two comments. One is, it seems that there should be a general 
rule that all disclosures in the coffee room are to be considered confi-
dential. 
But I would like to ampUfy on what Phil [Sharp] was saying and 
point up a specific case. We taUced this morning about ceU fusion in 
making hybridomas. A very, very active area of ceU fusion today is in 
protoplast fusion in Streptomyces and other antibiotic-producing strains. 
I am not a microbiologist active in that area, but my friends in the field 
teU me that vast improvements could be obtained if they could get access 
to the strains that are improved along one particular metaboUc pathway 
and are available in other people's labs-other industrial labs. People have 
been working on improving strains for years. There ought to be some 
mechanism for faciUtating this kind of interchange between these labs. 
The progress could be terrific, and the economic consequences for the 
public benefit could be great. 
ROWLAND: What you would like, of course, is for the industrial research to 
be added to the academic research, since they are going on simultaneously. 
That is not likely to happen. What is likely to happen is that academic 
research wiU continue and expand, presenting more opportunities to grad-
uate students to find jobs, and tiiere wiU be more money being poured in 
from industry. So as far as that is concerned, you are getting more than 
you had, in tiie sense that the academic community will expand. But it 
is very unUkely that industry is going to give you their research. You are 
going to wait for it through tiie patent Uterature or, in some instances, 
where they do provide organisms that tiiey are not interested in using 
commercially. 
Sydney Brenner added an interesting thing I was curious about. 
There is this ambiguity now, where professors are now part of scientific 
advisory boards in numerous corporations. This has created some stresses 
I have been aware of. I would like to hear tiie panel comment on tiiose 
kinds of stresses and how tiiey are being resolved in your laboratories. 
Open Forum on Scientific Issues / 63 
BRENNER: That is very simple in Britain, because we are employed by the 
Medical Research Council. It is not a university. We are under contractual 
obligations to ensure that our results are appUed in the public interest, 
whatever that may mean. There is government machinery set up to do this 
that has a monopoly of the results in the pubUc sector. There has been a 
development recentiy in which a company, CeUtech, has acquired certain 
of those interests from this organization in a particular subfield. We are 
bound contractuaUy to inform them. That has to be administered, and it is 
very difficult. We are bound contractually to inform either CeUtech or 
the National Research and Development Council of any discoveries in the 
lab which, in our opinion, may be of commercial interest. Then they 
have a procedure to take these up, by patenting. 
Now, there are strains involved here, in the sense that one has to be 
frank in this kind of environment. In the end, you cannot be completely 
academicaUy free. If people want academic freedom, they can be assisted 
towards that end in some other place. But I think that is what has to 
be done. This is taxpayers' money, and that is what the rules of the game 
are. There are contractual obligations, and it is very different from a 
university. 
But it has become very difficult to administer this interface, and 
part of the difficulty is the conflict between pubUcation and patent 
appUcation, particularly in Europe. 
CAREY: There has been a lot of experience over the years of academics col-
laborating with industry in a consulting role and in circumstances where 
they make their expertise available. The new situation here is academics 
with really strong financial interests in companies. This is bound to involve 
loss of freedom. It may be willing loss of freedom, but it is loss of 
freedom. The reason is that there is a distinct difference in the way that 
industrial organizations and academic organizations use the information 
which is the product of their research. As far as industrial organizations 
are concerned, they are out to make a product they can seU, and the 
information is a tool of the trade in making that product. In an academic 
organization, their job is actuaUy to generate and disseminate information 
and new knowledge, and the information is the product. 
If you put yourself under the constraint of not disseminating that 
information in order to obtain patents or to hand it over to a company 
you are actually giving up whatever freedom you have, or the component 
of freedom you have, in that part of the work that you do with that 
industrial organization. That is within the Umits of the constraints of 
pubUcation prior to patenting. 
SHARP: Could you explain the difference between that and what a consultant 
is asked to sign in an agreement in terms of confidentiaUty? 
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CAREY: In confidentiality, we would be asking you to keep information that 
we give to you that is ours confidential. That is ours before we give it to 
you. That doesn't necessarily prohibit you—although it may if you are 
wUling to do it—from doing whatever you like with your own information. 
PTASHNE: At places like Harvard and MIT, there is absolutely no question 
of a trade secret or any restrictions. It is actuaUy impossible. My lab is a 
big lab with a lot of students who do a lot of different things, and the 
same is true at MIT. First of aU, doing what you were saying just isn't 
true. If there is anything we claim to be able to do, it behooves us, in 
fact, to have people come to our lab to repeat it, and we expect the same 
of others. The only issue is if a strain is developed and some body wants 
to do an experiment with it before he publishes it, we leave it up to the 
student. He is perfectly within his rights not to send it out. Once it is pub-
Ushed, there is an absolute rule that it has to be sent out. 
Unfortunately, not every academic foUows that rule, but I think 
most do. When companies think that they can make arrangements at 
universities that wiU protect them in some way, it is out of the question. 
I don't see how it could ever be otherwise. 
DAVIES: I think it may be different in European universities, too. 
WILLIAMS: I think the answer to your question is that some universities, as 
contrasted to Harvard and MIT, are less weU funded. 
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" . . . lT]he patentee has produced a new bacterium with markedly differ-
ent characteristics from any found in nature and one having the potential 
for significant utility. His discovery is not nature's handiwork, but his 
own; accordingly, it is patentable subject matter.. ."^ 
That very profound statement by the Chief Justice of the United States Supreme 
Court in Diamond v. Chakrabarty"^ sets the stage for patenting Ufe forms. Today, 
it has become a reality to combine genetic material from one source with that 
from another using recombinant DNA techniques, opening new vistas for 
scientific exploration and an incentive for ingenuity. The natural consequence is 
that patents wiU be sought in this new field; the question arising now is what 
they wiU disclose and cover. 
This paper provides a brief overview of patenting inventions of life forms 
and of related aspects in the patent area. Some earUer developments relating to 
patenting microbiological inventions which led up to the famous Chakrabarty 
case wiU be explored, foUowed by a brief review of this case and its conse-
quences to research and development in genetic engineering and recombinant 
DNA areas and some important legislative developments resultmg from the 
Court's decision. This is followed by a brief review of selected genetic engineer-
ing inventions and related publications on seminal discoveries in this field. 
The subject of trade secret protection, Ucensing, patent validity, and in-
fringement are separate areas which are beyond the scope of this paper. 
JUDICIAL DEVELOPMENTS 
Historical Background 
As with aU things, especiaUy witii life forms, there is a beginning. U.S. patents in 
the microbiology field had their beginning over one hundred years ago. One of 
' Diamond v. Chakrabarty, 447 U.S. 303, 310,206 USPQ 193,197 (1980). 
M47 U.S. 303, 206 USPQ 193 (1980). 
*The views expressed in this paper are those of the author and not necessarily those 
of Exxon Research and Engineering Company or Exxon Corporation. 
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the first patents dealing with microbiology was granted to Louis Pasteur and, 
strangely enough, the patent included a claim to a biologically pure culture of a 
microorganism, that is, a yeast culture as a composition of matter.^ 
Since the granting of that historic patent to Pasteur, hundreds of U.S. 
patents have been issued on microbiological processes.* Although occasionally 
patents covering a microorganism and another material have been granted, rela-
tively few patents have claimed a new microorganism per se, other than Pasteur's 
patent. One explanation is that most microorganisms occur in nature and, as 
such, are not new. Also, most patent attorneys were satisfied with process-type 
patent coverage. 
A new era in patenting microbiological inventions emerged about 30 years 
ago. This began with a historic deposit of a microorganism sample in 1949 with 
the then Northern Regional Research Laboratory of the U.S. Department of 
Agriculture for the microorganism used to make chlorotetracycline.^ This 
deposit ultimately led to a practice of making deposits of microorganisms in 
patent cases where a new microorganism was involved. In the practice which 
developed, the depositor would arrange with the culture depository to main-
tain secrecy until the patent issued. This practice was challenged in the courts 
slightiy over 10 years ago. The U.S. Court of Customs and Patent Appeals 
(CCPA), in a landmark decision approving this practice,*^ set the stage for a series 
of important court decisions on microbiology to foUow,"' ultimately leading to 
Diamond v. Chakrabarty. From time to time, foUowing the historic patent 
deposit for Dr. Duggar's invention, patent appUcants have attempted to claim 
the microorganism per se, particularly where a new mutant was isolated. The 
response witiiin tiie Patent and Trademark Office (PTO) was the poUcy that if it 
is Uving, it is not patentable." 
This PTO poUcy was challenged by two patent appUcants in the CCPA in 
the cases oiln re Bergy^ and In re Chakrabarty,^^ 
'U.S. Patent No. 141,072, granted in 1873 to Louis Pasteur. Claim 2 of the patent 
reads: "Yeast, free from organic germs of disease, as an article of manufacture." 
*See Daus, Bond, and Rose, (1966) "Microbiological Plant Patents" IDEA 10 87 
footnote 36. . . . 
'The late Harvey Edelblute. a patent attorney, deposited the microorganism for 
Dr. Duggar s microorganism that produced chlorotetracydine. 
•/n reArgoudelis, 434 F.2d 1390,168 USPQ 99 (CCPA 1970) 
.-r ''^on'?^?r'f,o;^""'^'"P'^^^^-2«^ 1351,186 USPQ 108 (CCPA 1975)and/nre 
Money. 499 F.2d 1289. 182 USPQ 303 (CCPA 1974) (The court held that the use of a 
hitherto unknown strain in an old process was patentable due to the prior unavailability of 
the strain.). 
• Cellular forms of enzymes were rejected as unpatentable, whereas ceU-free enzymes 
were and still are held to be patentable. enzymes 
'573 F.2d 1031, 195 USPQ 344 (CCPA 1977). 
•°571 F.2d 40, 197 USPQ 72 (CCPA 1978). 
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The patent mvolved in In re Bergy, which related to purified fermentate," 
in legal terms was not much different from Pasteur's patent. 
The now famous In re Chakrabarty case" included a claim to a bacterium 
from the genus Pseudomonas containing at least two stable energy-generating 
plasmids, each having a separate hydrocarbon degradative pathway. Dr. (3iakra-
barty's human-made geneticaUy engineered bacterium was described as capable 
of breaking down multiple components of crude oil. 
In patent circles, these two cases had the drama and suspense of a Perry 
Mason prosecution. Both cases were twice considered by the CCPA,^ ^ and each 
time the court approved the patenting of man-made life forms.^ "^  On each trip 
to the court, the drama and notoriety increased. The cases brought an aware-
ness to the entire patent community (and others) of the possibiUty of patenting 
Ufe forms, per se. Scores of papers were written by legal scholars and journaUsts 
about these cases which contained commentaries extending beyond the narrow 
legal issue of statutory construction before the court to the much more popular 
field of recombinant DNA.^ * In fact, many people were of the mistaken view 
that Dr. Chakrabarty's invention involved recombinant DNA, a view which 
further heightened the notoriety of the Chakrabarty case. 
Diamond v. Chakrabarty 
During the summer of 1979, the Commissioner of Patents and Trademarks, 
Sidney Diamond, prevailed in having the Court of Appeals' decision examined 
by the U.S. Supreme Court.^^ 
This set the stage for even more drama. More legal papers were written, 
scores of articles were written by the popular press, and no less than 9 amicus 
^^In re Bergy, 573 F.2d 1031, 195 USPQ 344 (CCPA 1977). It is historically inter-
esting that Merck's patent on certain purified vitamin Bi, compositions was upheld in the 
face of a product-of-nature attack, even tiiough the composition occurred naturally in im-
pure form. The essence of this decision was the recognition that the natural fermentate was 
quite useless, while the purified patent composition was of great medical value. Merck & Co. 
V. Olin Mathieson Chemical Corp., 253 F.2d 156,116 USPQ 484 (4th Cir. 1958). 
"571 F.2d 40,197 USPQ 72 (CCPA 1978) 
" / « re Bergy and In re Chakrabarty, 596 F.2d 952, 201 USPQ 352 (CCPA 1979) 
"Both Chakrabarty and Bergy made deposits of their isolated strains pursuant to the 
court-approved practice under Argoudelis. 
**5ee, e.g., Whale, A.R. et al. (1979). The Pros and Cons on the Patentability of 
Microorganisms per se. APLA Quarterly Journal 7: Nos. 3 and 4; "The Miracles of Spliced 
Genes," Newsweek (March 17, 1980) pp. 62-71; "The Big IF in Cancer," T/me (March 31, 
1980) pp. 60-66; "Patenting Nature's Secrets and Protecting Microbiologists' Interests," 
Nature 284:590 et seq. (April 17,1980). 
"Diamond v. Chakrabarty, 204 USPQ 608 (1979). Certiorari was granted concur-
rently in the Bergy case. The sole claim in Bergy relating to the "living** invention issue was 
thereafter canceled (the remaining claims being to the process of using the microorganism), 
and Bergy's motion to the Supreme Court to dismiss the Bergy appeal was granted on the 
basis that the issue had been rendered moot. See footnote 61, infra. 
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briefs were filed in the U.S. Supreme Court.*^ While the legal issue before the 
Court remained the narrow one of statutory legal construction, the briefs were 
replete with reference to the new sciences of genetic engineering and 
recombinant DNA. 
On June 16, 1980, by a narrow vote (5-4), the Court struck down the 
erroneous notion of the PTO that there was a patent law distinction between 
Uving and nonUving compositions of matter. Noting that the Constitution 
authorizes Congress broadly to enact patent laws to encourage innovation, 
the majority of the Court was unpersuaded by the PTO's argument that the 
1930 Plant Patent Act provided evidence of Congress' intent to exclude bacteria, 
and presumably all other living things, from patent protection. 
The Court concluded that Dr. Chakrabarty's man-made plasmid-injected 
Pseudomonas was within the framework of the patent laws. Now that the 
Court has spoken, there is no longer a patent law distinction between Uving 
and nonUving compositions of matter as long as they are ^*rruin-rruide." 
Chakrabarty Aftermath 
What does the Court's decision mean to genetic engineering and recombinant 
DNA research and development? 
First, in strictly legal terms, it expands the kinds of patent protection 
available. In some cases, where the process of preparing the new "life form" is 
not patentable because of previous knowledge, or prior publications, the possi-
bility of obtaining any patent may rest on obtaining composition of matter 
coverage. Stated another way, the criteria for obtaining process patents on the 
one hand and composition of matter patents on tiie other are often different 
and mutuaUy exclusive. The composition of matter claims add a new dimension 
to what may or may not be patented. 
Secondly, if a U.S. patent only included process claims, a plagiarist might 
simply practice the process in some other country, and ship the product into the 
United States. The only possible remedy would be with the International Trade 
Commission, but this relief is limited to the case where economic harm can be 
shown to U.S. industry. This may pose difficulties in proof for a university or 
nonprofit organization, particularly in the case of a Ufe-saving drug. The Court's 
decision simply closes up a loophole to the would-be plagiarist by permitting 
composition of matter claims. 
^''Amicus curiae briefs were filed by: (a) American Societi for Microbiology; (b) 
American Patent Law Association; (c) The People Business Commission: (d) Genentech. 
Inc.; (e) The Regents of the University of California; (0 Pharmaceutical Manufacturers 
Association; (g) Leroy E. Hood, Thomas P. Maniatis, Peter S. Eisenberg, The American 
Society of Biological Chemists, The Association of American Medical Colleges, The Cali-
fornia Institute of Technology and the American Council on Education; (h) Dr. George 
Pieczenik; and (i) Cornell D. Cornish. 
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Thirdly, a plagiarist could make the same product by a different process 
and escape infringement of process claims, but not composition of matter 
claims. 
But most important is tiie psychological effect of the decision on the 
business community, that is, those investing capital for research or building a 
plant. Although this effect is hard to measure at this time, it appears to be 
positive, judging from the newspaper and magazine articles about the Court's 
decision. 
Probably more significant than whether life forms are patentable is the 
apparent change in attitude towards patents by the U.S. Supreme Court. The 
Court rejected the argument by the PTO and the government tiiat the Court 
should move cautiously in areas not foreseen by Congress. Prior to the 
Chakrabarty decision, the Court had spoken against patents in several other cases 
and created a legal climate hostile to patents and new scientific developments. 
Although only by a 5-4 majority, the Court firmly held that the patent 
laws are written broadly and that Congress' inabiUty to foresee a given 
technology would not, per se, be a bar to patenting.^* This is a very important 
outcome of the Court's decision. 
Also, this signal for a change continued. In just 2 weeks following the 
Chakrabarty decision, the Court, in another patent case, upheld a patentee's 
right to assert his patent by another sUm 5-4 majority.^ ^ Prior to Chakrabarty, 
the Supreme Court had not ruled in favor of a patent appUcant or patentee in 
15 years. 
'*The present recital of categories in 35 USC § 101, "any new and useful process, 
machine, manufacture, or composition of matter, or any new and useful improvement 
thereof" (emphasis added), has been the same ever since the Patent Act of 1793, except 
for substituting "process" for "art" and defining it (§ 101(b)) to include art. As noted 
by Judge Rich in Chakrabarty II (596 F.2d 952, 201 USPQ 352 (CCPA 1979), for almost 
200 years since, those words have been liberally construed to include the most diverse 
range imaginable of unforeseen developments in technology. Chief Justice Burger was 
mindful of the breadth of § 101, as evidenced by his statement: "Congress employed 
broad general language in drafting § 101 precisely because such inventions are often un-
foreseeable" (footnote omitted) Diamond v. Chakrabarty, 447 U.S. at 316, 206 USPQ 
at 210. 
See the excellent and thorough treatment by H. C. Wegner, "The Patentability of 
'New Manufactures'-The Living Invention, New Manufactures—Encouragement of Pioneer 
Research," 1978 Patent Law Conference Coursebook (BNA) 253-66. (Mr. Wegner has ex-
tensively researched the question while a fellow at the Max Planck Institute for Foreign and 
International Patent, Copyright, and Competition Law, Munich, Germany.) 
See also Wegner, 5 Int'lRev. Indus. Prop. & Copyright L. 235 (1976). 
"Dawson Chemical Co., v. Rohm & Haas Co., 448 U.S. 176, 206 USPQ 385 (1980). 
Dawson involved the right of a patentee to enforce a patent against a contributory infringer, 
the Supreme Court in Dawson accepting judicial legislation in 1952 that had overruled prior 
Supreme Court case law. The Supreme Court subsequently followed Chakrabarty in the area 
of computer software patent protection for industrial processes which are based upon 
computer programs. See Diamond v. Diehr, 450 U.S. 175, 209 USPQ 1 (1981). The 
Supreme Court since that time has refrained from granting a writ of certiorari in any patent 
case. 
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LEGISLATIVE DEVELOPMENTS 
Congressional Action 
The Court's signal for a change in attitude for research and patents did not by-
pass the legislative branch. FoUowing the Court's decision, the Congress passed 
legislation which tends to encourage research and innovation. 
Probably the most significant patent-related legislation enacted for genetic 
engineering research was the Patent Act of 1980,^ which includes uniform 
government patent poUcy provisions. This act, which was signed into law on 
December 12, 1980, after years of effort, unifies the multipUcity of statutes and 
regulations governing the disposition of patent rights in federaUy funded re-
search and development contracts. Under the new law, the government retains 
nonexclusive, royalty-free Ucenses as weU as "march-in" rights to federaUy 
funded inventions. Also, government-owned patents may now be exclusively 
licensed to responsible third parties. In view of the rather substantial federaUy 
funded research grants in genetic engineering and recombinant DNA, this law 
could have a substantial impact, possibly aiding in resolving our country's 
innovation problems.^ ^ This same Patent Act also provides for a new procedure 
whereby anyone can request the PTO to reexamine issued patents. This pro-
cedure seeks to reduce the costs of patent Utigation and to strengthen the pre-
sumption of validity of reexamined U.S. patents. 
Another law, the Stevenson Wydler Technology Innovation Act of 1980," 
which is designed to engage joint university-industry research, seeks to create 
"Centers of Industrial Technology". The Centers would acquire titie to 
inventions from the joint research. Unfortunately, however, this law may be 
treated with "aggressive neglect" by the Reagan administration due to funding 
considerations. 
More recentiy, Senator Mathias and others introduced a biU to permit an 
extension of the 17-year patent grant where government regulatory agencies 
prohibit use of a patented invention for pubUc health and environmental reasons 
during the testing period." This bUl was passed by the U.S. Senate on July 9, 
1981 and a similar biU (H.R. 1937) is pending in the U.S. House of Representa-
tives. 
Another major piece of legislation affecting patents and innovation is the 
U.S. Court of Appeals for tiie Federal Circuit Act.^ * This law, among other 
"(P.L. 96-517) 
" This benefit could be short-lived if a recent proposal by Representative Gore is 
enacted into law which would amend P.L. 96-517 to exclude the exclusive licensing rights of 
federally financed research in the field of recombinant DNA research. 
"(P.L. 96-480) 
"Patent Term Restoration Act of 1981 (S. 255) 
"The bill (H.R. 4482) twice passed both the House of Representatives, on November 
18, 1981 and March 9, 1982, and the Senate (S. 1700), on December 9. 1981, and March 
22, 1982. It was signed into law (P.L. 97-164) by President Reagan on April 2, 1982 The 
new court (named the Court of Appeals for the Federal Circuit (CAFC)) comes into 
existence on October 1,1982. 
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things, merges the CCPA and the U.S. Court of Claims. AU appeals in patent-
related matters and federal contract law will be decided by this new court, 
resulting in more uniformity in these areas of the law. 
One may say that aU this publicity over the Chakrabarty decision has 
contributed largely to pubUc awareness of the importance of innovation in 
general and of biotechnology in particular. 
ADMINISTRATIVE DEVELOPMENTS 
Types of U.S. Patents for Genetic Engineering Inventions'^ 
Against this background of the U.S. Supreme Court's decision in Chakrabarty 
and a new government patent policy which favors genetic engineering research, 
what type of biotechnology inventions can be the subject of a patent or patent 
appUcation? 
Before the specific patents which have been granted are examined, it is 
first important to recognize that one should always be aware of the overaU 
scheme of the processes and products emerging in the field of biotechnology. 
From this scheme, possible patent strategies and competitive advantages derived 
therefrom may be ascertained which otherwise might not be apparent. In the 
field of recombinant DNA technology, for example, the initial consideration is 
the starting materials (and their preparation) which include plasmids and vectors, 
mRNA and DNA preparations, cell lines and microorganisms, and promoters. 
From these starting materials recombinant plasmids and expression vehicles are 
prepared, and through transformation processes recombinant microorganisms are 
formed from such preparations. Finally, on subjecting the recombinant micro-
organisms to expression and fermentation processes, the final protein products 
are produced, which are thereafter generaUy purified and placed into a suitable 
form for commercial sale and use. The further one proceeds to the final end 
product and use, e.g., the recombinant molecules and protein product, the more 
related such process or product is to the actual commercial market. On the 
other hand, the starting materials and their preparation, whUe forming the basis 
for the overaU process and possibly the subject of rather generic patent coverage, 
are generaUy rather removed from the actual commercial market. It is recognized 
that several business market opportunities wiU exist for manufacturing and 
seUing of products such as plasmids. However, these markets wUl very likely be 
limited compared to markets for protein containing products such as enzymes, 
vaccines, hormones, drugs, etc. 
In developing a sound patent strategy, one should not overtook the im-
portance of where each product and process fits into tiie overaU scheme leading 
to tiie final commercial product. In other words, rapid filing of patent appU-
cations or rapid publishing on a piecemeal basis should be avoided. Such a 
"Reference is made to Table 1 (See, Appendbc B) which lists and describes in 
chronological order a number of selected U.S. patents that have issued in the field of bio-
technology in recent years. 
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patent or pubUcation strategy, or lack thereof, may result in loss of patent rights 
on possibly more important inventions which are later developed. Where it is 
essential rapidly to patent or publish the results of research due to competitive 
factors, it is generally advisable not to extend the disclosure beyond what was 
actually performed, since the speculative disclosure may not support the patent 
claim, but on the other hand may defeat a subsequent discovery based on actual 
data.'^ 
Patents in the United States may cover any new and useful process, 
machine, manufacture or composition of matter assuming they meet the 
conditions of novelty'^ and unobviousness.^ For the sake of simplicity in the 
'* It is, of course, true that a U.S. inventor may maintain his application in secrecy 
until the grant date of his patent, and may elect to forfeit his U.S. patent right in favor 
of secrecy. This is a largely theoretical right after 18 months from the filing date, as patent 
applications in Japan and most major European countries are automatically published 
at or shortly after the 18-month anniversary of the date of the first application. Presumably, 
any inventor will wish to patent in Japan and Europe, foreclosing the trade secret elec-
tion route after this time. Early disclosure of the invention before this date precludes 
broadening the scope of the invention in many foreign countries which have the "absolute 
novelty" system; such broadening is precluded in the United States only on the first 
anniversary of the first public disclosure. See In re Ruscetta, 255 F.2d 687, 118 USPQ 101 
(CCPA 1958). 
^'35 U.S.C. § 101. "Inventions patentable. Whoever invents or discovers any new 
and useful process, machine, manufacture, or composition of matter, or any new and useful 
improvement thereof, may obtain a patent therefor, subject to the conditions and require-
ments of this title", (emphasis added) 
35 U.S.C. § 102. "Conditions for patentability; novelty and loss of right to patent. 
A person shall be entitled to a patent unless-(a) the invention was known or used by 
others in this country, or patented or described in a printed publication in this or a foreign 
country, before the invention thereof by the applicant for patent, or (b) the invention 
was patented or described in a printed publication in this or a foreign country or in public 
use or on sale in this country, more than one year prior to the date of the application 
for patent in the United States, or (c) he has abandoned the invention, or (d) the inven-
tion was first patented or caused to be patented, or was the subject of an inventor's 
certificate, by the applicant or his legal representatives or assigns in a foreign country prior 
to the date of the application for patent in this country on an application for patent or 
inventor's certificate filed more than twelve months before the filing of the application in 
the United States, or (e) the invention was described in a patent granted on an appUcation 
for patent by another filed in the United States before Uie invention thereof by the appli-
cant for patent, or on an international appUcation by another who has fulfiUed the require-
ments of paragraphs (1), (2), and (4) of secUon 371(c) of this title before the invention 
thereof by the applicant for patent, or (0 he did not himself invent the subject matter 
sought to be patented, or (g) before the appUcant's invention thereof the invention was 
made in this country by another who had not abandoned, suppressed, or concealed it. In 
determining priority of invention there shaU be considered not only the respective dates of 
conception and reduction to practice of the invention, but also Uie reasonable dUigence of 
one who was first to conceive and last to reduce to practice, from a time prior to con-
ception by the other (Amended July 28. 1972)". 
"35 U.S.C. § 103. "Conditions for patentability; non-obvious subject matter. A pa-
tent may not be obtained thougli the invention is not identicaUy disclosed or described as 
set forth in section 102 of this title, if the differences between tiie subject matter sought to 
be patented and the prior art are such that the subject matter as a whole would have been 
obvious at the time the invention was made to a person having ordinary skiU in the art to 
which said subject matter pertains. PatentabiUty shall not be negatived by the manner in 
which the invention was made". 
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field of biotechnology, these patents faU into two general categories, i.e., 
processes and compositions of matter. 
Process Patents 
In the field of recombinant DNA, several of the early discoveries on the con-
struction of plasmids and vectors were published (Silver and Cohen 1972; Cohen 
et al. 1972; Cohen and Chang 1973; Hershfield et al. 1974; Bolivar et al. 1977), 
but patents on such processes and compositions were not sought. In recent 
years, patents have been sought and obtained on processes for obtaining vectors 
or plasmids.^' Also methods for preparing DNA, RNA, and mRNA preparations 
have become the subject of U.S. patents.^" 
Restriction endonucleases are recognized as being important in a funda-
mental sense in the overall recombinant DNA process. One seminal discovery 
relating to these enzymes was pubUshed by Mertz and Davis (1972) which re-
vealed a novel endonuclease, Eco RI, produced by certain plasmids carried in 
E. coli, but was never patented. (Richard Roberts wrote an excellent and com-
prehensive review of restriction endonucleases [Roberts 1976] and an updated 
list of the known nucleic enzymes can be found in a more recent article 
[Roberts 1982].) Recently however, patents have been granted on modified 
restriction/endonucleases ?^ 
"U.S. Patent No. 4,273,875, granted to J. J. Manis, assigned to the Upjohn 
Company, on June 16, 1981, from an application filed March 5, 1979-Pure culture of 
Streptomyces espinosus NRRL 11439 and plasmid pUC6 produced therefrom. 
U.S. Patent No. 4,322,499, granted to J. D. Baxter et al., on March 30, 1982, 
assigned to the Regents of the University of California, from an application filed December 
22, 197 8-Recombinant DNA plasmid or bacteriophage transfer vector comprising the 
endorphine gene cDNA sequence. 
'"U.S. Patent No. 4,224,408 granted to P. P. Hung et al., assigned to Abbott Labora-
tories, on September 23, 1980, from an application filed November 22, 1978-Deoxyribo-
nucleic acid synthesis by reverse transcription using binding protein. 
U.S. Patent No. 4,262,090 granted to C. Cplby, Jr. et al., assigned to Cetus Corpora-
tion, on April 14, 1981, from an application filed June 4, 1979-Production of mRNA 
specific for mammalian interferon by fusing semi-constitutive and wild type mammalian 
interferon cells. 
U.S. Patent No. 4,283,489 granted to H. M. Goodman et al., assigned to the Regents 
of the University of California, on August 11,1981, from an application filed on August 11, 
1977-Purification of nucleotide sequences suitable for expression in bacteria by subjecting 
DNA to restriction endonuclease enzymes and fractionating the DNA by length. 
U.S. Patent No. 4,293,652 granted to S. N. Cohen, assigned to Cetus Corporation, 
on October 6,1981, from an application filed May 25,1979-Method for synthesizing DNA 
by sequentially building DNA fragments in a cloning vector and foUowed by cloning. 
U.S. Patent No. 4,313,938, granted to H. Arimura et al., assigned to the Green Cross 
Corporation, on February 2, 1982, from an application filed July 28, 1978-Double-
stranded RNA is synthesized using native human DNA as template to provide an interferon 
inducer. 
"U.S. Patent No. 4,064,011 granted to H. Mayer et al., assigned to Gesellschaft fiir 
biotechnologische Forschung mbH, on December 20,1977, from an appUcation filed March 
16, 1977-Process for producing EcoRI restriction endonuclease with E. coli mutants having 
no antibiotic resistance. 
U.S. Patent No. 4,080,261 granted to T. Shibata et al., assigned to Rikagaku Ken-
kyusho, on March 21,1978, from an appUcation filed October 8,1975-Novel endonuclease 
and process for the production thereof. 
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A more recent development in recombinant DNA technology relates to the 
discovery of various promoters and adaptors. Processes for preparing or using 
such promoters and adaptors have only recentiy been patented in the U.S,,^^ 
and based on recent European patent publications in this area,^ ^ it is expected 
that more patents wiU issue on this important part of the recombinant DNA 
process. 
The discoveries relating to the production of expression vehicles and re-
combinant plasmids paved the way for recombinant DNA technology. The early 
work was published in the scientific Uterature (Jackson et al. 1972; SgarameUa 
1972; Lobban and Kaiser 1973) and was not patented. Coupled with this early 
pubUshed work was the discovery that if E. coli were treated with calcium ions, 
phage DNA or plasmid DNA could be taken up by a ceU (Mandel and Higa 1970; 
Cohen et al. 1972). These discoveries culminated in the first complete 
recombinant DNA experiments in which foreign DNA was joined to pSClOl 
DNA, introduced into E. coli, and repUcated many times, and the DNA was 
reisolated, studied, and used for expression of functions by the recombinant 
DNA. The pSClOl plasmid was essential for these early experiments as it was 
self-repUcating and had a single EcoRI site in a nonessential region so that the 
Mertz and Davis joining technique could be used. A key feature in pSClOl was 
its strong selectable marker (tetracycline resistance) which rendered the ceUs 
carrying pSClOl containing the new DNA fragments recognizable. This dis-
covery, first reported at the June 1973 Gordon Research Conference on Nucleic 
Acids (Lear 1978), was subsequently pubUshed (Cohen et al. 1973; Ziff 1973) 
and patented in the United States.^ This patent has been reportedly Ucensed 
"U.S. Patent No. 4,321,365 granted to R. J. Wu et al., assigned to Research Corpora-
tion, on March 23, 1982, from an application filed October 19, 1977-OUgonucleotides 
useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing 
adaptors and adapted molecules. 
"European Patent Publication No. 0,036,776 to D. G. Kleid, D. G. Yansura, H. L. 
Heyneker and G. F. Miozzari, assigned to Genentech, Inc., pubUshed September 30, 1981, 
from an appUcation fUed in the U.S. on March 24, 1980-Tryptophan promoter-operator 
system for plasmidic expression vehicles and use of same for production of polypeptides. 
European Patent Publication No. 0,040,466 to S. A. Narang and R. J. Wu. assigned 
to Canadian Patents and Development Limited, pubUshed November 25, 1981, from a 
U.S. appUcation filed March 27, 1980-Adaptor molecules having start or stop signals for 
protein synthesis in addition to recognition sites for restriction endonucleases. 
"U.S. Patent No. 4,237,224 granted to S. N. Cohen and H. W. Boyer, assigned to 
Board of Trustees of the Leland Stanford. Jr. University on December 2,1980, from a series 
of applications having an original filing date traceable to November 4, 1974. Process for 
producing biologicaUy functional molecular chimeras. 
It is interesting indeed that tiie U.K. Patent No. 1,521,032 (pubUshed August 9, 
1978, from an application fUed August 8, 1974), to D. PioU et al.. assigned to Imperial 
Chemical Industries Ltd., appears to have the earliest effective filing date of an application 
generaUy claiming the recombinant DNA process. A U.S. counterpart to this U.K. patent 
has not appeared to date. Whether any U.S. counterpart to tiiis U.K. patent is now pending 
in the U.S. PTO cannot be determined due to the secrecy restrictions under 35 USC § 
122. 
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to about 73 licensees. Various improvements on the process for forming DNA 
expression vehicles are also being patented.^^ 
Next in the series of processes is the transformation process to produce 
recombinant microorganisms. This process has also been the subject of pubUca-
tions (Curtiss III et al. 1977) and recent U.S. patents.^ 
An extremely important aspect of research in recombinant DNA 
technology is the testing and assay techniques. In recent years several pioneering 
discoveries have been reported in the scientific Uterature, (Sanger and Coulson 
1975; Maxam and Gilbert 1977; Sanger et al. 1977), but were never patented. 
Drs. Gilbert and Sanger won their Nobel prizes in chemistry in 1980 for their re-
spective contributions reported in these articles. Other testing and assay pro-
cedures have been covered by U.S. patents.^'' 
The last synthetic step in the recombinant DNA process is the expression 
step, i.e., the manufacture of the desired protein from the recombinant DNA 
molecules. This is the step in the process which has commercial significance and 
which raised socio-political concerns in the early 1970s. 
The discoveries relating to the expression step tend to focus on a specific 
protein product rather than on a broad principle. Because of this focus on 
marketable products, more patents are expected to be directed to the expression 
step than to other steps of the process. These discoveries are increasingly being 
published in the scientific literature (Cohen et al. 1973; Morrow et al. 1974; 
"U.S. Patent No. 4,264,731 granted to J. Shine, assigned to The Regents of the 
University of California, on AprU 28, 1981, from an appUcation filed May 27,1977-DNA 
joining method by pretreatment to remove 5'-terminal phosphate groups. 
"U.S. Patent No. 4,190,495 granted to R. Curtiss, III, assigned to Research Corpora-
tion, on February 26, 1980, from an appUcation filed September 27, 1976-Modified 
microorganisms (E. co//K-12xl976) and method of preparing and using same. 
U.S. Patent No. 4,237,224 granted to S. N. Cohen and H. W. Boyer, assigned to 
Board of Trustees of the Leland Stanford, Jr. University, on December 2, 1980, from a 
series of appUcations having an original fiUng date traceable to November 4, 1974. Process 
for producing biologicaUy functional molecular chimeras. 
"U.S. Patent 4,038,143 granted to E. Juni, assigned to The Regents of the 
University of Michigan, on July 26, 1977, from an application filed on October 29,1973-
Test kit for. the genetic detection of microorganisms. 
U.S. Patent No. 4,257,774 granted to C. L. Richardson and G. E. Schubnan, assigned 
to Meloy Laboratories, on March 24, 1981, from an application filed July 16,1979-Inter-
calation inhibition assay for compounds that interact with DNA or RNA. 
U.S. Patent No. 4,302,204 granted to G. M. Wahl and G. R. Stark, assigned to Board 
of Trustees of the Leland Stanford, Jr. University, on November 4, 1981, from an appUca-
tion filed July 2, 1979-Analysis of DNA having at least 10 bases by combining a soUd sub-
strate having polynucleotides covalentiy affixed tiiereto witii a hybridization solution con-
taining labeled polynucleotides. 
U S. Patent No. 4,303,752 granted to S. E. Kolehmainen and V. Tarkkanen, on 
December 1, 1981, from an application filed May 3, 1977-Selective determmation of 
nucleotides in viable somatic and microbial ceUs. 
U.S. Patent No. 4,322,497 granted to C. L. Hershberger, assigned to Eh LiUy and 
Company, on March 30, 1982, from an appUcation fUed June 2, 1978-Method of trans-
ducing genetic markers into strains ofE. coli K12xl776. 
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Ratzkin and Carison 1977;ViUa-Komaroff et al. 1978;Martial et al. 1979; BurreU 
et al. 1979) as weU as patented by universities and industrial concerns.^ ® 
A number of patent appUcations are stiU pending which claim the ex-
pression step for producing useful proteins as evidenced by the numerous patent 
pubUcations Usted in Tables 2,3, and 4. 
The final step in the overaU recombinant DNA process involves purifica-
tion and final product formulation. For example, a recent patent has issued on 
extracting interferon from bacteria.^' 
In addition, process patents have been granted on various fermentation 
processes*^ and cloning procedures.'*^ 
Finally, there exists a plurality of patents covering methods of use of the 
biological products. An example of one type of patent relating to interferon 
claims a topical treating method."*^ In the biotechnology field, in general, 
patents have been granted on microbiological processes for producing enzymes*^ 
and processes for producing useful chemical products."^ 
"U.S. Patent No. 4,082,613 granted to M. J. Thirumalachar.M. J. Narasimhan, and 
J. A. Anderson, assigned to the Regents of the University of Minnesota, on April 4,1978, 
from an appUcation filed AprU 23, 1976-Process for the production of insuUn by genetical-
ly transformed fungal ceUs. 
U.S. Patent No. 4,237,224 (Claim 12) granted to S. N. Cohen and H. W. Boyer, 
assigned to Board of Trustees of the Leland Stanford, Jr. University, on December 2.1980, 
from a series of appUcations having an original filing date traceable to November 4,1974-
Process for producing biologicaUy functional molecular chimeras. 
U.S. Patent No. 4,266,024 granted to P. Swetly et al., assigned to Boehringer Ingel-
heim GmbH, on May 5, 1981, from an application filed May 17,1978-Process for the pro-
duction of human interferon. 
"U.S. Patent No. 4,315,852 granted to P. Leibowitz and M. J. Weinstein. assigned to 
Schering Corporation, on February 16, 1982, from an appUcation filed November 26, 
1980-Extraction of Interferon from bacteria. 
*°U.S. Patent No. 3,632,476 granted to J. H. Fried, assigned to Chas. Pfizer & Co., 
Inc., on January 4, 1972, from an appUcation filed May 1, 1969-Method of producing 
citric acid by fermentation. 
*'U.S. Patent No. 3,950,224 granted to C. B. Ward and R. D. Bruner, assigned to 
Cetus Corporation, on AprU 13, 1976, from an application filed September 3, 1974-
Method for cloning filamentous microorganisms. 
"U.S. Patent No. 4.283,393 to A. K. Field and R. J. Harwood, assigned to 
Merck & Co., August 11, 1981. from an appUcation filed March 13, 1979-Treat-
ing virus infection by topical treatment using interferon inducers. 
"U.S. Patent No. 4,259,446 granted to T. Ando et al., assigned to Rikagaku 
Kenkyusho, on March 31, 1981. from an appUcation filed July 28. 1978-Process for 
preparation of deoxyribonucleases by culturing a Bacillus transformant. 
U.S. Patent No. 4,259.447 granted to R. HafeU, assigned to Alpha Patent Limited, 
on March 31, 1981, from an application fUed June 30, 1978-Process for the production of 
urokinase in pure condition. 
"U.S. Patent No. 4,247,641 granted to S. L. Neidleman. W. F. Amon, Jr.. and J. 
Geigert, assigned to Cetus Corporation, on January 27, 1981, from an appUcation filed 
September 8, 1978-Enzymatic production of epoxides and glycols from alkenes 
U.S. Patent No. 4,268,630 to R. N. Patel, C. T. Hou, and A. I. Uskin. assigned to 
Exxon Research and Engineering Company, on May 19, 1981, from an appUcation filed 
April 14, 1978-Microbiological conversion of C,-C, alkanes to ketones using methylo-
trophs. 
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Another important aspect of the genetic engineering field involves mono-
clonal antibodies and hybridoma techniques. SimUar to many of the seminal 
discoveries made in recombinant DNA technology, the basic discovery relating 
to monoclonal antibodies using hybridoma techniques was not afforded patent 
protection due to the eagerness of the researchers to pubUsh the results of their 
important invention as rapidly as possible (Kohler and Milstein 1975; Wade 
1982)! Others, however, have not lost sight of the potential for patenting in this 
growing and important field of genetic engineering."*^ 
Most recently, Cesar Milstein and other researchers have decided not to 
aUow their discoveries to escape patent coverage, as witnessed from numerous 
European patent publications on the subject .'*^  
Composition of Matter Patents 
Similar to the process patents described above, patents covering the composi-
tion resulting from the several steps of the overaU recombinant DNA process 
and other biotechnology processes may be granted in the United States, 
**U.S. Patent No. 4,172,124 granted to H. Koprowski and C. M. Croce, assigned to 
The Wistar Institute, on October 23, 1979, from an application filed on AprU 28, 1978-
Method of producing tumor antibodies. 
U.S. Patent No. 4,196,265 granted to H. Koprowski, W. Gerhard, and C. M. Croce, 
assigned to The Wistar Institute, on AprU 1,1980, from an appUcation tiled June 15,1977-
Process for producing viral antibodies by fusing a viral antibody ceU and a myeloma ceU to 
provide a fused ceU hybrid culture. 
U.S. Patent No. 4,271,145 granted to J. R. Wands and V. R. Zurawski, assigned to 
Massachusetts General Hospital, on June 2, 1981, from an appUcation fUed October 22, 
1979-Process for producing antibodies to hepatitis virus and ceU Uves therefor. 
*«European Patent Publication No. 0,043,718 to C. Milstein and B. W. Wright, 
assigned to National Research Development Corporation, published January 13,1982, from 
an appUcation filed July 7, 1980-Rat myeloma ceU Une which does not express an im-
munoglobulin chain. 
European Patent Publication No. 0,044,441 to C. A. MoUnaro and R. K. Nakamura, 
assigned to Scripps MiUs, Inc., pubUshed January 27, 1982, from an appUcation fUed July 
17, 1980-Monoclonal antibodies to drugs. 
European Patent Publication No. 0,044,710 to R. A. Lerner et al., assigned to Scripps 
Clinic and Research Foundation, published January 27,1982, from an appUcation filed July 
17, 1980-Synthetic specific antigenic determinant from a DNA sequence and method of 
manufacturing antigenic materials therefrom. 
European Patent Publication No. 0,044,722 to H. S. Kaplan and L. Olsson, assigned 
to The Board of Trustees of the Leland Stanford, Jr. University, pubUshed on January 27, 
1982, from an appUcation fUed July 18, 1980-Human-human hybridomas, precursors and 
products, produced by fusing lymphoid ceUs immunized against a predefined determinant 
site with rapidly growing HAT sensitive non-Epstein-Barr virus transformed neoplastic 
lymphoid cell in a fusing medium. 
European Patent Publication Nos. 0,030,449, 0,030,450, 0,030,814, and 0,030,815 
to P. C. Kung and G. Goldstein assigned to Ortho Pharmaceutical Corporation, pubUshed 
June 17, 1981, from appUcations filed December 4, 1979-Hybrid ceU line for producing 
monoclonal antibody to a human thymocyte or prothymocyte, antigen or antibody. 
European Patent Publication Nos. 0,033,578 and 0,033,579 to P. C. Kung and G. 
Goldstem, assigned to Ortho Pharmaceutical Corporation, pubUshed on August 12, 1981, 
from appUcations filed January 8, 1980-Hybrid ceU Unes for producing monoclonal anti-
body to human T ceU or human monocyte antigens or antibody. 
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assuming such compositions meet the conditions of novelty and unobvious-
ness ."^ ^ FoUowing Diamond v. Chakrabarty, there is no patentable distinction 
between living and nonliving compositions. 
In the field of recombinant DNA technology, U.S. patents have issued 
claiming vectors or plasmids, per se,^ synthetic RNA,*' restriction endonucle-
ases,^° and promoters or adaptors useful in DNA cloning.^* 
From an inspection of the claims of numerous European, United Kingdom 
(UK) and Patent Cooperation Treaty (PCT) patent pubUcations that have ap-
peared, it is evident that numerous patent appUcants are attempting to obtain 
composition of matter coverage in each of these important areas (See Tables 2, 
3, and 4 ) . " 
"35 USC § § 101,102 and \OZ.See footnotes 27 and 2%, supra. 
"U.S. Patent Nos. 4,273,875 and 4,322,499; see footnote 29, supra. It is interesting 
to note that U.S. Patent No. 4,273,875 claims the plasmid by reference to the restriction 
sites on a drawing of pUC6. Claim 1 specificaUy states: 
1. EssentiaUy pure plasmid pUC6 which is characterized by a molecular weight of 
approximately 6.0 megadaltons, and a restriction endonuclease cleavage map as shown in 
the drawing. 
(9.0) Xho I 
Bglll (0.0/9.2) (8.9) Bel I ^ O ^ / 
II (0.6) 
(8.0) Bel I 
(7.4) Pvu II 
(7.0) Xho I 
(6.9) Pvu II 
(6.2) Pvu II 
Bel I (3.8) 
49] 
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'U.S. Patent No. 4,313,938;see footnote 30, supra. 
'U.S. Patent No. 4,080,261;see footnote 31, supra. 
" U.S. Patent No. 4,321,365;see footnote 32,supn. 
"For example, 
Biogen's European Patent PubUcation No. 32,134 claims a DNA sequence having 
specified DNA inserts which are capable of expressing for a polypeptide having immuno-
logical or biological activity. 
G. D. Searle's U.K. Patent Publication No. 2,052,516A claims a plasmid as: 
A plasmid having an insertion site for a eukaryotic DNA fragment adjacent to a bac-
terial promoter and downstream from a prokaryotic ril>osome binding site and initia-
tor coder such that the bacterial promoter controls transcription and translation of 
an inserted DNA fragment. 
Biogen's European Patent PubUcation No. 41,767 claims a vector as: 
A vector comprising at least one DNA sequence comprising at least one promoter and 
operator derived from bacteriophage, characterized by at least one endonuclease 
recognition site located less than about 300 base pairs from tiiat portion of said DNA 
sequence comprising said promoter and operator. 
European Patent Publication No. 3,062 to UhUn et al. claims a pUsmid as: 
A plasmid showing a controlled constant plasmid copy number when host bacteria 
carrying the plasmid are cultivated at one temperature and showing, when tiie host 
bacteria carrying the plasmid are grown at a different temperature, an altered plasmid 
copy number control aUowing a much higher or totaUy uncontrolled copy number 
Patenting Overview / 81 
Composition of matter patent claims may also include recombinant 
plasmids. The most recent U.S. patent is derived from the eariy patent filing of 
Cohen and Boyer.^ ^ 
U.S. patents have issued claiming the host organism containing genetical-
ly engineered plasmids or synthetic DNA. The landmark patent on this subject 
is the patent involved in Diamond v. Chakrabarty.^ 
As witnessed from published patent applications,^^ attempts are being 
made to patent transformed hosts per se containing plasmids. 
Also, U.S. patents covering new host components suitable for host-vector 
systems are being granted.^* 
The final protein product resulting from the expression step may be 
patented and activity in obtaining patents on such products is evident from 
"U.S. Patent No. 4,339,538 granted to S. N. Cohen and H. W. Boyer, assigned to 
Board of Trustees of the Leland Stanford, Jr. University, on July 13,1982, from U.S. Serial 
No. 959,288, fUed November 9, 1978, and derived from earlier filed applications fUed on 
May 17, 1976 and November 4, 1974-"Biologically Functional Molecular Chimeras". 
Claims 1 and 19 of this patent read: 
1. As a composition of matter, a biologicaUy functional recombinant plasmid 
capable of selection and repUcation in a uniceUular microorganism ceU com-
prising: 
a first DNA segment containing an intact replicon recognized by said ceU 
derived by cleaving a virus or plasmid compatible with said cell at other than the 
repUcon site, which segment is covalentiy joined in vitro at its ends to the 
complementary ends of a second DNA segment foreign to said ceU having at least 
one intact gene, said second DNA segment derived from a source which does not 
exchange genetic information with said ceU. 
19. As a composition of matter a biologicaUy functional recombinant plasmid having 
been cloned at least once and capable of selection and repUcation, said plasmid 
having first and second Unear segments, wherein said first segment has an intact 
repUcon recognized by a uniceUular microorganism host and said second segment 
is a gene derived from a source which is foreign to and does not exchange genetic 
information with a said host. 
"U.S. Patent No. 4,259,444 granted to A. M. Chakrabarty, assigned to General 
Electric Company, on March 31, 1981, from an appUcation filed June 7, 1972. Claims 1 
reads: 
1. A bacterium from the genus Pseudomonas containing therein at least two stable 
energy-generating plasmids, each of said plasmids providing a separate hydro-
carbon degradative pathway. 
'^European Patent PubUcation No. 0,001,929 to K. Itakura and A. D. Riggs, assigned 
to Genentech, Inc., published May 16, 1979, from an appUcation filed November 8 ,1977-
Plasmid for transforming bacterial host to render it capable of polypeptide expression. 
European Patent PubUcation No. 0,021,468 to J. P. M. Sanders and A. J. P. 
Docherty, assigned to Gist-Brocades N. V., pubUshed January 7,1981, from an appUcation 
fUed May 11,1979-Plasmid, host containing it, its preparation and use. 
" U.S. Patent No. 4,302,544 granted to F. E. Young, G. A. WUson and S. L. Mottice, 
assigned to University of Rochester, on November 24, 1981, from an appUcation fUed 
October 15, 1979-Asporogenous mutant of B. subtilis for use as a host component of 
HVI system. 
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an inspection of the claims of numerous pubUshed European patent appUca-
tions." 
It is anticipated that chemical derivatives ofrecombmant DNA expression 
products wiU be the subject of patents in the future just as in the case of 
chemicaUy modified penicillin, tetracycUne, prostaglandin and cephalosporin 
compounds.^ ® Also, these expression products may be combined with other 
active or inert materials.^' 
Beyond the geneticaUy engineered microorganisms which were clearly de-
clared as patentable subject matter under 35 USC Section 101 in Diamorui 
V. Chakrabarty, there remained for a brief time the question of whether bio-
logicaUy pure cultures of a microorganism were patentable.^ 
The Bergy case never reached the U.S. Supreme Court, as the owner of 
the patent appUcation, through his attorney,^^ withdrew the composition of 
matter claim before the issue could reach the Court for disposition. 
"European Patent PubUcation No. 0,035,454 to R. Crea and R. B. Wetzel, assigned 
to Genentech, Inc., published September 8, 1981, from an appUcation filed February 28, 
1980-Claim 1 recites: 
1. A polypeptide having the formula, proceeding from the N-terminal to carboxy-
terminal end, of: 
NH,-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-
Leu-Lys-Glu-Lys-Glu-Glu-Val-Val-Glu-Glu-Ala-Glu-Asp-COOH. 
European Patent PubUcation No. 0,042,246 to L. P. Guarente, M. Ptashne, T. M. 
Roberts, and T. Taniguchi, assigned to President and FeUows of Harvard CoU^e and Cancer 
Institute of Japanese Foundation for Cancer Research, published December 23. 1981, from 
an appUcation filed June 12,1980-Claim 1 recites: 
1. Unglycosylated human fibroblast interferon. 
European Patent Publication No. 0,043,980 to D. V. N. Goeddel and S. Pestica, 
assigned to Genentech, Inc. and F. Hoffrnan-La Roche & Co., pubUshed on January 20, 1982, 
from an appUcation filed July 1,1980-Qaims 3 and 25 recite: 
3. A polypeptide comprising the amino acid sequence of a mature human leukocyte 
interferon, containing the amino acid methionine attached to the N-terminusof 
the ordinarily first amino acid of said interferon. 
25. A DNA sequence coding for human leukocyte mterferon A (LeIF A). 
Claim 50 recites: 
50. A composition of matter comprising a therapeuticaUy active fraction of a poly-
peptide consisting essentiaUy of the amino acid sequence of a mature human 
leukocyte interferon, the balance of said composition comprising soluble micro-
bial protein from which said polypeptide may be purified to a d^ree sufficient 
for effective therapeutic appUcation. 
*"5ee, for example, U.S. Patent Nos. 3,134,774, 4,261,885 and 4,302.541 as de-
scribed in Table J, 
"5ee, for example, U.S. Patent Nos. 4.252.791; 4,259,444 (claims 14 and 15 
(straw)); 4,259,445; and 4,276,381 as described in Table 1. 
*°This was the issue in In re Bergy, see footnotes 9, 11. and 13, supra. The CCPA 
held that Bergy's claim to a biologically pure culture was patentable subject matter because 
such compositions were developed by man's intervention and therefore were within the 
statutory classes of subject matter which can be patented under 35 USC § 101. 
*' Both the Chakrabarty and Bergy patent appUcations were originaUy before the U.S. 
Supreme Court. However, just prior to the filing of tiie Government's Brief, Harold C. 
Wegner, Counsel for Bergy's assignee, filed an amendment in the appUcation canceUng the 
composition of matter claim and fUed the appropriate motion to vacate the case from the 
Court's docket. 
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FoUowing the Chakrabarty decision, the PTO issued administrative guide-
lines for claims directed to compositions of matter involving microorganisms," 
thereby permitting the patenting of life forms, including claims of the type in-
volved in the Bergy case. Since promulgation of these guidelines, the PTO has 
granted numerous patents claiming various biologicaUy purified cultures.^^ 
It is interesting to note that prior to Chakrabarty, the PTO from time to 
time had granted patents to Ufe forms. A particularly interesting patent in this 
category claimed an isolated maize seed displaying genie male steriUty.^ It 
remains to be seen how the PTO and the courts wiU treat attempts to patent 
higher life forms and how or if they wiU make a patent distinction between 
genetically engineered plants or seeds and the types of plants aUowed to be 
covered in plant patents.*^ 
As many observers expected, the U.S. Supreme Court's decision in 
Chakrabarty has recentiy infiuenced the Canadian Patent Office in grantmg 
composition of matter clauns to Ufe forms.^ ^ Similarly, the Japanese Patent 
Office has recentiy decided to grant patents covering microorganisms. Thus, the 
U.S. Supreme Court, while ruUng on a narrow issue, has had a broad impact 
internationaUy on the entire field of biotechnology. 
U.S. Patent Application Disclosure Requirements 
For Biotechnology—Related Inventions 
Description Requirements 
AU U.S. patents must comply with the specific disclosure requirements of 
35 USC Section 112.*'' In essence, the U.S. appUcation as filed in the PTO must 
"997 OG 24, August 26,1980. 
"5ee, for example, U.S. Patent Nos. 4,248,970 (the first post-Chakrabarty composi-
tion of matter patent to issue); 4,259,451; 4,263,404; 4,266,034; 4,266,035; 4,286,059; 
4,292,406; 4,292,407; 4,293,651; 4,294,929; 4,296,203; 4,302,544 and 4,306,028, aU of 
which are described in Table 1. 
"U.S. Patent No. 3,861,079 granted to E. B. Patterson on January 21, 1975, from 
an appUcation filed AprU 21,1971. 
"Compare 35 USC § 161. 
'* Decision of the Commissioner of Patents in the Canadian Patent Office in an appU-
cation by J. E. Zajic et al., assigned to Abitibi Company (Serial No. 257,177), decided 
March 18,1982. 
*' 35 USC § 112 provides m the first and second paragraphs: 
The specification shaU contain a written description of the invention, and of 
the manner and process of makmg and using it, in such fuU, clear, concise, and 
exact terms as to enable any person skUled in the art to which it pertains, or 
with which it is most nearly connected, to make and use the same, and shaU 
set forth the best mode contemplated by the inventor of carrying out his 
invention. 
The specification shall conclude with one or more claims particularly pointing 
out and distinctiy claiming the subject matter which the appUcant regards as 
his invention. 
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include (i) a complete written description of the invention, (u) the exact terms 
as to enable any person skiUed in the art to which it pertains to make and use 
the invention, and (in) the best mode contemplated by the inventor. 
In the field of biotechnology, particularly where microorganisms are in-
volved, special disclosure requirements are frequentiy required to order to 
comply with 35 USC Section 112. Where a weU known and freely available 
microorganism, plasmid, vector or host is involved, it is generaUy sufficient to set 
forth that the microorganism is known and to describe its characteristics and in-
clude reference to its characterization in the technical Uterature and (or) patent 
art. However, if the microorganism, plasmid, vector, or host is newly isolated, 
novel, or man-made, special description and deposition of a sample of the 
organism or material may be necessary in order to comply with 35 USC Section 
112. It is suggested in such cases that the description include some or aU of 
the foUowing: 
(1) Characterization of the microorganism by genus and species, or by 
the genus and species which the microorganism most closely resembles, or 
in the case of a plasmid or vector, by the classical accepted name for such 
material. 
(2) A detaUed description of how the organism or plasmid or vector was 
obtained, where it was isolated (in the case of a microorganism) or how it was 
modified (in the case of mutations or genetic modification). 
(3) A morphological description of the organism including its shape, the 
nature of colonies formed and its behavior in various environments and media, 
pigments, etc. 
(4) MetaboUc characteristics of the organism, including growth and energy 
compositions and environment. 
(5) Effect of various external factors on the organism, plasmid or vector 
such as resistance to antibiotics (restriction sites in the case of plasmids) and 
abUity to grow in the presence of antibiotics and (or) metals. 
(6) Suitable growth conditions, such as media. pH, temperature, vitamins, 
etc. 
(7) A description of how to put the organism into use, i.e., the details of 
the process by which the desired product (e.g. amino acid, protein, antibiotic, 
chemicals, etc.) is produced. For example, tiie description should include the 
processing parameters, starting materials, media used, etc. 
(8) A description of a utility for tiie invention. In the case where a known 
useful product is prepared, e.g. known proteins, alcohols, amino acids and tiie 
like, a simple disclosure recognizing this fact is all tiiat is necessary. On the otiier 
hand, where the product itself is believed to be novel, it is necessary to describe 
the characteristics of the product produced to tiie extent possible and tiie use(s) 
for the product. In some cases, particulariy in tiie field of biologically active 
materials, in vitro testing data may be required. 
Patenting Overview / 85 
Deposition of Organism, Vector, Vector Host or Recombinant Host 
Under the first paragraph of 35 USC Section 112 a patent applicant must 
also provide a written description in the patent appUcation that is adequate 
to enable any person skilled in the relevant art to make and use the invention. 
When the invention involves or requires the use of an organism, plasmid, vector, 
host or recombinant host that is hoVel in its own right or not available to such 
persons skilled in the art, a detailed description as suggested above may not 
enable those skiUed in the art to reproduce the invention unless the organism, 
plasmid, vector, host or recombinant host is physically made avaUable to such 
person. A simUar situation has existed between scientists whereby such or-
ganisms, etc. are exchanged (on an informal basis) upon request when the or-
ganism has been described in a pubUcation. 
Prior to 1970 the PTO attempted to require aU patent appUcants with 
claims involving microorganisms which were not known or avaUable to the 
public to first deposit a culture of the microorganism in a depository to which 
the public had free access as of the date of filing of the application. This ad-
ministrative ruling was overruled by the CCPA.^ * In the Argoudelis case the 
court held that the microorganism need not be made freely available to the 
general pubUc at the time of patent filing; the deposited culture need only be 
made avaUable on the granting of the U.S. patent. Following the Argoudelis 
decision, the PTO established procedures for the deposition of microorgan-
isms.^' The PTO-imposed requirements for deposition of microorganisms are: 
(a) The applicant, his assignee or legal representative must deposit a 
culture of the microorganism in a pubUc depository by the effective fiUng date 
of the U.S. patent application. A foreign applicant must have made the deposit 
as of the filing date of the previously filed foreign appUcation in order to obtain 
the right of priority under 35 USC Section 119 on the foreign filing date, 
since under Section 119 the U.S. effective filing date of a convention-filed ap-
plication is the foreign priority date.''® 
*"/« re Argoudelis, supra.; see footnote 6. 
"886 OG 638 (May 25, 1971) and § 608.01 (p) of the Manual of Patent Examining 
Procedure. 
'"Some commentators (see Waddel A. Biggart, 1981, "PatentabiUty in the United 
States of microorganisms, processes utilizing microorganisms, products produced by micro-
organisms and microorganism imitational and genetic modification techniques" IDEA, 22(2) 
113-136, at page 123) are of the view that a culture deposit may be made at any time prior 
to the issuance of the U.S. patent, citing In re Fouche, 439 F. 2d 1237, 169 USPQ 429 
(CCPA 1971), Feldman v. Aunstrup, 517 F. 2d 1351,186 USPQ 108 (CCPA 1975), and/« 
reArgoudelis, 434 F. 2d 1390, 168 USPQ 99 (CCPA 1970), (Baldwin, J., concurring). The 
Fouche case is, however, a double-edged sword. In Fouche, there was an incorporation-by-
reference of vital material to make the novel compounds claimed in the appUcation, the 
incorporation-by-reference being to a copending and commonly owned appUcation. Absent 
a successful incorporation-by-reference of that patent appUcation, the invention was unsup-
ported under 35 USC §112. An amendment adding reference to the serial number was 
found to be permissible in Fouche because the appUcation was already fuUy incorporated by 
reference in the application as filed with sufficient information (Continued on Page 86) 
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(b) Restrictions on access to the deposited sample must be irrevocably re-
moved by the applicant or his assignee or legal representative, upon granting of 
the U.S. patent. This may be accomplished by expUcitly incorporating such a 
provision into the contract between the appUcant, or his assignee or legal repre-
sentative, and the culture depository relating to the deposit of the organism. 
The contract between the applicant and the depository may state that the 
culture is being deposited on a permanent basis in connection with the filing 
of the U.S. patent appUcation and will require adherence to the PTO regula-
tions pertaining to secrecy of pending appUcations,^ * which secrecy would be 
waived upon granting of the U.S. patent on his appUcation. 
(c) Name and address of depository and the accession number identifying 
the appUcant's outline. 
(d) An averment by the applicant or his assignee or legal representative 
assures the unUmited and permanent public avaUabUity of the deposited culture, 
subject to the granting of a patent on the appUcation, during the 17-year life of 
the U.S. patent. 
(Continued from Page 85) (example number, identification of the material disclosed in the 
copending appUcation, etc.), i.e., the original specification fuUy "fingerprinted" the identity 
of the earlier appUcation, so that adding the serial number was permitted. By analogy to 
Fouche, if a sample of a plasmid had already been deposited with the ATCC but the acces-
sion number was unknown at the time of filing the patent appUcation, the identity of the 
deposit could be "fingerprinted" by referring to the transmittal letter forwarding the 
deposit to ATCC, together with the name given the deposit and the date of mailing the 
sample. This information surely would "fingerprint" the identity of the plasmid sample and 
under Fouche the addition of the ATCC number after the fiUng date of the U.S. patent ap-
plication would not be new matter. Fouche clearly does not hold that a deposit can be filed 
after the U.S. fiUng date; Feldman also does not stand for this proposition, involving the 
question of release of secrecy restrictions after the filing date, where the microorganism 
sample was on file as of the filing date. Argoudelis, of course, involved a simUar issue of 
when secrecy restrictions on a deposit must be waived, the deposit in Argoudelis having also 
been made prior to the fUing date. That Argoudelis and Fouche do not necessarily lead to 
the conclusion that post-fiUng deposits are acceptable is seen from In re Hawkins, 486 F. 2d 
569, 179 USPQ 569 (CCPA 1973), In re Hawkins, 486 F. 2d 579, 179 USPQ 163 (CCPA 
1973). 
There is authority that the specification of a patent appUcation must be "enabUng" 
and describe "the best mode" (including the deposit of iiiicroorganisms, plasmids, hosts, etc. 
in a recognized depository) as of the effective filing date of the patent appUcation. See, for 
example, Ex parte Moersch, 104 USPQ 122 (PTO Bd. App. 1954); Ex parte Bickel, 122 
USPQ 27 (PTO Bd. App. 1957); Merck & Co., Inc. v. Commercial Solvents Corp., 222 F. 
Supp. 318, 140 USPQ 172 (DC,Md. 1964), Ex parte Kropp, 143 USPQ 148 (PTO Bd. App. 
1959); Merck & Co., Inc. v. Chase Chemical Co., 273 F. Supp. 68, 155 USPQ 139 (DC, 
Md 1967); Ex parte Argoudelis et al. 157 USPQ 437, 441 (PTO Bd. App. 1966, 1967);/« re 
Interference A v. B v. C 159 USPQ 538 (PTO Bd. Int. 1967); Tabuchi and Abe v. Nubel, 
I itts and Lorenzo 194 USPQ 521 (CCPA 1977);/« re Strahilevitz. —F.2d—. 212 USPQ 
561 (CCPA 1982). 
•" 37 CI R § 1.14 provides that, "except (for reissue applications and applications for 
which secrecy has been waived by tiie applicant] . . . pending patent appUcations are pre-
served in secrecy." 
In the case of deposits required for obtaining patents in foreign countries where there 
is automatic publication, the foreign patent offices should restrict access of patent deposits 
to the patent office and third parties who have a bona fide stake in the involved appUcation, 
e.g., those who file an opposition. If such were the case, many patent applicants might not 
be as reluctant to make deposits in patent cases. 
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(e) It is generally good practice for the applicant to include a statement 
under oath or declaration (under 35 USC Section 115) that the microorganism 
has been deposited, that the restrictions on access wiU be removed after the 
patent issues, and that the culture wiU be maintained during the Ufe of the 
patent. 
Following the Argoudelis case there was concern as to which depositories 
would comply with the PTO regulations. This is no longer a concern in view of 
the Budapest Treaty on the International Recognition of the Deposit of the 
Microorganisms for the Purposes of Patent Procedures.^^ The United States, 
Spain, West Germany, United Kingdom, Switzerland, U.S.S.R., Philippines, 
Liechtenstein, European Patent Commission, Bulgaria, France, Hungary, and 
Japan have become signatories to the Budapest Treaty. 
Under the Treaty, the U.S. Commissioner of Patents and Trademarks, 
representing the United States, is authorized to designate one or more micro-
organism depositories within U.S. territory to serve as international depository 
authorities. An international depository is authorized to receive and maintain 
deposits, and to dispense samples of such deposits, in accordance with the 
patent laws of each signatory state and the Treaty provisions. 
A memorandum issued by the World Intellectual Property Organization'^ ^ 
states that an international depository authority must meet certain requirements 
to achieve and maintain its status as a reception, storage and dispensation agency 
under the Treaty. For example, an intemational depository authority must be 
able to store deposited microorganisms in a viable condition for at least 30 years 
or until 5 years have elapsed from the last request for a microorganism sample, 
whichever is later. Storage must be under conditions that minimize risks of 
contamination and loss. Further, the depository must comply with the standards 
of reception, viabUity testing and secrecy imposed by the Treaty. The legal 
status of an institution applying for depository status under the Treaty, i.e., 
whether public or private, is irrelevant, provided that the prequisite of the 
Treaty are satisfied. 
The U.S. Commissioner of Patents and Trademarks accepts requests from 
private and public depositories located in the United States to serve as inter-
national depository authorities. At the present time, the American Type Culture 
CoUection (ATCC) in RockviUe, Maryland, the Agriculture Research Culture 
CoUection (NRRL) in Peoria, Illinois, Centraalbureau voor Schunmel-cultures 
(CBS) in the Netheriands, the German Institute for Microorganisms (DSM), and 
"961 OG 21-28 (August 23, 1977) The Budapest Treaty came into force on August 
19, 1980. Also see, 40 Fed. Reg. 61,009 (1980). The Budapest Treaty is directed to 
microorganism deposits, and there is some question whether from a technical standpoint a 
plasmid (for example) comes within the literal scope of the treaty. Early indications from 
the major Patent Offices of the world appear to indicate the Budapest Treaty may be used 
for genetic engineering deposits. It is to be noted that the Budapest Treaty permits the ap-
plicant to have certain depositories recognized for international treaty rights. To the extent 
that the U.S. government interprets the Budapest Treaty as covering genetic engineering 
deposits and the other major foreign Patent Offices do the same, there is no need for any 
revision of the Budapest treaty to explicitly cover plasmid deposits. 
" 4 0 Fed. Reg. 61,004 (1980) 
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the Fermentation Research Institute (FERM) in Japan have been granted status 
as recognized international depositories under the Budapest Treaty. The ATCC 
and Pasteur Institute have indicated that they accept plasmids. Other deposi-
tories may not accept plasmids at this time. FERM is a most important deposi-
tory in the world scheme of things in view of the importance of Japan in this 
field, being an arm of the Japanese government. FERM has been a required de-
pository for patent filings prior to the Budapest Treaty. Japan also has the Inter-
national Fermentation Organization (IFO)in Osaka, a private group not official-
ly recognized for Japanese filings but which meets U.S. case law standards. Its 
position on plasmid deposits is not clear at this date. 
Any depository, public or private, wUl Ukely satisfy PTO standards if it 
contracts with a U.S. patent appUcant, or his assignee or legal representative, to 
maintain a viable microorganism culture generaUy for at least the effective life-
time of any U.S. patent which would issue on the microorganism-related inven-
tion, and to dispense samples of the microorganism on request to the pubUc 
after granting of the patent. Deposition with foreign depositories such as CBS 
and FERM is considered acceptable under U.S. law. A copy of the form sug-
gested by the ATCC under the Budapest Treaty is provided as Appendix A. 
The question whether one must make a deposit of plasmids or vectors or 
recombinant DNA products has been the subject of debate. One school of 
thought urges that a detaUed description is quite sufficient to enable one to pre-
pare tiie necessary material.^ Another school urges that the written procedures 
are inadequate since a plurality of products may be obtained and even a minor 
modification may make a rather substantial change in function of the ultimate 
product. Further, subsequent developments and experiments may prove the 
original procedure to be inoperative in producing the desired plasmid or 
organisms. In view of tiiis uncertainty, in an important invention it would be 
most prudent to make a deposit!"" 
'* Assuming, for sake of discussion, that an operative method is capable of a written 
description, if one particular plasmid is considered by the inventor to be particuhrly good, 
and if the inventor cannot describe that plasmid fuUy by means of a "written description"' 
alone in a manner that the particular plasmid may be dupUcated absent access to a deposit 
at the ATCC (or elsewhere), the question tiien must be considered under 35 USC § 112 for 
any claim to plasmids inclusive of tiiat particularly preferred plasmid, whetiier tiie "best 
mode contemplated" requirement of 35 USC §112 (first paragraph) has been met, tiiis in-
quuy being totally independent of whetiier there is a "written description" and an "en-
abUng disclosure" under that same paragraph of 35 USC § 112. 
" It is interesting that such a revised interpreution has occurred witii respect to tiie 
origm of tiie plasmid pSClOl. (See Cohen and Chang 1977). In this article. Cohen et al 
f L / V M ! *'"^*"'' ''^ "^ ^ ^^^^ P^^^°^ ^^^ ^°''"*^ ^y recircularization of a fragmeni 
ot R6-5 DNA was mcorrect. This observation is particularly interesting in view of Dr 
Cohen s statement m his article in Scientific American (Cohen 1975) which reads- "For 
a time after our initial experiments the pSClOl plasmid was the only vehicle known to 
be suitable for cloning foreign DNA in E. coli...Chang and I were concernedTa^ 
manipulation of certam genes could give rise to novel organisms whose infectious properties 
and ecological effects could not be predicted. In agreeing to provide (Continued on P^e 89) 
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CONCLUSION 
The patent system, particularly foUowing the Chakrabarty case, affords everyone 
the opportunity to protect most of his property rights in inventions. It provides 
the much-needed incentive for progress in innovations to better mankind, just as 
the property right in minerals from this country's earth did one hundred and 
thirty years ago. The patent system aUows the bioengineer, the mnovator in this 
field, to stake out his claim on his discovery for an exclusive grant for a limited 
period, in exchange for his fuU disclosure of his invention. 
One can be grateful that our patent system is alive and weU. Enormously 
aided thereby are the science of genetic engineering, and the participation of 
academia in educating itself, its students, and society in general. 
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APPENDIX A 
AMERICAN TYPE CULTURE COLLECTION 
12301 Parklawn Drive 
RockviUe, Maryland 20852 U.S.A. 
Tel.: 301-881-2600 Telex: 908-768 
BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE 
DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT 
PROCEDURE 
* 1. Name of microorganism or culture , . 
2. Strain designation given by the depositor (number, symbols, etc.). 
3. Is this strain being deposited under the Budapest Treaty on the Intema-
tional Recognition of the Deposit of Microorganisms for the Purposes of Pa-
tent Procedure?. . — 
Name and Address of Depositor. 
4. Is this deposit a mixture of microorganisms? 
5. DetaUs and conditions necessary for the cultivation of the strain for its stor-
age and for testing its viabiUty and also, where a mixture of microorganisms 
is deposited, descriptions of the components of the mixture and at least one 
of the methods permitting the checking of their presence 
6. An indication of the properties of the strain which are or may be dangerous 
to health or the environment, or an indication that the depositor is not a-
ware of such properties 
*7, It is recommended that sufficient description be provided to aUow the 
ATCC to confirm that the strain deposited generaUy conforms to that which 
the depositor states is being deposited (i.e., gram negative rod) 
*8. Is this strain zoopathogenic? phytopathogenic?. 
*The answers to these questions are recommended but not required. 
FOR ATCC USE ONLY 
ATCC NO 
DATE CULTURE RECEIVED 
DATE VIABILITY TEST COMPLETED. 
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9. Does tills sti-ain contain plasmids relevant to tiie patent process? 
If so, what physical containment level is required for experiments as de-
scribed m tiie 1980 National Institutes of Health GuideUnes involving Re-
combinant DNA Molecules (i.e., Pi, P2, P3 and P4 fadUty)? 
•10. Isolated from? 
11. Do you wish the strain made available to: 
a. Those entitied to a sample under the Budapest Treaty?. 
b. Those entitied to a sample under the European Patent Convention?. 
c. Anyone who requests a culture? 
d. Other (please state) 
12. Do you wish the ATCC to inform you of aU requests for this strain? (This 
is allowed under the Treaty, but if you waive the right, the fee is reduced.) 
13. ViabiUty testing certificate and contracts should be directed to (if differ-
ent from that given under Item 3) 
14. Check in payment of service must accompany the deposit unless prior ar-
rangements are made and approved. If arrangements have been made to bUl 
you for services an invoice should be sent to: 
15. Additional Comments: 
I understand and agree that the deposit may not be withdrawn by me for 
the period specified in Rule 9.1 of the Budapest Treaty (at least 30 years 
after the date of deposit). 
DATE_ SIGNATURE OF DEPOSITOR 
On behalf of (Name of company or institution (Typed name of Depositor) 
if signed on their behalf) 
THIS FORM MUST BE COMPLETED IN ENGLISH 
ADDRESS SHIPMENTS AND FORM TO THE ATTENTION OF: 
Mrs. Bobbie A. Brandon 
American Type Culture Collection 
12301 Parklawn Drive 
RockviUe, Maryland 20852, U.S.A. 
•The answers to these questions are recommended but not required. 
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Primer on Law, Patents, and 
Other Intellectual Property 
DAVID W. PLANT 
Fish & Neave 
New York, New York 10172 
My viewpoint of patents is primarily from advising clients with regard to their 
own patent property after they have gotten it, or with regard to someone else's 
patent property that may be adverse to a client. I shall touch here not only 
on patents, but also on some aspects of trade secrets. 
There are a few general observations that I have about genetic engineering, 
which is fascinating and mysterious,-and the patent law and the trade secret law. 
From my standpoint, there really is not so much that is unique or novel with 
regard to the patents or the trade secret issues in this field. There is no doubt 
that they are terribly factually oriented. Each problem and each solution to a 
problem has to be considered in light of the facts that are particularly, peculiarly 
applicable to the situation under discussion. But to think that the patent laws or 
the trade secret laws require wholesale revision or Congressional restraint or 
other modification at this point is a mistake. We should try to arrive at a com-
mon understanding as to what the patent laws and the trade secret laws are—and 
I am going to focus on this country—and then try to bring to bear, in the 
context of those concepts, the principles that would control in the case of any 
particular fact situation that arises. 
Public Interest 
The patent system and the relief that flows from a patent have to be considered 
in l i^ t of the public interest. If the public is to benefit from the fruits of this 
field, some of us may have to be prepared to advise clients that some of the 
usual forms of relief that are attributable to patents may not always be available. 
I am not a proponent of compulsory licensing, but I do believe that if the public 
interest is demonstrated to compel a court to refrain from issuing an injunction, 
and to compel a court to order that compulsory licensing be the case in any 
given situation, it should not come as a great surprise especially, with regard to 
the medical, pharmaceutical, and health aspects of the work in this field. 
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Misconceptions about Patents 
Patents give to the patent owner the right to exclude others from doing some-
thing-from manufacturing, using, or selling a patented invention. A patent does 
not guarantee the patent owner income or commercial advantage just because 
it issues. A patent gives one the right to exclude, as a matter of law, but more 
practically, I believe it gives one the right to attempt to exclude others from 
practicing one's invention. That attempt may indeed be a very complicated 
and expensive proposition. Patent litigation is both complex and expensive, and 
many clients suffer as a result of that. That is an important attribute of the 
system that people who are not accustomed to it or familiar with it ought to 
have in mind. 
A patent gives the right to exclude for a limited time and with regard to 
limited subject matter. It is a 17-year period in the United States after the patent 
issues, and it has to do with the subject matter that is described in the claims of 
the patent, not the rest of the subject matter, necessarily, in the patent q>ecifica-
tion or the drawings. 
That right to exclude runs headlong into the strong public policy against 
monopolies that has pervaded our society in the United States. As a result, we 
have a very tender balance in the courts between the desire to hold valid and to 
give fair scope to a patent, which is a monopoly, and, on the other hand, to 
make available to the public that which perhaps it already had. That is a funda-
mental tension in the system that you have to have in mind. It is terribly 
dangerous to believe that one can stretch a patent too far beyond the claims. If 
one attempts it, one may find himself held to be guilty of **unclean hands." That 
is the patent may be held unenforceable. 
Trade Secrets 
Before reviewing the various aspects of patents, fshall touch on trade secrets for 
just a moment. This brief treatment of trade secrets should not be regarded as 
evidence of a view on my part that they are not of value. / beUeve that trade 
secrets can be just as valuable as patents. They should be considered carefully in 
regard to any intellectual property question that any of us may have. 
A trade secret-and this is a classic definition-may consist of any formula, 
pattern, device, or compilation of information which is used in one's business 
and gives one an opportunity to obtain an advantage over competitors who do 
not know or use it. The subject of a trade secret, therefore, must be secret. It 
must not be disclosed in a published paper. It should not be generally known to 
the interested public. If it is generally known in that segment of the community 
in which the industry or the art operates, even though not fully described in a 
single sheet of paper, it may not qualify as a trade secret. 
The requisite element of secrecy is not lost if the trade secret information 
is disclosed to another under appropriate conditions, typically a confidential 
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relationship, subject to which the recipient agrees to limit disclosure and use of 
the information. 
The rights in a trade secret last as long as the trade secret remains just 
that—a secret. There is no statutory term, as there is in the patent law (no 17-
year period that controls the life of a trade secret). The life of a trade secret is 
strictly subject to events, whether or not the trade secret owner continues to 
protect it as a trade secret, whether or not it continues to have value, and 
whether or not others, independently, on their own, come up with the trade 
secret. 
A patent can be infringed without copying the subject matter of the 
patent, without deriving directly from the patent owner. A trade secret right 
normally is not infringed without direct derivation, without either the violation 
of a confidential relationship or out-and-out theft. 
In those respects, patents and trade secrets differ substantially. Patents 
have a finite term, stated by statute. Trade secrets have an indefinite term, 
controlled by circumstances. Patents are infringed, whether you know about the 
patent or not. If you practice the invention, you may infringe it. Typically, one 
cannot infringe a trade secret right unless he derives from the trade secret owner, 
or if one breaches a confidential relationship with him, or steals from him. 
Patents 
Four terms are critical in patent law: validity, infringement, enforceability, and 
the public interest (see Fig. 1). A patent issues from the United States Patent Of-
fice with a statutory presumption of validity. That is given greater or lesser 
weight depending on the facts at the time the patent is litigated, but it is pre-
sumed valid at the time it issues. 
The patent must be valid to be infringed. An invalid patent cannot be in-
fringed. A patent must be enforceable in order to obtain relief as a result of in-
fringement. An unenforceable patent may lead to no relief, or it may lead to the 
necessity of the patent owner's changing his course of conduct in order to enable 
him to gain relief under the patent. 
All of these concepts must be considered in Hght of the public interest, 
which is to promote the advancement of the useful arts, according to the Consti-
tution. That is the purpose of our patent system. That objective is obtained by 
full disclosure in the patent of the invention and accurate description in the 
patent claims of what the patentee is attempting to exclude others from doing. 
That full disclosure is the consideration the patent owner gives for the right that 
the Government gives him to exclude others for 17 years. 
Patent Validity 
Validity has three elements: usefulness, novelty, and obviousness or nonobvious-
ness. I will pass usefuhiess (or utility) and discuss the other two points which are 
more critical. 
Validity 
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To consider novelty and obviousness, one must consider the prior art. The 
prior art is considered in terms of time and substance. This includes four events: 
conception, reduction to practice, the filing of the application, and the issuance 
of the patent. Validity is considered in light of two events in point of time: in-
vention, and the filing date of the appUcation, as far as novelty and obviousness 
are concerned. 
An invention consists of two steps. The two steps are the mental step of 
conceiving the invention, getting the idea, but that alone is not enough to sup-
port a patent. The idea should be reduced to practice—that is the manual aspect. 
There is a mental and a manual aspect of making an invention. I have separated 
them in time because it is not unusual for those two steps to occur at different 
points in time. They may occur simultaneously but frequently they do not. 
When the invention is made depends on when these two steps have occurred. 
This is important from the standpoint of when the so-called prior art becomes 
effective. 
To digress, the law provides that if, in fact, you don't reduce to practice 
(take the manual step), the filing of a patent application which comports with 
the statutory requirements and fully describes the invention, can be regarded as 
a constructive reduction to practice. In that case, the invention date would be 
the filing date of the application, because that is when the second step would 
have been completed. 
PTASHNE: Can you be interrupted for a simple question? 
PLANT: Any question. 
PTASHNE: The last thing you said didn't make much sense to me. If you think 
it up and you don't reduce it to practice, and then you apply for the ap-
plication, does that count as the second step? 
PLANT: Yes. The filing of the application is the constructive reduction to 
practice. 
PTASHNE: What is the onus on you to reduce it to practice? You are better 
off not reducing it to practice. 
PLANT: Not at all. You are flying in the dark if you haven't reduced it to 
practice. How sure are you that are you describing something that will 
work? 
PTASHNE: What have you got to lose? 
PLANT: You have the whole patent to lose, if you have an idea that is not 
mature, in the sense of not having all the information within the frame-
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work of the intellectual concept that will enable one skilled in the art to 
practice the invention, and if you attempt to draft a patent application 
with less than full information, there is a fair chance that either in the Pa-
tent Office or later in Utigation, or in a licensing negotiation, you are going 
to be challenged, and you wiU be with a useless piece of paper that costs 
somewhere from $10,000 to $50,000, perhaps, to obtain from the Patent 
Office. 
JUDGE RICH: This is not a dissent. Don't you have to distinguish two different 
classes of situations when discussing when the invention was made? If you 
are in an interference, which is a dispute between two people as to who 
made it first, it can go back to the conception date, which brings in the 
diUgence question, which you haven't explained. Suppose you are dealing 
with a contract situation that says invention made during an employment 
shall belong to so-and-so, then you have to have a construction of the 
word "made" to find out whether they are talking about reduction to 
practice or conception. It is a vague term to have in a contract. 
PLANT: It is. I think contracts ought to have, depending on which side you are 
on, if you want to capture everything, the word "conceived," not "made" 
or "developed," or "reduced to practice." You want to take it back to the 
earUest point in time in a contract situation, if you want to capture all the 
information. 
VOSSIUS: Don't you have only one year from the conception date to the ap-
pUcation date, a period of grace? 
PLANT: No. I have shown a narrow one-year period prior to the filing of the 
application. Prior art that appears more than a year prior to the filing date 
of the appUcation wiU affect the validity of the patent. The invention may 
be made IH years before the appUcation is filed. If nothing about that is 
pubUshed from the time the invention is made until the time the applica-
tion is filed, if nothing is known about it except to the inventor, there may 
be no prior art, there may be no invalidating information, and the patent 
may issue as a valid patent. 
I have separated the one-year point in time, one year prior to the 
filing of the application, from the date of the invention, because it is hard-
ly ever the case that the two coincide. I want to have two separate points 
in time from which to discuss the prior art. 
Novelty 
Backing up to the date of invention, which I have shown as more than a year 
prior to the filing date of the application, if the subject matter of the invention 
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has been patented anywhere—that is, claimed in an issued patent anywhere in 
the world—if the subject matter of the invention has been described in a pubUca-
tion, which may be a patent, anywhere in the world, a vaUd patent should not 
issue on that invention, if those events occurred prior to the date of the inven-
tion. If the subject matter of the invention was used or known in the United 
States—and that means it was in some tangible form and used to some com-
mercial advantage, typicaUy—in the United States, but not anywhere else in the 
world, prior to the date of the invention, that, too, may invaUdate a patent on 
the invention. For example, it may be that you are using a process within the 
four comers of your factory and turning out lOO's of whatever you are turning 
out, whatever the process produces, over a period of years. That may amount to 
an invalidating use, even though the rest of the world cannot walk through your 
factory and examine the process. 
JUDGE RICH: Do you want to add one more tricky situation, which is, is a pa-
tent good as of its filing date as prior art? (Laughter) That is part of it, 
secret prior art. Nobody ever heard of it except for the paten tor and the 
Patent Office. 
PLANT: If an appUcation for a patent were filed in the United States prior to 
the date of an invention, the patent issued at a later time, based on the ap-
pUcation filed prior to the date of the invention, would be prior art. 
The theory is that an inventor ought to have one year in which to attempt 
to perfect his invention, to see if it reaUy works (after he has made the first pre-
Uminary reduction to practice). He should not be compeUed to rush to the Pa-
tent Office instantaneously and file the patent appUcation. If, anywhere in the 
worid, the subject of the invention is the subject of a patent issued more than 
one year prior to the appUcation date that is described in the claims of a patent, 
the patent should not issue as a vaUd patent. 
JUDGE RICH: It doesn't have to be claimed. A patent is also a pubUca-
tion. 
PLANT: If the subject matter of the invention is described in a publication, 
anywhere in the worid, m a leamed joumal, such as Scientific American, 
or the specification of another patent, more than a year prior to the date 
of the invention, that wiU invalidate tiie patent. If in the United States 
there is a pubUc use or tiiere is an offer for sale or a sale of the subject 
matter of tiie invention more than one year prior to tiie filing date, that, 
too, WiU be invalidating prior art. This all goes to the issue of novelty. 
Those are the temporal considerations. The patent or tiie pubUcation or 
the use or tiie sale have to be of the subject matter tiiat is claimed in tiie 
appUcation or in tiie issued patent. There is some law tiiat says trivial 
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variants don't make a lot of difference. I would prefer to consider that 
under the heading of obviousness. 
JUDGE RICH: ActuaUy, I think it is helpful to think of the one year bar in 
terms of Section 102, which says in the heading, "Novelty and Loss of 
Right," and they are two different things. The one year really is a loss-of-
right situation rather than a novelty situation. If you let certain events oc-
cur and let them wait more than a year, instead of thinking of it as a grace 
period, think of losing your rights by waiting too long. 
Obviousness 
This is the battleground on which most validity disputes are fought in the courts, 
at least in my experience. Finding an exact anticipation by way of a prior patent 
or a publication of an invention that is claimed in a later-issued patent is some-
thing that does occur, but it doesn't occur frequently, at least as far as patents 
that get into litigation are concerned, because if it is that clear, they shouldn't 
get into Utigation. But sometimes they do, and the feUow who has the prior art 
is happy about that. Dr. Watson referred to something as trivial. I have heard this 
said many times before by scientists of your caUber in this room. You people 
may not be the people of ordinary skiU in the art. You may not represent the 
level of ordinary skill in the art. I would guess that most, if not all, of you rep-
resent something that transcends the person with ordinary skiU in the art. Those 
of you who look at inventions and caU them trivial mustn't speak too quickly in 
terms of putting yourselves in an ex cathedra position on that subject, because 
the courts may look at it-and indeed they are likely to look at it—in a different 
way. 
A sophisticated scientist may hold the view that once recombinant DNA 
has been understood, one can sit back and do anything with it you want to and 
anything that flows after the basic invention reaUy shouldn't be the subject of a 
patent. But that just isn't the way the patent system operates. For example, 
fermentation in the laboratory is something tiiat is done on a small scale and is 
apparentiy a relatively open book, whereas fermentation commercially done on 
a large scale in a factory may be entirely different. There may be inventive work 
in both areas. The fellow in the laboratory, who is ages ahead in terms of his 
understanding of the technology of the person who is turning the knobs on the 
vat in the large-scale operation, shouldn't make a judgment, really, as to whether 
or not what is a new wrinkle as far as the large-scale operation is concemed is 
obvious or not obvious. 
What one takes into account with regard to obviousness is the state of the 
art at the time the invention was made. It is not the state of the recombinant 
DNA art in general. It may be the state of tiie art having to do with fermenters 
or controUing temperature or regarding cultures. It may have very littie to do 
with the molecular structure of a DNA molecule. 
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The state of the art at the time an invention is made is viewed by the 
courts from the standpoint of not only the technological, but also the com-
mercial, realities. Was there a problem facing the art at the time the invention 
was made? Was there a need to solve that problem? Did others attempt to solve 
the problem? Did they fail? Did they succeed? What happened after the inven-
tion was made? Commercially or technologicaUy, was tribute paid to the 
inventor with regard to the contribution, if any, the inventor made to the art? 
That quick analysis suggests that the question of obviousness is a very 
difficult question. Judge Learned Hand said it was the most elusive concept in 
the law, as far as he knew. It suggests that it is something you can't answer at the 
time the invention is made as weU as you may be able to answer it at the time 
you file an appUcation, the time the patent issues, or 5 years into the life of a 
patent, because the ensuing commercial history is very important with regard to 
judging the obviousness or nonobviousness of an invention. 
For example, whether others have not been able to design around a 
patented invention, whether others have been forced, because of the contribu-
tion made by a nonobvious invention, to adopt the invention after it was made 
pubUc, is evidence of the nonobvious character of the work. 
The prior art as of the date of the invention—that is, the pubUcly avail-
able information in the field—is the art that is considered, with two exceptions 
that I know of. One is that if the invention was made more than one year prior 
to the filing date of the patent application, prior art that came into existence 
after the invention, but more than one year prior to the fiUng date of the appU-
cation, may be relevant. Secondly, even activities closer to the filing date than 
one year may be relevant, if they evidence independent, contemporaneous de-
velopment. If there are others in the field who later in time than the date of the 
invention also made the same invention under substantially the same 
circumstances, given the same tools, the same incentives, that is some evidence 
of obviousness. Once it is done by one there is no reason why someone else can't 
do it. If it turns out that others have been doing the same thing roughly at the 
same time, that may be evidence of obviousness. 
In contrast to the United States, there are many countries in the worid in 
which there is an absolute bar to novelty, if the subject matter of the invention 
is published (in almost any way, if you want to be cautious about it) prior to the 
fiUng date of the appUcation. That means that once you have the invention, 
you should msh to some patent office and file an appUcation before you 
publish. You may do yourself in, if you pubUsh anywhere-even in a room like 
this, which is not surrounded by confidential restrictions-the subject matter of 
your invention, and then file later. You may find that in European and other 
countries you have lost your patent rights. 
Specification 
The specification of a patent has to comply with statutory requirements. The 
specification is loosely referred to as the descriptive material m the appUcation, 
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including pictures and words prior to the claims, but as a matter of statute, it 
also includes the claims. The specification, insofar as the descriptive material is 
concerned, must provide an enabling description. The specification in that regard 
must teach the person skiUed in the art—and, interestingly, the statute uses two 
different terms; it uses any person skiUed in the art as far as this requirement is 
concerned; under obviousness, it is the person of ordinary skiU in the art who is 
the standard against which the advance is measured—any person skilled in the art 
must be able to read the enabling description and practice the invention. If there 
is not an enabling description in the specification, the patent may be held 
invalid. 
Secondly, the claims, which are the numbered paragraphs at the end of the 
specification, must particulariy point out and distinctly claim the invention. 
That is so the rest of the world wiU know what it can and carmot do with regard 
to the inventor's view of the monopoly that has been granted to the inventor by 
the Government. 
Claims are not to be read in a vacuum. They are riddled with ambiguity. 
They are written by lawyers. You have to look at the specification. An inventor 
is entitled to create his own lexicon. He can use words in the claims that to the 
rest of us may be ambiguous or unclear. You look to the specification to see 
what the inventor meant and what the inventor said he was not inventing. 
The prosecution is the activity that goes on in the patent office from the 
time the appUcation is filed until the time the patent issues. The patent examiner 
cites prior art. The words in the issued claims must be considered in light of 
what the appUcant in the Patent Office said he was attempting to claim as his 
invention. 
Then, oi course, the claims have to be read in Ught of the prior art, 
because patent claims cannot capture what is in the prior art. If they do, they 
are invalid. 
The specification thus must comply with the statutory requirements of 
teaching any person skUled in the art how to practice tiie invention and teUing 
the rest of tiie worid particulariy what it is tiiat is the claimed invention. 
Infringement 
Infringement is also provided for in tiie U.S. patent statutes. Anyone who witii-
out autiiorization makes, uses, or sells a claimed invention in tiie United States 
may be guilty of infringement. You may contribute to infringement and you 
may actively induce infringement. Those are compUcated concepts. Direct in-
fringement involves a person who makes a product, practices a process, seUs a 
machine in the United States, when tiiat product or process or machine is de-
scribed in the claim of a valid patent. A person who does tiiat in tiie United 
States without autiiorization is guUty of infringement. 
What is tiie relief that a patent owner may obtain if someone is held to 
mfringe a valid patent? What relief should an accused infringer fear? The most 
important is injunctive relief. 
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Secondly, past damages is part of the reUef that may be awarded, and 
future royalties if there is a Ucense that is granted with regard to future ac-
tivities. 
This relief may be tempered by a variety of considerations, which I have 
caUed equities. One that is now very popular, and has been for some years in 
U.S. patent law, has to do with the applicant's (in the Patent Office), or the 
patentee's (after the patent issues), conduct. In the Patent Office, if the appU-
cant hasn't met his uncompromising duty of candor and disclosed aU relevant 
information to enable the Patent Office to examine the appUcation fairly, a 
court may find that the appUcant's hands are unclean, that the patent is unen-
forceable, and there may be nothing that the patent owner can do about that. 
The patent may otherwise be regarded as valid, it may otherwise be regarded as 
infringed, but there is no relief awarded to the patent owner, because his con-
duct in connection with either obtaining the patent or exploiting the patent 
has been such as to violate the principles of the patent system. He hasn't fairly 
disclosed how to practice the invention or fairly disclosed prior art. He has at-
tempted to stretch the invention beyond the four corners of the claim and at-
tempted to use the Governmental monopoly that has been granted by the patent 
to control unpatented goods. A variety of things may have happened that have 
deprived him of the right to gain the ordinary reUef with respect to infringing 
activities. 
JUDGE RICH: Normally caUed misuse of the patent. 
PLANT: Misuse of the patent typicaUy applies to what happens after the pa-
tent issues, in my book anyway. 
JUDGE RICH: On the Patent Office aspect, not being candid and suppressing 
prior art and all that may result in your not getting the patent in the first 
place. Has any court held the patent invalid on account of so-caUed fraud 
on the Patent Office? 
PLANT: I don't know of a holding of invalidity based on fraud alone. I think 
invalidity and fraud go hand-in-hand. 
Activities with regard to a patent after it issues, with regard to attempts to 
exploit it, to stretch it beyond what it is entitied to cover, may be purged, 
may be altered. Two things are required: Not only should you change your 
course of conduct to conform to the law, but you should also cause the im-
pact of tiie prior improper conduct to be mitigated, dissipated, corrected. When 
tiiose two events occur, tiien tiie patent may become enforceable. From that 
time forward, you may be able to seek and obtain relief. 
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COMMENTS 
PTASHNE: Could you give an example of improper conduct? What would 
you be doing? 
PLANT: If you have a patent on a fermenting process and you are in the 
business of manufacturing a fermenter and seUing it, and if you do not 
permit the world to practice your invention unless they buy the unpa-
tented equipment from you, you may be guilty of patent misuse. What 
you are doing is using your Government-granted monopoly on a process 
to control commerce in unpatented goods, the fermenter. 
JUDGE RICH: EspeciaUy if the unpatented goods can be classified as staple 
commodity, like salt or something. A classic case is the Morton Salt case 
where the machine was a salt tablet dispenser, and they said, **You can use 
the dispenser, but you have to buy aU the salt tablets from us." 
PLANT: If the patent covers a technique, a process, a machine, an article that 
is so important to the public that it must have more than one source, and 
the patent owner isn't providing it, for instance, the patent owner may be 
inhibited from gaining injunctive reUef. A court may not grant injunctive 
relief, even though an infringer has been found to infringe the valid claims 
of a patent. That is not because the patent is unenforceable; it is because 
the public interest demands that the subject of the invention be made 
available more widely than the holder of the patent is making it available. 
KILEY: With respect to the latter point, I should point out that iimovation in 
industry is largely driven by the need to obtain and protect a market 
position. The opportunity to gain royalty income is distinctiy a secondary 
inducement. I think to the extent courts withhold injunctions, they 
diminish the incentives to innovate. The practice widely applied. I think, 
would lead to a significant downturn in industrial innovation. 
McELHENY: How many patents in a given year in the United States actuaUy 
are overturned in a court? 
PLANT: The statistics run upwards of 70^ f of those litigated being held invaUd. 
JUDGE RICH: Another study made by the Patent Office came out at approx-
imately 55%. 
KILEY: My former law partners defined as a perfect patent one tiiat was 
strong enough for one party to sue on and weak enough for the other 
party to defend against, leading to tiie cost of litigation you referred to. 
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MacPHERSON: Would you comment just one moment on best mode, because 
I think there is oftentimes a misunderstanding, particularly among 
European inventors, as to why we require it in the United States. 
PLANT: There is a requirement with regard to the information that is in-
cluded in the specification that the best mode for practicing the invention 
known to the inventor at the time the appUcation is filed is to be included 
in the specification. There is not a requirement to continue to update the 
application during prosecution, as your research shows new refinements 
and new wrinkles. But in the United States you should describe the best 
mode that you know of as of the time the appUcation is filed. 
De ROSNAY: There is a difference between European law and American law. 
I thmk I understand that if somebody is on a patent and he is not reaUy an 
inventor his patent would be invalid in the United States, if he has not 
really participated in the real invention. 
PLANT: Yes, but the law provides for corrective procedures. Either during 
prosecution or even after the patent issues, if that mistake was made 
without deceptive intent, it is possible to correct that. 
ZINDER: I thought you said something very important in the beginning of 
your presentation and that was that the patent law as it currently exists is 
not gomg to have to be changed in any real way for what we are now 
dealmg with. That is sort of a remarkable statement, since it is only 2 
years ago that the Supreme Court backed into a decision that said you 
could patent these kinds of things. So I take it you feel that that is aU 
over, the Supreme Court looking to Congress to rewrite the patent law, 
and other concems. 
PLANT: The point I make is that I am trying to encourage those who are 
here from Congress, to do nothing. There are going to be very serious and 
fundamental questions to deal with, I am sure, but I don't think anyone 
should attempt to anticipate them in a vacuum. 
TANENHOLTZ: The Chakrabarty case was a broad decision in some respects 
and a narrow decision m others, in that it permitted patenting of Ufe 
forms for the fu-st tune, by themselves. But anyone could always at-
tempt to patent, and has patented, compositions of matter, including 
the use of living thmgs. Plasmids would have always been patented also, 
since they are not living entities. 

Are the Fruits of Genetic Er^ gineering 
Patentable? ^ 
BERTRAM ROWLAND 
Townsend & Townsend 
Palo Alto, California 94304 
In addressing the question of patentabiUty, I would first like to consider the 
domestic statutory requirements for patentability, namely statutory subject 
matter, novelty, unobviousness, and description requirements, and then consider 
some of the pecuUar problems genetic engmeering engenders. 
Statutory Subject Matter 
In regard to statutory subject matter, the matter of Chakrabarty^ has already 
held that ceUs which are manipulated so as to provide a different function than 
was previously avaUable are patentable. From this it foUowed that other aspects 
of geneticaUy controUed repUcating life forms are patentable, such as plasmids, 
viruses, phages, and transposons. Extrapolating from the Chakrabarty decision, it 
is expected that eukaryotic ceUs would be patentable, certainly at the ceUular 
level. If mammaUan ceUs are patentable then should patentabiUty of an organ or 
organism foUow? Where the observed result is obtamed solely as the multi-
ceUular organ or organism, for complete patent protection one might wish to 
claim the organ or organism. 
Another question left open by Chakrabarty, which might have been solved 
by a decision by the Supreme Court In re Bergy'^ (this is sometimes referred to 
as "Bergy II") is whether the isolation of a naturaUy occurring ceU may be 
patentable. The Court of Customs and Patent Appeals (CCPA) has held this 
subject matter to be patentable and I understand the Patent office is aUowing 
claims to an isolated naturaUy occurring microorganism. 
Novelty 
Once having passed the hurdle of statutory subject matter, there remains the 
question of novelty. At the present time, the genes and regulatory signals of 
»571 F. 2d 40 (CCPA 1978);44 U.S. 303 (1980) 
M63 F.2d 952 (CCPA 1979); 563 F.2d 1031 (CCPA 1977) 
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interest are obtained from naturaUy occurring sources. It is the removal of these 
sequences from their natural habitat and their joining to other sequences which 
provides the manmade requirement of Chakrabarty. Thus it is not the sequence 
of interest that is new, but rather its environment, such as the host, DNA 
flanking regions, or novel combinations of DNA sequences. Such differences are 
sufficient for estabUshing novelty, but claiming with definiteness can be a 
problem. 
Suppose you are the first to isolate a DNA sequence coding for a regu-
latory signal, such as a ribosomal start site, and then show that the sequence has 
general appUcation in the expression of genes when constmctuig plasmids, you 
would wish to claim aU ribosomal start sites where the ribosomal start site is 
joined to other than the naturaUy occurring DNA sequences. Such a claim wiU 
not be granted for many reasons. How one then writes a claim which covers such 
a functional element can become a word game as intricate as Hesse's **Glass Bead 
Game." Moreover, as the Uterature continuously develops, it will become in-
creasingly difficult to chart a claim of substantial breadth through the shoals of 
the prior art. 
Unobviousness 
As far as unobviousness is concemed, we are admonished by the John Deere^ 
decision to determine what the existing prior art is at the time of the filing of 
the appUcation, then determine the differences between the invention and the 
prior art, and fmaUy determine whether the differences would have been ob-
vious to a man skiUed in the art. This raises a number of questions at the present 
time in determining what the prior art is. Prior art is only Uterature in the same 
or related fields. How one defmes the same or related fields wiU frequentiy 
determine whether an invention is patentable. The biological fields have ex-
tensive cross-fertUization, but no one investigator can be held to know all the 
relevant literature in aU tiie related fields. It wUl become important to estabUsh 
how retrievable tiie Uterature is in a related field as it appUes to an invention. 
What criteria are to be used to evaluate unobviousness? The regulatory 
signals and structural genes are known to exist. The difficulty in isolation, tiie 
preparation, superiority of result, are all criteria at present used in the chemical 
arts and should find appUcation in the biological arts. 
In tiie development of tiie patent system in the 19tii century, for the 
most part, patents were mechanical patents. The approach to patentobiUty 
developed in relation to apparatuses, where tiie function of a component part 
was readUy predictable once having been estabUshed and it was primarily in tiie 
combination of parts where patentable inventions lay. 
The advent of chemical inventions in tiie late 19tii century required new 
considerations. With chemical inventions, one began witii tiie proposition tiiat 
'Graham V.John Deere Co. 383 U.S. 1,7-10(1966) 
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properties, particularly biological properties, were unobvious from the stmcture 
of the compound. The proposition was developed that while one could evaluate 
the operabiUty of a mechanical mvention without requiring a prototype, the 
utiUty in chemical inventions was unpredictable and would require working 
exempUfication. 
BIOLOGICAL INVENTIONS 
In hybrid DNA technology there would appear to be a combination of the two 
situations: predictability of gene expression and of regulatory signal function, as 
contrasted with uncertainty as to isolation, operabiUty, efficiency and other 
aspects of utiUty. Also, biological inventions have unique considerations: 
1. In most instances, the invention wiU be capable of repUcation, so that once 
the DNA technology has been performed, ceUs wUl perpetuate the result. 
2. As indicated previously, the DNA sequence wUl have a predetermined func-
tion, normaUy as a regulatory signal or expressing a stmctural gene. 
3. SmaU compositional variations can have little effect or enormous effect, so 
that comparing stmctures of DNA or RNA may have Uttle or no relevance, 
and 
4. ReproducibiUty of prior experiments is problematical in many situations. 
With these considerations in mind, we are forced to look at particular types of 
inventions. Quite clearly, the foUowing list is not exhaustive, but highlights the 
major categories of present interest. 
Products 
The first group of inventions concerns products. The first type of product is 
ceUs, which have been modified to provide a new property or to enhance an 
existing property. The property can be achieved by introduction of a stable 
extrachromosomal element into the ceU which provides expression of one or 
more genes to produce protein end-products or enzymes which perform a 
desirable modification of a substance. The changes can range from transforma-
tion of a bacterium to provide a particular interferon to introduction of bare 
DNA into a human stem ceU to enhance DHFR production to protect the stem 
ceUs and their differentiated progeny from methotrexate. Other ceUular 
products wiU be ceUs acting in concert as a multiceUular organism, such as a 
plant. 
How one claims these various ceUs and organisms wiU depend on a number 
of factors, particulariy what has existed naturaUy and what has been developed 
in the prior art. Where one is in the forefront, desirably one would claim ceUs 
producing X or a multiceUular organism having a particular property, possibly 
Umited by the method of preparation of the ceU. When one claims an enhanced 
yield of a particular product, as in the case of dihydrofolate reductase (DHFR), 
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it may be that natural mutants occur which express enhanced amounts of 
DHFR. The claim woiild tiien have to be limited to requiring in vitro incorpora-
tion of a DFHR gene Uito a parent cell and the progeny of these ceUs. 
At least initially, the DHFR method envisions removing the cells from a 
patient, transforming the cells with the appropriate bare DNA, and returning 
the cells to the patient. This activity would be carried out in a hoq>itaI and 
normally would be considered the practice of medicine. In most countries out-
side the United States, claims covering the practice of medicine are forbidden. 
In the United States there has been a reluctance to claim methodologies for 
performing an operation. Yet, by claiming a modified stem cell one has in ef-
fect achieved the same result. Furthermore, by claiming the ceU, the cell host 
infringes. 
The claiming of ceUular products involving modific t^icm of a patient's 
cells may be disturbing to some, although I do not know why. The situation may 
be analogized to prosthetic devices which have long been the subject of patents. 
Where the composition employed for the modification is not patented there 
may be problems of enforcement^  althoug i^ the/{o/tm am///!iias^ decision which 
greatiy strengthened actions fdr contributory infringement should alleviate the 
problem. 
Modification of cells can also be achieved by inducing mutations with a 
mutagen and selecting for the mutated strain having the desired property. In 
this situation, would a claim be pemutted claiming a ceU having a desired 
property or is the ceU to be claimed in accordance with the manner in which it 
is prepared? In Chakrabarty, the claim concemed the use of the ceUs. 
In the chemical arts, one of the considerations in granting broad claims is 
that the demonstration of success wiU frequentiy aid subsequent investigators in 
achieving the desired result by alternative routes. However, mutagenesis and 
transformation could be totaUy separate routes or interdependent route$, where 
the mutagen is used as a source for the mutagenic DNA, which is then employed 
m genetic engineering. Since the examiner cannot foresee whether there will bd a 
relationship between the two routes, a decision must be made a priori whether 
one wiU be able to claim a ceU capable of a function or whether such a claim wUl 
be further limited by its history. 
In the chemical arts, one way to prove patentabUity is to show a better 
result. Unless one is able to compare the specific organism in the prior art 
directiy witii the claimed organism, such comparisons wiU be as meaningful as 
comparing the amount of fruit produced by one pear tree with the amount pro-
duced by a prior art pear tree. Plant patents do not require any showing of 
improvement and one has proved infringement in the past solely by proving 
derivation from tiie patented plant. Where tiie appUcant is wiUing to Umit his 
claim to a deposited organism, it might be reasonable to permit such claims 
witiiout any showing, in effect, a registration system. 
M47 U.S. 303 (1980) 
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Since the appUcant needs broad flexible language to provide a reaUstic 
basis to estabUsh infringement, the Patent Office has always been zealous in its 
efforts to provide certainty. Language is an amorphous material with which to 
provide certainty. In most instances, the aUeged infringer wiU have no difficulty 
in determining whether the invention of the patent is being infringed. In those 
instances where there could be some uncertainty and someone could reasonably 
beUeve that he is outside the patentee's invention, although arguably within the 
Uteral language of the claim, the doctrine of negative equivalency is available. 
Unfortunately, the courts in this country do not have the flexibiUty of the 
European courts, where the courts read the claim in the light of the entire 
specification and make an independent determination of what the patented in-
vention is. This creates uncertainty as to the scope of a patented invention, but 
it has found acceptance in Europe without substantial inhibition of industrial 
progress. 
Hybridomas 
The next type of organism capable of being claimed as a product is the 
hybridoma resulting from fusion of two different lymphocytes and provides for 
the production of monoclonal antibodies. The fusion technique may be 
extended to otiier types of ceUs for different products. Fused ceUs can be de-
posited but their stability is uncertain. WiU an appUcant be granted novel fusion 
partners, aU hybridoma ceUs producing the product, or only the deposited ceUs, 
which may change with time? Broad patents have already been issued for 
hybridomas and monoclonal antibodies. Patents for polyclonal antisera have 
long been known to be limited to the antigen eUciting the immune response. 
If appUcants are to be encouraged to fUe patent appUcations the claims 
should grant something more than the deposited hybridomas and the specific 
monoclonal antibodies which they produce. Otherwise, the appUcant may be 
able to achieve a comparable monopoly by retaining ownership and control of 
the hybridoma. The need to deposit the hybridoma for a patent appUcation 
diminishes the protection for the appUcant, since upon issuance of the U.S. 
patent or pubUcation of a foreign patent, the hybridoma ceU must be released 
to anyone who requests the ceU. 
What standard is to be used in determining the scope of a claim if the 
claim is to a specific hybridoma and its antibodies? If an appUcant has found a 
hybridoma which produces monoclonal antibodies to a specific epitopic site of 
an antigen and is the first to have estabUshed a monoclonal antibody for that 
antigen, can the appUcant claim aU monoclonal antibodies to the antigen and aU 
monoclonal antibodies to the specific site? Or, m the case of a surface antigen, 
couW t^lie appUcant claim monoclonal antibodies to the organism, for example, 
claiming antibodies diagnostic for a disease? When the Uterature teaches a 
specific hybridoma, but the hybridoma is not avaUable, how is one to estabUsh 
superiority? Each individual case wUl have to be evaluated as to the difficulty in 
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achieving the hybridoma and relating the monoclonal antibody to the specific 
antigen. Also, the enablement requirement may serve to limit the scope of the 
claim. I beUeve that aUowing claims solely to the deposited hybridomas and 
monoclonal antibodies derived therefrom is contrary to the purposes of the 
patent system in not providing an incentive to fUe for a patent appUcation as 
indicated m Kewanee Oil v. Bicron^. 
FinaUy for product claims, there wiU be intermediate products and 
materials. For the most part, these wUl be polynucleotides which serve as regu-
latory signals, stmctural genes, vectors, messengers, linkers, and other sequences 
aiding in the constmction of various extrachromosomal elements. It wUl be 
desirable that many of these genetic units be generally available under Ucense, so 
that the means for producing products wiU be generaUy available, while the 
combmation and fmits of the extrachromosomal elements wiU be capable of 
protection. Fortunately, many of these basic elements have been mventions in 
academia and wUl be generaUy avaUable for Ucensing. So far, there has been no 
announcement as to what a corporate patentee wiU do with a basic position. 
Compositional Claims 
In claimmg compositions one must always be concemed with the subsequent 
abUity to prove mfringement. As the claim becomes limited to include composi-
tional requirements in addition to function, provmg Uteral infringement could 
become difficult, since minor compositional variations wiU be permissible while 
retaining operabUity. When a claim of composition is made, the redundancy of 
the translational code aUows for substantial variation, but may introduce un-
desirable restriction sites making the method of preparation inoperative. At the 
present time, the courts are reasonably lenient in aUowing some degree of 
inoperabUity in the teaching in the specification. 
Processes 
Another statutory class of patentable invention is processes. One category 
includes producing organisms. Prior to tiie advent of hybrid DNA technology, 
mutagenesis was tiie primary, if not sole technique. Today, tiiere are a number 
of ways to modify organisms, which wiU provide a basis for patents. Improved 
metiiods for introducing tiie DNA mto tiie ceU, for estabUshing mtegration, 
enhancing yields, and enhancing properties of host ceUs wUl aU provide oppor-
tunities for patents. These types of metiiod claims fmd ample analogy in 
chemical claims and should not provide too much difficulty for the Patent 
Office and courts in tiieir evaluation of patentabUity and reasonable scope. 
The various types of product and process inventions do and wUl overlap, 
since processes for using organisms nonnaUy involve processes for making 
'A16 U.S. 470(1974) 
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genetic elements and the genetic elements employed m the modification of the 
organism. The scope granted as to any one of the inventions frequently 
determines the patentee's monopoly as to the entire package, smce each aspect 
may be essential to achieve the final result. For example, claims to a stmctural 
gene; plasmids containing the stmctural gene; transformants; the process for 
producing the product employing the transformants; and the products, may aU 
result from a single development. Therefore, a consistent poUcy must be fol-
lowed in the Patent Office, despite the probabUity that different Examiners wUl 
examine the various aspects. Effective communication m the Patent Office wUl 
be required to ensure that each Examiner is aware of what his coUeagues are 
doing in evaluating a right to a patent grant and the nature of the contribution 
at each stage of the development. 
ENABLEMENT 
A problem pecuUar to the biological invention wiU be the enablement requke-
ment—that the appUcant provide a description of the invention so that it may be 
practiced by another. This can be very difficult in this field, since frequently 
one is concemed with random cleavage of a genome or portion of a genome. One 
then selects for a fragment by function, infrequentiy reportmg the nucleotide 
sequence of the fragment. There is always the possibiUty that durmg the manipu-
lation of the various DNA fragments, changes have occurred or that durmg the 
synthesis of the plasmid or growth of the transformants, changes occurred m the 
plasmid, which is isolated. The final product may be quite different from the 
description provided by the appUcant, based on what the appUcant reasonably 
expected by virtue of his manipulative steps. Thus, even though the experi-
mentation may be accurately described, the product may substantiaUy differ 
from the description of the final product. 
Furthermore, it is common in this field to minimize the description of the 
various manipulative steps, to refer to an earUer article which teaches tiie pro-
cedure, which was identicaUy or substantiaUy repeated. Since smaU deviations 
can have significant effects, the description in the patent appUcation can be 
nonenabling. However, unlike chemistry, the nonenablement may not be con-
veniently estabUshed. 
As indicated, reproducibUity is very difficult, where a large number of 
fragments from a genomic Ubrary have been obtained, taUored, and then 
estabUshed as providing a particular function. Since repeatmg the experiment 
may result in a clone having a different fragment from the one taught by the 
appUcant, faUure to achieve the appUcant's result is not dispositive of the inoper-
abUity of the patented invention. Unless the specific genetic element is avaUable, 
there is no way to prove whether the patentee did in fact achieve the result 
claimed and described. 
At the present time, there is no requirement for depositing genetic ele-
ments, only ceUs. Where one is not claiming a specific plasmid or specific 
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sequence from a unique source, but rather a function, there has been no require-
ment to deposit the specific sequence which was shown to provide the function, 
nor, as far as I am aware, must one deposit a transformant. However, the law in 
Japan may be different. The Patent Office may wish to consider the desirabiUty 
of requiring various sequences to be deposited, either with the Patent Office or 
some depository. In most instances this wiU not affect the results reported by 
the appUcant but a continued accumulation of changes could result in sub-
stantial confusion. 
USE OF ORGANISMS 
The other area involving processes wiU be the use of organisms, and, of course, 
there is a long history of fermentation patents. There may be some difficulties 
in estabUshing utiUty. For example, where organisms are used in agriculture, 
modified nitrogen fixation organisms must not only provide nitrogen fixation, 
but must also be able to compete with the organisms which are naturaUy present 
in the soU. How is one to prove utiUty in such a situation where differences may 
be smaU and depending on the particular choice of the soil, one wUl obtain a 
variety of results? I do not foresee any serious problems m wording claims 
covering the use of organisms, but as in the case of utflity, there may be 
problems in estabUshing unobviousness. The enormous variety of approaches in 
trying to prove differences and superiority wUl require a substantial Uterature 
before the Patent Office is tmly able to evaluate the significance of any 
differences. 
There are many problems to be confronted in the near future. The present 
patent law is resiUent enough to adopt new approaches and new ways of 
thinking to accommodate the requirements of this field. In my estimation, the 
hybrid DNA technology is now and wUl be of sufficient moment to require new 
ways of thinking in evaluating disclosure and patentabiUty requirements. This 
process involves the mteractions between Exammers and attorneys, where both 
sides wUl become educated as to tiie other's needs. Where the accommodation 
cannot occur at the Examiner level, hopefuUy the Board of Appeals wUl provide 
an educated forum to evaluate the poUcies involved. In any event, tiie courts 
remam the final arbiter of the requirements for obtaining a patent and enforcing 
such patent. 
SUMMARY 
I have tried to give an overview of an enormous subject. The problems I have 
discussed are ones I anticipate encountering and which the other patent prac-
titioners wUl also encounter. The decisions we make now concerning patents 
wUl have far-reaching consequences in tiie development of patent rights in tiie 
field. 
The Patenting of Life Forms Unddr 
the European Patent Convention 
and German Patent Law: 
Patentable Inventions in the Field of 
Genetic Manipulations 
VOLKER VOSSIUS 
Patentanwalt and European Patent Attorney 
8000 Munich, West Germany 
INTRODUCTION TO THE EUROPEAN PATENT 
CONVENTION AND GERMAN PATENT LAW 
For many scientists, the territory of patent law unfortunately represents a con-
fused jungle to be avoided if at aU possible. However, if the economic value of an 
invention is to be exploited, patent protection may make aU the difference be-
tween success and failure of the commercial utilization of the invention. This is 
also tme in the field of biological research. An understanding of the funda-
mentals and functioning of the patent system, and especiaUy of the recent de-
velopments in the law conceming biological mventions, is an important con-
comitant to the scientific work conducted in the field of biotechnology. 
The following chapter provides an introduction to the fundamentals of 
patent law of the European Patent Convention^ (EPC) and West Germany for 
scientists working in the field of biology—biochemists, microbiologists, bota-
nists, mycologists, virologists, bioengineers, and geneticists. It is not a compre-
hensive analysis of these patent laws because the procedures for obtaining a pa-
tent, and the problems of patent invalidation and infringement in this speciaUzed 
field of the law, are rather complex. 
Theory and Purposes of the Patent System 
Although there are major national differences in the way that patent appUca-
tions are handled, the purposes behind the patent system are common to aU. 
The underlying theory behind the patent system is straightforward: It is de-
sirable and in the pubUc interest that, on the one hand, the inventor should have 
the opportunity to reap a just reward for his mvention through the exploitation 
* There are at present 10 member states of the European Patent Convention: Austria, 
Belgium, Federal Republic of Germany, France, Italy, Luxembourg, the Netherlands, 
Sweden, Switzerland (including Liechtenstein), and the United Kingdom. They too have 
amended, or are in the process of amending, their national patent laws to conform to 
the provisions of the EPC. 
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of it and, on the other hand, that technological progress, competition, and the 
inventive efforts of others be spurred on through the disclosure of the invention 
to the public. 
The rights conferred by a patent do not constitute a monopoly m the 
strict legal sense of that term. The patentee does not take anything from society 
that it previously enjoyed, since among the requirements for obtaining a patent 
is one that the invention be new and nonobvious. By grantmg patents, the State 
does not intend to restrict competition; the disclosure of the mvention by the 
appUcant for a patent fosters competition in that other mventors are made 
aware of the inventor's contribution and are encouraged to make other possibly 
patentable contributions. Indeed, the inventor is far more a pubUc benefactor. 
It is because he adds to the wealth and comfort enjoyed by society and pro-
motes the progress of civiUzation that he is awarded the exclusive right to ex-
ploit his invention for a limited period. 
Patentable and Nonpatentable Inventions 
GeneraUy speakmg, patent statutes begm by statmg that "any new invention" 
can form the subject matter of patent grant, and then proceed to define what is 
to be understood by an invention by narrowing the term ^Hnvention." 
For example, the EPC provides m Articles 52 and 53: 
Article 52 
Patentable inventions 
(1) European patents shaU be granted for any mventions which are 
susceptible of industrial appUcation, which are new and which involve an 
inventive step. 
(2) The foUowing in particular shaU not be regarded as inventions within 
the meaning of paragraph 1: 
(a) discoveries, scientific theories and mathematical methods; 
(b) aesthetic creations; 
(c) schemes, rules and methods for performing mental acts, playing 
games or doing business, and programs for computers; 
(d) presentations of information. 
(3) The provisions of paragraph 2 shaU exclude patentability of the 
subject-matter or activities referred to in that provision only to the extent 
to which a European patent application or European patent relates to such 
subject-matter or activities as such. 
(4) Methods for treatment of the human or animal body by surgery or 
therapy and diagnostic metiiods practised on the human or animal body 
shall not be regarded as inventions which are susceptible of mdustrial 
application within tiie meaning of paragraph 1. This provision shall not 
apply to products, in particular substances or compositions, for use in any 
of these methods. 
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Article 53 
Exceptions to patentabiUty 
European patents shaU not be granted in respect of: 
(a) mventions the pubUcation or exploitation of which would be contrary 
to "ordre pubUc" or morality, provided that the exploitation shall not be 
deemed to be so contrary merely because it is prohibited by law or regula-
tion in some or aU of the Contracting States; 
(b) plant or animal varieties or essentiaUy biolo^cal processes for the pro-
duction of plants or animals; this provision does not apply to microbio-
logical processes or the products thereof. 
Thus Article 52, Para. 1 enumerates the prerequisites for a patentable invention. 
This is dealt with below under Section 2, "Substantive Requirements of Patent-
abUity." Conversely, Article 52, Paras. 2 to 4, and Article 53 Ust what may not 
in any case be considered an invention under this law. Articles 1 and 2 of the 
German Patent Law (GPL) essentially contain the same provisions. 
Discoveries 
Of these exemptions from patentabUity, the distinction made between dis-
coveries and mventions is of particular interest to the biologist. A discovery is 
the act of finding something that was already in existence but not previously 
known about. It is a pure act of cognition, not the utUization of cognition with a 
view to producing a technical effect for practical purposes that can be repro-
duced at any time. It is agreed, therefore, that a pure "product of nature" is 
unpatentable. As under 35 USC, Section 101, only a "new" invention is 
patentable. A claim to a microorganism that has existed for years is not 
patentable any more than a claim to the discovery of a manganese nodule found 
by searching the bottom of the Pacific Ocean. An appUcant should not be per-
mitted to roam the forests and oceans and then patent each bush, tree, or 
mineral merely because he was the first to discover a plant product, organism, or 
crystal existing in nature, no matter whether these products were hitherto not 
recognized to possess a certain beneficial property. 
If an invention utilizes natural phenomena, this does not necessarily mean 
that the mvention faUs to provide a technical teaching and is therefore un-
patentable. In generally distinguishing those inventions which are patentable 
from unpatentable matter, the language of the U.S. Supreme Court in the 1978 
decision Parker v. Flook^ is illuminating: 
A principle in the abstract is a fundamental tmth; an original cause; a 
motive, these cannot be patented, as no one can claim in either of them an 
exclusive right. Phenomena of nature, though just discovered, mental 
'Parker v. Flook, 198 USPQ 193 (1978). 
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processes, and abstract inteUectual concepts are not patentable, as they are 
the basic tools of scientific and technological work . . . 
While a scientific tmth, or the mathematical expression of it, is not a 
patentable invention, a novel and useful stmcture created with the aid of 
knowledge of the scientific truth may be (patentable). 
He who discovers a hitherto unknown phenomenon of nature has no claim 
to a monopoly of it which the law recognizes. If there is to be invention 
from such a discovery, it must come from the appUcation of the law of 
nature to a new and useful end . . . 
Patentability of Biological Inventions 
In accordance with the landmark decision *Rote Taube* (Red Dove) and 
^Bdckerhefe* (Baker's yeast) by the CJerman Federal Supreme Court (BGH) of 
27 March 1969^ and 11 March 1975*, the systematic utilization of biological 
forces and phenomena can be protected by patent. The question of whether life 
forms or products of nature are concerned is quite irrelevant. The only decisive 
factor is whether technical inventions are mvolved, as opposed to mere dis-
coveries or mental processes.^  
Article 53, Para, (b) of the EPC and the corresponding regulation adapted 
to it in the GPL exclude from patentabiUty plant or animal varieties or es-
sentiaUy biological processes for the production of plants or animals. This 
provision stimulates refiection as to how biological inventions can best be pro-
tected. The expression "essentiaUy biological processes for the production of 
plants or animals" means that standard biological (natural) processes for 
propagating plants and animals are not patentable. A further essential criterion 
is that a technical invention be involved and not merely perceptions or intel-
lectual processes. A techmcal invention is involved if an instmction is given to 
achieve a technical result by using specified technical means to solve a technical 
problem. The systematic use of controUable natural forces is an mdispensable 
prerequisite for affirming the techmcal nature of a biological mvention. 
With respect to the patentabiUty of plant and animal species, reference is 
made to the Guidelines for Examination m the European Patent Office (EPO), 
C-IV.3.4 and 3.5, where examples are given as to how the term "essentiaUy 
biological" is to be interpreted. An example of what is patentable would be 
a process for treating plants or animals so as to improve their properties or 
their yield, or else to promote or inhibit their growth. Further examples of 
patentable processes are also given in C-IV.4.3. The guideUnes further state 
that not only those processes are patentable that make use of microorganisms, 
as weU as nonUving products where these are prepared by means of such a 
'GRUR 1969,672; lie Vol. 1 (1970), 136 (EngUsh translation). 
*GRUR, 1975, 430; lie Vol. 6 (1975), 207 (EngUsh translation). 
'BGH decision 22 June 1976, GRUR 1977, 96-Dispositions programme IIC VoL 
8 (1977), 558 (EngUsh translation). 
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microbiological process, but also that a patent can be granted for microor-
ganisms themselves. Special attention, however, should be paid to the requUe-
ments as to reproducibUity (C-II.4.11). 
The Various Types of Biological Inventions 
Biological forces can be activated m the foUowing ways: 
1. the course of a biological phenomenon is influenced by inanimate natural 
means; 
2. inanimate nature is influenced with the aid of biological forces; 
3. effects in the field of biological phenomena are achieved using biological 
means. 
The first-mentioned kind of mventions embrace, for example, disinfection 
and pest control, agricultural cultivation processes, therapeutic and cosmetic 
processes, mduced mutation and selection processes, the preparation of active 
dry yeast, the chemical dedikaryotization of basidiomycetes, the isolation of 
protoplasts and the creation of plants from isolated protoplasts by treatment 
with phytohormones, the production of Upid vehicles, the isolation of plasmids, 
processes for the mtroduction of hybrid DNA into host ceUs, and the chemical 
attenuation of pathogenic microorganisms and viruses. 
The second kind of inventions relate to fermentation processes caused by 
microorganisms, for example alcohoUc fermentation; production of butanoland 
acetone; production of beer, organic acids such as oxalic acid and citric acid, 
amino acids such as glutamic acid and lysine, and of vitamins, antibiotics, and 
antitoxic serums; processes for culturing pearls in oysters and for microbially 
leaching ores; processes in which microbes are used to combat poUution by 
cmde oU;and biologic processing of waste water. 
The third kind of inventions mclude the production (propagation) of vkus 
material in the embryonated chick egg or in tissue cultures; the breeding of 
microorganisms such as yeasts, and of plants and animals; somatic hybridization; 
gene technology; and the cloning of higher organisms. 
Patent Categories 
The term patent categories means the specific forms of the invention subject 
matter as reflected in the claims. These are distinguished from each other by 
variations in the scope of patent protection. In principle, there are two cate-
gories of patents: (1) product patents and (2) process patents. Table 1 shows the 
categories of inventions, together with examples taken mamly from the field of 
biological inventions. 
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Unity of Inventions and Categories of Claims 
According to the principles recently elaborated upon, predominately by the 
German Federal Patent Court and Supreme Court*, on the question of unity of 
a complex of inventions, claims of several patent categories can be set up in one 
and the same appUcation if the claims are based on a unitary problem and if the 
claims of the various patent categories relate to the same invention in their 
different patent law forms. According to German law, unity is to be assessed on 
the principles of the decisions by the Reichspatentamt of September 24, 1913 
(GRUR 1913, 281), which principles have been taken over by tiie BGH (GRUR 
1971, 512—Isomerisierung). According to these principles the term "invention" 
defined in Section 35, Para. 1, Sentence 2 of the GPL can if necessary also be 
taken to mean a complex of inventions. When assessing the necessary commercial 
and technical context, care should also be taken to avoid an unnecessary frag-
mentation of appUcations and to ensure that interrelated questions are dealt 
with in the same procedure (BGH decision Isomerisierung, loc. cit.; GRUR 1974, 
774—Alkalidiamidophosphite). Of course, this also applies to inventions in the 
field of microbiology''. A patent application is uniform if the parts of the appU-
cation are technically linked to each other and aU contribute to the solution of 
the overall problem. The patent law guarantees the inventor or his successor in 
title a legal right to grant a patent for the invention in the legaUy estabUshed 
grant procedure. The inventor can thus demand that the patent basically be 
granted in the form corresponding to the new technical teaching given (BGH 
GRUR 1970, 601—Fungizid). If this teaching can be embodied in more than one 
claim form, then the claim for patent grant by the applicant must be interpreted 
so as to encompass all forms in which the invention might appear. This appUes to 
a teaching that can be classified into various claim categories (BGH, loc. cit.), 
and in the same way to a teaching that can be expressed in several ways within 
the same category, as long as these are eligible for protection (BGH, December 
14,1978, GRUR 1979, page 461-Farbbildrdhre). 
In the EPC, tiie permissibiUty of claims for more tiian one patent category 
can be inferred from Article 82 and Rule 29, Paras. 2 and 30. From this it 
follows that the foUowing three types of claims, for example, can be set up in 
one patent appUcation: 
1. Antibiotic X. 
2. Process for preparing the antibiotic X of claim 1, characterized by cultivating 
the microorganism Y (if necessary further identified by the depository and 
the deposition serial number) in a nutrient medium and isolating the anti-
biotic from the culture broth. 
3. The use of antibiotic X of claim 1 for combating bacterial infections, or 
pharmaceutical composition characterized by a content of the antibiotic X 
according to claim 1. 
«GRUR 1970, 601-Fungizid; GRUR 1971, 512-Isomerisierung; GRUR 1972, 
638-Aufhellungsmittel; GRUR 1972,644 -Gelbe Pigmente. 
'GRUR 1975,430-Beickerhefe. 
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It goes without saymg that in a single claim an unlimited number of micro-
organisms may be clauned for carrying out a specific process if the problem 
underlying the invention is novel and solved for the first time or if the problem 
is old and was not solved before. 
In order for a microorganism to be protected by a product claim, the BGH 
at present requires that a practicable teaching for producing the microorganism 
be given. The BGH has expressly noted that it is not sufficient to deposit a new 
microorganism in order to secure a product claim (BGH, GRUR 1975, 430— 
Bdckerhefe (Baker's yeast); GRUR 1978, \62-7-Chlor-6-demethyltetracyclin). 
Only a short time ago, the BGH confirmed these decisions and stated that no 
aspects had arisen that would cause this viewpoint to be abandoned (BGH, 
GRUR 1981, 263-Bakterienkonzentrat). One can, however, read into this 
observation a wilUngness to reconsider m the future the viewpomt that has pre-
vaUed to date. This could, in particular, be brought about by the enactment of 
the amended provisions on the prerequisites for patentabiUty in Sections 1 and 2 
of the GPL—which now conform to the EPC—and the enactment of the 
Budapest Treaty on the Intemational Recognition of the Deposit of Micro-
organisms. The opinion in the German scientific Uterature is that product daims 
are admissible for new microorganisms if the microorganism in question has 
been deposited and is accessible at a depository (see V. Vossius, "Der Patent-
schutz von Mikroorganismen und Viren nach dem deutschen Patentgesetz und 
dem zukunftigen europaischen PatenterteUungsverfahren," GRUR 1973, 159; 
W. Triistedt^ 'Tatentierung mikrobiologischer Erfindungen," GRUR 1981, 
95; and R. Teschemacher^, "Die Patentfahigkeit von MUcroorganismen nach 
deutschem und europaischem Recht," GRUR Int. 1981,357). 
The EPO, on the other hand, aUows product claims solely on the basis of 
deposition of a new microorganism. It remains to be seen whether such extended 
or faciUtated patent protection for microorganisms wiU be confirmed in op-
position proceedings before the EPO. 
According to decisions of the BGH and the Federal Patent Court product-
by-process claims (e.g., for microorganisms) are admissible if the product cannot 
be identified by distinctive characteristic parameters* ° . 
Furthermore, the recent decisions of the BGH and the Federal Patent 
Court concerning the patentabUity of intermediate products can be appUed to 
microbiological processes and novel products obtained according to these 
processes. A novel intermediate product is patentable if: 
I. The novel end-product obtained tiierefrom by further reaction exhibits ad-
vanced and nonobvious properties or effects over comparable prior art pro-
ducts and an adequate causal relationship exists between the properties, 
*Note: Former Presiding Judge of the Xth Senate of the Federal Supreme Court, i.e. 
the "Patent Senate." 
^Note: Member of the EPO. 
'"GRUR. 1972, SO-Trioxan; GRUR. 1973. A6l~Thermothiocin\ GRUR, 1978, 
S%\-Lactobacillus bavaricus. 
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e.g., the chemical constitution of the intermediate product and properties 
or effects that become evident when the end-product is used* *. However, 
the original case papers must disclose how the mtermediate product is further 
reacted to obtain the end-product, unless this is obvious to those skiUed in 
tiie art* ^ . 
2. A known end-product can be prepared from the intermediate product in an 
advanced and not foreseeable manner, i.e., by a nonobvious process*^. 
SUBSTANTIVE REQUIREMENTS FOR PATENTABILITY 
Industrial Applicability and Utility 
The patent laws of most countries require that the invention show some utUity 
in order for it to be patentable. This requirement is also known as that of in-
dustrial appUcabiUty**. 
The requirement of industrial appUcabiUty of an invention means under 
the EPC and GPL that the subject matter of the invention is suited either to 
manufacture in an industrial plant or to industrial use. The mere possibiUty of 
manufacturing or using the invention in an industrial field of any kind is 
sufficient. 
In U.S. patent law, the utiUty requirement and its original disclosure in 
the appUcation play an important role in establishing patentabiUty. Indeed, it 
has been commented that the basic consideration contemplated by the U.S. 
Constitution and the U.S. Congress for granting a patent monopoly is the 
benefit to be derived by the pubUc from an invention with substantial utility. 
In authorizing Congress to estabUsh a patent system, the Constitution specif-
ically mentions that it is the **useful Arts," today understood to mean the 
technological arts, which are to be promoted by the patent system. Thus, Sec-
tion 101 of the U.S. Patent Act proclaims that it is "any new and useful process, 
machine, manufacture, or composition of matter, or any new and useful 
improvement thereof..." that may be patented*^. 
The UtiUty of the invention must either be verbaUy disclosed in the specifi-
cation 6t be such that the average expert can deduce it therefrom. In order to 
comply with U.S. law, a patent must adequately teach those skiUed in the art 
how to use the mvention. The utiUty must further be a technical one. Mere 
usefulness for chemical research wiU not satisfy the patent law's utiUty re-
quuement. Thus, a claim that the invention is useful "in having biological 
properties'* is not a sufficient disclosure of utiUty. By contrast, a Uve vaccine 
against measles possesses utiUty. 
'»GRUR 1969,26S-Disihxan;GRUR 1974, l\Z-Chinolizine. 
•'GRUR \912,\6A2-Lactame. 
• 'GRUR 1974,27 2-Aminomethylindole. 
** Article 52(1) of the EPC provides that: "European patents shaU be granted for any 
inventions which are susceptible of industrial appUcation, which are new and which involve 
an inventive step." 
' ^See Peter D. Rosenhtig, Patent law fundamentals, 2nd ed., chapter 8 (1980). 
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Novelty 
A further basic requUement for every mvention to be patented is that it is 
"novel." This in general means that its subject matter was not yet pubUcly 
known before the date of the appUcation or priority date for a patent. The 
entire knowledge (written or oral pubUcations, prior use) before the date of the 
appUcation or priority date is generaUy caUed the "state of the art" or "prior 
art." However, in the various countries, certain differences exist as to the kind 
of knowledge that has to be regarded as a bar to the novelty of an mvention. 
Many countries have adopted the so-caUed "absolute novelty" criterion. 
This means that everything made avaUable to the pubUc anywhere in the worid, 
even 1 day before the date of filing of the patent appUcation, is considered a bar 
to novelty. The EPC and GPL, for instance, contain a strict novelty requirement 
of tius type; Article 54 (1) to (3) of the EPC states: 
(1) An invention shaU be considered to be new if it does not form part of 
the state of the art. 
(2) The state of the art shaU be held to comprise everythmg made available 
to the pubUc by means of a written or oral description, by use, or in any 
other way, before the date of fiUng of the European patent appUcation. 
(3) AdditionaUy, the content of European patent appUcations as filed, of 
which the dates of filing are prior to the date referred to in paragraph 2 
and which were published under Article 93 on or after that date, shaU be 
considered as comprised in the state of the art. 
The U.S. Patent Act, by contrast, contains a more restricted concept of 
novelty. Section 102(a) provides that: 
A person shaU be entitied to a patent unless—(a) the mvention was known 
or used by others in this country, or patented or described in a printed 
pubUcation in this or a foreign country, before the mvention thereof by 
the appUcant for patent. 
Although the oral or written pubUcation of research results is a contribu-
tion to the scientific commumty, such a description even 1 day before the filing, 
of a patent appUcation is judged detrimental to novelty m most countries. Be-
fore any written or oral description of an invention is made, the poUcy as to 
fiUng a patent appUcation and the patentabUity of the invention should there-
fore first be carefuUy reviewed. If patent protection is to be sought, it is essential 
to file a patent appUcation before any essential details about the invention are 
published. 
In order to constitute a bar to novelty, the technical teaching of the in-
vention must be described in a prior pubUcation in such a way that the 
average expert, on the basis of his technical knowledge at the time the invention 
was filed, and without any additional effort of his own, is able directiy to 
deduce the invention. Nothing may be introduced that is not already contained 
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in the technical teachmg; neither can anything be described as prior art that the 
expert thinks he can deduce from the description by drawing upon his own 
knowledge and experience to enlarge upon what is described there. 
Patentable subject matter must be new, not merely previously unknown. 
The policy reason for this rule is founded upon the proposition that in the 
granting of patent rights the pubUc must not be deprived of any rights that it 
previously freely enjoyed. 
The foUowing question has been controversial: Do inventions in the field 
of natural (biological) products satisfy the novelty requirement or are they 
part of the public domain because the subject of the invention exists in nature? 
The volume of case law that has been concemed with this question is large; how-
ever, recent developments in the patent law of West Germany clearly indicate 
that the mere fact that an invention exists in some form in nature wUl not in 
itself present a bar to patentabUity; see for example, the Naturstoffe Decision 
of tiie German Federal Patent Court, GRUR 1978,238 (product protection for 
the natural substance antamanide prepared using a synthetic process is not 
excluded simply because antamanide also occurred in nature); the 
Menthonthiole Decision of the German Federal Patent Court, GRUR 1978,702 
(discovering the active ingredient of a natural scent and then inventing a process 
for the synthetic production held patentable notwithstanding that the product 
also occurred in nature); and the Lactobacillus bavaricus Decision of the German 
Federal Patent Court, GRUR 1978, 586 (a pure culture of a microorganism 
where the invention meets the other requirements of patentabUity). 
Where a prepublished reference relates to a biological process that makes 
use of a specific microorganism or virus, the use of its teaching is only possible 
if the strain itself is readily obtainable, i.e., can be produced or reisolated. If the 
stram becomes accessible only after prepublication, then the information given 
in the publication can on principle be considered prior art only from this point 
onwards. In this case the mere description of a microorganism or the process 
carried out with its aid is not sufficient to negate the novelty of a later patent 
appUcation*^. 
Nonobviousness (Inventive Step) 
Apart from the requirement that an invention show utility and be novel, patent 
laws also demand that the invention show an inventive step or not have been 
obvious from what was already known in the relevant art at the time the ap-
pUcation was filed. Thus, according to Article 56 of the EPO: "An invention 
shall be considered as involvmg an inventive step if, having regard to the state 
of the art, it is not obvious to a person skiUed m the art." 
• 'Decision of German Federal Patent Court of 17 November 1970, Bl. f. PMZ 1971, 
190. 
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The U.S. Patent Act in Section 103 proceeds from the requirement that 
the invention must not be obvious to a "person havmg ordinary skiU in the 
art*^." Therefore, a vaUd patent cannot be granted if the subject matter of the 
invention as a whole had been obvious to the "average expert" m the relevant 
field of technology to which the invention belongs. 
Although patent laws up to now have been unable to define clearly what is 
meant by nonobviousness or inventive step, and although the requirements in 
this respect may vary from one country to another, the concept of mventive 
activity carmot be based upon the inventor's own opiiuon of what he has 
achieved. Rather, the question of nonobviousness of a (novel) invention must be 
decided from the viewpomt of the average expert having knowledge of the prior 
art. The assessment of whether an inventive step has been achieved is based upon 
an objective judgment. Furthermore, the entire state of the art must be taken 
mto consideration when assessmg whether an inventive step has been made**. 
In German case law, a set of considerations or indications has developed 
for determining whether an mvention meets the requirements of mventiveness. 
These considerations are deemed to be indicia of nonobviousness. They may in-
clude, among others, that the invention: 
1. have a surprising effect; 
2. satisfy a longfelt demand; 
3. be a pioneer invention; 
4. overcome a general prejudice on the part of experts in the field; 
5. achieve a commercial success; 
6. overcome previous difficulties; 
7. have been perfected only after extensive research and development; 
8. make use of a longstanding prior art; 
9. be in a field in which Uttie research has been undertaken; 
10. constitute a "lucky strike" out of a multitude of possibUities (selection 
invention); 
11. demonstrate technical advance. 
It is not requUed that the invention should have come to the inventor in a "flash 
of genius." 
Under no circumstances can inventiveness be determined using the 
knowledge of hindsight. The level of inventiveness, just as tiie determination of 
whether an invention is novel, must be made in consideration of the knowledge 
* i7 35 U.S.C. 103 provides that: "A patent may not be obtained tiiough the invention 
IS not identically disclosed or described as set forth in section 102 of tiiis title" (i.e., tiiough 
It IS novel) If the differences between the subject matter sought to be patented and the 
prior art are such that the subject matter as a whole would have been obvious at die time 
the invenUon was made to a person having ordinary skUl in tiie art to which said subject 
matter pertains. PatentabiUty shaU not be negatived by tiie manner in which die invention 
was made. 
"See e.g., BGH decision 2 October 1973, GRUR 1974, \AB-Stromversorgungsein-
richtung. 
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of the average expert at the time of the appUcation who was not yet famUiar 
with the invention. 
Inventions in microbiology generaUy possess inventiveness*'. The use of 
a novel or known microorganism strain with specific properties in a biotechno-
logical process is deemed a "lucky strike," i.e., it must be considered inventive^®. 
Inventiveness must as a rule be affirmed if a process uses the metaboUc 
activity of a newly discovered microorganism in order to manufacture a known 
product. These observations reflect the general knowledge of microbiologists 
that analogous conclusions drawn from the metaboUsm of one species about that 
of another are not reUable. In view of the fact that predictions in the micro-
biological sector are rather uncertam, a process claim based on the use of a novel 
or known microorganism to produce a novel or known product is prima facie 
not obvious. 
Disclosure 
General Remarks 
As previously mentioned, a patent is a document granted by a government 
patent office, i.e., the State. This document describes an invention and claims 
certain exclusive rights in the subject matter of that invention. Thus, it is a 
document that attests legal rights. This document consists essentiaUy of two 
parts: (1) the descriptive portion (description) and (2) the claims, specifying the 
legal protection granted. The validity and scope of protection of the patent 
depend decisively upon the manner in which the description and claims are 
written. It is therefore highly important to understand the functions of the 
written representation of the patent. 
The Description 
The function of the description is to describe the invention in such terms that 
any person skUled m the art to which it pertams may practice it. This requue-
ment is common to all patent systems and is generally referred to as the "dis-
closure requirement." Article 83 of the EPC states: "The European patent 
appUcation must disclose the invention in a manner sufficientiy clear and com-
plete for it to be carried out by a person skiUed in the art." 
Generally, an invention is sufficientiy disclosed if the technical teaching 
is such that the average expert havmg the disclosure before him could practice 
the invention without applying inventive effort of his own, even if some experi-
ments are first required. These experiments, however, may not exceed reason-
able limits. If undue experimentation is requhed, the disclosure is insufficient. 
"German Federal Patent Court of 26 June 1964, BP at GE 6, 33. 
"German Federal Patent Court of 30 June 1967, BP at GE 9,150. 
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It should be noted that the skiU expected of the average expert is not a fixed 
woridwide standard, i.e., it may be differentiy mterpreted in the Umted States 
than in the European Convention countries. 
In the United States, Section 112 of the Patent Act provides that the de-
scription of the invention be "in such fuU, clear, concise and exact terms as to 
enable any person skiUed in the art to which it pertains, or with which it is most 
nearly connected, to make and use the same." This requirement is the basis for 
the so-called "enabUng" disclosure in the United States. AdditionaUy, this 
Section requires that the specification "set forth the best mode contemplated by 
the inventor of carrying out his mvention." There is no corresponding pro-
vision in the GPL or the EPO. 
In most cases the description begins with a title, foUowed by a short dis-
cussion of the prior art, the definition of the problem (the technical task) to 
which the invention is addressed, the proposed solution with a clear and 
complete description of the invention, and, finaUy, workmg examples to 
iUustrate the invention. The description of the invention usuaUy contains aU the 
technical detaUs, starting with a description of, for example, the microorganism, 
virus, or vector, and any drawings, etc., that are used. It is a matter of course 
that the characterization and nomenclature of microorgamsms and viruses con-
form to scientifically acknowledged principles. Parameters (e.g., pressure, 
temperature, concentration, permissible substitutes, etc.) are usuaUy expressed 
in several ranges, i.e., the widest possible region within which the invention is 
operable, and the preferred and most preferred range. The mvention should be 
Ulustrated by way of specific examples set forth in sufficient detaU so that the 
average expert skilled in the pertinent art can reproduce the results of the 
invention. One or two examples are common for mechanical mventions, whereas 
it is not unusual for chemical or biological patents to have as many as 20 or 
more. 
In drafting the specification, it is advisable to make the disclosure as 
complete and thorough as possible. As in the United States, it is a ground for 
denying the grant of a patent or for invaUdating one that is aheady issued, if 
the invention is not disclosed sufficiently clearly and completely^*. Thus, if 
there is any doubt whether certain measures are generaUy known to experts in 
the field, it is by far the wiser practice to fuUy describe such measures in the 
specification. In tiiis way a rejection by the Examiner owing to insufficient 
disclosure wiU be avoided. 
Deposition of Microorganisms 
When microbiological inventions are concerned, e.g., biotechnical processes 
using microorganisms so far unknown and the cultivation of new microor-
ganisms, considerable difficulties wUl arise in meeting the requirement that the 
invention must be disclosed sufficientiy clearly and completely in a written de-
" Article 100 EPC and Articles 21 and 22 of tiie German Patent Uw. 
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scription that it may be carried out by a person skiUed in the art. In order to 
enable others skiUed in the art to use such inventions, it is not sufficient to state 
in the specification where the microorganism was found. The isolation procedure 
must be described. Moreover, a good taxonomic description should be ^ven 
and the morphological and physiological properties of the microorganism must 
be disclosed in order to identify it unambiguously^^. 
With regard to the controversial question of sufficient disclosure of a 
microbiological invention on tiie appUcation date, the German Federal Patent 
Court rendered a decision on 30 June 1967^^ acknowledging the fact that the 
description of such an invention in writing, drawing, and formula is not 
sufficient if the invention makes use of the metaboUsm of a microorganism not 
described in the literature. In the case of such inventions, the Federal Patent 
Court wUl only regard the disclosure on the appUcation date as sufficient if the 
microorganism is deposited at a suitable depository at the latest on the appUca-
tion date, and if the place of deposition and the designation of deposition are 
indicated in the original case papers. With respect to the possibiUty of repro-
ducing such processes by opponents, this decision states that opponents are 
entitled to be suppUed with a culture of the organism. The Federal Patent Court 
did not make a final statement on the question of unUmited availabiUty to the 
pubUc, but merely referred to the practice of the U.S. Patent Office. 
In line with this case law, the German Federal Patent Court in its Levorin 
decision of 9 October 1973^ "* rejected an appUcation owing to insufficient dis-
closure on the grounds that the microorganism claimed was not deposited. In 
its decision of 12 October 1973^^ the German Federal Patent Court considered 
the date of publication of the Auslegeschrift (examined German patent pubUca-
tion) to be the latest possible date for access to the microorganism. The German 
Federal Supreme Court in its Bdckerhefe decision^^ did not accept this point 
of view and ruled that the deposited microorganism should be released to 
interested parties at the time of first pubUcation of the application papers, i.e., 
about 18 months after the priority or fiUng date, whichever is applicable. 
In the landmark decision Mikroorganismen (Microorganisms) by the 
German Federal Patent Court of 22 March 1976^" ,^ the procedure of releasing 
deposited microorganisms was dealt with point by point. Thus, the effectiveness 
of an irrevocable declaration of release for a deposited microorganism 
presupposes: 
1. that the microorganism is deposited at a suitable depository (not necessarily 
a (Jerman depository) for a sufficient period of time; 
''See also the decision of British Patent Office of 5 April 1974, Pfizer Incorporated 
AppUcation; RPC 1974,689. 
"BPatGE9,150. 
"GRUR 1974, 392. 
"BL.f. PMZ 1974, 201. 
"GRUR 1975,430. 
"GRUR 1977, 30; IIC VoL 8 (1977), 533 (English translation). 
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2. that the depository was irrevocably authorized to release as of the date of the 
first pubUcation, at any time, viable samples to the authorities mvolved in the 
patent-granting procedure and to third parties; 
3. that, as of the first pubUcation, the depositor no longer has any power of 
disposition with respect to the deposited microorganism; 
4. that the wiUingness of the depository to proceed m accordance with the 
declaration of release is proved; 
5. that tlurd parties can, on reasonable conditions, obtain viable samples of the 
deposited microorganism. 
Regarding pomt 1, when fixmg the storage period m its decision of October 6, 
1977^®, tiie Federal Patent Court was guided by Rule 9 of the Regulations of 
the Budapest Treaty on the Intemational Recogmtion of the Deposit of Micro-
organisms for the Purpose of Patent Procedure. This means that the deposited 
strain has to be stored for at least the legaUy possible Ufe of the (jerman patent 
(20 years) plus 5 years after the last request for a sample, however, at least 30 
years after deposition. 
Thus, from the viewpoint of patent law, it appears reasonable, when 
referring to microbiological mventions, to so interpret the respective legal 
provisions that for a sufficient disclosure of the invention, the foUowing should 
be considered adequate: the disclosure of its isolation or selection, the 
taxonomy, morphology and physiology, and, if necessary, the deposition of the 
strain and its accessibiUty to those skiUed m the art. 
The requirements with regard to reproducibiUty that biochemical 
process have to fulfiU for the purposes of adequate disclosure correspond to the 
requirements which the German Patent Office and the Federal Supreme Court 
have ruled in the case of other mventions. It suffices if the description and the 
patent claims indicate the key direction, i.e.. the features of the teaching 
essential to the invention, and the person skUled in the art can be expected to 
carry out a series of tests. The average expert must, however, be able to carry 
out these tests using the information given by the appUcants and drawing upon 
his own technical knowledge and skiUs, and without the need for inventive 
effort on his part. He must further be able to do this so expedientiy that witii 
reasonable expenditure of time and effort he wUl presentiy be able to form a 
reUable picture as to which of the measures indicated he must take in order to 
arrive at the desired result. 
As already mentioned, accorduig to Article 83 of the EPC, "the European 
patent appUcation must disclose tiie invenUon in a manner sufficientiy clear 
and complete for it to be carried out by a person skUled in tiie art." In Rule 
28 and Rule 28a of the Implementing Regulations to tiie EPC. specific pro-
visions have been included for patent appUcations relating to microorganisms 
with a view to meeting the requirements of Article 83. Rule 28 reads as foUows: 
"BPatGE20,127. 
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Rule 2 8 " 
Requirements of European patent appUcations relating to micro-organisms 
(1) If an invention concerns a microbiological process or the product 
thereof and involves the use of a micro-organism which is not avaUable to 
the pubUc and which cannot be described in the European patent applica-
tion in such a manner as to enable the invention to be carried out by a 
person skiUed in the art, the invention shaU only be regarded as being 
disclosed as prescribed in Article 83 if: 
(a) a culture of the micro-organism has been deposited with a recognised 
depositary institution not later than the date of filing of the application; 
(b) the appUcation as filed gives such relevant information as is avaUable 
to the applicant on the characteristics of the micro-organism; 
(c) the depositary institution and the file number of the culture deposit 
are stated in the application; 
(2) The information referred to in paragraph 1(c) may be submitted: 
(a) within a period of sixteen months after the date of filing of the appU-
cation or, if priority is claimed, after the priority date; 
(b) up to the date of submission of a request for early pubUcation of the 
appUcation; 
(c) within one month after the European Patent Office has communi-
cated to the applicant that a right to inspection of the files, pursuant to 
Article 128, paragraph 2, exists. 
The ruUng period shall be the one which is the first to expire. The com-
munication of this information shaU be considered as constituting the 
unreserved and irrevocable consent of the appUcant to the deposited 
culture being made available to the pubUc in accordance with this Rule. 
(3) The deposited culture shaU be avaUable upon request to any person 
from the date of pubUcation of the European patent appUcation and to 
any person having the right to inspect the files under the provisions of 
Article 128, paragraph 2, prior to that date. Subject to the provisions of 
paragraph 4, such avaUabiUty shaU be effected by the issue of a sample 
of the micro-organism to the person making the request (hereinafter 
referred to as the "requester"). Said issue shall be made only if the re-
quester has undertaken vis-a-vis the applicant for or proprietor of the 
patent: 
(a) not to make the deposited culture or any culture derived therefrom 
avaUable to any third party before the appUcation has been refused or 
withdrawn or is deemed to be withdrawn or,if a patent is granted, before 
the expiry of the patent in the designated State in which it last expires; 
(b) to use the deposited culture or any culture derived therefrom for ex-
perimental purposes only, untU such time as the patent application is 
"Amended by decision of the Administrative Council of 30. 11. 1979 which en-
tered into force on 1. 6.1980 (Official Joumal 11-12/79, p. 447). 
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refused or withdrawn or is deemed to be withdrawn, or up to the date of 
pubUcation of the mention of the grant of the European patent. This 
provision shall not apply insofar as the requester is using the culture 
under a compulsory licence. The term "compulsory Ucence" shaU be 
construed as including ex officio Ucences and the right to use patented 
inventions in the public interest. 
(4) UntU the date on which the techmcal preparations for pubUcation of 
the appUcation are deemed to have been completed, the appUcant may 
inform the European Patent Office that, untU the pubUcation of the 
mention of the grant of the European patent or until the date on which 
the appUcation has been refused or withdrawn or is deemed to be with-
drawn, the availabiUty referred to m paragraph 3 shaU be effected only 
by the issue of a sample to an expert nommated by the requester. 
(5) The foUowing may be nominated as an expert: 
(a) any natural person provided that the requester furnishes evidence, 
when fiUng the request, that the nomination has the approval of the 
appUcant; 
(b) any natural person recognised as an expert by the President of the 
European Patent Office. The nomination shaU be accompanied by an 
undertaking from the expert vis-a-vis the appUcant; paragraph 3 (a) and 
(b) shall apply, the requester bemg regarded as a third party. 
(6) For the purposes of paragraph 3, a derived culture is deemed to be any 
culture of the microorgamsm which stiU exhibits those characteristics of 
the deposited culture which are essential to carrymg out the invention. 
The undertaking referred to in paragraph 3 shaU not impede a deposit of 
a derived culture, necessary for the purpose of patent procedure. 
(7) The request provided for m paragraph 3 shaU be submitted to the 
European Patent Office on a form recognised by that Office. The 
European Patent Office shall certify on the form that a European patent 
appUcation referring to the deposit of the micro-organism has been fUed. 
and that the requester or the expert nominated by him is entitied to the 
issue of a sample of the micro-organism. 
(8) The European Patent Office shall transmit a copy of the request, 
with the certification provided for in paragraph 7, to the depositary 
institution as weU as to the appUcant for or the proprietor of the patent. 
(9) The President of tiie European Patent Office shall pubUsh in tiie 
Official Journal of the European Patent Office the list of depositary 
institutions and experts recognised for the purpose of this Rule. 
Rule 28a reads: 
Rule 28a^° 
New deposit of a micro-organism 
(1) If a micro-organism deposited in accordance with Rule 28, paragraph 
"Inserted by decision of the Administrative CouncU of 30. 11.1979 which entered 
into force on 1.6. 1980 (Official Journal 11-12/79, p. 449). 
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1, ceases to be avaUable from the institution with which it was deposited 
because: 
(a) the micro-organism is no longer viable, or 
(b) for any other reason the depositary institution is unable to supply 
samples, 
and if the micro-organism has not been transferred to another depositary 
institution recognised for the purposes of Rule 28, from which it con-
tinues to be available, an interruption m availabiUty shall be deemed not to 
have occurred if a new deposit of the micro-organism origmaUy deposited 
is made within a period of three months from the date on which the 
depositor was notified of the interruption by the depositary mstitution 
and if a copy of the receipt of the deposit issued by the institution is 
forwarded to the European Patent Office within four months from the 
date of the new deposit stating the number of the application or of the 
European patent. 
(2) In the case provided for in paragraph 1(a), the new deposit shaU be 
made with the depositary institution with which the original deposit was 
made; in the cases provided for in paragraph 1(b), it may be made with 
another depositary institution recognised for the purposes of Rule 28. 
(3) Where the institution with which the original deposit was made ceases 
to be recognised for the purposes of the appUcation of Rule 28, either 
entirely or for the kmd of micro-organism to which the deposited micro-
organism belongs, or where that institution discontinues, temporarUy or 
definitively, the performance of its functions as regards deposited micro-
organisms, and the notification referred to in paragraph 1 from the 
depositary institution is not received within six months from the date of 
such event, the three-month period referred to in paragraph 1 shaU begin 
on the date on which this event is announced in the Official Joumal of 
the European Patent Office. 
(4) Any new deposit shaU be accompanied by a statement signed by the 
depositor alleging that the newly deposited micro-organism is the same as 
that originally deposited. 
(5) If the new deposit provided for in the present Rule has been made 
under the provisions of the Budapest Treaty on the International Recog-
nition of the Deposit of Micro-organisms for the Purposes of Patent 
Procedure^* of 28 April 1977, the provisions of that Treaty shaU prevail 
in case of conflict. 
Rule 28, Para. 9 authorizes the President of the EPO to enter into agreements 
with culture collections for the purposes of patent procedure. 
Below is a list of some culture coUections with which an agreement has 
been concluded or is to be concluded: 
^^Note: The Budapest Treaty provides, among other things, that the deposition of 
patent strains with a single internationaUy recognized depository shall be recognized by the 
patent offices of the contracting states. 
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1. Institut Pasteur 
28 rue du Docteur Roux 
75724 Paris, Cedex 15, France 
2. Centraal Bureau voor Schimmelcultures 
Oosterstraat 1 
Baam, The Netherlands 
3. Torry Research Station 
P.O. Box 31 
135 Abbey Road 
Aberdeen AB9 8DG, Scotiand 
4. Commonwealth Mycological Institute 
Ferry Lane 
Kew, Surrey, England 
5. National CoUection of Plant Pathogenic 
Bacteria 
Plant Pathology Laboratory 
Hatching Green, Harpenden (Herts.), England 
6. National CoUection of Yeast Cultures 
Brewmg Industry Research Foundation 
Lyttel HaU, Nuffield 
RedhUl, Surrey RHl 4HY, England 
7. National CoUection of Type Cultures 
Central PubUc Health Laboratory 
Colindale Avenue 
London, NW9 5HT, England 
8. Statens Bakteriologiska Laboratorium 
10521 Stockholm, Sweden 
9. Deutsche Sanunlung von MUoro-Organismen 
Griesebachstrai3e 8 
3400 CJottingen, West Germany 
10. Forschungsinstitut Borstel 
Institut fur ExperimenteUe Biologie und 
Medizin 
2061 Borstel, Schleswig-Holstein, West Germany 
11. Agriculture Research Service 
Culture CoUection 
Northern Regional Research Laboratory 
Peoria, lUinois 61604, USA 
12. American Type Culture CoUection 
12301 Parklawn Drive 
RockviUe, Maryland 20852, USA 
13. Fermentation Research Institute 
Inage 
Chiba City, Japan 
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14. Institute for Fermentation 
17-85 Juso-Honmachi 
2-Chome 
Yodogawa-Ku 
Osaka 532, Japan 
The Claims—Scope of Protection of a Patent 
The legislation and the courts in various countries have tried in various ways to 
solve the problem of the conflicting interests of the patentee (or his successor 
m titie) and the pubUc. The fact that these interests are not identical is mdicated 
by the concem of the patentee to be appropriately rewarded with an exclusive 
right for having disclosed his invention and enriched the art, as agamst the 
interest of the public (i.e., competitors) to be confronted with protective rights 
whose scope of protection is as readUy ascertainable as possible. 
In some countries greater account has been taken of the interests of the 
inventor or patentee, whUe in other countries the courts have attempted to 
ensure maximum legal certamty or free competition. In order to balance these 
different interests, most countries have one by one adopted the system of 
patent claims first introduced in the United States. In domg this, however, 
some countries simply stipulate in their provisions for drafting patent appUca-
tions that one or more claims should be drawn up specifying what is to be 
protected. In other countries the patent acts place greater emphasis on the 
significance of the patent claims in determming the scope of protection. 
As a general rule, patent claims (if necessary, interpreted with the aid of 
the description) must be worded in such a way that both the patentee and the 
interested public can immediately recognize what is bemg protected. A 
European patent appUcation must, according to Article 78(1) (c), contain one or 
more claims. The claims must define the matter for which protection is sought, 
and they must be clear and concise and supported by the description (Article 
84 EPC). The U.S. Patent Act also requires that the clauns be concisely formu-
lated. Section 112 of the Act states, inter alia: "The specification shall conclude 
with one or more claims particularly pointing out and distinctiy claiming the 
subject matter which the appUcant regards as his .invention." 
The breadth of the protection conferred by a patent depends on how 
narrowly or broadly the claim is interpreted. Such interpretation varies to a 
considerable extent in the different countries. In the rather strict system of 
patent claiming operating in Japan and to some extent in the United States, 
the scope of protection is Imiited to what is UteraUy defined by the claim. In 
some patent systems, on the other hand, the outer reaches or periphery of an 
invention are not expUcitly clauned; here, protection is granted to the mvention 
as described by the patentee in the entirety of the patent specification. Under 
the EPC, a middle-of-the-road position is adopted, rulmg that: "The extent 
of the protection conferred by a European patent or a European patent 
170 / V. Vossius 
appUcation shall be determined by the terms of the claims. Nevertheless, the 
description and drawings shaU be used to interpret the claims." (Article 
69 EPC) 
The Protocol on the Interpretation of Article 69 deals with the limits of 
the scope of protection which is accorded to European patents: 
Article 69 should not be interpreted in the sense that the extent of the 
protection conferred by a European patent is to be understood as that 
defined by the strict, Uteral meaning of the wordmg used in the claims, 
the description and drawmgs being employed only for the purpose of 
resolving an ambiguity found in the claims. Neither should it be 
interpreted in the sense that the claims serve only as a guideline and 
that the actual protection conferred may extend to what, from a con-
sideration of the description and drawings by a person skiUed in the 
art, the patentee has contemplated. On the contrary, it is to be mterpreted 
as defming a position between these extremes which combines a faU 
protection for the patentee with a reasonable degree of certainty for third 
parties. 
This provision is thought to prevent the national courts from interpreting the 
extent of protection of a European patent m such a manner as to place the 
matter disclosed m the description and drawings m the foreground and assign 
to the patent claims the function of guidelines only. However, this does not 
mean that the technical characteristics used m the claims to define the mvention 
may only be drawn upon m theu: concrete (direct) meanmg m an assessment of 
the objective scope of protection and that any abstract interpretation of the 
features or terms used m the claims would be excluded. The decisive point 
in this respect is whether the patentee is accorded fair protection for his in-
vention without adverse effect on the requisite reasonable degree of legal certain-
ty for third parties. This is specificaUy laid down in the third sentence of the 
Protocol as a guideUne for the assessment of the objective extent of protection 
of European patents. 
Just as there are differences among the various patent systems as to the 
scope of protection of tiie patent generaUy. tiiere are also differences in tiie 
protection afforded by specific types of claims witiiin a patent. As mdicated in 
tiie discussion under *Tatent Categories," an invention may be categorized, for 
example, as a "product" and/or a "process" and claimed accordingly. 
GeneraUy, product clauns may be considered to be more desirable, since 
tiiey offer absolute protection for a product, regardless of tiie manner in which 
tiie product has been prepared. In addition, tiie protection of a product patent 
encompasses any use of tiie product protected. If Uie subject matter of a patent 
is a process, tiie protection conferred by tiie patent in some countries also 
extends to tiie product directiy obtained by such process (see, for example 
Article 64, Para. 2, EPC). 
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Duty of Candor and Good Faith 
In their dealings with the Patent Office and Courts, the parties and their repre-
sentatives owe a duty of candor and good faith. This duty rests upon any m-
dividual who is substantiaUy involved, e.g., in the preparation or prosecution 
of the appUcation, and obUgates him to disclose to the Office or Court informa-
tion that is material to the exammation of the application or patent (see Article 
124 German Patent Law). There is no corresponding provision in the EPC. This 
does not, however, mean that there is no duty of candor and good faith in pro-
cedures before the EPO! 
In the United States, the inaccurate statement of facts or even the faUure 
to disclose relevant information to the Patent Office may lead to a later ruling 
of "fraudulent procurement" or "inequitable conduct" that would preclude 
enforcement of the patent. For instance, since only the inventor may be the 
appUcant for a patent, it would therefore be fraudulent for a person other than 
the mventor to be named as appUcant. (Of course, once the inventor has filed 
the appUcation, he may assign his rights therem to third parties.) Fraudulent 
procurement may also lead to (a) UabUity for damages under the U.S. antitrust 
laws, (b) administrative proceedings before the U.S. Federal Trade Commission, 
and (c) an award of attorney's fees to the prevaUmg defendant in an infrmge-
ment suit. 
PATENTABLE INVENTIONS IN THE FIELD 
OF GENETIC MANIPULATION 
For some years now, molecular genetics, just as nuclear physics, has been a 
major focal point of pubUc interest. It can confidently be predicted that over the 
commg decades molecular genetics wUl have a greater influence on Ufe than any 
other area of the biosciences. It is now possible for man to control and genetical-
ly manipulate his own biological development and to have a hand m the evo-
lutionary process of all other forms of life. In 1974 a group of leading American 
geneticists warned of some of the potential dangers of genetic manipulation in 
an appeal to caU a temporary halt to certain genetic engmeermg experiments 
(Berg et al. 1974). These events prompt a consideration of the problem of 
genetic manipulations and the question of their patentabiUty. The foUowing 
discussion wUl briefly attempt to shed light on some aspects of the subject. 
Altering the Composition of the Gene Pool by 
New Propagation Techniques 
The types of genetic manipulation techniques discussed here do not consist m 
altering the genetic make-up of an individual, but of modifymg the quantitative 
composition of the gene pool of a population. 
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Sex Preselection 
Experiments with animals to determine the sex of offspring m advance have 
already been underway for some time, not oitiy from purely scientific con-
siderations, but with the commerciaUy mterestmg aim m mind of achieving a 
higher birth rate of males among, for example, cattie, smce male animals yield 
more meat in a shorter time. It is possible to alter the natural sex ratio of 
roughly 50:50 by pretreating the male semen and subsequentiy employing arti-
ficial insemmation methods. The most successful method to date involves 
separating the gametes (sex ceUs) bearing X chromosomes from those with Y 
chromosomes on the basis of their different sedimentation behavior. This 
technique results in an increased incidence—m the region of 50% to 70%—of 
births of the desired sex. It is expected that improved methods of separating the 
gametes wiU lead to even greater success in sex predetermmation. 
Cloning Higher Organisms 
The so-caUed process of cloning is a method of propagating identical genes or 
organisms. The expression origmates from the genetics of nucrobes, where it is 
used to denote the vegetative (asexual) reproduction of organisms, for example 
by ceU division, which results m colomes of geneticaUy identical mdividuals, 
i.e., clones. 
In higher animals and in humans, which as is known can only reproduce 
sexuaUy, it is thinkable to engineer vegetative reproduction with the aid of the 
foUowing genetic manipulations. The nucleus from a body ceU (somatic ceU) 
is transplanted or injected into an enucleated, unfertiUzed egg ceU. The body 
ceU nucleus contains a diploid set of chromosomes with the complete genetic 
information of the donor organism. Under the influence of the egg cytoplasm, 
the somatic ceU nucleus becomes dedifferentiated and normal embryonic 
development begins. As a virtuaUy unUnuted number of somatic ceUs are avaU-
able as nucleus donors, it would be possible to breed any number of geneticaUy 
identical individuals in this manner. Gurdon and UehUnger (1966;Gurdon 1968) 
succeeded m breeding normal. fuUy developed and fertUe frogs which were 
geneticaUy identical by transplanting body ceUs from tiie mtestinal mucosa of 
frogs of the species Xenopus laevis into unfertUized. enucleated egg ceUs. Gener-
al schemes of cloning procedures are iUustrated in Figure 1, a and b (pp. 000 and 
000). By substituting the nucleus from a body ceU for tiie total inlierited genetic 
material of an egg cell, it is possible to produce uniovular **twins," i.e., off-
spring tiiat are genetically identical to tiie donor of tiie nucleus from tiie body 
ceU and one of which is one generation older tiian tiie otiier. The success of tius 
experiment has not been restricted to frogs; it has since also been carried out 
witii insects and very recentiy with mice (Ulmensee 1978; Illmensee and Hoppe 
1981). 
The Patenting of Life Forms / 173 
The idea of cloning humans wiU certainly not remam within the realms of 
science fiction. What an appaUing thought! In his essay **The Dilemma of 
Science and Morals," Gunther S. Stent (1974) put it as foUows: 
A phUosophical point of interest is that the prospect of populating the 
Earth with clones of geneticaUy identical humans is not, m fact, tempting 
at all. Why is it that while it would be fun to have Kant, Beethoven, 
Bettina von Amim, Einstem, Picasso, Clark Gable and MarUyn Monroe 
living on our block, the thought of having hundreds or thousands of their 
repUcas in town is a nightmare? 
The Genetic IVIodif ication of Cells by Incorporation 
of Foreign Genome Parts 
Of far more relevance for today than the clonuig of higher animals is the 
question of gene transplantation and manipulation (Cohen 1975,1977;Kagaku 
1977; Smsheimer 1977; Vosberg 1977; Arber 1978). Under suitable conditions, 
free DNA (the carrier of the genetic information) can be transferred (transfor-
mation) into microorganisms (bacteria and yeasts). Isolated chromosomes or 
naked DNA has already successfuUy been incorporated into eukaryotic ceUs 
too, although as a rule only very smaU chance fragments of the donor chromo-
some were mcorporated into the genome. 
Thanks to techniques developed since about 1973, and which have become 
known by such names as "genetic engmeering," "gene cloning," "gene tech-
nology," "gene recombination," or "m vitro DNA recombination," it is now 
possible to introduce certain genome parts into host organisms. Geneticists 
believe that this technique "is going to generate the most exciting period of 
research in biology." What is involved is, in fact, a series of the most dramatic 
discoveries of the modem scientific age. 
Genes of one organism are liberated usuig biochemical techniques from 
their structural complex, i.e., from a DNA molecule (donor genome) and m-
staUed as an independent genetic unit in a host organism. In order to introduce 
specific genome parts into the host organism, they are coupled with DNA carrier 
molecules known as vectors, which are readUy accepted by the host organisms. 
For this purpose DNA from, for example, bacterial plasmids, bacteriophages, 
or animal viruses is used. (Plasmids are extrachromosomal, circular, and self-
repUcating DNA molecules of the bacterial ceU. Bacteriophages are viruses that 
use a bacterium as host ceU.) It is possible to transfer not only chromosomal 
genes from one organism to extrachromosomal elements of the same species, 
but also genes of the most different organisms (from prokaryotic or eukaryotic 
sources) can be Imked to the vector and infiltrated into suitable host organisms 
(transformed). The transformed host organisms can be isolated (selected). 
They are purified by cloning, i.e., by growing a culture from one smgle ceU. 
Therefore all ceUs of a clone are genetically and functionally identical. By 
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Experimental scheme of nuclear transplantation in the mouse. Donor blastocysts were col-
lected from strain LT/Sv or CBA/H-T6 females on day 4 (p.c.) and kept in culture medium. 
After surgical removal of the zone pellucida, the blastocysts were dissected manuaUy into 
the inner ceU mass (ICM) and trophectoderm (TE) which were then dissociated enzymatical-
ly into single ceUs. An ICM or TE cell was mechanically disrupted by sucking it into a smaU 
glass pipet and the cell nucleus with surrounding cytoplasm was subsequentiy injected into a 
fertilized C57BL/6 egg. FoUowing nuclear injection, the genome of the recipient egg was re-
moved by sucking the male and female pronucleus into the micropipet. The nuclear-
transplant embryos were cultured in vitro to the blastocyst stage and then transferred 
together with some control embryos of the ICR/Swiss or BALB/c strain into the uterus of a 
pseudopregnant ICR/Swiss foster female in order to aUow development to term. Live-bom 
mice were analyzed chromosomaUy and biochemically for the genetic markers of the trans-
planted nuclei. In breeding tests, the nuclear-transplant mice were examined for the func-
tional germ-line transmission of the nuclear-transplant genome. (Reprinted, with permission, 
from Illmensee and Hoppe 1981.) 
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means of special experimental procedures, it is possible to greatly increase their 
number. The scheme of a technique for recombinmg genetic material between a 
plasmid DNA and a donor DNA and its selection and clonmg m bacteria is 
iUustrated in Figure 2. 
Formation of Recombinant DNA 
The fragmentation of the donor genome into DNA molecules that promote 
transformation is achieved through the effect on the donor DNA of restriction 
enzymes, the so-caUed restriction endonucleases. 
Restriction endonucleases are enzymes that are commonly found in 
bacteria and can fragment DNA. Cleavage of a DNA molecule takes place after 
recognition of a nucleotide sequence that is specific for each restriction endo-
nuclease in the donor DNA. When suitable restriction endonucleases are used, by 
cleavmg at the same specific nucleotide sequences at each DNA, complementary 
single-stranded ends result which are identical in sequence and can combine 
again. Thus, for example, a circular DNA fragment can result if both ends of the 
same strand combine. likewise, it has become possible m the laboratory to link 
together in vitro DNA fragments of different origms. 
Vector Molecules 
As vector molecules for DNA segments that promote transformation, plasmid or 
phage DNA fragments or animal viruses may be used. These are obtamed by 
enzymatic hydrolysis with the same restriction endonuclease that was used to 
fragment the donor DNA. Convenientiy, the vectors bear features (markers) 
that the host organism lacks, and these markers enable transformed host or-
ganisms to be distinguished from nontransformed organisms. As a suitable vector 
a plasmid, for example, is chosen which subsequent to treatment with a restric-
tion endonuclease is spUced in such a way that a fragment mamtains aU the 
information necessary for it to repUcate itself and. in addition, stiU contains the 
information for a marker such as, for example, resistance to an antibiotic (see 
Fig. 2). This plasmid fragment is Unked with foreign prokaryotic or even 
eukaryotic DNA to a chimeric DNA molecule (recombmant DNA molecule) 
by which, for instance, bacteria cells or yeast ceUs (host organisms) are trans-
formed. The transformed host organisms are separated from those which are 
nontransformed by selection for a plasmid marker (e.g.. resistance to an anti-
biotic). Cloning of these host organisms then permits reproduction of the 
foreign information on a massive scale. Figure 3 shows a scheme of an in vitro re-
combination experiment in rather more detaU. 
In the experiment shown in Figure 3, the vector used is a small 
autonomously repUcating plasmid carrymg only a few weU-characterized genes 
and with only one cleavage site for the EcoKl restriction endonuclease. On 
cleavage with EcoRI, a linear DNA molecule witii single-strand ends (sticky 
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Recombination of genetic material between a plasmid DNA and a donor DNA and its 
cloning in bacteria. (RE) Restriction enzyme; (M) marker; (R) gene for repUcation; (L) 
ligase. (Reprinted, with permission, from Micheler 1978.) 
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Scheme of an in vitro recombination experiment in detaU (see text for explanation). 
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ends) is formed from the circular plasmid, and these ends can easily recombine 
under renaturation conditions. If, however, donor DNA that has lUcewise been 
cleaved with EcoKl is added, one or more donor DNA fragments are often in-
corporated into the ring that is formed. CycUzation to a covalentiy bound rmg 
can be achieved using the enzyme DNA ligase. In the transformation step, the 
plasmid DNA (chimeric DNA molecule) penetrates an Escherichia coli cell 
with a low but reproducible degree of probabUity. The ceUs transformed with 
recombined plasmids can be selected from the large number of nontransformed 
E. coli ceUs by skiUed choice of the vector based on a consideration of specific 
vector functions (markers). The transformed bacteria are then purified by 
cloning. In the experiment shown, each transformed £". coli ceU contains several 
plasmids. By following a special experimental procedure, their number can be 
increased more. The recombined donor DNA fragment can be obtained in 
its purified form and in the desired quantity by isolation of the recombined 
plasmids from the transformed clone and recleavage of the plasmid with EcoRI. 
Before recombination, a specific donor DNA fragment size can be chosen by 
gel electrophoresis, i.e., a DNA molecule with a acertain molecular weight, 
or alternatively all donor DNA fragments can be put into the renaturation 
mixture. This last-named technique is known as the shotgun experiment. 
Biotechnological AppUcations 
Useful results can be achieved with the in vitro DNA recombination techniques. 
Far-reaching, and commerciaUy very interesting, projects are being discussed that 
are to be realized by the appUcation of gene manipulation. It is hoped, usmg 
biotechnical techniques, to produce natural substances that today are only very 
painstakingly isolated or else are synthesized at great cost and very labor-
intensively from organisms that are difficult to cultivate. One possible use is 
bacteria for combating environmental poUution such as crude oU spiUages as 
a result of tanker accidents or by chlorinated hydrocarbons. Possible appUca-
tions that may result from the recombination of DNA include the manufacture 
of medical, agricultural, or industriaUy important products by means of 
genetically "programmed" microorganisms, their use to obtain vaccines and 
other substances active against viral and bacterial pathogens, commercial produc-
tion of high-value foodstuffs, the genetic "perfecting" of certain useful plants, 
and the construction of special waste-processmg organisms or even their use as 
energy sources. 
It is only recentiy that a synthetic gene of the hormone somatostatm 
(growth hormone) was successfuUy instaUed in E. coli and approximately 5 mg 
of the hormone was obtamed from 10 Uters of bacteria culture (Itakura 1977). 
In a lecture at the University of Chicago m June 1978, Walter Gilbert of Harvard 
University reported the construction of bacteria that produce small amounts 
of rat proinsuUn, the immediate precursor of biologicaUy active insuUn (Gilbert 
1978). 
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A clonmg system must satisfy two basic requirements: (1) the host or-
gamsm must be capable of accepting DNA and (2) there must be vectors to 
integrate foreign DNA with genetic markers that can be easUy selected. The 
cloning experiments to date have been almost exclusively restricted to E. coli. 
Several teams are working on the development of a cloning system for Bacillus 
subtilis. G. R. Fink*s team (1978) has succeeded in transforming yeast. Yeast 
is a simple eukaryote that is, moreover, of far greater technical unportance than 
E. coli. It can be assumed that, with the aid of yeast, gene technology wUl 
achieve great importance m the future, especiaUy as it is already possible to con-
struct suitable vectors. J. Biggs (1978) constructed a vector from yeast genes and 
a yeast plasmid and an E. coli plasmid that can be used m both yeast and E. coli. 
A. N. Chakrabarty (1976) was able to introduce several plasmids into Pseudo-
monas bacteria. These transformed host ceUs utiUze complex hydrocarbons such 
as crude oU as a carbon source. 
Further research has been aimed at improving the construction of "safe 
bacteria and bacteriophages" that are not viable outside of specific laboratory 
conditions as Curtiss has done. (See, Curtiss, R. Ill, 1980. U.S. 4,190,495.) 
Examples of Possible Patentable Inventions in the Field 
of Genetic Manipulations 
From the schemes reproduced m Figures 1 to 3, it is clear that the foUowing 
examples of patentable inventions m the field of genetic manipulations with 
theu respective claims categories, would be possible: 
1. New vectors—substance, process, and use claims; 
2. New DNA restriction endonucleases—substance, process, and use claims; 
3. New DNA Ugases—substance, process, and use claims; 
4. New cMmeric DNA molecules (hybrid vectors)-substance, process, and use 
claims; 
5. New genetically modified host orgatusms—substance, process, and use 
claims; 
6. Process for the introduction of chimeric hybrid vectors into a host organism 
(microorganism or plant ceU)-process claims; 
7. New transformed host organisms-substance, process, and use claims; 
8. Process for preparing new or known substances (gene products) with the aid 
of transformed host organisms-process claims and. where the gene product 
is novel, substance claims; 
9. Cloning of higher organisms-process claims; 
10. Combmation of protoplasts (somatic hybridization)—substance, process and 
use claims. 
From the cloning scheme hi Figure 1, it is apparent that a substance claim is not 
possible for tiie subsequent members of the clone since the members are an 
identical copy of the nucleus donor and tiierefore lack novelty. Furthermore, 
The Patenting of Life Forms / 181 
according to Article 53 (b) of the EPC and the correspondmg adapted national 
patent laws of the signatory States, a substance claim is not possible for the 
members of the clone. The patentable inventions are process inventions, namely 
processes for, for example, enucleation of an egg ceU, for obtainmg nuclei from 
body ceUs, and for transplanting or alternatively mjeefmg the nucleus mto the 
enucleated egg ceU. 
Multicategory Patent Claims 
From the patent claim categories Usted above, it is evident that m the field of 
genetic manipulations several categories of claims may be drafted m one patent 
appUcation (see also section above. Unity of Inventions and Categories of 
Claims). Claims in more than one patent category are admissible m the same 
appUcation where the application is shown to be uniform under the terms of 
Section 35, Para. 1, Sentence 2 of the GPL (Article 82 of the EPC), and where 
there is a heed for legal protection for all categories claimed. 
FINAL REMARKS 
There is, unfortunately, the possibiUty that patent offices m some highly in-
dustriaUzed countries with "obsolete" patent laws may not consider patentable 
certain inventions in the field of Ufe forms, e.g., new modified plasmid vectors, 
new recombmant plasmids, and new transformed host ceUs, on the grounds 
that such inventions are one of the foUowmg: 
Uving things; Uve orgamsms; plants or animals; things that are grown; 
products of nature; not constituting manufactures or compositions of 
matter; articles which do not possess 'a new or distinctive form, quaUty 
or property*; articles whose essential nature has not been substantiaUy 
altered; not constituting the creation of new Ufe, 
and finaUy that 
the law-makers did not intend living organisms to be patented .^ ^ 
Such arguments seem to me to be very unconvincmg. Did not the opponents of 
the first airplane object th^t had God mtended man to fiy, He would surely have 
given him wings? It is not permissible to "freeze" the concept of technology at 
its 19th century level, pretending to respect the wiU of the legislators of that 
period. This means faiUng to recognize the patent law's aim of understandmg 
the basic concept of "technology" m each instance as requured in order to 
guarantee a fair measure of protection for the inventive control of natural forces. 
The decision by the Australian Commissioner of Patents In re Ranks Hovis 
"Decision of the High Court of Ireland of 25 May 1978, Ranks Hovis McDougaU 
Ltd. V. The ControUer of Patents, Designs and Trademarks, Justice McWilUam, Fleet Street 
Reports, VoL 4, Part 12,588 (1978). 
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McDougall Limited (46 Austral. Official Joumal of Patents, Trademarks and 
Designs, 21 Oct. 1976, p. 3915 et seq.) states on page 3915, right-hand colunm, 
last paragraph: 
The truth is that any attempt to state the ambit of § 6 of the Statute of 
MonopoUes by precisely defining "manufacture" is bound to faU. The 
purpose of § 6, it must be remembered, was to aUow the use of the 
prerogative to encourage national development in a field which already, 
in 1623, was seen to be excitmgly unpredictable. To attempt to place 
upon the idea the fetters of an exact verbal formula could never have 
been sound. It would be unsound to the pomt of foUy to attempt to do so 
now, when science has made such advances that the concrete appUcations 
of the notion which were familiar m 1623 can be seen to provide only the 
more obvious, not to say the more primitive, iUustrations of the broad 
sweep of the concept. 
In his dissenting opinion on Chakrabarty's mvention^^ Judge Baldwin, for 
example, took the view: 
I beUeve that the essential nature of the unpatentable organism with which 
appUcant started was its animateness or Ufe. AppeUant has not changed 
this essential nature; he has not created a new Ufe. Rather, he has merely 
geneticaUy grafted an extra plasmid on to the organism and, thereby, 
made the orgamsm better at cleanmg up oU spills. 
It seems to me that, with aU due respect, Judge Baldwm has missed the point 
of Chakrabarty's invention. It is necessary that mventions be weU understood 
and thoroughly analyzed as to their object and the solution they propose. In 
the fields of microbiology, virology, genetic manipulation, and cloning this 
may be difficult, and it makes great demands on aU parties concemed. AU con-
cerned must work hard to ensure that inventors receive their proper reward, to 
which they are entitied according to the spirit of the patent laws. 
I should Uke to close with the splendid remarks made by CCPA Chief 
Judge Markey in his opinion In re Chakrabarty: 
As witii Fulton's steamboat '*foUy" and BeU's telephone "toy", new 
technologies have historicaUy encountered resistance. But if our patent 
laws are to achieve their objective, extra-legal efforts to restrict whoUy 
new technologies to the technological parameters of the past must be 
eschewed. Administrative difficulties, in fmding and training Patent and 
Trademark Office examiners in new technologies, should not frustrate the 
invention disclosures, whetiier tiiose disclosures be m famiUar arts or in 
areas on the forefront of science and technology. 
33 In re Chakrabarty, 197 USPQ 72 (CCPA 1978). 
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COMMENTS 
VOSSIUS: Before answering questions, I would Uke to review the aspects of 
law and implementmg regulations you must observe when you fUe in the 
EPO. Regarding exceptions to patentabiUty, you cannot obtain patents 
and product claims on plants, higher orgarusms or animals. Also, you can-
not obtain a product claim on the clonmg product of a higher organism, 
because it is a higher organism and it is not novel, Le.^  the original animal 
was known. 
As regards obviousness, I thmk I fuUy agree both with Mr. Plant 
and Bertram Rowland that the criteria are essentiaUy the same. Our way to 
prove unobviousness is to show that there is an unexpected technical re-
sult, a demand was met, and a general prejudice was overcome. I think 
these are the most important criteria. 
As far as the aspect of description is concemed, here the quarreling 
started on how to describe an mvention. I can only recommend that you 
describe your inventions in such a way that would enable a subordinate of 
yours to repeat the mvention. This is, I think, an enabUng disclosure. 
There are certamly several ways to describe an invention. Nobody can 
claim to have invented the best mode m which to exphun an invention 
m a patent appUcation. 
If you want to obtain product claims, which, of course, is most 
desirable—because then any mode for preparing a compound is covered by 
such a claim—you should try to identify the product as correctiy as 
possible, if necessary by a product-by-process claim, that is, by explaining 
how it has been prepared, how it has been obtamed, how it has been 
isolated, and how it has been fused. In addition, you should use accepted 
parameters, accepted in your field—molecular weight, daltons, kUobases, 
migration speed in the electric field, RF values, NMR values, and 
whatnot. 
If you can describe a microorganism or a hybridoma in such a way 
that it can be reproduced, that the invention can be carried out by a 
person skiUed in tiie art, as laid down in Rule 28 of the Implementmg Reg-
ulations, then you do not need to deposit such a thmg. If an invention 
concerns a microbiological process or tiie product thereof and involves 
the use of a microorganism that is not avaUable to the pubUc, and which 
cannot be described in the European patent appUcation (the same is true, 
of course, for a national application) in such a manner as to enable tiie 
invention to be carried out by a person skiUed in the art, the invention 
shall only be regarded as being disclosed as prescribed in Article 83 if you 
deposit the microorganism. 
It may be difficult for foreigners to deposit patiiogenic micro-
organisms, for example, viruses, as tiiey might have problems in fmding 
depositories. Importation, of course, is prohibited, and would violate 
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U.S. national laws and vice versa. So a few difficulties could be foreseen. 
It is very difficult to find depositories in Europe that can ensure safe de-
posit for 30 years, as predescribed by the Budapest agreement. I don't 
know whether the Institut Pasteur, for mstance, although it is a depository 
recognized by the EPO, can reaUy ensure such a deposition for such 
a long time. 
What we recommend, of course, to European and other applicants 
is that they should use the Agricultural Research Culture CoUection m 
Peoria, Dlinois, for instance, which is rather inexpensive. In addition, 
we hope that U.S. law could perhaps apply in misappropriation cases. With 
U.S. dvU law procedures, it may be easier for a plaintiff to prosecute such 
a case. 
You can obtain in one patent appUcation several categories of 
claims. As you perhaps know, there are mainly two categories of claims, 
product claims and process claims. If you have invented, say, a novel 
hybridoma, according to European and German national law you would 
be able to obtain a product claim for the hybridoma, a process for pre-
paring the hybridoma, and the use of the hybridoma for detecting a 
certain disease and for preparing antibodies, i.e., monoclonal antibodies. 
This would then give you sufficient protection. 
You could also obtain a process claim for preparmg something and a 
claim for the apparatus for carrying out the process, say, the process for 
separating certain genome parts and then the apparatus for carrying out 
the process. If the mvention resides solely in the improvement of a 
process, say, the improvement of the transformation efficiency, you 
could only get a process claim for this improvement. 
Whether you can get a product claim on a natural isolate of a micro-
organism or a virus is still an open question. According to German national 
law, you must show a technical mode of how you have obtained this 
microorganism. Mere deposition and citing the deposition number is not 
considered a complete teaching of how you have obtamed the product. 
But our Supreme Court indicated in one of its last decisions, i.e., the 
decisions Bakterienkonzentrat (GRUR 1981, 263) that if further argu-
ments came up and further points of view could be shown, then this court 
would perhaps change its attitude. 
The EPO, at the examination level, wUl grant product clauns on a 
microorganism found in nature. Whether this practice is upheld at the 
Board of Appeal level is not yet known. UntU now, no case has come up 
that far. I do not know of any, and I telephoned the people at the EPO, 
and was told that they do not know of any case pending before the 
Board of Appeal. 
McELHENY: I want to just mention, what has been referred to several tunes in 
the talk is a smaU book called The European Patent Convention. 
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VOSSIUS: It is very easy to get. The text of the law and the Implementing 
Regulations is available (from the EPO) but of course, also through other 
sources. (This book, pubUshed by Dr. Haertel, the father of European 
Patent Law, with the preface, introduction, and the subject index trans-
lated by our office, is valuable because of its subject mdex.) 
DE ROSNAY: I would like to go back to the plants and higher organisms that 
you mentioned. For instance, you mentioned that a genetic engineering 
company m the Umted States wiU develop a system to aUow plants to 
grow in salted water. It is a general methodology, a general process, where-
by different seeds wiU be able to be planted and grow m salted water. Or 
imagine another example, that a genetic engineering company has de-
veloped a strain of mice or gumea pigs with artificial mutations so they 
can be used by people seUing lab animals for experiments and so on. 
I understand this is not patentable in Europe. 
VOSSIUS: The product, the animal per se, is not. EssentiaUy biological 
processes for preparmg such plants or animals are also not patentable. 
DE ROSNAY: If this company seUs the seeds to a European company, and 
you want to grow those plants to produce crops in salted water in Italy, 
for mstance, or in North Africa, what happens? 
VOSSIUS: You cannot, of course, enforce your U.S. Patent anywhere abroad. 
WATSON: What about ceUs from higher orgarusms? 
VOSSIUS: They should be patentable. Exemptions in the law must be in-
terpreted narrowly. A plant or an animal cannot be compared with an 
individual cell derived from this animal. Since there is no negative defini-
tion and there is no definition in this respect m the law, I think they 
should be patentable. 
PHILLIPS: Would you lUce to comment on the rationale for the EPO granting 
claims to naturaUy occurring species, which apparentiy you said they 
would do? 
VOSSIUS: The EPO only grants claims to microorganisms and viruses, for 
instance, or hybridoma cells, if tiiey can be properly described and/or 
if they are deposited. 
PHILLIPS: Even tiiough tiiey lack novelty? 
VOSSIUS: Well, if tiiey lack novelty, tiiey should not be patentable. 
The Patenting of Life Forms /187 
PHILLIPS: WeU, aren't you saying two things? 
VOSSIUS: If something is found m nature just by grabbing it, like a manga-
nese nodule, of course, we all agree this should not be patentable. If you 
roam around m the forests and find a mushroom, you cannot get a pa-
tent on every mushroom you come across. If you find in a population a 
certam species of Lactobacillus—Lactobacillus bavaricus, for mstance—and 
you give a technical teaching on how to obtain the pure species, you 
would get a product claim, if necessary identified in the product claim by 
its way of isolation. 
ROWLAND: You say that you could claim any DNA sequence that was novel. 
So, in effect, you could, avoiding the host, just claim the DNA sequence. 
VOSSIUS: In addition, of course, you have the requirement of utiUty; we 
have the requhement of commercial usefuhiess, as an mdependent re-
quirement—apart from novelty, inventive step, and nonobviousness. 
ROWLAND: What about the situation where you cure someone? Let's take 
the methotrexate example I gave. Can I claim a host ceU havmg an ex-
cessive amount of the dUiydrofolate reductase gene? 
VOSSIUS: Why not? 
ROWLAND: But then I am claiming the human bemg. 
VOSSIUS: A method of treatment claim, by the way, as permitted in the 
United States, is not allowable, in any of the European countries. If per-
mitted, by sneakmg through the examination proceedmgs they would be 
considered invalid. 
ULLRICH: Can't you define an animal or a higher organism as just an accumu-
lation of simple ceUs? They aU contam the same DNA. You can claim the 
DNA that you have modified somehow affects different ceUs in the or-
gamsm m a different way. That shouldn't be a big deal. So you can define 
the DNA, and the way the DNA then is expressed in the ceU is a second 
question. 
CAREY: You can compUcate it quite a lot by the fact that you can conceive of 
doing a genetic engineering step upon a single ceU, which you could then 
claun. But by culture methods, you could grow out a whole plant from 
that ceU. What would the situation be then? 
VOSSIUS: On the national level, the EPO and, for mstance, (Jerman patent 
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law is a littie bit schizophremc here. You can obtain plant patents if the 
plant is not mentioned in the plant register, for which we have an inde-
pendent law. So m this case you could get a process for preparing it if U 
is a technical process and not a biological process, or an essentiaUy bio-
logical process, like propagating horses. 
WATSON: I am confused by "obviousness." By your defirution, I somehow 
believe that if we made a monoclonal antibody against insuUn, you would 
say that that is not obvious, and therefore we could get a patent on it. 
But I would think that is the most obvious thing m the world. It requires 
no new knowledge. VirtuaUy anyone can do it. Admittedly, we can't 
see it, in the sense that it is obvious like the mushroom. 
VOSSIUS: Posing the problem may be obvious, but then findmg the solution 
may not be obvious. 
WATSON: What is obvious? I mean, a rather stupid techiucian workmg for 6 
months.. . . 
VOSSIUS: You cannot, I think, apply here the inteUectual level of a janitor 
in your field. Here, of course, the skiUed man in the art, havmg average 
experience and average knowledge, would be you and your coUeagues. 
This is such a sophisticated field that the skiUed man would be a Ph.D. 
having a couple of years of experience workmg m your lab. 
McELHENY: How much has this question of obviousness, or the definition 
of it, been argued, let's say, in the (Jerman courts, such as the Supreme 
Court that you referred to? Have there been a lot of cases that have argued 
obviousness? 
VOSSIUS: As Mr. Plant indicated yesterday, obviousness is a major attack also 
in trying to kiU a patent and trying to avoid the patenting of a patent 
application. There is a huge amount of case law, of what kmd of mdicia 
speak against a pro and contra m an inventive step. 
WATSON: I would lUce to ask about radiochemicals. You have, say, glycine 
and you make a substitution and put in fluorine someplace, or you make 
something which is a '*C. 
VOSSIUS: Where do you want to put the fluorine in? On the nitrogen? 
WATSON: Let's say you do something very obvious. You just use **C instead 
of *^ C to make an amino acid. Can you patent it? 
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VOSSIUS: With the present knowledge, I don't believe that this is an invention, 
a patentable invention. 
WATSON: But that is much harder than makmg a monoclonal antibody. 
PTASHNE: Do you think you could patent a monoclonal antibody on insuUn 
now? 
VOSSIUS: I assume that you had only scientific assumptions that sUch a com-
pound must be present somewhere, but you had no idea what it looked 
like, no idea about its molecular weight 
PTASHNE: Assume that you have a very good idea of what it looks like and 
what its molecular weight is. 
O'NEILL: If it is high affinity and high selectivity.... 
VOSSIUS: It can detect 98% of pancreas cancer, could you predict this, as 
Carlo told us yesterday? 
PTASHNE: But the simple question is, if you take insuUn, make a monoclonal 
antibody, an experiment that anybody in the field can d o . . . . 
BRENNER: I think you don't know which mouse to immunize. It may not be 
as obvious as all that. 
WATSON: WeU, any vaccine, just putting somethmg into a rabbit, can you 
patent that? 
VOSSIUS: So far as I know, if you find a better rabies vaccme, an attenuated 
rabies vaccine, starting from a field virus, and find a method to attenuate 
it, how to multiply, propagate it on certain baby hamster ceUs, and so 
on—of course, a couple of steps are conventional, the cloning step, cloning 
of these viruses, multiplying that virus three times, I think is the min-
imum—and then propagating and passaging, say, 90 times on rat kidney 
ceUs, this is considered, under present European and German law, and I 
think under U.S. law too, an invention meeting all the requuements of 
Articles 101, 102, 103 of the U.S. Patent Law. Of course, you must fuUy 
describe it. 
GOULD: I think the history of claiming of thmgs like antibodies foUows the 
old catalyst art in chemistry, which traditionaUy has been held to be the 
so-called black art. Although you knew the methodology that you wished 
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to employ to achieve the results you wanted to achieve, the results were 
so unpredictable that the Patent Office would, if you did succeed, grant 
you a patent. Now, I know you can say that everybody knows what 
steps you have to take to make an antibody, but m many instances the 
antibody that one achieves—either there is a whole fanuly of antibodies, 
in which case you have to select one that has a certain usefulness for 
the problem you are trymg to solve, or there are other aspects to it that 
make it unpredictable and aUow you to establish patentabiUty at the end. 
So even though you can predict what steps you would have to take 
to get there, you stUl don't know, when you achieve it, what the nature 
of the antibody wUl be. 
VOSSIUS: Yesterday Dr. Brenner asked if he finds a sequence of codons that 
can be understood much better than another one—although, of course, 
theoretically, you could see that the resuU, the gene product, should be 
the same—but, suppose the yield is much higher, then this is a classical 
example of a patentable selection mvention. 
Speculations on Proprietary Rights 
and Biotechnology 
THOMAS D. KILEY 
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South San Francisco, California 94080 
Patent rights form only a subset of the armamentarium lawyers bring to bio-
technology. Issues of trade secrecy and personal property mterests in the 
tangible creations of modern biology also need to be reckoned with. 
TRADE SECRECY 
It has been (Jenentech's poUcy, largely, to eschew attempts to protect trade 
secrets, at least in the core technologies of molecular biology, organic synthesis, 
and protein chemistry. We have done this out of necessity, not altruism, and that 
because of the special characteristics of this new industry. One of those charac-
teristics is explosive growth. Another is the very Umited talent pool upon which 
one can draw in this period of explosive growth. Another is the academic origin 
of key workers in the field and the fact that they have been raised in a tradition 
of information sharing, wherein the chief reward of science is regarded as the 
adoption (with attribution) of one's work by his closest competitors. That teUs 
you an awful lot about the UkelUiood of a company's preservmg trade secrecy 
and, at the same time, attracting from the academic community the finest 
scientific talent that is avaUable. 
So long as trained scientists are the Umiting resource m this dynamic new 
industry-and I think that wUl remain a characteristic of the industry over the 
gestation period of many years—the universiti' system wiU be required to spawn 
additional scientists—companies that take a hidebound approach to trade secrecy 
wUl find themselves out-competed for scientific talent by those less hidebound 
companies that adopt a more coUegial, more open, atmosphere. 
This is not to say that there wiU not arise opportunities for trade secrecy 
m biotechnology, any more than to say there don't arise opportunities for trade 
secrecy in academia. I refer to somethmg caUed the short-term trade secret, and 
that is the secret one keeps until he has decided to pubUsh his paper, or the 
secret that one keeps untU he has filed his patent appUcation, and only until 
that time. 
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At (Jenentech, no manuscript has been delayed by the patenting pro-
cedure. It is not necessary that any such delay ensue. As a matter of fact, most 
commonly, the patent appUcations are fUed before the scientific manuscripts 
themselves have been written. 
There are differences between the needs of scientists and the needs of 
lawyers as this patenting process unfolds, as can be iUustrated by one point. 
Suppose that one isolates and sequences a particular gene and then chooses to 
pubUsh it because-and I quote—"it belongs to a class of compounds that is now 
the subject of serious scientific investigation." That achievement, the elabora-
tion of the gene, may not yet have advanced to the point where a patent can be 
filed. 
The sentence I quoted was from a decision of our Supreme Court, ^ en/ier 
vs. Manson, 383 U.S. 519 (1966), which held that an analogous advance was 
insufficient to support a patent, because it must be taken the next step. The 
advance must be demonstrated to be useful—one of the three polestars of 
patentabiUty. There may arise from time to time occasions in which scientists 
wish to publish something that is of scientific mterest, yet not sufficientiy 
advanced to support a claim for patent and these must of necessity be dealt with 
on a case-by-case basis. 
Trade secrets have two features that have not yet been mentioned. One is 
that, in order for an enforceable right to arise, the purported owner of a trade 
secret must be able to demonstrate that he knew the trade secret. Information 
embodied in a ceU Une that leaves the hands of its originator and is then un-
raveled by another is information never known to the original holder and there-
fore, by definition, not any trade secret of his. 
Secondly, it should be pom ted out that a trade secret is regarded m the 
law as an mtangible value. It is not a thmg. Therefore, one ^ose ceU line is 
misappropriated has no action for theft of trade secret, but rather is relegated to 
the ancient realms of the law of personal property, to which I wiU next attend. 
PERSONAL PROPERTY 
One of the most interesting things about biotechnology to lawyers has nothing 
to do with patent law. It has to do with the law of personal property. In order 
to approach this in any mteUigent fashion, I think it is necessary to attend to 
first principles or, as the scientists say, the central dogma of the law of property. 
What is property? 
Property is domimon over a thing that the law wUl recognize and protect. 
What can one do with property? One can seU it, rent it, use it, lose it, 
abuse it, indeed all the things that you can do with your personal automobUe 
or your pet dog. 
There are two critically different types of property, and it is necessary to 
make a distinction between tiiem. The fust is the kmd of property in which the 
law recognizes only a possessory interest. That is, the law wiU preserve your 
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possession against him who would disturb it. This has nothing to do with a 
special characteristic, called "title," that the law appUes to some thmgs and not 
to others. 
The second type of property, of course, is that which the law wiU recog-
nize as ownership in the sense of applymg to it the characteristic called "title." 
The difference between a possessory interest and a titled interest is that when 
a thmg is imbued with the fiction referred to as "title," the titie runs with 
the thing and can be carried with that thing mto the hands of any third party to 
whom the thing may faU. A mere possessory interest, once disturbed by a 
trespasser, may be lost if the property is taken by a trespasser and given mto the 
hands of another who receives it without knowledge of the wrongful talqng. 
There is no property of title runnmg with the thing. The thing has been cleansed 
of the possessory interest by passing througji the hands of a launderer, who then 
hands it to somebody whose bona fides is beyond question. 
I would like to discuss some examples of property and parse them out 
amongst their several categories. 
One doesn't own a trade secret in the sense of having title to it. You have 
oiUy the right to the undisturbed possession of that trade secret. If a thief takes 
my trade secret and pubUshes it to the world, I may have a remedy agamst the 
thief, but I cannot later prevent the world from making use of it, because other 
persons in the world have done me no wrong. No title runs with the trade secret. 
One may own a domesticated animal, like a beef cow. You can own and 
have title in a wolf that you have tamed. But if the wolf reverts to the wild, your 
title, although once recognized by the law, is lost because of the special nature 
of animals of the wUd. You may never own a swarm of bees, even if you are m 
the honey business, because the law regards bees as wUd animals that are 
mcapable of domestication and therefore incapable of reduction to titled owner-
ship. Accordingly, your right to the possession of bees on your property and in 
your beehive may be protected, but if they swarm mto your neighbor's yard, 
they are lost to you. 
Now, what in the world is the relevance of bees and wolves to what we 
are talking about? WeU, certainly the law recognizes title m manufactured or-
ganisms, like bacteria that produce insulin or that produce antibiotics. The law 
is wilUng to recognize titie, and in the past has, in domesticated orgarusms, 
organisms that have been caught in the wUd, brought in-house, and made to 
produce antibiotics. At least title has been recognized until such an organism is 
permitted, like a wolf, to revert to the wUd state. 
The question of whether the law wiU recognize any titled property interest 
in human body parts can be asked. Certainly, we are no longer in this country 
permitted to own a live, whole human being. The law of dead bodies is a 
fascmating study, for those interested in the arcane, and the law recognizes at 
least a possessory interest in that event. Whether parts of dead bodies wUl be 
recognized by the law as permitting the property of title or not is open. But it 
may not matter. Why? Because if the owner of a ceU Une—and I regard that. 
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largely, as a body part—cannot show the maimer in which title came to him, 
then he has no titie to assert agamst someone who takes from him. 
Secondly, one who has title in ceUs can lose it if he sends them swarming 
around the country, like the swarm of bees. 
Thirdly, title may be given away. How many of you, when you have sent 
out ceU lines, have said, **Here's my ceU line. Use it only for these purposes. 
And, remember, it remains my property, and give it back to me when you are 
done"? To the extent you haven't done that, there is a fair mference that you 
have made a gift of the titie to the recipient. If the recipient provides the cells 
to another you have no claim because your title has gone to him and his has 
gone to the ultimate donee. 
Now, suppose you provide the ceUs to another under circumstances 
that pass titie, but subject to an undertakmg that he wiU not pass them on. 
If he breaks his pronuse and provides the ceUs to a third party who takes them 
unaware of your agreement, you have no claim against the third party. Instead, 
your grievance is with the middleman alone, for breadi of contract. 
SCHARFF: Could I ask a quick question? The person who donated the ceUs 
that (^rlo Croce used to make a monoclonal antibody against islet ceUs, 
did they have titie to those ceUs? 
KILEY: If the law wUl recognize titie m that kmd of property. Giving is one 
way of conferring titie so under that circumstance Carlo may have gotten 
titie. However, the donor may have only lent the ceUs or given possession 
of the ceUs without an mtent to pass titie, m which case, perhaps, the 
donor retains an interest if the law decides that it wants to apply the 
perquisites of titie to that kmd of tangible article. 
Microorganism Deposit 
I briefly discuss microorganism deposit, because that also relates to the tangible 
aspects of biology. Most of the jurisprudence of microorganism deposit was 
developed at a time when new microorganisms were found by serendipity. 
Now, with the incredible descriptive power of this technology, one can very 
well enable the public, by tiie written description within the four comers of 
a patent alone, to practice an invention without necessitating the gift of the 
plasmid or microorganism, within the context of which the invention is 
practiced. 
IBM can describe the manner of creatuig a mamframe computer, and the 
patent may be several feet thick when the descriptive process is completed. But 
having described the manner of practicing tiie invention, it becomes unneces-
sary for IBM to make gifts of its mainframe computers to its competitors. Like-
wise, someone who spends years of time, treasure, toU and perspiration to create 
a new microorganism, if he can describe it, ought not be obliged to give it, lUce a 
mainframe computer, to his competitors. 
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How Broad Shall the Patents Be? 
Sydney Brenner has suggested that patents in genetic engmeering wiU be easUy 
avoided, because silent mutations or other inconsequential changes in genes wiU 
permit competitors to practice outside the scope of patent claims. This assumes, 
mcorrectiy I think, that patent clauns wiU be narrowly drawn in the first place. 
Even where they are. Courts are not prone to reward the cynical infringer who 
would so nimbly sidestep the claims to an invention, whUe takmg its benefit to 
himself. I had the very great good fortune several years ago to participate in the 
trial of a case on behalf of a smaU California company against ITT in Boston.* 
The subject of the invention was an aircraft wire construction that had as its 
only genius its abUity to save about 600 pounds per fighter airplane. According-
ly, Bob McNamara's TFX fighter could be gotten off the deck of a carrier. 
One component of the aircraft wire construction was a polymeric sub-
stance called polyvinyUdene fluoride. It was made up, of course, of a long series 
of repeat units of vinyUdene fluoride. 
Our friends at ITT took the position before the court that they did not 
infringe the patent, "because polyvmyUdene fluoride," they said, "is a word that 
means homopolymer. A homopolymer has no other repeat units, whereas we 
have slipped in a co-monomer, and about every 50 units along this chain, one 
finds an ethylene vinyl acetate, and therefore we do not infringe the patent." 
We were able to stand up before Judge Tauro, bless his good heart, and pomt 
out that if one painted a yeUow Une about every 60 feet across Route 128, the 
expressway outside Boston, it wouldn't make any difference, because, by God, 
that would StiU be the road to Boston. Likewise, ITT's material was stiU, for aU 
intents and purposes, polyvmyUdene fluoride, and sUent mutations or other 
minor modifications in genes that don't make a difference in science or to the 
gene aren't going to make a difference to the courts. 
Secondly, Dr. Brenner expressed some concern that future discoveries 
would not be patentable, because, after aU, the Boyer-Cohen patent^ covers 
everything. There is a misapprehension that floats around the world of scientists 
that is very persistent with respect to the difference between what is a patent-
able invention and what infringes a patent claim on it. One who makes a pioneer 
invention is, by virtue of his pioneering contribution, entitled to a very broad 
scope of patent coverage. Others may make mdependent inventions that are 
themselves patentable when compared to the teaching of the earlier one, which 
are nevertheless within the scope of the earlier patent, and therefore infringe 
that patent. Our Supreme Court has so held, just about 100 years ago in 
Cochrane v. Deener, 94 U.S. 780 (1876). 
One wUl accordingly see many patents arismg within the scope of the 
Boyer-Cohen patent that are independentiy patentable, but nevertheless m-
frmge the earlier patent. In fact, one can anticipate an evolving situation of 
'Raychem Corp. v. ITT, 188 U.S. P.Q. 214 (D. Mass. 1975), aff'd 538 F.2d.453 (1 
Cir. 1976). 
'U.S. patent no. 4,237,224. 
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overlapping patent coverage. That is an unhappy, but I think necessary, outcome 
of the patent system, and it faUs to the lawyers to sort it aU out. 
A famous New York jurist, Leamed Hand, said that a patentee may bend 
his saUs upon many yards. What that means is that he is obliged to look at an 
invention not as the concrete thing that has been brought into being, but rather 
to imagine the outer bounds of the concept that happens to be represented m 
part by one concrete embodiment, in part by another. How broad is that con-
cept? How far does it run? To what extent can one make a broad disclosure, 
commensurate in scope with a broad claim, and thereby enable the practice not 
only of the creation of a first concrete embodiment, but also those other things 
out m the future that are within the field of defined equivalents? In short, there 
are broad patents and narrow patents. 
There are patents on methods and patents on things. Patents on methods 
have classic limitations. Because of the territoriaUty of patents, method patents 
can, with exceptions, be practiced overseas with impunity, and the unpatented 
product of that practice shipped m. There is a remedy for this before the United 
States International Trade Commission but it has its problems. 
Another difficulty with method patents is that it is sometimes difficult to 
detect theu infringement, because the method might weU be practiced within 
the closed confines of a competitor's factory, and one never finds out that his 
rights are being trammeled. 
That is not to say that simUar difficulties don't arise m the case of some 
product patent claims. We should distinguish between product patent claims on 
microorganisms, plasmids, and other thmgs of an intermediate kmd and product 
claims on the end product of aU of this, like a hybrid mterferon, because the 
hybrid interferon may weU be seen in the marketplace, and detection of infringe-
ment accordingly faciUtated. But though one has a product patent on the bug, 
the bug itself remains hidden away m the bowels of the competitor's factory, 
and is never seen again. 
I think we should also distinguish between methods of creating organisms 
and methods of usmg them in the production of a valuable substance. To 
Ulustrate: A method of making a recombinant gene which comprises various 
steps has this defect: If one files his patent appUcation and then pubUshes 
his method, the method can then be practiced for the 18-plus months that 
it takes the patent to issue. In the course of that unprotected practice, new 
microorganisms can be caUed into being. The patent issues, but only after a 
competitor's microorganisms have been created by the method steps. The 
now-patented method need never again be practiced, because, from that point 
forward, the microorganism recreates itself. And. of course, there is no remedy 
for the infringement of a patent before the patent has issued from tiie Patent 
Office. 
In contrast, a method of using a microorganism (for example a method of 
expressing a smaU polypeptide which comprises the steps of transcribing and 
translating a gene for a conjugate, from which tiie desired product is subse-
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quently cleaved away by cyanogen bromide) is a method that wiU be practiced 
m industry, both prior to and after the grant of a patent. 
In the final analysis the universe of possibly patentable inventions and 
patents can be segregated into two discrete bodies. There are the good patents. 
By those I mean my own. And there are the bad patents, which, of course, go to 
the other feUow. 
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COMMENTS 
McELHENY: As somebody who does quite a lot of writing, I certainly feel 
the ground trembling under my feet, since aU of these words, mcluding 
the word "obvious," seem to have quite uncertain meanings. 
ROWLAND: I wonder if Tom would distinguish between an E. coli, which is 
taken from the gut, and a leukemia ceU taken from the blood, so far as 
their patentabUity. 
KILEY: Let's first talk about the patentabiUty of products purified from 
nature, whether they are quick or dead. The courts have for a long time 
permitted patents on the novel composition of matter that comes into 
bemg when one separates something valuable from the gimisch that sur-
rounds it in nature and claims it as a pure substance. The Courts of Ap-
peals have uniformly upheld such patents, but the Supreme Court has 
never gotten the question, so far as I know. 
In the Supreme Court's opinion m Diamond v. Chakrabarty, 65 
L.Ed.2d 144 (1980) one senses the possibUity that if the orgaiusm iso-
lated from nature by UpJohn m the undecided comparuon case had 
come before the court, a very different result might have come down. 
Likewise, and by the same reasoning, if the question of whether vitamin B-
12 or prostaglandins isolated from nature can, m their pure form, be pa-
tented gets to the Supreme Court, who knows? I know how I think the 
issue should come out-as favoring patentabUity. I think, under the right 
circumstances, the same logic should apply to leukemia ceUs or special 
kinds of £. coli ceUs. 
BRENNER: You mentioned one thmg which I was interested in. You took 
that diagram and you said that, of course, a later invention would be 
patentable, but would infringe the eariier patent. But then you didn't 
say what happened. 
KILEY: A number of things can happen. One may be asked to accept a license. 
One may conceal his infringement of the patent. One may proceed in spite 
of the patent and dare the patent holder out into the middle of the street. 
One might go to litigation. One might seek reexamination of tiie patent 
before tiie Patent Office, if tiie other requisites of tiiat procedure are 
satisfied. One might file an action after having been threatened witii 
infringement, seeking to invalidate the patent. Many options, all of tiiem 
with potentially dire results. 
BRENNER: But I take it if you went witii one of tiiose tilings to tiie Patent 
Office, it would be rejected. 
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KILEY: Let US assume, for the sake of argument only, that the Boyer-Cohen 
patent is valid. (Laughter) Now, irrespective of whether Paul Berg or Boyer 
or Cohen or someone else made this gene spUcing mvention, I think one 
must accept the fact that it wiU be perceived for many, many decades as 
a landmark in science. This entitles the inventor to claim very broadly, 
because he has pioneered, he was the first, as the poet says, *ever to burst 
into that sUent sea.' Yet that doesn't mean that mventive acts can't be 
later performed withm the broad reach of the pioneer's patent. Is it un-
obvious to one of ordinary skiU in the art to buUd a Taq promoter? If 
so, then the Taq promoter construction should be patentable, even though 
it is within the compass of the broad patent issued earlier to Boyer and 
Cohen. 
BRENNER: So if one does that and then begins to practice one's own patents, 
what happens next? 
KILEY: One goes and talks to the owner of the pioneer patent. 
SHARP: I want to argue against one statement you made m terms of pubUc 
interest and molecular biology. You argued that reporting the sequence, 
that position of the sequence, should be aU that is necessary in terms of 
patenting an organism that is producing a useful product, and not the 
deposition of the organism itself. As a biologist, each organism is differ-
ent, and if you are going to claim that you can produce a product with a 
microorganism, I see no way of someone else reproducing that claim 
unless they have that organism and that sequence. 
KILEY: WeU, let's take it apart. To begin with, the sequence can be dupU-
cated, as was demonstrated in the recent ICI case involving interferon, by 
synthesis. Secondly, the host employed might be a gut bacterium that we 
are all carrying around m our gastrointestinal tract. The law shouldn't 
require the useless act of depositing what is already available to aU comers. 
Beyond which, one may resolve this dilemma by depositing the host and 
holding back the plasmid. Now he can describe to the nth degree the 
manner in which the plasmid is constructed, and he can send you to his 
deposit of the empty host to complete the description of what he cannot 
describe: how the whole living host is put together. 
WATSON: You are proposing a change in the law. 
KILEY: No. I am saymg that rules that were devised for a tune when new 
organisms were found by serendipity, when the maimer of their con-
struction could not be written mto a patent, don't apply to this different 
situation, where our descriptive abUities are greater. 
200 / T. D. Kiley 
WATSON: That is your opmion, not necessarily everyone else's in this room. 
KILEY: It is my highly quaUfied opinion. 
SHARP: E. coli in your gut, each and every one is different from another. No 
smgle orgaiusm, no one organism is identical to another. Deposition of an 
orgaiusm is a unique feature, and I don't think you can argue that. I mean, 
you might argue it, but I don't think it is scientificaUy vaUd. 
KILEY: Does it make a difference? In other words, do these mmute differ-
entiations amongst mdividual members of the strain xl'776 make a differ-
ence to the practice of the invention, or does the deposit of one serve aU? 
SHARP: That is aU of molecular biology, that difference. 
SCHARFF: Isn't it the responsibUity of a putative depositor to show that they 
don't make a difference? Otherwise, they must deposit—I don't mean 
legaUy, but-
KILEY: WeU, no. The patent examiner must first ask the question, does it 
make a difference? Then he must demonstrate sufficient basis for his 
skepticism as to require the patent appUcant to assume the burden of 
going forward with persuasive evidence. So, m that sense, the job is that of 
the exammer to show reason why additional proof should be required. 
KARNY: If there is no difference, why don't you want to deposit the final 
organism? What is the competitive advantage to your holding back that 
final organism if there is technicaUy no difference? 
KILEY: No difference between it and what? 
KARNY: Between the sUrting organisms, for example, or perhaps there is 
some serendipity working in your final orgaiusm. 
KILEY: Because the organism is tiie same as that in your gut-for the sake of 
discussion. But my organism in mdustrial use comprises both the host and 
tiie mtemal machinery tiiat makes it valuable, for example, tiiat which 
permits its high yield production of interferon. 
KARNY: But if you have described tiiat new organism tiie way you are sup-
posed to to meet tiie best mode requirements, tiiat is aU interchangeable. 
What is your competitive advantage in holding back an organism? 
KILEY: Time. It takes time to buUd a plasmid. It costs money. Likewise, it 
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takes time and money to buUd a mainframe computer. Why should I then 
be obliged to give them away? 
SHARP: A computer doesn't repUcate. 
ZINDER: I am afraid that I have to agree with PhU [Sharp], because what 
Tom [Kiley] is domg to us is what the proponents of the recombinant 
DNA tried to do a couple years ago, and say that aU E. coli are alike; the 
E. coli is in your gut and it is a dangerous organism. Now, the K12 that 
you are using, at Genentech, won't go m your gut. So it is a totally differ-
ent organism. 
KILEY: WeU, I think I get into trouble when, to make a pomt, I find myself 
domg molecular biology instead of law. I think the issue is not whether 
it is in your gut, but whether it is commonly avaUable or whether fungible 
alternatives are commonly available. 
ZINDER: WeU, you have to show me that it is different from mine. We were 
just discussing before how, if we give out pBR322 aU over the world, 
everyone's pBR322 is no longer pBR322.1 don't know what the definition 
of pBR322 is, but I wUl agree with that statement because it is my own 
experience, and it is PhU's experience, that thmgs change. You say these 
changes don't matter, they are all fungible. And I say I think you have to 
show that to us. 
KILEY: Some changes obviously wUl matter, some won't. And the issue is 
where that line wiU be drawn, and that is going to depend on the cucum-
stances. 
ULLRICH: With pBR322, it doesn't matter if our 4,300 base pairs are the 
same, as long as they are stiU Tet resistant. Amp resistant, and have some 
single restriction sites. So that is the important part of pBR322. 
KILEY: Not whether every 60 feet there is a yeUow Ime pamted across the 
gene. 
DE ROSNAY: Tom, in your favorite case, the one of Hoffmann-La Roche and 
the University of California^—Do you thmk the famUy of the donor 
should be entitled to claim some property rights on the genes accordmg 
to what you said about titie? Is title hereditary? I mean, are people en-
titied to keep a property right in the gene if somebody has been a donator 
^Hoffmann-La Roche v. Regents of the University of California et al. (Civ. No. C 80 
3601 AJZ, N.V. Cal. 1980). 
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and then this person dies, and the gene is being used to produce a useful 
product which is being sold on the market? Is the family entitied to claim 
tiiat? 
KILEY: Let's assume, for the sake of argument, that the law recognizes titie 
in ceUs that become ceU Unes. Then the question arises whether, since no 
one disturbed the possessory mterest of the patient in his ceU line because 
he pernutted the ceUs to be withdrawn, the manner in which he gave the 
ceUs passed that title to the doctor who took them. One signs a consent 
form, and indeed a consent form was signed m this case, permitting the ex-
traction. The consent form faUs to distinguish between a gift of possession 
and a gift of titie. The most Ukely inference is that the patient mtended to 
pass whatever interest he had m the ceU Une to whoever took it. There-
fore, he is holding an empty sack; his titie has gone into the hands of the 
doctor who extracted the ceUs. 
DE ROSNAY: If he had written a paper saying that he would give the ceUs, but 
whatever happened with the ceUs, if he does, would be the property of his 
famUy, would that be different? 
KILEY: Very possibly, if the law recognizes a titied mterest in that. But if the 
law does not, and suppose the doctor breaches that understanding and, in 
the course of domg so, publishes the ceU line, as one might pubU^ a trade 
secret, to the world, then third party recipients aren't Uable for use. 
SCHARFF: You left out an important word. You said the patient signed a 
consent form, but was it an mformed consent form? And if so, was the 
patient property mformed of the potential usefuhiess? I mean, that is in-
conceivable, because I am sure no qne anticipated that usefulness. So it 
seems to me that you have oversimplified the issue. 
KILEY: Sorry. As far as I am aware, the law of informed consent has not 
evolved along these Unes because, until the present time, there has been no 
need to ask the question. Certainly, I assume the patient was informed of 
the possible health consequences of the extraction. I am certain he was not 
informed of the possibiUty, unknown either to the doctor or, for that 
matter, to Dave Golde that the ceU line might contam a sequence encoding 
leukocyte interferon. 
SCHARFF: But in tiie future we may be required to put in such an informed 
consent. 
KILEY: We are Uable to be up to our nudpoints in paper work, yes. It is 
going to be a mess. 
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McELHENY: Dr. Johnson, you were raising the issue of utUity. 
JOHNSON: I wonder if you could spend a Uttle more time on utiUty in the 
legal sense. 
KILEY: The law requires that an invention be useful because the constitu-
tional authority for the grant of patents refers to the desire of the Framers 
to advance the progress of the useful arts. Now, that means that a mini-
mum threshold of utility must be crossed in order to gain a patent. The m-
vention doesn't have to be the greatest thmg smce sUced bread. It doesn't 
even have to be a technical advance. It can simply be somethmg that is 
useful, albeit only equivalent m its utUity to some previously existmg 
technology, at least in the United States. 
Oftentunes, the question bites most deeply when you are looking at 
a new chemical entity and asking whether it is good for anythmg. Fre-
quently you don't know the answer to that untU you have gone through a 
lot of mindless screening and found some therapeutic activity. When, how-
ever the new technology is being used to make things old m the body, one 
can assume, on the basis of past knowledge that the product is useful. For 
example, insuUn is useful, interferon is useful, because we know what they 
do. So we can say that the product (assuming proper folding and other 
things that we produce) is useful by reference to the past utiUty of insuUn 
or mterferon when gotten by other means. 
Just as soon as we begm to create hybrid products or analogues by 
mismatch repair synthesis, or anything else, we get a Uttle beyond the pale, 
and then you have to ask the question, what is it good for? It is not reaUy 
a good idea to make a guess and then file a patent appUcation, because if 
you guess wrong, you may have obtamed the patent through misleadmg 
conduct, and such a patent wUl be unenforceable. So m the case of new 
products, you may have to demonstrate utility before you can fUe a patent 
appUcation. 
JUDGE RICH: I would elaborate your thought a Uttle beyond the Constitution, 
which refers to the useful art, by saying it is also in the statute. Section 
101, the one that was mvolved in Chakrabarty, which begms, "Any person 
who has discovered any new and useful," and so on. It is reaUy a statutory 
requirement that the courts have to comply with. 
McELHENY: How frequently, empuicaUy, does this come up as a ground for 
overtummg? 
JUDGE RICH: WeU, in this case that Tom mentioned, Brenner v. Manson, 
Brenner was the Comnussioner of Patents and Manson was the appUcant 
for a patent, and I wrote the opinion holdmg it was useful. It went to the 
204 / T. D. Kiley 
Supreme Court, and Mr. Justice Fortas, who used to be on the Court, said 
it had to have practical utiUty, whatever that means. 
KILEY: I think it is a question that arises far more frequentiy in the patent-
getting process, in the Patent Office and before the Court of Customs and 
Patent Appeals, than in the patent trial courts, because one seldom joins 
battie over a patent that is demonstrably useless. ITiere is no economic 
incentive to do so. 
TANENHOLTZ: One pomt with regard to therapeutic compounds, and that is 
that in many cases you can't show utiUty m humans, because it requires 
a great deal of study. The choice is to show it m mice or in some other 
animal. That is suitable to meet the requirements of 101 as far as utiUty 
is concerned, that it cures leukemic mice, for example. 
KILEY: The dreadful dUemma comes when you seek a patent on a method 
of treatmg afflicted subjects, human subjects for cancer, for example, be-
cause no one is going to make a lot of money curing mice of cancer. You 
are asked by the Patent Office to prove your claim and to do that you 
have to have climcal evidence m humans, and that evidence is in hand only 
years after your patent appUcation should first be fUed. It is m hand only 
years after your first pubUcation. If you get your patent under examina-
tion before you have coUected this evidence of cUnical utiUty, you may 
have serious problems. 
GOULD: There is another aspect to the utiUty problem, which I think should 
be addressed also. There is a lot of attention being paid to genetic en-
gineermg, the sexy part of aU this technology, but there is a lot of slop-
piness at the other end, which gets into the plumbing part, which is reaUy 
equaUy important. I am referring to purification. That is especiaUy so 
when you have therapeutic agents, because utUity means that the material 
that comes out the other end has to be useful in a practical sense. When 
we deal with known therapeutic agents, such as interferon and human 
growth hormone, there is sort of a feeUng that everybody knows how to 
use these agents, and we don't reaUy have to get into much of a descrip-
tion. But, in reality, when one is making these substances through genetic 
engineering of a microorganism, one is dealmg with a different environ-
ment, deaUng with essentially toxic proteins that have to be removed be-
fore this material is useful. You can't get away with a crude mixture, 
such as you can by inducing human ceUs to make an interferon, for 
example. 
So there has to be some teaching that is pretty expUcit as to how to 
remove the pyrogens, the endotoxins, and so on, which would not aUow 
that substance to be used. 
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VOSSIUS: Under European law and the adapted national laws, we have only 
the concept of "susceptible of industrial appUcation." This means that the 
thing can be manufactured in a commercial plant or enterprise, and it has 
to satisfy a so-called social need. Nothmg else. We do not have these 
stringent requirements of utility, the requirement to include these pro-
cedures which amount to meeting the demands of your Food and Drug 
Admmistration. We do not need to have examples of how the product 
later on is formulated mto a pharmaceutical composition. It is unneces-
sary—it only costs money—for a patent appUcation. 
KILEY: Of course, in this country one is not obliged to include disclosure of 
that kind if it can be demonstrated that the further steps required to take 
an invention from the end point of the patent disclosure to the end pomt 
of practical use require only standardized techniques weU known to the 
world; ergo, no point m including them m the patent appUcation. 
WATSON: With interferon that would not be the case, though. You would 
have to test it and show that it worked in cUnical trials. 
KILEY: Interferon purified from the body is undergoing cUnical mvestigation. 
Formulations for its administration have been devised. One who subse-
quently produces interferon via this new technology ought to take some 
comfort in whatever level of knowledge has accumulated with respect to 
the mode of admmistering this identical substance— 
WATSON: It is not identical. 
KILEY: Put quotes around it, because it may be different only in inconse-
quential respects. That remains to be seen. 
WATSON: But since it wasn't pure in previous things . . . 
KILEY: But neither was the interferon that was bemg admmistered m the 
clinical tests. One-tenth of 1 percent pure material was bemg given to 
patients. 
WATSON: No, but I am saying in both cases you don't reaUy have any prior 
basis for assuming that you can judge whether or not it is. 
KILEY: And then one question becomes whether the means of takmg it the 
next step, the means of purifying it, are already avaUable to the world, 
and hence needn't be mvented anew. To take that further, if you now 
have the ability to make vast quantities of mterferon, you don't require a 
very sophisticated purification methodology to take the material to 
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homogeneity, because you can throw an awful lot of it away in the course 
of doing that. 
WATSON: It depends on what degree of contaminant wiU make you sick. You 
don't know that untU you have proven that. I don't think there is any-
one here who would a priori beUeve that. Just seen from the viewpomt 
of 'Vould you take it," the answer is no. There is no basis for assuming 
that it is not gomg to harm you. 
KILEY: As one of the few people m this room that has already had mjections 
of a biosynthetic hormone, I suppose it was pure enough for me to take. 
ROWLAND: You don't want to confuse the role of the FDA and the Patent 
Office here. 
KILEY: No. And more importantiy, I don't want the Patent Office to confiise 
its role. The courts have remmded the Patent Office from time to time, 
and the Patent Office has taken heed, of its different mission. Certainly 
its job is to require, where there is reason for suspicion, a demonstration 
of UtiUty, but only a threshold demonstration, not one like that required 
by tiie FDA. 
JUDGE RICH: One of the ways it comes up, m a practical way, is m inter-
ferences, where there are two inventors, and the one who gets Ucked on 
dates always thinks up every possible way to keep his competitor from 
gettmg the patent, if he hasn't gotten one yet. So he wUl raise this lack of 
UtUity argument. We have had a lot of cases Uke this, antibiotics mostiy 
that have to go through the whole thmg, mice, bigger animals, monkeys, 
men, and so on. We haven't reached the man stage yet. So it is the pot 
calUng the kettle black situation. Where one feUow only had animal 
tests, the court has said ammal tests for the other feUow are sufficient to 
meet the utUity requuement. 
KILEY: In the fmal analysis, whether a particular set of animal tests wUl or 
wiU not be regarded as sufficient depends upon the particular subject 
under judicial scrutiny. It can vary from mvention to invention. 
KARNY: I would lUce to get back to this titie versus possessory interest. I 
haven't looked at tiie law properly m a long time, but it is my under-
standing that a titied interest is something more formal, e.g., recording 
interests in real property. You have an entire mechanism for tracing 
ownership and so fortii. If tiiat is tiie case, are we not, for living ceUs, 
talking about a mere possessory interest, where possession would be the 
equivalent of ownership? I don't see how a court could find a titied 
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interest in a Uving ceU. And if it did, wouldn't it take more to transfer that 
titled interest than simply aUowmg the extraction of the ceUs from the 
body? Would it not take some formal written assignment? 
KILEY: In common law England, we did thmgs with a great deal more for-
mality and sealing wax than we do at present. Nevertheless, there are 
means of recording title, as you do when you purchase a house, that are 
erected as defenses against someone who subsequently takes possession of 
your property without knowledge of your interest in it. You can cut off 
what are called the rights of bona fide purchasers for value by recording. 
Now, we are not going to go down to the county hall of records and 
record the passage of microorganisms. That won't be required in order to 
pass title. It may be required in order to put otherwise bona fide pur-
chasers for value on notice of your interest. But now I begm to blur the 
distinction between possessory and titled mterest, and I don't think we 
had best pursue that here, because it is rather compUcated. 
JUDGE RICH: About the copyright business, do you thmk is to be taken 
seriously? Do you know anybody that has tried it on yet? I know that 
Professor Irv Kayton told his class that he thought these thmgs were 
copyrightable. 
KILEY: Let me suggest one of the problems I see with it. I don't know any-
body who has tried it. But suppose that I pubUsh the DNA sequence of a 
gene that encodes a valuable substance, and that sequence is quite lengthy 
and someone reads the pubUcation and uses the genetic sequence to devise 
a probe that is radioactive and wUl hybridize with the copy of that gene 
that is found in the human genomic library. Now, has he made "fair use" 
of my copyrighted information by takmg only a bit of it to do another 
task, without physicaUy or otherwise copying the published gene? If he 
has, then the copyright remedy isn't avaUable to the copyright holder. 
AU he has done is pubUshed his perhaps putative secret, to no apparent 
good end. 
BRENNER: Are cookmg recipes copyrightable in that sense? 
KILEY: Yes, cookbooks are copyrightable. 
BRENNER: But if I cook the meal and eat it, am I infringuig the copyright? 
KILEY: No. If you copy the cookbook and seU it, you are infrmging. 
BRENNER: But if you make a Xerox copy of the page, which is copymg the 
sequence—you can imagine the sequence to be a recipe. 
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SCANLON: I have worried about this issue of copyright protection a Uttie bit. 
I was very worried about the issue raised about only authors being entitled 
to copyrights. But it turns out that the Copyright Office, since before the 
provisions in the Copyright Act just m December, has been registering 
copyrights in these littie masks that are used to make microcucuits on 
sUicon chips. Their justification for that has been that the utiUtarian func-
tion of these masks is separable from the mformation content, you might 
say, because more than one mask can be used to make the same micro-
circuit. 
JUDGE RICH: What are they registermg them as, works of art or books or 
what? 
SCANLON: Pictorial, graphic, and sculpture. Now, of course, I think they 
might also be registering them as computer programs. 
MacPHERSON: Several years ago, the American Electronics Association was 
offered the opportimity to support the registration of mtegrated circuits 
as copyrightable material, and it nearly spUt the organization m two. Cer-
tam companies found it advantageous to attempt to puU what previously 
had been considered to be a manufactured article, fair game to be copied 
by others who wished to reverse engmeer the product, from that particu-
lar category and develop some proprietary rights m that product, particu-
larly because many of these mtegrated circuits were not patentable. They 
were merely larger assemblages of stuff that had been done earUer and 
perhaps had been patented, perhaps had not been. 
The opposition to this particular attempt argued very strongly that 
the integrated circuits were utUitarian items m which the particular form 
of expression was, in fact, dictated by function which the device was to 
serve, and therefore not subject to copyright registration. 
Subsequentiy, one company m the industry brought suit against the 
Copyright Office to require the Copyright Office to register these particu-
lar masked sets used to make the mtegrated cucuits as copyrightable 
material. The ultimate resolution of that suit, so I was informed by the 
attomey who brought the suit, was that the Copyright Office acquiesced 
solely on the grounds that it was a ministerial function which it must carry 
out. That is, it must register what was submitted but it was making no 
judgment as to the legitimacy of the copyright. 
SCANLON: I can take that one step further. If tiie Copyright Office did that, I 
am afraid, if you look at the decisions in the copyright area-once the 
register of copyrights decides that something wiU be registered for copy-
right protection, the courts, almost uniformly, foUow that determination, 
Proprietary Rights and Biotechnology / 209 
and therefore hold that the subject matter that the copyright was granted 
for is, m fact, copyrightable. 
So it could be in this case that the copyright exammer claimed, 
"WeU, I am not making a decision." But I am afraid if that got to the 
courts, the courts would say, "WeU, the register said it is copyrightable"— 
the probabiUty is very high that the courts would say, "Then it is copy-
rightable subject matter." 
KILEY: It is ironic that the courts are very zealous in their protection of trivia 
protected by copyright or trade secret law, but tum mto patent-kUUng 
ogres as soon as a patent comes before them. 
CiOULD: One problem also is that you always have to pubUsh the sequence 
with notice. You have a problem: If you patent that sequence, they won't 
publish the notice m the patent. 
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Antitrust and patent laws represent fundamental policy in the United States. 
As the Supreme Court said in Dawson Chem. Co., Inc. v. Rohm & Haas Co., 
448 U.S. 176, 221 (1980), "the policy of free competition runs deep in our 
law.. . . But the policy of stimulating invention that underlies the entire patent 
system runs no less deep." 
I wUl describe the general nature of patent rights and antitrust prohibi-
tions and the apparent legal conflict between them and wUl outline briefly some 
of the issues the Courts have decided and some of what they have said in at-
tempting to resolve that conflict. I wiU then describe briefly how economic 
analysis appUes to patent law and provides the analytical framework for decidmg 
whether patent-related business conduct is lawful under the antitrust laws. 
THE NATURE OF PATENT RIGHTS AND THEIR RELATION 
TO ANTITRUST AND PATENT MISUSE LAW 
Beginning in 1790, Congress enacted patent laws. A patent grants, for the term 
of 17 years, the right to exclude others from making, using, or seUing the in-
vention throughout the United States. When the patent expires, the invention is 
avaUable to the public to use freely and without restriction. 
The Constitution specifically gave Congress that power and provides the 
reason for domg so. Article I, Section 8, Clause 8 states: 
"The Congress shall have Power . . . [t] o promote the progress of Science 
and useful Arts, by securing for limited Times to Authors and Inventors 
the exclusive Right to their respective Writings and Discoveries." 
The Courts have said frequentiy that a fundamental purpose of the patent 
laws is to provide mcentive for inventors to mcur and to risk the costs of 
research and development in making mventions.^ In 1964, the Court put it 
»Kewanee OU Co. v. Bicron Corp., 416 U.S. 470,480-81,484 (1974). 
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as foUows {Sears, Roebuck & Co. v. Stiffel Co., 376 U.S. 225,229-30(1964)): 
"Patents are not given as favors, as was the case of monopoUes given by 
the Tudor Monarchs..., but are meant to encourage invention by re-
wardmg the inventor." 
The antitrust statute which bears most directiy on the activities of a patent 
owner is the Sherman Act. Section 1 relates to agreements between two or more 
separate enterprises. In general. Section 1, as construed by the Courts, prohibits 
every contract, combmation or conspiracy which unreasonably restrains trade. 
Unreasonable restraints are those which are not reasonably anciUary to a lawful, 
main purpose of an agreement. Analysis under this rule of reason involves a fiiU 
factual inquiry into the purpose and effect of the restramt. The Courts have 
from time to time attempted to identify restramts, which are never reasonable, 
and are therefore said to be per se unlawful, regardless of their purpose or effect. 
Section 2 of the Sherman Act prohibits monopoUzation or attempts to monopo-
Uze and relates primarily to conduct by a smgle enterprise which unlawfuUy ob-
tains or attempts to obtam monopoly power m a market. One test of monopoly 
power is the power to raise prices and exclude competition. 
The antitrust laws are not the only legal constramt on a patent owner's 
conduct arising from policies about competition and monopoly. The defense of 
patent misuse also has the effect of limiting that conduct. One Court has de-
scribed the role of the misuse defense m patent mfringement Utigation as 
foUows {Bryan v. Sid W. Richardson, 254 F.2d 191 (5tii Cir. 1958)): 
"Each defense having thus successively coUapsed, Bryan retreats now 
to the last, but favorite isle of resistance, to claim that whUe found to be a 
poacher, he may nonetheless keep his game because the patent owner has 
been guUty of monopoUstic abuses." 
Misuse renders the patent unenforceable, but not mvalid.^ The period of unen-
forceabUity ends when the patent owner shows that the misuse has been 
abandoned and that the consequences of the misuse have been ftiUy dissipated.^  
Patent misuse must be considered separately from antitrust liabUity because mis-
use may be established by facts which do not estabUsh an antitrust violation. 
In addition and unUke an antitrust cause of action, patent misuse is a defense 
avaUable to an infringer, which has not been injured or even affected by the 
misuse.* 
That brief description of patent law and antitrust law may suggest that 
these laws appear to be working at cross purposes. The Sherman Act seems to 
rest on the premise that unrestrained competition wUl yield the best aUocation 
'Morton Salt Co. v. G. S. Suppiger Co., 314 U.S. 488.491-493 (1942). 
'United States Gypsum Co. v. National Gypsum Co.. 352 U.S. 457, 465 (1957); 
Morton Salt Co. v. G. S. Suppiger Co., 314 U.S. 488, 492-94 (1942); B. B. Chemical Co.. 
V.Ellis, 314 U.S. 495. 498 (1942). 
^Zenith Radio Corp. v. Hazeltine Research, 395 U.S. 100, 140-41 (1969); Morton 
Salt Co. V. G. S. Suppiger Co.. 314 U.S. 488. 490.494 (1942). 
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of economic resources, the lowest prices, the highest quaUty, and the greatest 
material progress.^ The Patent Act seems to rest on the premise that unre-
strained competition in the use of an invention wiU not yield the greatest 
material progress.^ In particular, such unrestrained competition wiU cause too 
few resources to be allocated to making mventions and too little progress as 
fewer inventions are made. A patent, therefore, grants a 17-year "monopoly" 
of the use of the invention.'' The exclusion of competition from use of the 
invention is said to be the essence of the right conferred by a patent.® However 
stated, those results of patent law sound like results antitmst laws are designed 
to prevent. 
After passage of the Sherman Act in 1890, the Courts began the process 
of trying to resolve this seeming conflict. A brief review of some decisions on 
selected issues suggests the nature of this accommodation process. 
Acquisition and Enforcement of a Patent 
Suppose that an inventor discovers a new product which is certain to be so 
superior to existing substitutes that, with patent protection, he wiU obtain an 
economic monopoly. The fundamental question seems to be whether it is iUegal 
to obtain and enforce the patent for that purpose and with that effect. It seems 
clear enough that the mere acquisition and enforcement of such a patent does 
not violate the antitrust laws, at least where there is no attempt to obtam the 
patent by fraud.^ Recentiy, in SCM Corp. v. Xerox, 645 F.2d 1195, 1204 (2d 
Cir. 1981) (1981-1 Trade Cas. para. 63,876, at 75,532), the Court observed that 
"[n]o court has ever held that the antitrust laws requure a patent holder to 
forfeit the exclusionary power inherent in his patent the instant his patent 
monopoly affords him monopoly power over a relevant product market." 
In 1965, the Supreme Court held for the first time that the maintenance 
and enforcement of a patent obtained by fraud on the patent office may be 
conduct which violates Section 2 of the Sherman Act, where all the other 
necessary elements of a Section 2 violation exist.*° Such a claim must be based 
on proof of the existence of a relevant market for antitmst purposes, a market 
defined by economic factors, and the exclusionary power of the Ulegal patent m 
that market. A requirement of such a Section 2 cause of action is proof of pro-
curement of the patent by "intentional fraud." At least one Court has said that, 
'c/., Northern Pacific Railway Co. v. United States, 356 U.S. 1,4-5 (1958). 
*c/., United States Constitution, Article I, Section 8. 
'United States v. Dubilier Condensor Corp., 289 U.S. 178, 186 (1932); Dement v. 
National Harrow Co., 186 U.S. 70, 91 (1902). 
'Dawson Chem. Co. v. Rohm & Haas, 448 U.S. 176 (1980); Transparent-Wrap 
Machine Corp. v. Stokes & Smith Co., 329 U.S. 637, 643 (1947); Continental Paper Bag 
Co. v. Eastern Paper Bag Co., 210 U.S. 405,429 (1908). 
'Walker Process Equipment, Inc. v. Food Machinery & Chemical Corp., 382 U.S. 
172,177(1965). 
'"Walker Process Equipment, Inc. v. Food Machinery & Chemical Corp., 382 U.S. 
172,177-79(1965). 
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independent of fraudulent procurement, enforcement of a patent by actions for 
infringement brought and main tamed in bad faith may violate Section 2 of the 
Sherman Act, if pursued with intent to monopolize and if the other elements of 
an antitmst violation are shown." 
Settlement of Patent Disputes 
The Courts have found that the antitrust laws and the doctrine of patent misuse 
do not preclude the settlement of a patent controversy, so long as the settiement 
is not made in a bad faith or is not otherwise part of an unlawful scheme." In 
Lhiplan, Corp. v. Deering Milliken, Inc., 540 F.2d 1215 (4tii Cir. 1976), the 
Court recently said: 
"Furthermore, it must bom m mmd that settlement of patent Utigation, 
m and of itself, does not violate the antitmst laws It is only when 
settiement agreements are entered mto m bad faith and are utilized as part 
of a scheme to restram or monopolize trade that antitmst violations may 
occur." 
The subtle problems arismg from settlement of patent controversies are 
Ulustrated by United States v. Singer, 374 U.S. 174 (1963). In tiiat case tiie 
Court held that Singer, an American manufacturer of household sewing 
machmes, UlegaUy conspired witii two of its competitors, Gegauf and VigoreUi, 
for the purpose of usmg patents to exclude Japanese competitors from the U.S. 
market. In settlement of patent controversies, Smger and the others entered a 
number of written agreements, includmg a cross-Ucense agreement between 
Singer and Gegauf under which each licensed the other under its U.S. patents 
and appUcations. Subsequentiy, Gegauf assigned to Smger its U.S. appUcation 
and any patent which might be granted on it, and Singer mstitiited mfringement 
actions and otiier proceedings against Japanese manufacmrers. The Supreme 
Court found, contrary to the trial court, tiiat Smger agreed with Gegauf and 
VigoreUi to enforce tiie patent "to tiie benefit of aU tiiree parties," ratiier tiian 
to protect its own machme and thereby violated tiie antitrust laws. The Court 
inferred that there was such an agreement based on its fmding that tius was tiieir 
main "purpose" in entering the other agreements. 
Nonuse of Patented Inventions 
Neither the patent law nor tiie antitrust law requires tiiat tiie patent owner use 
the patented invention or license otiiers to do so. In Continental Paper Bag Co. 
v. Eastern Paper Bag Co., 210 U.S. 405,426-30 (1908), tiie Court said: 
"As to tiie suggestion that competitors were excluded from tiie use of tiie 
I'Handgards, Inc. v. Ethicon, Inc., 601 F.2d 986 (9th Cir 1979) 
StandardOilCo.v. United States, 283 U.S. 163, 171 (1931). 
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new patent, we answer that such exclusion may be said to have been the 
very essence of the right conferred by the patent, as it is the privUege of 
any owner of property to use or not use it, without question of motive." 
As the Court said in Hartford-Empire Co. v. United States, 323 U.S. 386, 
417-18,431-33(1945): 
"A patent owner is not in the position of a quasi-tmstee for the pubUc or 
under any obligation to see that the public acquires the free right to use 
the mvention. He has no obUgation either to use it or to grant its use to 
others. If he discloses the invention in his application so that it wiU come 
into the public domain at the end of the 17-year period of exclusive right, 
he has fulfilled the only obUgation imposed by the statute. This has been 
settled doctrine since at least 1896." 
Patent License Agreements 
The Courts have long held that the patent owner has the right to exploit the in-
vention by granting licenses to others. A license is a waiver of at least some of 
the rights to exclude others from making, using, and seUing the patented in-
vention. Patents are often licensed to others in retum for somethmg of value to 
the patent owner. 
The Amount of the Royalty 
A patentee has the right to exploit the patented invention by charging and fixmg 
a royalty payment.^^ Unlike certain pubUc utiUties whose rates are regulated by 
an admmistrative agency to permit only a reasonable rate of retum, the patent 
laws provide no limits on the amount a patent owner may charge for a Ucense 
under the patent. A patent owner has the right to charge as high a royalty as he 
can obtain.^* However, an agreement among owners of patents covering 
competing products or methods fixing the royalty of licenses under those 
patents may violate Section 1 of the Sherman Act.^ ^ 
Relation of Royalty Base to the Patent 
A patent owner may base the formula for royalty payments on many different 
activities, includmg Ucensee's revenue from sales, the number of units the 
Ucensee seUs, and so forth. The nature of the royalty base does not raise anti-
tmst or misuse issues, except in one instance. The royalty may be based on the 
"Standard Oil Co. v. United States, 283 U.S. 163, 172, 179 (1931); Hartford-
Empire Co. v. United States, 323 U.S. 386,413-16 (1945). 
"Brulotte v. Thys Co., 379 U.S. 29, 33 (1964); W.L. Gore & Associates v. CarUsle 
Co., 529 F.2d 614,623 (3d Cir. 1976). 
"Standard OU Co. v. United States, 283 U.S. 163 (1931). 
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licensee's sales, even though the making, using, or selling of such products is 
not covered by a Ucensed patent, but only where the patent owner does not 
condition the grant of the Ucense on the payment of such royalties. When the 
patent owner does so, he misuses the patent.** Where the royalty base is agreed 
to for the mutual convemence and efficiency of the partiesthere is no con-
ditioning and no misuse.*^ 
Relation of Royalty Payments to the Patent Term 
Patent royalties may not be coUected based upon activities taking place after the 
expiration of the patent. In Brulotte v. Thys Co., 379 U.S. 29^3 (1964), tiie 
Court, with Justice Harlan dissentmg, held that, when a patentee sold a patented 
hop-pickmg machine and separately granted a Ucense to use the machine and 
caUmg for royalties based on use before and after expiration of the last patent 
"incorporated into the machine," the patentee could not enforce the Ucense 
to the extent it caUed for post-expiration royalties. 
Licensing More Than One Patent 
The Courts have also found that a patent owner who conditions the grant of a 
Ucense under one patent on the acceptance of a Ucense under another patent 
has misused the patents." Some Courts have refused to find UlegaUty where 
the mventions are related in such a way that the mvention of one patent may 
not be used without infringing the other patent.*' 
Restrictions or Limitations in the License 
The patent owner may decide that the revenue earned from commercial use of 
the invention wUl increase if he authorizes the Ucensee to use the invention only 
to make a particular type of product, to use the mvention only with products 
suppUed by the patent owner; to make and seU only in a particular part of the 
United States, or to make and seU at an agreed price. In nonpatent contexts, 
agreements between present horizontal competitors to divide product markets, 
divide territorial markets or fix prices are per se viplations of the antitmst laws. 
The Court wUl not consider any justification for such restrictions. Witii tiie 
possible exception of price fixing, tiie legaUty of such agreements between 
vertically related enterprises turns on rule of reason analysis. SimUarly, a seUer 
'•Zenith Radio Corp. v. Hazeltine Research. Inc., 395 U.S. 100, 135-40 (1969). 
"Automatic Radio Mfg. Co. v. Hazeltine Research, Inc., 339 U.S. 827, 830-33 
(1950). 
"Automatic Radio Mfg. Co. v. Hazeltine Research, Inc., 339 U.S. 827,831 (1950); 
Hazeltme Research, Inc. v. Zenith Radio Corp., 388 F.2d 25. 33-35 (7di Cir. 1961), aff'd 
in part, rev'd on other grounds. 395 U.S. 100 (1969). 
"International Mfg. Co. v. Landon, Inc., 336 F.2d 723 (9th Cir. 1964). 
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of a product who suppUes it only on the condition that the purchaser also buy a 
separate product may have violated the antitmst laws. 
Field of Use Restrictions 
When a patent owner licenses the patent but testricts its use to a particular type, 
mode, class, or size of product or process^ he is sometimes said to impose a 
"field of use" restriction. In General Talking Pictures Corp. v. Western Electric 
Co., 304 U.S. 175, aff'd on rehearing, 305 U.S. 124 (1938), the owner of 
patents on ampUfiers Ucensed its own subsidiary to make and seU equipment 
using the ampUfiers for theater use, and separately licensed others to make and 
seU radio receivers using the amplifiers for home use. The defendant purchased 
ampUfiers for use in a theater from one of those licensed only to seU to the 
private home market. The defendant had actual notice of the seUer's limited 
license. The Supreme Court upheld the field of use restriction, and ruled that 
the purchaser was guUty of infringement. It found that (304 U.S. at 818): 
"Patent owners may grant licenses extending to all uses or limited to use 
in a defined field." [Citations omitted]. 
Field of use restrictions in patent licenses have repeatedly been found not 
to violate the antitrust laws and not to constitute misuse based upon General 
Talking Pictures. 
In spite of the expUcit holdmg m General Talking Pictures, many lower 
Courts have held that a patent owner may not himself make and seU a patented 
product and limit the field of use of a purchaser. The distmction these Courts 
make is between restraints on first sale and restraints on resale. In 1977, the 
Court in Continental T.V., Inc. v. G.T.E. Sylvania, Inc., 430 U.S. 36 (1977), 
held that non-price vertical resale restrictions were not per se violations of the 
Sherman Act and were to be judged under the mle of reason. G.T.E. Sylvania 
did not involve a patented product or a patent license, but the decision would 
appear to require that resale field of use restrictions in patent licenses, which 
result from agreement between the patent owner and each Ucensee (not from 
agreement among licensees), violate the antitmst laws only if they are found, 
under all the cucumstances, to be unreasonable. 
Tying Arrangements 
In 1912, the Court had before it a situation in which the owner of a patent on 
mimeograph machines made and sold the machme under a license attached to it 
stating that it is sold with the "license restriction" that it may be used only with 
paper, ink, and other suppUes made by the patent owner. Another company sold 
ink suitable for use in the machine, with knowledge of the restriction and with 
the expectation of its use with the machine. The Court held that this was 
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contributory mfringement, which it enjomed.^ The Court that reversed its posi-
tion m Motion Picture Patents Co. v. Universal Film Mfg. Co., 243 U.S. 501, 
508, 516-518 (1917). In that action, a patent owner Ucensed a company which 
made and sold a motion picture projector with a patented film feeding part. 
There was a notice on the projector that the purchase gives only the right to 
use it with unpatented fUms leased from the patent owner. The Court held 
that the restriction was unenforceable, and the use of the projector with fUms 
of others did not constitute infringement. likewise, the sale of films for that 
use did not constimte contributory mfrmgement. The decision in Motion 
Picture Patents was extended subsequently to preclude similar conditions in 
patent licenses under process and combination patents. 
In 1942, the Court first held that misuse of this type rendered a patent 
unenforceable against a direct mfrmger." In the Morton Salt case matter, the 
patent owner leased a patented salt dispensing machme to canners under a 
Ucense to use it upon the condition and with the agreement of the Ucensee that 
only the patent owner's salt tablets be used m the machme. In an action for in-
fringement against a maker of aUegedly infringmg machines, the Court held that 
the patent was unenforceable, even though that infringer had not been harmed 
by the conduct constituting the misuse and even thou^ no antitrust violation 
was estabUshed. 
Beginnmg m 1936, antitrust mles evolved from the earUer patent infringe-
ment cases. The Court held, that the sale or lease of a patented product only on 
a condition that the buyer or leasee also purchase a different product may, in 
certam circumstances, violate Section I of the Sherman Act or Section 3 of the 
Clayton Act." 
Recentiy, the Court in Dawson Chem. Co., Inc. v. Rohm &. Haas Co., 
448 U.S. 176 (1980) confronted a situation in which the owner of a process 
patent sold a material (which if sold by another would constitute contributory 
infringement) with instmctions for performing the patented process and stated 
its intention not to grant licenses to other material manufacturers or to process 
users, who obtained their materials from another source. The Court held that 
Section 271(d) of the Patent Act precluded a findmg of misuse m that case. 
Price Limitations 
In certain situations, a patent owner's mdependent fixing of the prices for a 
manufacturing licensee's sale of patented goods does not violate the Sherman 
^"^Henry v. A. B. Dick Co. 224 U.S. 1, 25-26 (1912). 
"fl. B. Chemical Co. v. Ellis, 314 U.S. 495. 496-98 (1942): Leitch Mfg. Co. v. 
Barber Co., 302 U.S. 458 (193%); Carbice Corp. v. American PatentsDeveL Corp., 283 U.S. 
27,30-35(1931). 
**Morton Salt Co. v. G.S. Suppinger Co.. 314 U.S. 488. 491-94 (1942). 
"International Salt Co. v. United States, 332 U.S. 391 {1941); Intemational Business 
Machines Corp. v. United States, 298 U.S. 131 (1936). 
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Act.^ In 1948, in United States v. Line Material Co., 333 U.S. 287, 293-97, 
305-15 (1948), the Court held that a license under patents owned by two or 
more patent owners, restricting the price at which the manufacturing licensee 
sold, violated Section 1. The patents were complementary in the sense that only 
when both patents were used in a smgle product could the pubUc or the 
patentees obtain fuU benefit of the efficiencies provided by both inventions. The 
Ucense made possible the use of both inventions. Nonetheless, the Court found 
that, because the license was under patents owned by different patent owners, 
that fact rendered the agreement iUegal. 
There are many other situations in which the patent law has been found 
not to justify price fixing. In the 1940s, the Court in United States v. Univis 
Lens Co., 316 U.S. 241, 243-45, 249-51 (1942) and Ethyl Gasoline Corp. v. 
United States, 309 U.S. 436, 446-48, 452, 457 (1940), held that a patent 
owner violated Section 1 when it sold the patented product to its licensee for 
resale (Ethyl) or sold an unpatented product useful only in making a patented 
product for sale (Univis) and granted a license to seU the patented product at 
a fixed price. The Court noted that the patent owner received no royalty pay-
ments from the licensee's sales. In 1942, the Court held in United States v. 
Masonite Corp., 314 U.S. 265, 276-80 (1942), tiiat when a patent owner, 
pursuant to a horizontal agreement among itself and its competitors, enters sub-
stantially identical "agency" agreements to estabUsh those competitors as agents 
for distribution of the patent owner's product at fixed mmimum prices, those 
agreements violated the Sherman Act. The Court reasoned that such agreements 
are not reasonably related to the patent owner's earning maximum returns from 
the patented article, but rather have the purpose of maximizing returns to the 
patent owner and its competitors by fixing the price at which they seU the 
patented article. The Masonite decision is merely one example of the rule that a 
patent owner's right to restrain trade in a patented article does not mclude the 
right to do so in concert with Ucensees or other patentees. The legality of re-
straints resulting from such horizontal combinations is judged by the standards 
of the Sherman Act.^ ^ 
Territorial Restrictions 
The Courts have held that a patent owner may grant a license limiting the 
licensee's right to make, use or seU a patented product to a particular territory 
witiiin the United States.^^ 
"United States v. General Electric Co., 272 U.S. 476, 478-79, 488-94 (1926); 
Bement v. National Harrow Co., 186 U.S. 70,72, 93 (1902). 
"United States v. United States Gypsum Co., 333 U.S. 364, 399-401 (1948); 
Standard Sanitary Mfg. Co. v. United States, 226 U.S. 20, 39-49 (1912); United States v. 
New Wrinkle, Inc., 342 U.S. 371, 374, 378-80 (1952). 
"Bement v. National Harrow Co., 186 U.S. 70, 92-93 (1902); Adams v. Burke, 17 
WaU. 453 (1873); BrowneU v. Ketham, 211 F.2d 121, 128 (9th Cir. 1954). ("It is a funda-
mental rule of patent law that the owner of a patent may Ucense another and prescribe 
territorial limitations.") 
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A patent owner's right to restrict the place of use or sale by a purchaser 
of a patented product may be more limited. In Bloomer v.McQuewan, 55 U.S. 
539 (1852), the Court stated: 
"And when the machine passes to the hands of the purchaser, it is 
no longer withm the lunits of the monopoly. It passes outside of it, and 
is no longer under the protection of the [patent] act of Congress." 
FoUowing that decision, the Court held that an unrestricted sale by a territorial 
assignee whose right to seU for use elsewhere was not restricted, gave fuU rights 
to the purchaser to use the article elsewhere and such use did not constitute 
infringement.^^ 
The Tests Applied by the Courts in Patent-Antitrust Actions 
In decidmg these cases, the Courts repeatedly said that exploitation of the 
patent m a manner not inconsistent with the scope of the patent monopoly 
is lawful.^ ^ In United States v. United Shoe Mach. Co., 247 U.S. 32, 57 (1917), 
the Court put it as follows: 
"Of course, there is restramt m a patent. Its strength is in the re-
straint. . . . This strength is the compensation which the law imparts for 
the exercise of invention. Its exertion withm the field covered by the 
patent law is not an offense agamst the Anti-Tmst A c t . . . In other cir-
cumstances, it may be . . .". 
Conversely, if a patent owner uses or attempts to use the patent to obtain 
a monopoly beyond the scope of the patent or agrees to restram trade beyond 
the scope of the patent, the patent owner's conduct may be Ulegal under the 
Sherman Act. As stated in Ethyl Gasoline Corp. v. United States, 209 U.S. 346, 
456(1939): 
"The patent law confers on the patentee a Umited monopoly, the 
right to exclude aU others from manufacturing, using or seUing the 
invention.. . . The extent of that right is limited by the defmition of his 
invention, as its boundaries are marked by the specification and clauns 
of the patent. . . . He may grant licenses to make, use or vend, restricted 
in point of space or time, or with any other restriction upon the exercise 
of the granted privUege, save only that by attaching a condition to his 
"Adams v. Burke. 17 Wall. 453 (1873); Hobbie v. Jennison, 149 U.S. 355 (1893) 
(territorial assignee who knew the buyer intended to use the product in another territory is 
not liable for infringement by reason of sale); Keeler v. Standard Folding Bed Co., 157 U.S. 
659 (1895). ("Whether a patentee may protect himself and his assignees by special con-
tracts brought home to the purchasers is not a question before u s . . . [However] . . . such 
a question would arise as a question of contract not as one under the inherent 
meaning . . . of the patent laws.") 
"General Talking Pictures Corp. v. Western Electric Co., 304 U.S. 175. 181 ,^don 
reh.. 305 U.S. 124 (1938). rWi. denied, 305 U.S. 675 (1939). 
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Ucense he may not erUarge his monopoly and thus acquire some which 
the statute and the patent together did not give." 
Two additional cases articulate frequentiy cited tests. In United States v. 
Line Material Co., 333 U.S. 287,308 (1948), the Court said: 
"[T]he legality of a patent owner's use of the patent or his agreements 
with others relating to the patent is determined by whether the use or 
agreement is reasonably related to maximizing the patent owner's returns 
from the demand for and value of the patent invention or is a means of 
maximizing profits from another source, such as, by creatmg monopoly 
power or unreasonably restraining trade m products or processes not 
protected by the patent." 
In United States v. General Electric Co., 272 U.S. 476, 189-90 (1926), the 
Supreme Court stated the following standard: 
"Conveying less than title to the patent, or part of it, the patentee 
may grant a license to make, use and vend articles under the specifications 
of his patent for any royalty and upon any condition the performance of 
which is reasonably withm the reward which the patentee by the grant of 
the patent is entitled to secure.... The patentee may make and grant a 
Ucense to another to make and use the patented articles, but withhold its 
rights to seU them.. . . If the patentee goes further, and licenses the selUng 
of articles, may he limit the seUing by Umiting the method of sale and 
price? We think he may do so, provided that the conditions of sale are 
normally and reasonably adapted to secure pecuniary reward for the 
patentee's monopoly." 
You might be tempted to conclude from this "beyond the scope" and 
"enlarge the monopoly" language that so long as the Ucensee's competition is 
restrained only with respect to sales of the patented product or use of the 
patented process, there can be no antitmst violation. Indeed, I suspect that 
many lawyers have been informed by their cUents that a restriction in a license 
agreement cannot possibly be anticompetitive. This is because, without the 
restriction, no license wiU be granted and the prospective licensee excluded 
totally. That result leaves no competition. Therefore, the proposed restriction is 
necessarUy pro-competitive because, with it, at least some competition exists. 
They are not without company. Consider the foUowmg comments by Justice 
Burton m United States v. Line Material Co., 333 U.S. 287 (1948), in defense of 
price-fixing restrictions in a license: 
"Just as an unlimited license is a partial, but lawful, relaxation of the 
lawful restraint of trade imposed by the patent, so a limited license is but a 
correspondingly less relaxation of that same restraint.... [T] he restramt 
of trade unposed by the patent itself is lawful. Therefore, as long as the 
Ucense agreement has orUy the effect of reducing the lawful restraint 
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unposed by the patent, such agreement merely converts the original lawful 
restramt into a lesser restramt, equaUy lawful." 
The Justice made those remarks in a dissentmg opimon. The majority found 
that patent license to be Ulegal. The logic of the argument depends, of course, on 
whether you compare the restrictive Ucense to no license or to a Ucense without 
the restriction. The possibUity of grantmg an unrestricted Ucense renders the 
syUogism defective. I hasten to add that, merely because this logic does not 
compel the conclusion that aU license restrictions are legal, the question of what 
the patent owner wUl do under different mles should be very important to the 
decision of which mle to adopt. 
You may at this pomt be less than satisfied that these statements from the 
cases resolve very much about the supposed conflict between patent and anti-
tmst law. What restrictions are "within the scope," when is the "monopoly 
enlarged," and what is "normal and reasonable?" 
The Legal and Economic Framework for Resolving 
Patent-Antitrust Issues 
Certainly there must be a more expUcit analysis of the relation between patent 
and antitmst law to mform and give meaning to the law. One method of analysis 
which is consistent with much of what the Courts have said proceeds from the 
premise that both patent and antitrust laws are designed to provide conditions 
for the market to achieve the best aUocation of resources, and hence, maximize 
the welfare of consumers.^' 
Viewed in this way, the production of inventions is the production of a 
type of information. The market system allocates scarce resources into their 
most productive uses where private decisions to maximize private welfare are 
the same decisions which maximize the welfare of society as a whole. Price 
theory recognizes that this desirable state of affaurs wiU only exist under certain 
conditions. Of those conditions, there are two related ones which faU in the case 
of information and tend to insure that society wiU not aUocate sufficient re-
sources to the production of information (and inventions), in the absence of 
some corrective action (such as patent laws). These related faUures are the 
presence of indivisibUities and extemaUties in production and use. 
The problem of indivisibUities exists when the nature of the production 
of a commodity requires that in order to satisfy the demand of one consumer, 
someone must produce a unit of a good which is also capable of satisfying the 
demands of many other consumers. Once such a good is produced, additional 
consumers can use it without interfering with the use of other consumers and 
" Regarding antitrust law generaUy, see, Baxter, W.F., Cootner, P.H. and Scott, K.E., 
Retail Banking in the Electronic Age, The Law and Economics of Electronic Funds 
Transfer, (1977); Bork, Ril., The Antitrust Paradox, A Policy at War with Itself (1978); 
Posner, R.A., Antitrust Law, An Economic Perspective (1976). 
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without requiring additional resources to be expended. An example of an 
indivisible product is a bridge. In order to satisfy part of the total demand for 
bridge services at a particular location, a single bridge must be buUt at great 
expense. The only way for bridge producers to recover their buUding costs is 
through a charge on users. Assuming that the bridge doesn't wear out through 
use, the marginal cost of providing an additional unit of crossmg service is zero. 
Maximizing the benefits society receives from use of an existing bridge requires 
that any user who has a finite positive utiUty for crossing should be aUowed to 
cross. Since any price greater than that utility wiU deter some use which should 
have been allowed for optimal utilization of the bridge, the provision of a price 
wUl cause undemtUization of the existing bridge. The dUemma for the price 
system when faced with indivisibUities is that a single price for all users cannot 
serve both to efficiently ration the existing supply of such goods and provide 
accurate signals to producers as to what goods should be produced in the future 
and the proper incentives to produce them. 
External benefits exist when users benefit from production without 
making any payment to the producer providmg them. In the bridge example, 
users can only be made to pay if they can be prohibited from crossing if they 
do not. If we disallow the right to exclude users, and thereby charge them, and 
producers can foresee such mles, no bridges wUl be buUt by private buUders. 
However, it is clear that society's total utility for many bridges is greater than 
the total cost of buUding them. Therefore, we underinvest in their production if 
we rely on private producers and disaUow the right to exclude and thereby 
charge price for use. 
In the absence of corrective rules, the market for information is likely to 
exhibit mdivisibUities and external effects. The costs of producing inventions 
are fixed costs. Once produced, the intangible technological knowledge may be 
used without additional production cost. Since information, like aU goods, is 
only valuable to the extent that it is used and since use may require disclosure 
to users, users may benefit from existing information without being required to 
pay. A producer who can predict this inabUity to internalize aU of the benefits 
of the information he produces, wUl spend too few resources producing informa-
tion. Competition in the use of inventions, in the absence of some rule to correct 
for these defects, wUl not yield proper resource aUocation. 
The patent laws are the main, market-oriented corrective mle. Those laws 
grant to the producer of an mvention the temporary right to exclude others 
from using it. In a sense, patent law merely gives to the producer of intangible 
information the right to exclude, which property law gives to the producer of 
physical property. However, that right is given to the inventor only for a Umited 
period of tune in an attempt to balance the gains from an improved level of 
production against the losses from underutiUzation of inventions once pro-
duced. Importantly, this purpose of the patent law is not inconsistent with the 
purpose of the antitmst laws, which is to preserve certam other conditions neces-
sary for the price system to efficiently allocate resources. Stated imprecisely. 
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these other conditions are the existence of competition among producers and 
seUers, each seeking his own gain, and the absence of unjustified monopoly m 
the production and sale of products. Viewed in this way, botii patent and anti-
trust law are designed to achieve the same ultimate purpose. 
The leader in applymg modem microeconomic analysis to patent-antitmst 
problems is WiUiam F. Baxter, whose 1966 article laid tiie groundwork for 
others. Barter's article and another autiior. Ward Bowman's later book (Bowman 
1973) cites important describe how this analysis which can be appUed to particu-
lar issues. One recurring problem in doing so involves determimng whether a pa-
tent owner's conduct is designed to exploit the value of the invention covered by 
the patent or to acquire monopoly power beyond that afforded by the patent. 
Recently, in Mannington Mills, Inc. v. Congoleum Industiies, Inc., 610 F.2d 
1059 (3 Cir. 1979), the Third Circuit Court of Appeals wrote: 
"Vertical restrictions imposed upon Ucensees by a patentee, lUce those im-
posed by a non-patentee upon its distributors, may often be useful, and 
perhaps even essential, to the patentee's effort to maximize the monopoly 
income to which the patent grant entities him. See W. Bowman, (1973); 
. . .and Baxter (1966). 
***'*Where a patentee's Ucense restrictions are imposed verticaUy 
upon the Ucensee, in pursuit of the patentee's own marketing strategy, 
that circumstance suggests that the patentee's licensing decision is in fact 
directed toward the legitimate exploitation of the patent monopoly 
By parity of reasonmg, it also may be taken as mdicatmg that the restric-
tions thus imposed are among those significant to the patentee's initial 
decision whether to license the manufacturer or sale of the patented 
invention...." 
This analysis may lead to different results in certain types of cases. The 
part of Bowman's book cited by that Court criticized one of the most long-
standing and rigid of the patent-antitrust prohibitions-the mle against tie-ins. 
Bowman wrote, in part: 
"In contrast, those agreements-vertical contracts-which patentees make 
with licensees for the purpose of 'restricting' the use licensees may make 
of the patent under the terms of the Ucense, as the subsequent analysis 
demonstrates, are not monopoly-ex tending. Ascribing to these vertical 
contracts a monopoly-ex tending effect is indulgmg m the 'leverage faUacy.' 
Such arrangements are profit-maximization devices. 
"An example of the monopoly-extension fallacy in the patent con-
text is the way courts have come to judge tie-in cases." 
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REIMERS: First, I wUl give an overview of the various modes of interaction 
of uruversity and industry, including the mode of patents and licensmg, 
which mode, I think, has been the subject of disproportionate attention. 
Second, I wUl review the various orgaruzational forms employed in the 
United States, Europe, Japan, and elsewhere for directed transfer of 
university research results to industry. I wiU focus on Stanford University 
in particular, describe its Ucensing program, its purposes, organization, 
and, its operating modes. Then Roger Ditzel and I wUl review some con-
siderations of a university-to-company license agreement that differ 
from a company-to-company Ucense agreement. We wUl discuss licensing 
of genetic engineering products. And, lastly, I would like to touch on 
some issues concerning the effects of patents on open research, diversion 
of scientists from the search for truth to the search for doUars, and so 
on. 
I want to note that the most important mode of transfer of technol-
ogy from a university to industry has to be the graduated student (see Fig. 
1). The other modes are perhaps less significant, and are not arranged in 
any particular order. At Stanford, we have something called industry affiU-
ate programs. 
There are various organizational forms for directed transfer of uni-
versity research results to industry. In 1978,1 spent 3 months, while based 
in Norway, visiting universities and research organizations in Europe. I also 
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SOME FORMS OF TECHNOLOGY 
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THE GRADUATED STUDENT 
PUBLICATIONS 
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TECHNOLOGY LICENSING 
Figure 1 
sent questionnakes to universities in other countries asking how they were 
orgaruzed and what method they used for the transfer of their research re-
sults to industry (see Fig. 2). I found there were three primary forms used: 
one is the national research development organization, commonly caUed 
RDOs, usuaUy government-chartered. Another mode is one of a university 
licensing office-Stanford and CaUfomia are examples of that mode. There 
is another mode, employed mostly in Europe, of an industrial liaison of-
fice, usuaUy separately incorporated, but under control of the university's 
governing body. An example would be Loughborou^ Consultants, Ltd. at 
the University of Loughborough in England and Unikontakt in Germany. 
ORGANIZATIONAL FORMS FOR DIRECTED TRANSFER OF 
UNIVERSITY RESEARCH RESULTS TO INDUSTRY 
PRIMARY FORMS 
• NATIONAL RESEARCH DEVELOPMENT ORGANIZATION 
GOVERNMENT CHARTERED. EXAMPLES ARE NRDC OF THE UNITED 
KINGDOM AND ANVAR OF FRANCE. 
• UNIVERSITY LICENSING OFFICES 
WITHIN UNIVERSITY ADMINISTRATIVE STRUCTURE. 
EXAMPLES ARE STANFORD AND CALIFORNIA UNIVERSITIES. 
• INDUSTRIAL LIAISON OFFICES 
SEPARATELY INCORPORATED BUT UNDER CONTROL OF UNIVERSITY 
GOVERNMENT BODY. EXAMPLES ARE LOUGHBOROUGH CONSULTANTS. 
LTD., AND UNIKONTAKT (GERMANY). 
SOME LESS COMMON FORMS 
ALUMNI-CONTROLLED NON-PROFIT INSTITUTION (US) 
UNIVERSITY RESEARCH INSTITUTE (NORWAY) 
ASSOCIATION OF FACULTY (JAPAN) 
Figure 2 
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A less common form of transfer is an alumni-controUed nonprofit mstitu-
tion. The Wisconsin Alumni Research Foundation, is one such form which 
has turned more than $100 miUion back to the University of Wisconsin 
over the years and has consistently provided approximately 5% of its re-
search budget. I think it has contributed significantiy to Wisconsin having 
that "free" research money. Japan has somethmg caUed the Japan En-
gineering Development Corporation. 
At Stanford we have three elements: the faculty, our office, and 
students (see Fig. 3). When we Ucense, we Ucense the property rights, the 
tangible and intangible property rights, but we don't agree to do prospec-
tive work for a company in a Ucense agreement, nor do we transfer the 
know-how and show-how through our office. All that is handled by 
separate consulting arrangement, either by an mdividual faculty member 
or by a student or research associate, duectly with the company. It is a 
separate agreement. 
SCHARFF: Do you require that your Office of Technology have knowledge of 
those agreements? 
REIMERS: No, generally they wiU be negotiated at the same time. 
UDRY: Who owns the patents at Stanford? 
REIMERS: Stanford's patent policy is that your inteUectual product belongs 
to you, except when the terms of an external research agreement require 
otherwise, liiis includes the student, faculty member, employee, myself, 
anybody associated with the university. 
Of course, many times when we engage m a license agreement, the 
student may be hired by the company. The mteUectual product belongs 
to the inventor, except when the terms of an external research agreement 
require otherwise. 
STAMFORD 
ronvEBSiry 
FACUITY 
OFFICE OF 
TECaHOLOGf 
UCENSING 
STUDENTS 
CONSUKTING 
ARRANGEMENTS 
LICENSE 
AGREEMENTS 
EMPLOYMPrr fc CONSUITING 
ARRANGEMENTS 
Figure 3 
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WILLIAMS: There is no employment agreement between the faculty and the 
university itself under which the faculty member or researcher is obUged 
to assign title to any inventions to the university administration? 
REIMERS: All people engaged in research at Stanford have to sign an inven-
tion assignment agreement, which states any involvement with a research 
agreement requues the assignment of rights and Stanford has title. We 
have to take title to carry out the terms of these grants and contracts. 
HICKS: What about a company-funded contract? 
REIMERS: The same applies there, too. We have to be able to deUver title or 
the license to the company that wants the research. 
WILLIAMS: The inventions ultimately belong to the university. 
REIMERS: Yes, if it is done under a sponsored research agreement. 
DELLENBAUGH: That occurs only if there is external funding. 
REIMERS: However, we wUl waive inventions back to the inventor if they so 
request and if it is possible to do so. 
HICKS: Does the university have the opportunity to give it back to the indi-
vidual? Or does the university have to take it? In other words, can the 
individual get it? 
REIMERS: The university has to take it, but tiien it can retum it to tiie mdi-
vidual, subject to agreement of the sponsor. 
HICKS: Okay, so all of tiie options are stUl open. It just depends on the 
agreement. There is no restriction. 
REIMERS: Our licensing program is optional. If somethmg is developed on 
Stanford money, tiie inventor can decide whether to work through us 
or go out on their own. 
SHARP: Are you referring to exclusive and nonexclusive licensing agreements? 
Are they both handled m the same manner? 
REIMERS: Most of our license agreements are exclusive. It is rare tiiat we non-
exclusively license. Usually, tiie invention is at such an undeveloped 
stage tiiat it is going to require great investment by a company to bring it 
forward to a product; therefore tiie right to exclude otiiers from com-
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peting is important. We negotiate the period of time that the Ucense is 
exclusive. After that we license it nonexclusively. But, in the meantune 
a company has buUt up its own proprietary position and its own improve-
ments. 
PTASHNE: At Harvard it depends on what the subject is: in the field of health 
and therapeutics, you are constrained by an agreement you must sign that 
Harvard owns that patent, for historical reasons. In any other field, elec-
tronics or chemistry, you own it yourself. 
REIMERS: Hasn't that poUcy changed recentiy? 
PTASHNE: If it has changed I don't know about the change. But, if it has 
been altered it would be stated that the university owned the patent. 
SCHARFF: Am I to understand that if a scientist invents somethmg and it is 
on a grant Stanford wUl give it to them? 
REIMERS: That is a different question. No. 
MacPHERSON: What is your policy when an employee of a company adjacent 
to Stanford takes courses at Stanford and in his work comes up with an 
invention relating to that employee's lab activity at the corporation but 
which is supposedly done in conjunction with your university employees? 
REIMERS: If the inventor derived the idea from class work, it is his and he can 
assign it to the company. If it is done under a research agreement, that is 
something else entirely. We do have a problem with that. We are fair game 
for some local companies, or at least they perceive that is the case. We are 
in the process of working thmgs out. 
Perhaps an explanation of the Stanford structure (Fig. 4) and our 
office at Stanford wiU help clarify matters (Fig. 5). 
Recently, an explosion in technology is occurrmg in two areas: the 
genetic engineering area, and information sciences. Obviously, we have a 
lot of inventions other than in genetic engineering. We share royalties as in-
dicated in Fig. 5. To give you a complete feeUng, of the gross royalty dol-
lar, 15% is taken off the top to support our office. Direct expenses are 
then deducted. These are the out-of-pocket expenses that we have paid 
which include patent fiUng expenses, sometimes a trip to the prospective 
Ucensee, and that sort of thing. The balance is caUed net. Of the net 
royalties, a one-thud portion is distributed equaUy to inventors, the in-
ventor's department and the inventor's school as shown m Figure 3. The 
school share is a relatively recent change. It used to be disbursed into a 
general fund of the university itself. 
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A RESEARCH UNIVERSITY (1979-80) 
5,980 GRADUATES, 6,638 UNDERGRADUATES 
1,739 FACULTY (INCLUDING INSTRUCTORS) 
1979-80 RESEARCH VOLUME 
DEPT OF HUMAN SERVICES 
(PRIMARILY NIH) 
NATIONAL SCIENCE FOUNDATION 
DEPT OF ENERGY 
DEPT OF DEFENSE 
NASA 
OTHER 
TOTAL 
$128 MILLION 
43% 
18% 
5% 
17% 
5% 
12% 
100% 
Figure 4 
STANFORD 
OFFICE OF TECHNOLOGY LICENSING 
142 DISCOVERIES (INVENTION DISCLOSURES RECEIVED) IN 1980 
25% THROUGH EVALUATION 
40-50% OF WHICH ARE LICENSED 
10-25% OF WHICH MAY REACH MARKET 
NET ROYALTIES: 1/3 TO INVENTOR(S) 
1/3 TO INVENTOR(S') DEPARTMENT 
1/3 TO INVENTOR(S') SCHOOL 
STAFF: DIRECTOR, ASSOCIATE. OFFICE MANAGER/SECRETARY. 
VARIABLE PART-TIME HELP 
Figure 5 
Some considerations of a university license are different tfian a 
normal company-to-company license (see Fig. 6). We are a 501(c) (3) non-
profit institution, and only income incident with running tiie educa-
tional establishment is legal, or "related" income. Examples would be 
tuition, room, and board. There are two exceptions: rents and royalties. 
We cannot compete with the private sector, so we have to be careful of 
what we are engaged in doing there. 
In our licenses, there is mmimal know-how and show-how transfer. 
There might be some documentation in the software program. But, 
generally, we are licensing the intangible property right, tiie intellectual 
SOME CONSIDERATIONS OF A UNIVERSITY LICENSE 
• NON-PROFIT 
- MINIMAL KNOWHOW, SHOWHOW 
- LIMITED IMPROVEMENTS 
- P U B L I C SERVICE 
• LACK OF "CORPORATE CONTROL" 
- FACULTY CONSULTING 
• GOVERNMENT RIGHTS 
-GOVERNMENT LICENSE 
- LIMITED EXCLUSIVITY 
- REASONABLE ROYALTIES 
• PATENT INFRINGEMENT 
-CROSS LICENSE 
• NATURE OF LICENSED TECHNOLOGY 
- UNDEVELOPED, UNPROVEN 
- BASIC PATENT POSITION POSSIBLE 
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Figure 6 
property rights of patents, copyrights, trademarks, and so on. There are 
some tangible property rights that are licensed, such as a cell line. I would 
guess 95% of the world's licensing is of a fuUy developed process, where 
all the documentation, the engineering drawmgs, quality control pro-
cedures and parts lists are included. We (universities) form a very smaU 
subset of the world's Ucensing, and we have smaU amounts of documenta-
tion to transfer. We can't deliver improvements. We also have to keep in 
mind our pubUc service role. 
Again, we have the lack of corporate control. We can't "deliver" in-
dividuals, absent a specific agreement in writing. Sometimes it is difficult 
for a first-time licensee at a university to understand this, because it relates 
to different problems in the agreement. They have to separately negotiate 
with the faculty member or the student. 
Invariably, Government rights are involved. There is a very smaU 
amount of research done at Stanford that doesn't have some Government 
strings. The Government gets a license to practice for its purposes and 
generally limits the period of exclusivity. But even if it doesn't come 
under Government support, we also Umit the period of exclusivity: this re-
lates to the pubUc service aspect mentioned above. We will negotiate an 
adequate period of exclusivity for the company to recover its risk capital 
investment, after which we Ucense non-exclusively. 
232 / Discussion 
As a matter of practice, if it takes a lot longer for a company to 
commercialize an invention than was anticipated at the start, we wiU 
negotiate an extended period of exclusivity, because the first Ucensee is 
the one that is taking the risk; if they have a good reason, we wiU negotiate 
an extension to the period of exclusivity. 
In respect to patent infringement, as we are not a manufacturer, 
cross-licensing is meaningless to us. If a company is infringing a second 
company's patents, the second company may come after the first. The 
first company wiU then, if there is an mfringement, point to theu patents 
that are being used by the second company, and they wiU negotiate cross 
licenses from there. 
KILEY: Niels, to the extent that Stanford University is performing a research 
service for a private corporation, under a research contract that wiU bring 
it royalties, and in the course of doing so practices the patent of another, 
cannot it be said that you are indeed in the business and require a Ucense 
from that third party? What you choose to style research is, in fact, going 
to bring you a royalty. So you might very weU require a Ucense from 
someone else. 
REIMERS: WeU, that is an interesting question. I don't know if a company has 
ever brought an action against a university for using theu technology in 
research. 
SCHARFF: Can I ask sort of the opposite question? WUl you sign an exclushr-
ity agreement which also excludes providing to other scientists or to NIH 
or to tissue banks of ceU Unes or things lUce that? 
ROWLAND: Niels, you could put in your Ucense the right to a greater percent 
of royalties, which is not a common kind of term in a Ucense agreement. 
Having created a situation, you Ucense the Cohen-Boyer case and say you 
claun royalties on royalties. In fact, couldn't a patentee claim a percentage 
of the royalties Stanford receives, based on the fact that you developed a 
process usmg your technology? 
REIMERS: I guess we wUl cross tiiat bridge when we come to it. The negative 
feature of university technology-and tiiis is for tiie companies to think 
about-is it is undeveloped, it is unproven. But, on tiie other hand, a basic 
patent position is often possible. 
The licensing of genetic engineering products raises a number of 
questions rather tiian answers: How is the product handled? Do you trade 
secret? Do you patent? The university, or tiie company, for tiiat matter, 
must study tiiese matters carefuUy as tiiey proceed in tiiese issues (see 
Fig. 7). 
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LICENSING GENETIC ENGINEERING PRODUCTS 
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- PATENT? 
-ORGANISM DEPOSIT 
- REGISTRATION OR TRADEMARK 
-COPYRIGHT? 
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- DERIVED PRODUCT PROOF 
Figure 7 
An aspect of registration, or trademark, which hasn't been talked 
about, a procedure foUowed in our office-voluntary for people at Stan-
ford to use-is a Biological Product Registration Log. We put names on 
these biological organisms, so that we can track them. If an inventor 
offers somethmg to us that involves an organism or a biological product, 
we wUl assign a registration number to it. They don't have to use the 
number in their publication, although it is not a bad idea. 
For us, I should mention, m Ucensing computer software, the 
issues involved are the same as they are in Ucensmg biological orgarusms. 
Our software is trademarked as a means of protection. But I don't think 
we wiU trademark for biological organisms because of the danger of trade-
mark liabiUty extending back to the university. We probably wiU continue 
with our registration system. 
I don't have the answers regardmg regulatory approval and patents. 
This has been talked about eariier. If somebody gets a broad patent to the 
first strain-let's say a hybridoma is fused usmg a spleen ceU from a hepa-
titis patient in San Francisco, and a broad patent is obtamed to hepatitis 
monoclonal antibodies. Simultaneously, perhaps somebody in London has 
a patient with hepatitis, and also obtains hepatitis monoclonal antibodies. 
It is not clear to me that the second antibody, when used m a patient, 
wouldn't behave differentiy than the first one. Suppose the first patent 
holder doesn't license. That is not in the pubUc mterest. 
Another question: What about the second antibody going through 
FDA regulations? Its route wUl be easier, but wiU the first company's 
investments and proprietary protection be chaUenged? The second com-
pany would have a much easier patii to foUow. Enforcmg inteUectual 
property rights and estabUshing derived product proof is going to be a 
problem in the future. 
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There is sort of a visceral feeling of many scientists that patents 
somehow "control" their research. Many scientists are bothered by the 
fact that they are working in an area already patented, and perhaps one 
that is broadly covered with a patent like the Cohen-Boyer patent. How-
ever, a patent does not "control" your research. Patents don't engender 
secret research. This points out a rule to foUow: "A patent is not a vaUd 
excuse for not disclosmg your research to your coUeagues or delaying a 
pubUcation." If we have to lose patent rights, we wUl. Generally, we are 
faster than a joumal in terms of fiUng a patent application; we have done 
it in a day. Tom Kiley mentioned that Genentech has the same problem. 
But please don't use a patent as a reason for not talking about your re-
search with your coUeagues. 
SCHARFF: Do you agree to let your scientist's license be restricted, so that 
things are not available to the scientific community? 
REIMERS: Within our Committee on Research we are discussing a policy we 
developed called "tangible research product" policy (see Fig. 8). There are 
several facets to that policy, some of which may be too detailed to discuss 
at this time. A few points worth discussing however are: first, get your 
research out to your academic coUeagues as soon as possible. If it is of 
commercial usefulness, we try to establisli proprietary riglits. The second 
point is the question of who determines when or if a biological organism 
should be distributed. We are recommending that the Committee on Re-
search allow the decision to be up to the principal investigator, or, in tiie 
absence of a principal investigator, the laboratory director. 
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A thud facet of the poUcy is royalties. There is reaUy no invention— 
or at present people haven't considered it an invention—to make just 
another hybridoma. The inventors at Stanford, those who have made hy-
bridomas, have waived their claim to individual royalties to their labora-
tory, to be used for further research. But there may be cases where the 
development of a biological product does involve an invention; this poUcy 
provides in such cases that the principal investigator and I may propose an 
appropriate distribution of individual royalties to the Provost for approval 
or disapproval. 
To change the pace, Roger Ditzel wUl explain his poUcies. 
DITZEL: Change is the name of the game. Almost everything I have heard at 
this meeting involves change. Patent lawyers say things are changing, that 
things won't be defined for years. Scientists, on the other hand, say we 
don't know what is going to happen, that there are many variations and 
mutations. 
University patent administrators sit between those two groups of 
people, and must make the tough business decisions with respect to fUing 
patent applications, spending money, and Ucensing. We try to encourage 
the development of a rational basis for the licensing and transfer to in-
dustry of the results of the change that comes about because of the 
university scientists' work. 
Scientists have it tough understanding the strange language re-
lating to patents. But it is difficult for us to understand the science at 
times, because we are not in the middle of the rapidly evolving events. 
There is much public press about scientific developments and much pubUc 
interest. (I always wonder what I am going to read in the papers in the 
morning, whether it be a lost invention or some additional problem.) 
State legislators in California, citizens, and other regulatory bodies in the 
state are very, very weU aware that the University of California is a public 
institution deeply involved in change and innovation. The state wants 
innovation. The Legislature just authorized $ 1 mUlion to match industry 
funding for work in microelectronics. It is possible there wiU be simUar 
funding for gene spUcmg also. 
There is great concern in California about conflict of interest on the 
part of public employees, including the possibility of loss of inventions 
from university laboratories into private companies, resultmg in the use of 
public funds for private gain. 
Into this background of conflict and change in biological science and 
the pubUc's knowledge of it comes the fact that government funding 
is being reduced for biology and many other sciences. It is going to hurt 
university research. It has caused biological scientists to worry about 
funding, when for years they have had secure funding. As a result faculty 
are leaving for private industry, along with postdoctoral students and grad-
uate students. 
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On top of that, the Federal patent poUcy changed as of July 1, 
1981, and we are stiU arguing with the Federal Government over how the 
regulations implementing the new law should read. 
Everything seems to be in turmoU. We are all uneasy because we do 
not have a firm ground on which to plant our feet, and to figure out the 
rate of change or even what is changing. It is a very exciting time. 
Let me discuss patents in universities. Some of you come from such 
institutions, and some of you probably don't even know what your in-
stitution's patent policies are. Many of the private practice people are not 
famUiar with university patent policies. Niels discussed some of those 
policy elements previously. 
Again, it is very difficult to generalize. There are probably only 15 
or 20 out of 1500 universities in the United States, that employ exper-
ienced patent admmistrators. Every institution has its own peculiar charac-
teristics and differences. Don't assume aU universities wUl handle patenting 
simUariy. However, there are some common threads in university patent 
policies. Patents exist in universities for essentiaUy two reasons, and 
neither goes to developing a market share of products. The first reason is 
to increase the technology transfer process, which Niels referred to. The 
second is to bring in royalty income. When money is tight, any source 
of income becomes very, very important. Admiiustrators, department 
heads, deans that have never thought of the patent income before want to 
have it used to fund their particular research or solve a particular problem. 
The good side effect of this latter concem is that faculty members from 
aU disciplines are thinking about mteUectual property and the transfer of 
advances from the university to industry. After aU. that is reaUy why we 
exist, to cause change to happen in tiie marketplace. With tfiat as back-
ground, I would next Uke to discuss some of tiie detaUs of University of 
California patent and patent Ucensing policies, and tiie reason for tiiese 
policies. 
Universities, as Niels indicated, have one of two types of patent 
assignment poUcies as a condition of employment. Either it is voluntary, 
absent a grant or contract, or it is mandatory. Many pubUc universities 
have mandatory assignment poUcies. Under Federal funding, we must be 
able to pass patent riglits onto tiie Federal Government if we don't fUe or 
don't have right to keep title. Such federal funding has accounted for 80% 
of our total research funding, and our research expenditures tius year wiU 
be well over $500 mUlion. Trying to run tiiat type of a system witiiout 
having a blanket assignment rule would be unworkable. This absolute 
assignment policy has given us some problems in tiie area of visiting 
scientists from industry, but we are able to work most of tiiose out. 
The University of California has a poUcy of releasing inventions to 
tiie inventor, if we don't want to file, and if tiiere are no otiier funding 
obhgations. When release is requested, we Uke to have tiie inventors ex-
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plain whether they have ownership m a company that is m a related 
business as a matter of ethical disclosure. We want a duty of candor on 
the part of our inventors. 
As a matter of poUcy, we share net royalty mcome with the m-
ventors, very much Uke Stanford. We license very broadly and have some 
250 licensees now. About half our licenses are nonexclusive, but most of 
those are plant patent licenses. Half are limited exclusive or fuU-term 
exclusive Ucenses. 
All our licenses have a dUigence provision if there is any degree of 
exclusivity in them, because the thmg we cannot afford to happen, as a 
pubUc institution, is for an exclusive Ucensee to develop competitive 
technology, and not develop the licensed technology. For the same reason, 
we wUl not agree to assign patent rights to a sponsor. We wiU agree to give 
them an exclusive Ucense but not assignment, because it is easier for us to 
recover the license if there is a lack of dUigence than when an outright 
assignment exists. 
Everyone should be aware of the magic words of "conceived or re-
duced to practice" that occur in research grants funded by the Federal 
Government. As a result, when industrial companies want to fund uni-
versity research, we have to say, "We can only promise you exclusive 
license rights if an invention is conceived and first actuaUy reduced to 
practice under your funding." That initiaUy causes some concern to 
potential industrial research sponsors. But because of the nature of our 
Federal funding, on either end of industrial funding, we have to be very 
careful and explicit in that language, so that we do not promise more than 
we can deliver. 
Because of public concern, we generaUy require that companies pay 
about 30% of direct costs as an overhead cost if they want exclusive Ufe-
of-patent patent rights to inventions arising under their sponsorship. 
Industrial companies also want rights to the biological materials and 
other tangible products commg out of that research, and we do the best 
we can to accommodate those desires. The problem we run into in these 
cases is the resulting restriction on the use of those materials which could 
Umit their avaUability to other academic scientists. We do not want such 
strict limitations. 
The whole area of gene spUcing isn't without analogies or models. 
For example, we have a major plant patent Ucensing program at the Uni-
versity of California, a major component of which is strawberry plants. 
We now have about 80% U.S. strawberry production in University-
patented varieties. Plant breeders work for 20 years in traditional ways 
before they release a strawberry, a grapevine, a peach tree, or walnut tree 
or even asparagus. (Plant patents are appUcable only to asexuaUy propa-
gated plants.) In this discipline, research is shifting from the traditional 
plant breeder to the tissue culture, meristemming, and in vitro work. 
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rather than testing out m the field. So the rate of change wiU mcrease 
substantiaUy. 
You also should recognize that there is a way to protect rights in 
sexuaUy propagated materials, under the Plant Variety Protection Act 
in the United States, and internationaUy under the Intemational Under-
standing on the Protection of Varieties (UPOV). Things that are patent-
able in the Uiuted States as plant patents are protected under variety pro-
tection in some other countries. There have been a number of recent 
changes in the intemational law in that area, so that the law is now much 
more consistent from country to country. 
The introduction of the Plant Variety Protection Act in 1973 
caused a great change in the seed com, grass seed, and other segments of 
the seed industry. SmaU seed companies aU of a sudden became good 
acquisition candidates for large companies. In 1971, there were 400 seed 
com companies in Iowa, many just selling seed in a limited geographical 
area. That number has dropped considerably, and the major multina-
tionals are now in the seed business, primarUy as a result of the Plant 
Variety Protection Act. 
To analogize with respect to the newer genetic materials, our straw-
berries can be seen in the field, in uruversity experimental plots. If some-
one wants to be surreptitious, they can take a leaf, put it in their pocket, 
fiy halfway around the world, take it out, recover the tissue, and grow 
plants. Or they can plant a strawberry plant and it wiU propagate itself. 
The plant is capable of repUcation by its very nature, or using newer 
laboratory techniques. 
It is difficult to detect resulting patent infringement, because uiUess 
there is a lot of fmit shipped, and examined, you don't know who is 
growing what patented varieties. New tools are just becoming avaUable to 
prove the genealogy of the plant, through enzyme typing. We can't quite 
do it yet, but we wiU be able to very quickly. 
Further, in plants, sports and mutants occur, which can themselves 
then be patented if they are asexually propagated. In some plant testing 
agreements we require tiiat all sports and mutants be retumed to us, 
with titie remaining in the University. 
With all these problems, which are simUar to some of the forseeable 
genetic materials problems, we do have a successful licensing program. We 
license growers to grow the strawberries. Licensing is done through nurser-
ies, who coUect the royalties from the growers for our account. In tiiis 
way, we do not have an exhaustion of rights by licensing and collectuig 
royalties at tiie nursery level. Strawberry plants are planted annually. 
After the berries are harvested, tiie plants are plowed under, and a differ-
ent crop is planted on the same land. This is a major licensing program, 
and WiU result in an income of some $300,000 tiiis current year. It is not 
a lot of money in industrial terms, but it is awfully nice money in a 
university. 
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Academic plant breeders exchange materials under test agreements. 
We also have test agreements with commercial companies so that they can 
put strawberry plants out for testing under commercial conditions m 
various parts of the State of California. 
Based on the foregoing analogy, I thiiik there is great hope in this 
whole area of change in the newer biological materials. We wUl, I believe, 
come down to something that is very reasonable and practical in the 
licensing of such products. 
There are other concerns arising at universities as a result of the 
changes in science and law being discussed at this conference. 
Since the objective of any university is change, we are very con-
cemed about our continuing ability to maintain prompt pubUcation. We 
want to maintain the tradition of open communications m the subdisci-
plines, i.e., among the small, informal groups that exist. We recognize that 
scientists located at different institutions comprise such workmg groups. 
They talk back and forth in their sub-subdisciplmes. We want to keep 
encouraging that. We want it to happen. We know they work together. 
Yet the way the system is organized, patent rights generally go to 
the employer of each mdividual. As a result, we have organization con-
flicts. We have any number of inventions where they are joint inventors, 
one at the University of California and one at another mstitution. We 
have one such case with Cold Spring Harbor. Universities work well to-
gether in such situations in carrying that out, because we don't want 
misjoinder on inventorship, and our institutional interests are simUar. 
With respect to tangible research products, such as computer pro-
grams and ceU lines, we want to continue to have a policy of making such 
materials widely available between researchers for academic purposes, but 
at the same time, protect the values m those materials for commercial 
development. We don't know what aU the forms of that wiU be yet. But 
that is our objective, because we feel it is so very important that our 
basic research mission go first and that we find some way to accommodate 
the other needs of society. Just as the patent law and the antitmst law 
are in balance for the purpose of meeting varied societal needs, hopefully 
we can do the same thmg in tangible research products to balance the 
needs of the scientists and the needs of our free market society. 
We are concerned about the loss of faculty being experienced as a 
result of the shift of genetic engineering to the industrial sector. We have 
been losuig faculty members and graduate students at a rate that wUl not 
aUow us to replace experienced educators quickly. (In CaUfomia we have 
the additional problem of high housmg costs.) Yet I am personaUy very 
optimistic. This change is really good in spite of the problems of uni-
versities. Industries take a lot of people and it gives universities a dis-
continuity which we are going to have to redefine. 
O'NEILL: FoUowing Roger's strawberry story, all I can teU you is that I am 
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going to talk a little bit about the fruits of academic research. I would 
like to present an industrial perspective which is derived from many 
interactions with academicians and academic Ucensing officers, such as 
Roger and Niels. In particular, I wiU explain the importance of patents 
on academic inventions from my own background in the health care 
product industry. I think it is fair to say that there is a marked difference, 
depending upon the particular industry you are talking about. 
The diagnostic industry is typicaUy not a very patent-conscious field. 
It is a field ui which products have a relatively short lifetime. The pro-
prietary basis of companies has depended primarily upon secrets in manu-
facturing, on quality control in production, and reliabiUty of the product. 
It is a field in which novelty is frequent and product lifetime is relatively 
short. Often the utiUty of new products is difficult to assess, but there is 
a lot of tumover in products. In fact, the market leaders tend to be re-
sponsible for that tumover. 
Therapeutic products, on the other hand, take quite a whUe to 
develop, test, and gain approval from regulatory authorities. The invest-
ment is an order of magnitude greater than that associated with the 
development of a typical diagnostic product. After the investment has 
been made, one's fate is determined ui a bureaucracy that lacks incentives 
to expedite the approval process. It may take years to get the nod from 
the FDA. 
Fred Weston of UCLA and John Wirts of EU LiUy made a pharma-
ceutical industry survey a couple of years ago, that showed the average 
cost of developmg a new dmg was $70 mUlion in 1979. Most so-caUed 
"new chemical entities" require more than 20 years to generate accumu-
lated sales as large as the estimated cost to bring an average one to market. 
Less than 25% of the new chenucal entities marketed yield annual sales 
greater than the annual research and development of such an agent. By 
the way, the same authors identified an average lag of 23 months between 
approval of a new chemical entity by a sophisticated regulatory agency 
somewhere in the worid and approval m the United States. Curiously, the 
lost years did not result in any data or conclusions that reflected adverse-
ly upon the seven LUly dmgs examined. Patients are deprived of the bene-
fits of the dmgs and companies are deprived of the potential sales, earn-
ings, and lead over their competitors. But, that is the way the regulatory 
system is, and our purpose today is not to reform the system. 
On the other end of the product life cycle, the loss of patent protec-
tion in the therapeutic field can reaUy be devastatmg. A contemporary 
example is provided by Schering-Plough, which developed an antibiotic 
called gentamicin back in the early 1960s. In fact, the patents were issued 
in 1963-64, and they have just expired in this last year. The effect on the 
sales and profits of the firm has been catastrophic. The woridwide sales 
of that drug, specificaUy tiie brand, Garamycin®, marketed by Schering-
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Plough, were over $280 mUUon last year, accordmg to a recent article in 
The Wall Street Joumal (October 9, 1981). In the United States, the sales 
were about $90 miUion. The U.S. sales this year are gomg to be only about 
$30 mUlion. In part, that is due to Schering-Plough's reaction to the ex-
piration of the patent. But the important thing is that because of patent 
protection Schering had enjoyed a very lucrative position for years, which 
aUowed it to recoup the costs of the gentamicin research and reinvest m 
other areas. 
That ratio, 280:30, for the world market in comparison to U.S. 
sales, is not typical, but it is indicative of the fact that the pharmaceutical 
field is very much an intemational one. I don't know of any industry that 
is more international m character. The U.S. companies have been very 
aggressive in takmg advantage of their technology and entering markets 
abroad. Over the last 20 years, we have seen the entry of many major 
foreign pharmaceutical companies into the United States, setting up re-
search laboratories, manufacturing, and marketmg. 
Hence, international patent licenses are extremely important. I 
think it is significant that more than half of the Ucensees of the Stanford 
human hybridoma patent and ceU line were of foreign origin. There is a 
strong desire and need for worldwide patents, or at least patents m the 
world major markets. 
That is the cause of a significant problem when it comes to the 
question of academic pubUcation, because aU too often, the opportunity 
to obtam foreign patents is lost by publication prior to filing. The m-
dustry, as weU as the academicians, have to increase recognition of the 
impUcations of the fact to the subsequent development of products. Inter-
feron is a good example. Everybody in the industry ignored it for decades, 
because they couldn't see a patent position. Once an element of patent-
abUity and basis for a proprietary process became apparent, they all 
charged in on the great interferon race. 
As we have heard at this meetmg, many biologists have never been 
concerned with patents before. If they were cognizant of any rules with 
respect to patents at all, they had this notion that you have up to a year to 
file after pubUcation. So, there was a wait-and-see attitude. WeU, as we 
have heard, that is tme for a U.S. patent, but in the meantune you may 
have lost all your mtemational rights. Wait-and-see is a very expensive 
decision! The mdustrial representatives consulted should take the time to 
consider the inventions disclosed to them by universities, draw on their 
own staffs expertise and unagination (if that is permissible), respond m a 
tunely fashion, and refer the university representative to other mdustrial 
contacts who might have a different or better perspective. 
The pomt is, I beUeve, that both mdustry and academe wUl benefit 
from unproved patenting of academic inventions, and that caUs for cooper-
ation, early in the innovation process. The initiative can come from both 
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sides. As I have said, the academic patent officer should belong to organi-
zations such as the Licensing Executives Society, from which contacts can 
be derived. Visitors from industry should be welcomed on campus, es-
peciaUy in the inteUectual property management office. 
On the industry side, broadly knowledgeable, considerate repre-
sentatives need to be appouited, to make themselves known and be access-
ible for the consultations I have referred to. Often the appropriate mdi-
vidual for such contacts, is not the individual who wiU actuaUy negotiate 
Ucenses—being concerned with the legaUties and patent niceties. Rather he 
or she is a scientist or technologist famUiar with an industry. 
At DNAX, and at many other biomedical companies, we make use 
of an outstanding board of scientific advisors, who are weU informed and 
part of the informal information network of academia to identify, culti-
vate, and foster technology of potential commercial significance. We 
vigorously encourage the patenting of inventions made in academia and, 
recognizing the limited funds and manpower avaUable to support academic 
patenting efforts, we are prepared to provide substantial assistance when-
ever possible. We beUeve that the best relationships are buUt upon respect 
and sharing, and we are endeavoring to estabUsh such relationships with 
our academic counterparts. 
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The importance of patents in the semiconductor industry depends upon your 
perspective. I sense a certain amount of impatience from the scientists over the 
lack of preciseness in the attorneys' answers to the various questions that have 
been raised as to what is patentable m the life form industry and how to de-
scribe and claim the patentable material. 
But are there procedures which might help m understanding where the life 
form industry wUl go with respect to patent practices? Some may be provided 
by an mdustry which, 30 years ago, was just about in the same position that the 
life form industry is in today. That industry is the semiconductor mdustry. 
To understand the importance of patents in the semiconductor industry, a 
brief technical description of a typical semiconductor process may be useful. An 
iUustration of certain crosssections of a portion of a semiconductur substrate at 
various stages in one tjrpical production process is shown in Figures 1 through 5. 
The iUustration briefiy summarizes the process used to make what we caU 
bipolar type devices—only one of several types of devices that are made using 
semiconductor technology. There are also metal oxide semiconductor devices 
(MOS devices) and complementary metal oxide semiconductor devices (CMOS 
devices). The CMOS devices have certain advantages for certain appUcations re-
quuing low power. The semiconductor mdustry also makes charge coupled 
devices (CCD devices), which likewise have certain appUcations and uses, inte-
grated injection logic devices (I^L devices) and some others. But, typicaUy, 
bipolar and MOS processes make up the buUc of semiconductor production. 
To make a bipolar device using a typical process, a manufacturer starts 
with substrate 41 of monocrystalline siUcon material (Fig. 1), typicaUy of P type 
conductivity, and wiU form on the top surface of this substrate a mask (not 
shown) of thermaUy grown oxide of the sUicon material. Once the oxide is 
formed, a window is opened in the oxide so that a selected impurity can then 
diffuse or otherwise pass into the semiconductor substrate to convert the con-
ductivity type of a region (such as regions 43a and 43b) of the substrate from 
one type, typicaUy P type, to the opposite conductivity type, typicaUy N type. 
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FoUowing the formation of what are commonly caUed N type buried 
layers 43a and 43b, the manufacturer wiU next remove the previous oxide mask, 
and then grow a P type epitaxial layer 42. This layer could also be N type. Epi-
taxial layer 42 wiU have a crystaUographic stmcture which repUcates the crystal-
lographic stmcture of the underlying substrate 41. That is, it wiU have that 
stmcture if the process is carried out conectly. If the process is not carried out 
correctly, at this pomt the manufacturer wiU perhaps throw away the wafers and 
start agam. 
A processing error is not necessarUy fatal. Sometimes, wafers can be re-
worked if they are improperly processed. Certam of the layers that have been 
formed on the wafer can sometimes be stripped and the processing can be 
started again at some intermediate pomt in the process. 
FoUowing the formation of the epitaxial layer 42, a mask (141) wiU be 
placed on the surface of layer 42. The mask wiU be formed, for example, of 
sUicon lutride, or it can be formed of a composite layer of thermaUy grown 
oxide foUowed by a deposit of sUic9n nitride. The mask wiU then be patterned 
and selectively removed (Fig. 2) and grooves wiU be etched in the exposed 
epitaxial layer a selected distance mto the surface, using a chemical etchant. A 
number of weU-known etchants are used for this purpose. Each company 
typicaUy wiU have favorite etchants which it has developed over time. 
FoUowmg the formation of grooves, the masking material 141 wiU be left 
on the surface. The device wUl now be oxidized to form field or "isolation" 
oxide 44a, 44b, 44c and 44d. Oxidation is a long, high-temperature process, 
which grows an oxide layer from the sUicon exposed m the grooves typicaUy 
down to the N type buried layers 43a and 43b. During aU of this high tempera-
ture oxidation as m aU high temperature steps, the buried layers 43a and 43b are 
constantiy expanding due to the diffusion of the high concentration of theu 
dopant atoms into the adjacent semiconductor material. The extent to which 
layers 43 a and 43b expand is dependent upon the total time that the device is 
left at the high temperatures. 
FoUowing the formation of the oxide regions 44, certam of the masking 
layers 141 left on the surface of the device to prevent the oxidation of the 
underlying sUicon material 42 are then stripped from the device (Fig. 3). Certain 
additional impurities are then placed in the device, usmg diffusion or ion im-
plantation techniques. There are a number of different techniques that can be 
used to form these regions 45a, 45d, 45c, 47 (Fig. 4). 
The N type smk region 45a, known as the coUector contact region, wUl 
then be used to make electrical contact through the top surface of the device to 
the N+ buried layer region 43a (Fig. 4). Buried layer 43a aUows electrical 
contact to be made under part 44b of the isolation oxide to a region 45d of this 
device caUed the coUector region. 
A base region 142 is also formed in the device. FoUowmg the formation of 
base region 142, an emitter region 47 is then formed. Prior to formation of 
emitter 47, additional passivating oxide 46 is placed on the surface of the 
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device, overlying the intersection of the to-be-formed PN junction between base 
142 and emitter 47 with the surface. Metal contacts 144a, 144b, 144c are then 
formed on the top surface of the device to provide electrical contact to and 
assist m the interconnection of the active regions of the device. 
This process contains many other steps—cleaning steps, drying steps, and 
often mcludes test measurements which are made at various points in the 
process. But the result is a semiconductor wafer which has a pluraUty of dice, 
each an exact repUca, theoreticaUy, of the others. In practice, however, this 
process sometimes yields only a few good devices because of various 
uncertainties introduced during the processmg. TypicaUy, yields of good devices 
from wafers wiU vary, depending upon the age and complexity of the process, 
from just a few good dice per wafer up to maybe 50% or more, depending 
upon the type of product being made. 
The remainder of the wafer is basicaUy waste. These inoperative devices 
are lost and cannot be used except to reclaim any precious metals that may have 
been used in their manufacture. 
Among the factors that affect yield are unperfections in the materials and 
masks, human errors during processing and the tolerances on the various opera-
tions carried out to produce the devices. I thmk aU of these factors have 
analogues in genetic engineering. From what I can gather in life form engmeering 
there is a possibiUty of error, of impurities gettmg into the processes and of 
experiments being mmed by foreign particles entering the envuoiunent. The 
same problems occur in semiconductor processing. 
HISTORY OF SEMICONDUCTORS 
Although the transistor was invented m 1947 at BeU Telephone Labs by Drs. 
Shockley, Bardeen, and Brattam, not until about 12 years later did the mdustry 
reaUy begin to develop. In the early fifties, AT&T entered mto a poUcy of 
granting patent licenses and know-how Ucenses to companies desuous of making 
semiconductor products. This was a very significant step since it resulted m the 
dissemmation of basic technology from Westem Electric to compaiues such as 
Texas Instruments. Westem Electric, of course, was paid for this mformation. 
This decision by AT&T was most significant. AT&T must have decided 
that there were sigmficant advantages to be gamed by makmg this technology 
avaUable to the pubUc. 
At that tune, AT&T and Westem Electric were mvolved m antitmst 
Utigation with the Government. In 1956, the antitmst litigation was settied witii 
a consent decree that dedicated certain AT&T and Western Electric patents 
issued prior to January 24, 1956 to pubUc use, and requured AT&T and Western 
Electric subsequentiy to Ucense theu patents to the pubUc at reasonable 
royalties. Since Westem Electric and BeU Telephone Laboratories had done 
research in the semiconductor area, I think that tiie AT&T and Western Electric 
decision to Ucense broadly their semiconductor technology, as weU as tiie 
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consent decree, gave to the semiconductor industry a significant access to val-
uable technology. 
I assume that m the genetic industry, aU you can hope for is a similar situa-
tion to occur, perhaps, with respect to a large company that has a significant 
patent position. 
JOHNSON: It is caUed Stanford. 
MacPHERSON: I don't know that a university has ever been subject to a con-
sent decree. 
In 1955, Dr. Shockley left BeU Telephone Laboratories and went to Palo 
Alto, California, where he set up Shockley Laboratories to make transistors. 
Shockley Laboratories grew and prospered. In fact, it prospered so much that in 
2 years eight young scientists at Shockley Laboratories left and received 
fmancial backing from Sherman FauchUd and founded FairchUd Semiconductor. 
In 1959, FairchUd invented what became known as the planar process for the 
manufacture of sUicon semiconductor products, filed patent appUcations on the 
planar process and planar stmcture, and also invented what ultimately was held, 
m 1969, to have been tiie first mtegrated circuit. Dr. Robert Noyce, who subse-
quentiy became a founder of Intel Corporation, was the inventor at FairchUd 
of the mtegrated circuit. 
FairchUd began to manufacture sUicon devices made using the planar 
process. The planar process was important because it reduced the wide varia-
tion m device characteristics that previously had resulted in very low yields from 
the prior art semiconductor processes. Consequentiy yields went up, costs went 
down, and senuconductor products with predictable characteristics became avaU-
able Ul large quantities. 
Shortiy after FairchUd began manufacturing planar product. Jean Hoemi, 
the inventor of the planar process and structure, left to found an mdependent 
semiconductor company Amelco, headed Union Carbide Microcircuits, and sub-
sequentiy founded InteroU and tiien EurosU in Europe. He is now said to be 
back in SiUcon Valley in California, working on anotiier company. 
Shortiy thereafter, anotiier individual left FairchUd, Howard Bobb, and 
founded a company known as General Micro-electronics, ultimately bought by 
Ford and then sold to General Instruments on Long Island. Howard Bobb. 
by tills time, however, had left General Micro-electronics and had founded, in 
1967, a company known as American Microsystems. American Microsystems is 
the major factor now ui an area of tiie semiconductor business known as tiie 
custom MOS busmess. 
Shortiy after Howard Bobb left FairchUd, two of FairchUd's prime linear 
designers, Talbott and Widlar, left FairchUd and went to work for a very smaU 
company witii headquarters in Danbury, Connecticut, now known as National 
Semiconductor. National Semiconductor had been founded, and was tiie sub-
ject of a trade secret suit as a spin-out from Sperry Rand (see Sperry Rand 
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Corporation v. Rothlein et al, 143 USPQ 172 (D.C. Ct. 1964)). Widlar and Tal-
bott used their professional skUls to design linear cucuits for National. They 
soon enabled National Semiconductor to become a predominant factor in the 
linear circuit busmess. 
Shortly after Widlar and Talbott left FauchUd, Charles Sporck left 
FairchUd to become president of National. Sporck took National from about 
$3 mUlion a year annual sales in 1966 to close to $1 bUUon a year m annual sales 
in 1980—a very successful operation, you might say. 
In 1968 Noyce, Gordon Moore, and Andrew Grove left FauchUd to found 
Intel. They were replaced by Les Hogan, who jomed FauchUd^from Motorola. 
Motorola had been in the semiconductor business for some time and had a repu-
tation for very effective manufacturing abUity. Motorola was able to chum out 
semiconductor products like jeUy beans. In the pharmaceutical industry you 
might say Uke piUs. They and aU other manufacturers were able to repUcate 
theu devices so the devices were substantiaUy identical. When you bought a 
device with certain characteristics, you were sure you got those characteristics, 
within a tolerance of course. 
Hogan's departure from Motorola precipitated the Motorola-FairchUd Uti-
gation, a famous trade secret suit that dealt with the issue of whether or not a 
manager could leave a company and take with him seven or eight key assistants. 
The case also involved a serious* question of trade secrets. Motorola aUeged that 
part of the reason for hirmg these gentiemen had been to transfer to FauchUd 
certam Motorola trade secrets. Motorola Usted m the complamt 140 or so trade 
secrets that they aUeged to have been misappropriated. 
A trial foUowed, at which Motorola presented its case. Judge Copple of the 
District Court in Phoenix, Arizona then granted a FairchUd motion for summary 
judgment fUed on the completion of Motorola's case, before FairchUd presented 
its case. (See Motorola, Inc. v. FairchUd Camera and Instrument Corp., 177 
USPQ 614 (D.C. Az, 1973)). On cross-exammation, FairchUd showed that each 
of the trade secrets supposedly misappropriated by FairchUd had, in fact, been 
in the pubUc domain or made avaUable to the pubUc by Motorola without any 
restrictions whatsoever. 
The court essentiaUy said that individuals are free to move about an in-
dustry and practice their general professional skUls. I think the semiconductor 
industry has shown that individuals can do this despite trade secret suits which 
have attempted to stop them. That doesn't mean that trade secret suits don't 
have theu place. 
After Hogan joined FauchUd, thmgs quieted down somewhat. There 
were, however, some significant events in the industry. In about 1968-69, 
Westinghouse dropped out of the merchant market. Other old Une companies 
such as Sylvania and General Electric also faded m relative importance. 
There were numerous other companies that manufacture semiconductor 
devices-SiUconix, Signetics, Teledyne, Pacific Semiconductor (a division 
of TRW), GE, Transitron, RCA, Westmghouse, General Motors, PhUco, 
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Solid State Scientific, Union Carbide, Sperry Univac, ITT, Advanced Micro De-
vices, Cogar, Unitrode, TI, Motorola, Harris, Mostek and Analog Devices. 
Later on in the 1970s other companies were founded: Supertex, Synertek, 
ZUog, MonoUthic Memories, and Nitron, for example. AU of these companies 
used a labor pool which, to some extent, had passed through one or more 
companies such as FairchUd. FairchUd tumed out to be an exceUent place to 
train for this business. 
FACTORS AFFECTING PATENTS 
With this background, the factors which have affected the importance of patents 
in the mdustry can be discussed. ActuaUy, I think there is only one overridmg 
factor which reaUy has affected the importance of patents in the semiconductor 
industry-competition. The semiconductor industry has been characterized by 
one reality, and that reality is fierce, effective, continuing competition. 
The main practical importance of patents is that they cover certain 
products that are ui demand. The unportance of a patent depends upon whether 
or not there are other products which can be made without infringing the patent 
and which wiU fiU the same need. 
Competition 
However, competition and not patents has been the one reaUty of the semi-
conductor mdustry which has influenced its development. Competition depends 
upon many factors: 
1. ease of entry; 
2. number of competitors; 
3. number of alternate sources for the same type of product; 
4. nature of competition (by that I mean, is tiie competition on a component 
level or is it on a functional level?); 
5. rate of technical innovation; 
6. rate of product obsolescence: 
7. pricuig poUcies; 
8. profits (which are important ui determining tiie strength of competition); and 
9. mobUity of labor (which has had an extremely unportant role in determining 
the nature of competition in tiie semiconductor mdustry). 
Ease of Entry 
Ease of entry is an important factor. For many years, it was possible to enter tiie 
semiconductor business witii a capital expenditure of a few mUUon doUars, some 
diffusion tubes, furnaces, and reactors to carry out tiie various process steps con-
ducted on the wafers, perhaps a scribe-and-break machme to break up tiie wafers 
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fabricated usmg the wafer fabrication processes, and then some assembly equip-
ment to put the good dice into pack^es for sale to the customers. A person 
might even have had some test equipment to test the product before it was 
shipped. But if the person didn't, that was no problem. A person could go out 
and hire someone else to do the testing. 
Over the last few years, because of the increased complexity of semi-
conductor devices, the cost of entering the business has increased. I have been 
told by a number of people that it now costs from $20 miUion to $40 milUon in 
capital equipment to enter the semiconductor business, should a person desire to 
do wafer fabrication. 
But what if you elect not to fabricate wafers? There are a number of new 
companies now bemg formed with a much smaUer amount of capital; these 
companies are going to be very effective competitors, because they are taking 
advantage of a new phenomenon in the industry, the "sUicon foundries." These 
foundries comprise companies with excess capacity which make that capacity 
avaUable to a start-up company or an existing company for a price, so that the 
start-up company or the existing company can mn selected wafers through a 
semiconductor process and come up with wafers suitable for assembly into 
finished product. 
The emergence of silicon foundries is important, because if a company 
buys its wafers from a company already estabUshed which has a Ucense under 
the important industry patents, the buyer does not even have to worry about a 
patent Ucense, because the seUer, of course, is operating under its Ucense. 
Competitors 
The number of competitors is unportant. With a number of companies offering 
the same product in the marketplace, there is fierce price competition for that 
product. 
Competition, though, isn't just between identical products. There are 
several different semiconductor technologies that are m use. Oftentimes, you 
wUl find that an MOS product-that is, a product made using MOS technology-
wUl offer the same function to a system designer as a product made using bipolar 
technology. If a company has a predommant patent on bipolar technology and 
another company is unable to obtam a license under that patent, then the other 
company can make the same functional product usmg MOS technology and 
avoid the patent. Consequentiy, tiie value of certam patents is reduced some-
what by the avaUabUity of competitive altemative technologies. 
Competition spreads beyond price and technologies mto the arenas of 
specUications, quality of devices, deUvery schedules, and payment schedules. 
In bad times competition reaUy becomes heated because each semiconductor 
manufacturer has a large capacity which it desues to keep busy. Companies 
reduce prices to take business away from tiieir competitors. Oftentimes, a 
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company wUl soUcit business at prices beneatii its cost, just to keep its fadUty 
from going idle. 
During recessions when the semiconductor business is down approxi-
mately 25 or 30% from tiie expected demand, products are avaflable at bargain 
prices to mdustries tiiat wish to use them. Unfortunately, during recessions 
usuaUy industries do not wish to buy many semiconductor products since they 
have already bought semiconductor products during periods of tight supply, and 
therefore wish to work down their inventories to reduce their inventory costs. 
This compounds the problem m the semiconductor industry. Profits drop 
drasticaUy reducing the abUity of companies to invest in new products at the 
very time new products are needed to compete more effectively. 
Alternate Sources 
In the semiconductor industry, there is a remarkable practice-giving away 
technology to a competitor for no money. This creates alternate sources for a 
product. It happens for this reason: Many years ago, some original equipment 
manufacturers made the mistake of ordering parts from what is known as 
a sole source, one company. Unfortunately, semiconductor manufacturing 
processes sometimes yield very Uttie product. In fact, early in the senuconductor 
business, there would be periods of time when the yield would be zero. If a 
manufacturer is awaiting deUveiy of components and is unable to receive the 
parts because they were ordered from a sole source who "lost the process," the 
manufacturer wUl not be pleased. To protect themselves from loss of process or 
zero yield, buyers soon began to insist that before committiiig to a design, 
the design had to be made by more than one company. The result was that, in 
order to get the busmess, companies such as FairchUd, National, Motorola and 
TI had to go to their competitors and say, "Look, I have a good deal. I can seU 
this product if you wiU make this product with me." If the competitor was 
smart, he would sit back and say, **What wiU you give me to make this 
product?" WeU, the negotiations developed mto patterns, untU finaUy, the 
company requested to be an alternate source would be promised by the original 
suppUer those masks necessary to make the product, and would sometimes be 
promised whatever technology necessary to bring its process into conformance 
with the originator's process. In some cases they would even be given a patent 
Ucense to be free from any patent infringement claims by the originator. 
The original developer of the process and the product found it absolutely 
necessary to go out and transfer certain of its technology and patent rights to 
make the products using that technology, ui order to be able to seU product 
into the marketplace. 
This doesn't mean royalty free. Often the alternate source would have a 
product that the origmal company would want, and there would be a swap. 
Patents reaUy weren't a factor in tiiis type of relationship. They may have been 
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of secondary unportance in a few of the negotiations, but for the most part, the 
companies wanted to buy market share, and the way they bought market share 
was to present to the marketplace a second source. 
The ideal second source was usuaUy a company m trouble. But that 
practice soon ended, because the manufacturers of the finished goods soon in-
sisted that the second source company be in good health and be able to make 
the product. Alternate sources were a major reason why technology and patent 
rights became somewhat disseminated throughout the mdustry. 
Nature of Competition 
An alternate source, of course, made a component identical, to the extent it 
could be done, to the component being manufactured by the prime source. Of 
course, there was also functional competition between functionaUy equivalent 
components. Logical components, for example, could be made by bipolar 
processes or MOS processes. These logical components would compete func-
tionaUy, although they would not necessarUy be pm-for-pin replacements in a 
circuit board for each other. Hiere was also circuit board competition at a higher 
level of integration of the components into a fiiushed system. 
Rate of Technical Innovation 
The semiconductor industry was characterized by a rapid development of the 
technology and rapid introduction of products. Both of these factors though not 
tmly tied together do, of course, impact each other. 
Product Obsolescence 
In any one year, it has been estunated that from 10 to 30% of the products 
offered by the mdustry become obsolete and are replaced by new products-
oftentimes more highly dense products. That is, they offer more functions per 
unit area, many more functions per doUar than the older products, and perhaps 
greater flexibility of use. They may have microprocessors mcluded in them, 
whereas the prior products did not include microprocessors. The result is that a 
product's lifetime wUl typicaUy be 5 years. When it takes 3-4 years to obtain a 
patent and another 2 or 3 years to negotiate a Ucense, if ever, patents don't seem 
to have the unportance that they would have if the product was going to have a 
contmuing Ufetune substantiaUy beyond the issuance of the patent. A 10-year 
Ufetime for a product m the industry is somewhat unusual. 
A company recognized as a leader at a given time might very weU not be a 
leader 3-5 years in the future. A company with patents would grant Ucenses to 
otiier parties under its patents in a broad field of activity, a field of use Ucense, 
so to speak, and would uisist that it get back a nonexclusive Ucense covering tiie 
same field under any patents which the competitor nught subsequentiy obtain 
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relatuig to the same field. Broad cross-Ucenses thus became commonplace m the 
mdustry. They were helped by the fact that a typical company would offer any-
where from 1000 to 10,000 products, of which 10 to 30% would change in any 
year. 
The number of products meant that patent infringement studies were 
rarely done, merely because there was no manpower to do the studies. The 
products were changmg faster than they could be analyzed. If a company tried 
to do a patent mfringement study, by the time the study was finished, the 
product would have been sold and sometimes it would have been dropped, and 
another product would have been substituted m its place. The result was that 
oftentimes broad patent Ucenses were entered into with some study of a few key 
patents—and there were key patents in the industry—but with no real study of 
the broad product line m view of aU semiconductor patents. In fact, many 
companies clearly stated that their goal in Ucensing was to remove an impedi-
ment to doing business and no other purpose. 
Often the weaker company would pay either royalties or a lump sum to 
the stronger company. In general, patents were not thought to be an obstacle to 
either entering the busmess or continuing to stay in the business. 
Pricing 
Another factor that affected competition was pricing. The Boston Consulting 
Group pubUshed the learning curve or "experience curve" which said that cost 
dropped as a function of time. The abscissa is a logarithmic scale. The semi-
conductor industry experience curve showed approximately 30% per year drop 
Ul cost (Fig. 6). 
Some companies used this curve to justify the uiitial pricing of new 
products under theu actual costs at the time of product introduction. This was 
done on the theory that even if a Uttie was lost on each unit sold it would be 
made up in volume. 
cost as a function of cumulative 
volume 
Cost 
Price 
Time Volume 
Figure 6 
Experience Curve 
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The theory is: if a price is set beneath cost at product introduction, it 
may become above cost at a later time. This time can be translated into volume. 
If time is replaced with an equivalent concept of volume, (volume means total 
number of units produced) as the total number of units produced rises, cost per 
unit goes down. If a large market share is purchased at the start, the volume at 
which cost is beneath price wUl be reached earlier in time than if that large mitial 
market share is not purchased. Consequentiy, costs wiU go down much faster if 
prices are set below initial cost at the start, because a large number of design-
ins wUl be obtained that otherwise would not be obtained. The demand for your 
product, hopefuUy, wiU be greater. By this phUosophy the profits can be reached 
sooner than if the initial price is set high. 
This particular strategy worked—many companies made a great deal of 
money by using it. However, it agam reduced the amount that management was 
willing to pay in patient royalties for the privUege of making any product, be-
cause obviously management could argue initiaUy that it was losing money on a 
product. The result of this phUosophy was that profits often tended to be 
somewhat out of proportion to sales—companies lost money. This particular 
phUosophy assumes that volume is gomg to go up and a company is going to gain 
market share. There were companies that tried this phUosophy, and unfortunate-
ly never quite got to the crossover pomt. 
Profits 
There is a law of survival in the United States that says you have to make money 
sometime. ActuaUy, there are companies in busmess today in the semiconductor 
industry which, over their Ufetune, have neither made nor lost much money. 
This is a unique tribute to the competitive nature of the semiconductor busmess. 
It has UteraUy aUowed these people to stmggle along on a shoestring, stay in 
business, support a lot of people who otherwise would be unemployed, and 
aUow, more importantiy, theu shareholders to make substantial monies from the 
ups and downs of the share prices of stock. And that has a sociaUy useful 
function, too, in an entrepreneurial community, where investment capital is 
sought. It is a very pleasant thing to be the scientist-owner of a company that 
has its stock going up and therefore creates profits, potentiaUy, to the scientist-
owner. 
But there are also companies that have made substantial profits in the 
semiconductor busmess. 
JUDGE RICH: Aren't you forgettmg the salaries tiiey pay themselves? 
MacPHERSON: Oh, yes, the salaries are unportant, but the salaries are an 
interestmg phenomenon. Oftentimes, the salaries are relatively low. The 
stock options and the incentives are what reaUy keep the people m the 
companies. Once those stock incentives are removed-and this happens 
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sometimes when companies are purchased by other companies that are not 
familiar with the practices in the semiconductor industry-those people 
then leave. You can teU when people are going to leave in the industry, 
because you know when stock options vest. It is one of the laws of nature. 
Mobility of Labor 
Such labor mobiUty, of course, strongly influences competition. I think we have 
covered that very rucely by Judge Rich's question. Semiconductor products 
are characterized by Jerry Sanders of Advanced Micro Devices as being the cmde 
oU of the technological age. The semiconductor industry basicaUy suppUes a raw 
material, a highly technological raw material, to other manufacturers, who take 
the product and place it into finished goods or semi-finished goods for sale 
further into industry, to consumers, or whatever. Semiconductors are ubiquitous 
in their uses. They are used in almost everything, I guess, except life forms. They 
are even used in analytical machines, of course, to aUow you to achieve new and 
more accurate results. 
The result is that a good semiconductor engineer can command a veiy 
admirable salary and a very admirable stock option package. Engineers have 
leamed that during recession times the employer is gomg to be quite willing to 
lay them off. 
A company does that once to employees, and the employees soon learn 
that loyalty is a one-way thing. Companies demand it of employees, but aren't 
willing to give it to them. When that happens, a company suddenly discovers it 
has a very mobUe labor force. That is free enterprise; that is the capitaUst 
system. They wUl take their general professional skUls (and perhaps more) with 
them to their new employer. 
The result, again, is a rapid dissemination throughout the industry of that 
nonpatentable technology that is the key for doing things weU. Techniques in 
people's heads that don't rise to the level of patentiibUity go with those people 
to their new employers. 
Practices have developed m the semiconductor industry for trying to at 
least prevent big secrets from moving from one employer to another. Employees 
are ahnost always debriefed at tiie big companies before they leave. The de-
briefing essentiaUy comprises an interview with the employee, where the em-
ployee sits down on one side of the desk with a company patent attomey or 
personnel director at tiie other side of tiie desk. The two tiien discuss what tiie 
employee has done; who he worked for and on what project; new inventions; 
pubUshed articles resulting from mventions; and, disclosures. 
It tums out that engineers are very smart. They pave the way so they can 
leave, use what tiiey developed, botii tiirough patent disclosures, (which wUl be 
filed in tiie Patent Office) and tiirough papers which are given at technical con-
ferences (which disclose tiie essence of tiie work, so it is m tiie public domain) 
so they can use them at the next company. 
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Most companies have a procedure by which aU pubUcations must be ap-
proved by the patent department. That stUl doesn't prevent employees, thou^, 
from disclosing key information at these conferences, which are often oral ex-
changes as weU as written exchanges. 
Thus, trade secrets have been used and have been effective in many 
contexts, but oftentimes they have not been able to prevent a low-level dissemi-
nation of the operating technology throughout the industry. 
There have been some very famous trade secret suits in the industry. 
Judges tend to look upon trade secrets as sacrosanct—a point Tom KUey aUuded 
to-and patents as potentiaUy invalid disclosure documents. It is very uonic. I 
think a company is often much more successful in protecting its trade secrets 
than its patents, if it can show that it has taken reasonable steps to do so. What 
are these steps? Cases seem to say that a company must inform employees of 
the nature of the trade secrets on a periodic basis, must label areas m which 
trade secrets are practiced as secure areas, must debrief employees, and should 
write letters to the new employer of a former employee, informmg the new em-
ployer of the work which the former employee did in a broad sense and let the 
new employer know that the former employer is going to be looking carefuUy at 
the products being produced by the new employer over the next year or two to 
determine whether or not the new employer used the old employer's proprietary 
mformation. 
Many companies have been successful in obtaming injunctions against the 
use of theu trade secrets under these cucumstances. However, trade secret pro-
tection has so many risks that I think most companies have decided that the best 
protection is patent protection. The classical problem in relyuig upon trade 
secret protection is that the company which retauis the innovation as a trade 
secret potentiaUy mns the risk of mfringuig a patent obtamed by another party, 
who although later to invent, decides to patent the innovation, and successfuUy 
obtains the patent. Under 35 U.S.G. 102(g), there is a very express statement 
that a party who suppresses, conceals, or abandons an invention is not entitled 
to a patent vis-a-vis another who subsequently appUes first for a patent on the 
same invention. I think the courts would hold in such circumstances that the 
maintenance of an invention as a trade secret might very weU comprise the con-
cealment or the suppression of an invention. Judge Rich, can you comment on 
tius? 
JUDGE RICH: I wUl comment right now whUe the iron is hot. You let out the 
last part of it. One doesn't get a patent when he is in an interference with 
somebody else who made the same mvention. Absent that interference 
situation, his not doing anythmg with it is not gomg to prevent his gettmg 
a patent at aU. He sunply sacrifices it to another independent inventor. 
MacPHERSON: That is correct, but then doesn't that create the situation where 
he, the trade secret owner, is potentiaUy infringmg the other mventor's 
patent? 
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JUDGE RICH: Sure. 
MacPHERSON: And that is what I am trying to avoid. I think most of us are 
concerned that that not happen in the industry. So I think most of us have 
concluded that the best type of protection to obtain is patent protection, 
as soon as possible. 
There is, of course, a large use of patents in the industry, and there are im-
portant patents in the industry. I don't want to give the impression that there 
aren't. Westem Electric, FairchUd, Westing i^ouse and TI have aU had numerous 
patents of importance, and they have Ucensed these patents. However, the total 
consideration paid for these Ucenses is a relatively smaU proportion of the total 
sales of the mdustry. By the way, there are other patents in the industry, which I 
haven't mentioned, which are of particular use ui particular circumstances. They, 
too, have been Ucensed. 
But the fact is, the industry is not driven by patents. The industry does 
not rely on patents for protection of markets. The industry reUes upon 
technical innovation. It reUes upon ever-increasing complexity of devices, so that 
devices can be sold at lower and lower prices per function, to maintain ever-
expanduig markets. I think the industry has done this very successfuUy. 
The genetics life form industry has the opportunity now to make a 
decision as to which way it wants to go, whether it wants to go the way the 
pharmaceutical industry has developed-and the pharmaceutical industry has 
developed, for very real and legitimate reasons, into an industry which depends 
upon patents for protection of products-or to foUow the semiconductor in-
dustry. Now, if you foUow the semiconductor industry and develop a situation 
where anyone with a cage of nuce, a centrifuge, and a business plan can go into 
busmess, you are gomg to have a lot of fun. 
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COMMENTS 
SHARP: What is a typical Ucensmg royalty for a broad patentmg m the semi-
conductor field? 
MacPHERSON: It is hard to say. 
SHARP: What about the typical Ucensmg royalty on a fundamental patent? 
MacPHERSON: There are some fundamental patents m the industry, and 
licensmg royalties oftentimes aren't charged, but rather lump-sum pay-
ments are. One aspect of a royalty arrangement is that you usuaUy arrange 
an auditing schedule of the payments—a clerical and bookkeeping night-
mare m an industry with one to 10,000 products. It is a very practical 
problem. If the genetic Itfe form industry introduces a commensurate 
number of products, as I suspect it might, it wiU probably have that same 
problem. So a very practical solution was adopted. People started selling 
paid-up or lump-sum licenses either on a non-exclusive basis for the Uves 
of specified patents or for a defined time for a specific fixed fee, based 
upon estimated usage of patents. 
But royalty rates were also used from tune to time, and they ranged 
up to about 5% or so. 
DAVIES: When the semiconductor industry began with a group of smaU 
companies, in the same way that the life form industry has begun, was 
there the same question about whether things should or should not be 
patented? Was there the same attempt to communicate between lawyers 
and those workmg in the field as to what should be done about it? Or was 
it aU very clear? 
MacPHERSON: What do you mean, when the mdustry first began? The same 
questions are being asked today, 30 years after the industry started, by the 
enguieers and scientists in the semiconductor industry that are being asked 
at this meeting by the geneticists: "What can I patent?" "What are the 
mles?" The fact is that, yes, there were real questions bemg asked, though, 
as to whether or not patents should be fUed, for example, on combinations 
of logic functions on a single chip of sUicon, when the same logic functions 
had been carried out using mdividual logic components or a pluraUty of 
logic components (such as vacuum tubes) from the prior art. They are 
tough questions to answer, but you ahnost have to answer them on a case-
by-case basis, looking at the facts. 
ARNO: Could you comment on the use of patents merely as a means to ensure 
freedom to practice your own inventions? 
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MacPHERSON: That is an important factor in the semiconductor mdustry. 
Oftentunes, patents are filed not because the patent is intended to be used 
offensively-that doesn't mean it won't be used offensively, but it is not so 
intended at the tune of filing-but rather to gam a period of secrecy be-
tween the disclosure of the invention in the Patent Office and the ultunate 
issuance of the patent. This is done so that anyone who then sees the 
issued patent wiU not be able to get back of the patentee's first date and 
take the invention through interference, for example thereby causing the 
patentee to have to pay royalties to them. There is a defensive purpose 
in fUing patents. The AppUcant wants to pubUsh its invention so no one 
else can get a patent on it. 
Another method is used to do that. IBM has the Technical Dis-
closure Bulletin, which is circulated to a limited number of Ubraries in 
the United States. It describes novel developments by IBM which are not 
the subject of patent appUcation. I tried for years to subscribe to that 
buUetin, because it has exceUent disclosures on semiconductor technology, 
and IBM for years refused to send it to me. But one year they sUpped up, 
and I had a subscription for several years. Then they discovered that they 
were sending me the buUetin, and they withdrew the subscription. But 
that is another way. 
ARNO: WeU, maybe it is not a pubUcation after aU. 
MacPHERSON: WeU, it is avaUable at the Patent Office, and at selected Ubraries 
around the country. 
JOHNSON: Did BeU have an umbreUa patent? 
MacPHERSON: The development of the transistor was very much a part of BeU 
Telephone Laboratories thing in the eariy days. AT&T had the consent de-
cree in 1956, about 9 years after BeU had first invented the transistor. It 
required AT&T, Westem, and Bell to Ucense certain of their patents issued 
prior to 1956, royalty-free. That swept in a lot of basic semiconductor 
patents dealmg, for example, with point contact transistors, aUoy 
transistors, and some basic junction transistors proposed by Dr. Shockley. 
The patents that issued to BeU foUowing 1956 included some very 
basic and important semiconductor patents that arguably could be con-
sidered umbreUa patents. They had a patent, for example, on tiie use of an 
oxide maskmg layer-that was a basic patent. 
However, otiier companies in the industry also had basic patents. At 
one time I counted up on one product, just as a matter of curiosity, some-
tiiing lUce 30 patents tiiat were used m tiiat product, many owned by 
different companies. Now, if every company exacts a 5% or a 3% royalty, 
it is an impossible situation. NaturaUy, practical minds prevaUed. 
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JOHNSON: You mdicated it was 12 years after the mitial discovery before 
anything reaUy happened. That is unlike the life form industry, in a way. 
But the other thing that impressed me is that you were reaUy just talking 
about a commodity market. 
MacPHERSON: You are absolutely right. We are talking about a commodity 
market. FoUowing the invention of the transistor, 12 years passed before 
the people figured out the technology associated with the siUcon system. 
The transistors had been made primarily with germanium prior to 1959 
and the result was that the devices would not operate over the range of 
temperatures that was desired with the required stabiUty. 
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JUDGE RICH: Perhaps you should know a little bit about the court and how 
it works. Practically aU good lawyers do their level best to keep their 
clients out of court, with very good reason. You shouldn't come to the 
CCPA because you have scared me to death about these technologies. I 
haven't learned them, and I can assure you, there isn't another judge-
certainly, now that I have been exposed, I wUl guarantee it-there is no 
other judge on the court that yet knows much about it. 
The basic purpose of the Chakrabarty opinion-which sounds more 
or less lUce an elementary textbook on patent law in certain spots-was to 
hook at least a couple more law clerks. The previous 1978 Supreme Court 
patent case had had three dissenters (Parker v. Flook, 437 U.S. 584), and 
aU I wanted was two more dissenters, which would make a majority, and 
that is what we got {Diamond v. Chakrabarty, 447 U.S. 303). 
The patent people are aU divided, like Gaul, mto three parts. There is 
the group of examiners in the Patent Office, of aU grades, from the bottom 
to the top. There are the corporate patent lawyers, of which we have two 
present at this meeting. The private sector represents the third part. 
This panel is comprised of two corporate patent lawyers and myself. 
The private sector is represented by many participants at this meeting. 
You all realize that the Patent Office no longer exists. The name was 
changed a few years ago to reflect the fact that it also handles trademarks, 
and they got this impossibly long name, the Patent and Trademark Office 
(PTO). 
We also have on the panel a representative of the Patent and Trade-
mark Office. The first speaker on our panel is George Gould of Hoffmann 
LaRoche who wiU examme one smaU issue in the patent law occurring 
recently. He wiU also reinforce some of the concepts that David Plant 
discussed. 
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GOULD: Before turning to this particular aspect, I would like to take you aU 
back to the days of yesteryear in the westem United States to the pro-
cedures by which people were able to claim mineral rights to pubUc lands. 
That involved essentiaUy two steps: first, staking your claim which ui-
volved UteraUy walking around the perimeter of the land that you were 
interested m* and physicaUy knocking in some stakes with your own 
indicia. This would be foUowed by the act of going to some recording 
office estabUshed by the U.S. Govemment and establishing your claim 
by presenting in writing your claim for rights. 
There were certain people who thought this was a rather inefficient 
process and wanted to avoid this terrible trek through the desert or 
mountains or whatever, and proceeded directly to the second part, which 
would be to the recording office. These people were given the name of 
claim jumpers. 
There are certain patents which are appearing with the same charac-
teristics—claim-jumping—trying to estabUsh a property right ahead of 
actually going through your penance in the desert. 
This can lead to some rather difficult legal situations for large 
companies who decide to reaUy go ahead and do the necessary work. 
JUDGE RICH: I would just Uke to add that that is one of the technologies that 
we got at the court, and we got it several times. 
GOULD: Very briefly. What would happen is tius. Company "X" has hired 
a molecular geneticist but has not yet provided him with a laboratory. 
The scientist sees something very exciting that he knows a lot of people 
are going to pursue. He may just sit down with an aggressive patent 
attorney and say, "WeU, some sequences have been published recentiy. 
I think we can write out the whole procedure for getting to where we 
want to. Why don't we file a patent appUcation, because all tiie work 
WiU never be able to be done in a time frame that will get us any mean-
ingful protection against otiier parties?" So, a patent application is 
filed. 
For purposes of our analysis today, it would be useful to consider 
a U.S. patent appUcation because tiiat gives you tiie worst-case analysis. 
For a period of 18 montiis notiiing happens. You wiU not see any 
scientific Uterature, press releases or read any accounts in newspapers. 
This is what we would call secret priority. There is no way of knowing 
that it exists. 
All of a sudden 18 months after the U.S. fiUng date, tiiere is a 
European patent or some other eariy publication which gives you tiie 
first clue that something is wrong. 
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JUDGE RICH: Why wouldn't that be a year longer? You have a year to file 
abroad under the convention. 
GOULD: WeU, 6 months after the convention year, which would be a little bit 
before the twelfth month they would file abroad, and then that would 
issue 6 months later, in the first pubUcation. 
VOSSIUS: As an unexamined publication. 
GOULD: Yes, as an unexammed pubUcation laid open for public inspection. 
That is correct. But it would appear in a pubUcation such as Derwent, 
which is circulated and would be avaUable. 
For example, company XL has started a real project, has people 
actively working, and lots of money is being spent. We have achieved a 
positive result. We have a reduction to practice of the fuU process, which 
may involve many steps, obviously, message isolation and perhaps cDNA, 
and then into a plasmid, and then transformation and expression. AU these 
steps are accomplished, we have reduction to practice, and we mn to a 
diligent patent attomey who fUes a U.S. patent appUcation approxunately 
1 week before this pubUcation comes out. 
You are then faced with a dUemma. What are the problems? There 
are two aspects that we have to examme. What is the problem this pa-
tent or its U.S. progeny, if and when it ever issues, would have on our 
freedom to operate? Are they going to get such broad claims that would 
make it difficult for us to operate m our process, if we are foUowing 
the same procedure for the same end point? There, of course, one could 
give certain solace. You could attack the disclosure on questions of 
enablement, inadequacy, and perhaps even get to the point where you 
can say it would be unenforceable, that it could never issue claims that 
would be enforceable agamst your process. 
The second aspect is, what does that reference do agamst your own 
U.S. patent appUcation? Remember now, we are going to be mvesting tens 
of mUlions of doUars to get this product into the marketplace. Your 
management is going to ask you some pretty hard questions as to the 
possibUity of gettmg exclusive rights, before you start plunging m the 
remainder mUlions of doUars into this project. 
You could give your management the opinion that this patent isn't 
worth much in terms of supportmg domuiatmg claims to you, because of a 
lack of proper enablement. There is a different standard for the disclosure 
of that patent for purposes of anticipation. In many mstances this could 
be a very rational disclosure ui the first patent. It could be documented at 
each step by literature references showmg analogy to weU-known steps. It 
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may be exactly the same process you wiU ultimately foUow in your own 
case. You can't attack it as not working, because you have actuaUy demon-
strated that this is a process that wiU work. 
If the disclosure comes out after the U.S. patent has been filed 
there are no problems. But, if a U.S. Patent issues based on the same 
disclosure, and that disclosure is very broad, it speaks as of its filing 
date, and now becomes priority. 
How do you overcome this problem? You can try to use an argu-
ment to convince an examiner that this is not reaUy enabling, because it is 
reaUy paper chemistry, and there is no real manipulative step shown or 
proper conditions, or there may be some genetic engineering part of the 
gene to get it to express properly, or the message may give you a form 
of the active compound, not actuaUy the compound itself. But if that 
can't be done you have to go back to a second potential way of avoiding 
this reference to file a declaration in the U.S. Patent Office, under Rule 
131. 
GOULD: It's now caUed 37 CFR 1.131. You teU the Patent Office tiiat you 
had an earUer conception than the filing date of that patent and that 
people were diligentiy working day and night this whole period with 
laboratory notebook pages to prove aU the steps from A to E. You must 
show that you got a patent attomey and worked day and night to fUe 
the patent appUcation right away. Therefore, this earUer conception, 
coupled with this diligence, to the filing date, would give you a priority 
of invention. 
This is not a very desirable outcome, even if you swear back, because 
it opens you up to possible attack later on. If you said something that you 
shouldn't have or your documentation is unperfect, you can have 
problems later on in enforcing your own patent. 
TANENHOLTZ: It may not mature mto a patent, because if you are claiming 
the same thing, then you have to get into an uiterference. 
GOULD: But I am not gettmg into tiiat aspect. I am reaUy just taUdng about 
sunple 131 practice. 
AU these acts that you rely on have to be in the United States. You 
have a buUt-in bias agamst anybody working in the same manner in a 
foreign country. He has no chance at aU of ever getting behmd that date. 
So this could be a very insidious result to people working abroad. 
SQUIRES: hi that case, you have lost your foreign rights. 
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GOULD: Your foreign rights are lost. I am just talkmg about the U.S. patent. 
In order to avoid the situation, it is yery unportant to have adequate 
records. Record-keepmg becomes extremely unportant both in inter-
ference situations and to overcome situations like this. It has happened 
many tunes over in the molecular genetic field because of the way you can 
predict the sequence of events ahead of time. Secondly, whenever possible, 
do your work in the United States. It is a very parochial statute, but it is 
of advantage. 
WATSON: Why don't you also do the step above? Why don't you do both 
steps? Why don't you foUow the path of firm X? 
GOULD: I think you Would want to seU the product, so you eventuaUy want 
to have the material. Why don't you file early? 
SCHARFF: Why don't you file every time you initiate? 
GOULD: WeU, you can do that, if you want to take chances but it is not a 
strategy I would advise, because it sets the clock mnning. If you really 
want to get meaningful protection around the world, you may not be able 
to do the work in time to put in the necessary particulars. Foreign patent 
offices wiU require, for example, that you put in melting points of the 
material and operating conditions, and you may not be able to get that 
in time. 
TANENHOLTZ: I wiU iUustrate the kind of subject matter that can be pa-
tented by referring to the classification schedule of Class 435, Molec-
ular Biology and Microbiology. Class 435 replaced old class 195 and 
came into existence about 3 years ago. At the beginning of the schedule is 
found the measuring and testuig area and contains subclasses drawn to 
processes involving enzymes or microorganisms and processes of forming 
test compositions. Other assay subclasses are those involvmg a vuus or a 
bacteriophage, and antibody-bmding assays. The largest group of sub-
classes are those devoted to microorganism, tissue ceU culture, or enzyme-
using processes to synthesize a desired chemical compound. Here one finds 
methods of making antibiotics, ethanol, heterocycUc compounds, and 
processes of modifyuig cyclopentanohydrophenanthrene compounds. 
Further on down the schedule, one finds only a single subclass 
devoted to mutation and genetic engmeering. Since that subclass is Usted 
below the chemical synthesis areas m the schedule, any genetic engmeering 
process of preparing a chemical compound is classified for examination 
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purposes in those subclasses devoted to processes of synthesizing chemical 
compounds while those claiming only the genetic engineering of a micro-
organism, for example where you insert some foreign DNA into the 
plasmid, are grouped separately in that one subclass. 
The 435 classification schedule also provides for subclasses devoted 
to carrier-bound or unmobUized enzymes or microbial ceUs. There are 
many subclasses devoted to enzymes, for example, Ugases, oxy reductases, 
ribonucleases, and penicUUn amidase. The schedule also Usts a subclass, 
drawn to undifferentiated animal or plant ceUs, for example, ceU Unes, 
whUe another subclass is devoted to microorganisms per se, including 
protozoa. 
BasicaUy, to create this classification schedule, U.S. patents had to 
be found supporting each subclass. The patents were analyzed and cate-
gorized accordmg to claimed subject matter and finaUy the categories were 
arranged m a hierarchical system. 
I have coUected a group of recentiy issued patents which wiU give 
you some idea as to what we are aUowing. I wUl read a claim or part of a 
claun to give you the gist. 
This is the first patent (4,248,970) to issue on a nucroorganism as a 
result of Chakrabarty. Its claim reads, "A biological pure culture of the 
microorganism Streptosperangium species ATCC3II29, said culture being 
capable of producing the antibiotic complex figaroic acid complex, in a 
recoverable quantity upon cultivation in an aqueous nutrient medium con-
taining assumable sources of nitrogen and carbon." 
Another patent (4,262,090) directed to interferon production, re-
centiy issued in April 1981, and its claim reads *'A method for producmg 
messenger RNA specific for mammalian interferon in amounts sufficient 
to be useful for formation of recombinant DNA capable of transformation 
of microorganisms to form transformants." 
Smce the Cohen-Boyer patent (4,237,224) is weU known I won't 
bother readuig it. 
The famous Chakrabarty patent (4,259,444), claims "A bacterium 
from the genus Pseudomonas containing therein at least two stable energy-
generating plasmids, each of said pUsmids providing a separate hydro-
carbon degradative pathway." 
Another patent (4,293,652) is drawn to, "A method for producing a 
clonmg vector containing a synthesized gene of predetermined compo-
sition and length," et cetera. 
A patent of Roy Curtiss III (4,190,495)-is drawn to a metiiod of 
using his microorganism in a recombinant DNA process. 
Patent (4,080,261) is drawn to, and claims "Endonuclease R Nl 
capable of selectably recognizing specific nucleic acids and cleaving the 
phosphodiesterase bond ui the nucleic acids in at least one non-terminal 
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position to produce nucleic acid fragments havmg discrete molecular 
weight, of molecular weight between 10,000 and 100,000, capable of 
cleaving E. coli phage lambda in five positions." This patent, as you 
recognize, is claiming a restriction enzyme. 
Another patent (4,184,917) is for modifying interferon, and claims 
"A process for the production of a structuraUy modified interferon com-
prising enzymaticaUy spUtting off the termmal galactose unit in asialo-
uiterferon by incubating with beta-galactosidase and recovering the modi-
fied interferon." 
The first plasmid patent (4,273,875) pUC6 for plasmid, owned by 
Upjohn reads this way: "EssentiaUy pure plasnud pUC6, which is charac-
terized by a molecular weight of approximately 6 megadaltons and a 
restriction endonuclease cleavage map as shown in the drawing." 
Patent (4,264,731) is for a DNA joining metiiod, and claims "A 
method of transferring a segment of DNA havmg cohesive ends, having five 
phosphate termiiu, into a microorganism, preparing a plasmid DNA havmg 
cohesive ends complementary to the cohesive ends of a segment of DNA 
and havmg 5' phosphate termini." The inventor. Shine, is from the 
University of California. 
Although no U.S. patent has issued yet, I can read from an abstract 
of an Intemational AppUcation published under the patent cooperation 
treaty. It is drawn to a process for inserting DNA into eukaryotic ceUs for 
producing proteinaceous materials. The inventors are Richard Axel, 
Michael Wigler, and Sol SUverstein. Wigler is from Cold Spruig Harbor 
Laboratory. The number is PCT W081/02426. 
Now, those U.S. patents are typical. If you were to foUow the 
format in those patents, it would give you an idea of how to claim simUar 
subject matter. There may be other ways. The resulting claim language is 
arrived at by a meeting of the minds between the examiner and the at-
tomey. 
DAHLING: In talking with other attorneys, I have found that many have 
received Office Actions requuing restriction. I wonder whether it would 
be desirable for you and the other exammers who work in this technology 
to jouitiy consider restriction requirements and what the best poUcy 
should be. At least then the practice might be more uniform. 
TANENHOLTZ: I reaUy don't have that much control over exammers, other 
than those whom I supervise. So I can only speak for myself and others 
who request my guidance as to how to proceed in that area. 
HALLUIN: For the benefit of those non-patent people, could you explain 
what a restriction is? 
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TANENHOLTZ: A restriction is a procedure where two different inventions 
are separated even though they may be related. The appUcant is forced to 
select which invention he wants to prosecute at that time, and he can hold 
the other one in abeyance and later refile in another appUcation. Some ap-
plications may have only two inventions, others may have more. 
DAHLING: I was thinking specificaUy as to whether the practice of restricting 
a recombinant DNA method from the cloning vectors and transformants 
required to practice the method is poUcy in your area. I think vectors, 
transformants, and theu use, are aU part of the same inventive concept. 
TANENHOLTZ: BasicaUy, we try to handle the subject matter the best way. If, 
in fact, they are divisible, we have a choice. If it is going to be eaaer to 
examine both inventions, sometimes we don't require restriction, even 
though it can be done. We examine aU of the claims. In other cases, it is 
perhaps easier to separate out the different inventive areas, and so we do 
that. There is no set way of handling it. 
PHILLIPS: How many examiners are involved in 435 technology? 
TANENHOLTZ: There are some that examine part class 435 subject matter and 
part other subject matter. There are about five that are exclusively 435 
examiners. There are two other examiners that have dockets in class 435 m 
addition to other classes. 
PHILLIPS: The practicing attorneys m this field are looking at deaUng with 
potentiaUy seven different people. 
TANENHOLTZ: Yes as of now approximately seven. The manner in which an 
appUcation is exammed in the Patent Office must be explained. Techiucal-
ly you can write an appUcation, and even though the subject matter be-
longs in one area, you can include claims in that appUcation to have it 
exammed m another area, where the expertise may be lacking for the 
basic invention. In that situation there would be consultation between 
examiners. 
PHILLIPS: What takes priority in tiie Patent Office over Class 435? 
TANENHOLTZ: If tiiere are tiierapeutic compositions included in an appUca-
tion tiiat is basicaUy 435, molecular biology, tiiat may end up being 
exammed in the medical area. OrdUiarily, a restriction requirement would 
be made. That portion would be excised and we would eventiiaUy examine 
it. In some cases there is an overiap of expertise. 
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BRENNER: What are the legal costs and govemment fees mvolved in securmg a 
patent? 
GOULD: Relatively modest in the U.S., probably between $5,000 to $10,000. 
I haven't really biUed any outside services. 
ROWLAND: I don't think it is that high. 
UDRY: It depends on how compUcated it is. 
DAHLING: For a recombinant case, it can be substantiaUy more than that. 
BERNARD: For example, Al [Tanenholtz] mentioned that he has received 
some cases that are quite lengthy. It aU depends on the time factor. 
Roughly, I would guess anywhere from $3,000 to $10,000. 
JUDGE RICH: Does in-house work m a corporation patent department get 
broken down mto cost analysis for this purpose? 
PHILLIPS: No. 
JUDGE RICH: Nobody reaUy knows what it costs, right? 
BRENNER: I think this is a real question. If one asks, does one patent every-
thmg, then clearly it would cost so much that one wouldn't. 
VOSSIUS: Dr. Brenner, costs may go up considerably if the PTO keeps re-
questing you to divide a case, because they don't have the concept of in-
vented complex. I look at each patent as one single invention. In Europe 
we caU it an invention complex. 
JUDGE RICH: Does anyone want to speculate on the cost of getting the 
Chakrabarty case through, after two appeals and going to the Supreme 
Court? 
HERR: There is some discussion gomg on that the PTO should be more self-
supportmg-that the fees may go up as high $650 for fUuig and $2,000 for 
issuance fees. 
UDRY: The European patent fiUng, which is, I am told, about $2,000 for 
each filing is quite a steep price, but they do incorporate the invention 
complex. 
VOSSIUS: The official fees are rather high, but the prosecution fees in the be-
guming are not that high. 
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DAHLING: There is another factor. It can also be very expensive not to file a 
case if later, for example, 5 years down the line, the invention becomes 
important. I think it is better to err on the side of fUing too many cases, 
even if some go nowhere commerciaUy, than to be overly selective and end 
up missing the few inventions that pay off. If you miss the boat, you could 
be out of luck. 
WILLIAMS: How many patent appUcations do you have in this class 435 in-
cluding non-recombinant DNA genetic engineering appUcations? 
TANENHOLTZ: The overaU figure is approximately 400 to 500. 
WILLIAMS: Have you noticed this number increasing in the past year? 
TANENHOLTZ: No, I wouldn't say any significant increase yet. However, I 
anticipate a flood of appUcations soon. 
McELHENY: For the last 2 or 3 years, you have been dealing with a rate of, 
say, 400 a year. 
JUDGE RICH: Awaiting the Supreme Court decision in Chakrabarty, was there 
actuaUy a holding up of appUcations? 
TANENHOLTZ: Yes, there were appUcations held up for months, even years. 
I thmk they accumulated to a total of approximately 130. Many of those 
appUcations were not exclusively drawn to clainung microorganisms. Some 
of them involved claiming a plasmid, and would have been examined re-
gardless of how the Supreme Court mled but since plasnuds are involved in 
the microbial genetic engineering and Ufe form area, the Patent Office 
decided to hold such cases up to see what the Supreme Court would say. 
JUDGE RICH: The Bergy case went to the Supreme Court and then was puUed 
out. Is the Patent Office foUowing tiie CCPA Bergy decision? 
TANENHOLTZ: That is correct. It is Ulustrated by one of the patents that has 
issued. The Supreme Court basicaUy said tiiat Uving organisms can be 
patented as long as tiiere is some intervention of man. And claiming a 
microorganism as a biologicaUy pure culture means that there was some 
intervention of man. 
JUDGE RICH: That was a real victoiy for Bergy. 
TANENHOLTZ: Yes, tiiat is true. 
JUDGE RICH: As a matter of history, does anybody want to explain why tiie 
Bergy case was puUed out of the Supreme Court review? 
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SCANLON: I do not have authoritative information. I started at Upjohn long 
after the decision was made to remove Bergy from consideration by the 
Supreme Court. The historians wiU need to talk to others for first-hand 
information. 
Bergy had been won twice at the CCPA. So the law, going into the 
Supreme Court, was favorable for securing clauns Uke that at issue in 
Bergy's appUcation—a claim to a man-made, biologicaUy pure culture of a 
species of microorganism found m nature only in association with other 
species of microorganisms. 
Of course, some things were given up in not proceeding with jBeigy. 
In avoiding Supreme Court review, a chance was lost that a definitive 
decision would be made at the highest judicial level on the patentabiUty of 
a claim involvmg livuig subject matter in the factual situation presented by 
Bergy's appUcation. In order to avoid Supreme Court review, the patent 
claim at issue in the particular case had to be canceled. But for the sake of 
pendmg or future appUcations that might have sunUar claims, it was con-
sidered too risky to chance Supreme Court reversal of the favorable legal 
situation estabUshed at the CCPA. 
Now reversal by the Supreme Court of the CCPA's favorable de-
cisions in Chakrabarty would also have made Bergy-Vke clauns untenable. 
So an additional question, given the possibUity that Chakrabarty would go 
forward to a Supreme Court decision, was what the unpact might be on 
that decision of hawing Bergy considered at the same time. 
The facts in Bergy were more compUcated than in Chakrabarty. The 
claim in Bergy involved a man-made culture of an organism that existed in 
nature. Chakrabarty involved a man-made organism per se, without any 
"product of nature" or "purity-impurity" distmctions Ungermg m the 
background. The legal issue of the patentabiUty of man-made, Uving 
subject matter under Section 101 of titie Patent Act, was presented to the 
Supreme Court more cleanly and duectly in Chakrabarty. 
It was not logicaUy possible for the Court to reverse m Chakrabarty 
without also reversing in Bergy. 
It was perceived that the additional complexity, that would have 
been brought to the Supreme Court if Bergy had gone to a decision with 
Chakrabarty, would have decreased the lUceUhood that the CCPA's de-
cision in Chakrabarty would have been affirmed. 
An adverse decision in Chakrabarty at the Supreme Court could have 
seriously damaged the effectiveness of the patent system m "promoting 
the progress of the useful arts." Beyond the Uving-non-living issue, such a 
decision could have, for example, suggested that subject matter embraced 
by Section 101 should not expand along with advances in science and 
technology without expUcit Congressional action. It was of the utmost im-
portance that the probabUity of an adverse decision by the Supreme Court 
in Chakrabarty be mmimized. 
Even if Chakrabarty were affirmed, the additional complexities of 
Bergy made the risk not msignUicant tiiat it would be reversed anyway. 
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perhaps as the result of a compromise decision and particularly if the de-
cision on the fundamental issue presented in both cases, but more cleanly 
in Chakrabarty, were close. 
Given the poUtics and media attention surrounding the two cases 
by the tune they had been decided at the CCPA for the second time, 
the probabiUty of some sort of compromise decision was certamly not 
diminished. 
BasicaUy, as far as I am aware, the decision to not go forward with 
Bergy was a result of such general considerations, that there was Uttle to 
gain and much at risk in keeping the case aUve, not oiUy for Upjohn but 
also for the patent system, science and technology, and society. 
HALLUIN: It was a strategic decision, and lots of members of the bar were 
consulted, for a cross-fertUization of opinions. 
O'NEILL: Can the same be said of why GE spent so much money prosecuting 
the Chakrabarty case? 
HALLUIN: I won't comment on that. 
WILLIAMS: Al, does your classification include plant genetics in 435? 
TANENHOLTZ: Only to the point of geneticaUy modifying plant ceUs. 
WILLIAMS: Does that include protoplasts? 
TANENHOLTZ: Yes as weU as just plant ceUs themselves. And growing plant 
tissue is also included in class 435. If it becomes a plant, then it goes 
someplace else. 
HALLUIN: There has been a controversy on the issue of depositing of die 
microorganisms. A number of years ago you had to make a deposit of a 
microorganism to comply witii tiie formal requirements under 35 U.S.C. 
112. We have a new area right now in tiie area of plasmids and different 
types of gene fragments. The question of avaUabUity has been questioned. 
Do you personaUy view this as a problem? Do you require people to prove 
avaUabUity of certain plasmid strains as starting materials for fmal 
products? 
TANENHOLTZ: Basically, tiie same criteria tiiat we used for known naturaUy 
occurring organisms would be used for geneticaUy engineered micro-
organisms, as far as tiie host is concemed. If you can produce tiie host 
from known and available organisms, tiien you don't have to deposit. The 
same tiiuig witii a plasmid. if you can produce tiie plasmid and guarantee 
that you can produce it, you don't have to deposit it 
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HALLUIN: WeU, I hear from these distmguished gentiemen that that is not 
reaUy so clear. These are biological organisms. You don't know that you 
are gomg to get exactly the same thmg every time. 
TANENHOLTZ: But the sUght changes and differences don't appear to affect 
whatever use it is put to. 
JUDGE RICH: In other words, one of the pouits in your exammation is, after 
you have read the specification you have to make a decision on that point, 
as to whether or not there should be, in practicaUy every case, don't you? 
TANENHOLTZ: Right. 
PHILLIPS: How about a practice where you make a deposit, but you don't 
identify it unless you raise the issue? 
TANENHOLTZ: WeU, you have to determme whetiier the culture is avaUable 
to the pubUc. If it is not, you raise the issue. Even if you feel it may, in 
fact, be avaUable, but you don't know for certain from the disclosure the 
question should be raised. 
JUDGE RICH: What is the U.S. law? Does it have to be deposited in this 
country? Does the depository have to be a U.S. depository? 
TANENHOLTZ: No, it does not. 
ZINDER: Since the goal is to have the engineered organism avaUable to the 
pubUc, it seems to me the simplest way to achieve that end would be to 
have aU engineered organisms deposited, rather than to have the pieces 
available or attemptmg to reconstmct the organism from the description. 
It wouldn't hurt just to have all the organisms deposited. 
GOULD: I don't think that is an accurate depiction. You are under a requue-
ment to make the organism avaUable. You have to make your disclosure 
of how you made your organism avaUable. 
HERR: Perhaps at this point m the discussion it would be useful to have some 
comments on the relationship between universities and industry, particu-
larly big industry, as viewed from the perspective of one who is associated 
with industry. You heard from Roger Ditzel that academia was passing the 
baton to industry. WeU, I think industry would like to pick it up, but I 
think, in aU tmthfuhiess, if the universities and the medical schools hope 
industry to fund projects to the same extent that the Federal Govemment 
has been funding them in the past, I think you may be incorrect. I don't 
thiiUc that industry reaUy can afford to do that. 
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From an industry standpoint, of course, they Uke to have exclusive 
Ucenses. They Uke to pay tow royalties. Their purpose is to maxinuze 
profits, whUe the university's purpose is to train students and disseminate 
mformation. 
I don't think numy people in industry feel that the universities 
should be put under any pressure to retain trade secrets. But they do feel 
that it is reasonable if there is a delay so that industry can go ahead and 
get their entue patent portfoUo into shape before there is any pubUcation. 
Large companies are generaUy not as fast as Genentech in getting cases 
fUed simply because there tend to be more internal procedures to deal 
with. They feel it is more reasonable to request anywhere from 3 to 9 
months to get aU the filings in shape, partkularly around the world. 
There is a concem, and perhaps it is not shared by aU other 
companies, that arises when the imiversities are funded by the Federal 
Govemment and those funds are comingled with funds that are received 
from industry. Often this causes the period of exclusivity to be Unuted, 
possibly from the start of the contract ot from the date of conunercial-
ization. 
Most companies would, of course, like to have exclusivity extend as 
long as possible, but they realize at times that there may be a need to put 
a limitation on this. StiU, they have a concem about march-in rights. If 
one is dUigentiy trying to produce the product he isn't anxious to have 
somebody else step in and take away the exclusivity. 
There is a realization that industry should be diligent in trying to 
commercialize a product. Therefore, if at times you need to insist upon a 
buUt in encouragement, such as minimum annual royalties, this may be 
acceptable m some mstances. It has been our observation that many 
universities do not want to negotiate a defiiute royalty rate untU the 
specific invention is actuaUy made. 
On the one hand, industry is delighted at being able to employ ex-
perienced faculty members. On the other hand, universities are troubled 
about the loss of faculty to industry.. Thus, we have tried a number of in-
novative steps to help academia keep top-quaUty people, for example by 
sponsoring research with few ties and with no direct control over the 
activities of a principal investigator. We hope that by doing so the frontiers 
of science wUl continue to be pushed back. 
I want to just mention two other things briefly. There hasn't been 
much said about the NIH guideUnes and the safety aspect. I don't want to 
spend much time on it, but there is a concem that I have found among 
other people m mdustry about the fact that if the Federal guideUnes are 
disposed of, then the local, state, and county governments may want to 
pass ordUiances against this type of research. I think you, as members of 
the bar or the scientific community, may want to consider if there are any 
steps you may wish to take in respect of this issue. 
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JOHNSON: NIH itself has a responsibiUty, I think, if they approve the decision 
in January. Dr. Krause and the RAC (Recombmant DNA Advisory Com-
mittee) should make a very strong statement that they don't think that is 
necessary. 
HERR: That would be very helpful. 
JOHNSON: It is certainly being discussed. I think they have a responsibiUty to 
doit. 
WATSON: Could we keep one symboUc guideline? 
ZINDER: The NIH guidelines are not going to disappear right now, so we 
needn't be concemed about it. Even if the NIH guidelines disappear, 
RAC would not disappear, since it is chartered by the Secretary of Health 
and Human Services. 
As currently projected, the NIH guidelines wUl exist as guidelines, 
not regulations. That means they wUl refer to everybody, mcluding in-
dustry. There wiU stiU be some few prohibited experiments; I think they 
are going to caU them admonitions, some toxin insertion experiments and 
also some antibiotic insertion experiments. 
There wiU be a recommendation that one generaUy foUows the CDC 
(Centers for Disease Control) guidelines with regard to containment. 
JOHNSON: The CDC guideUnes are bemg rewritten, I beUeve, are they not? 
ZINDER: Yes. EssentiaUy what the NIH guideUnes are going to say is that the 
containment should be appropriate to the most dangerous component of 
the recombmant DNA experiment. That is essentiaUy something that Hans 
Stettin recommended some years ago. 
There wiU be guidelines which everyone wiU be obliged to foUow. 
The main argument for retention of any guideUnes was to prevent 
local situations from getting out of hand. I don't think we should hold on 
to the NIH guidelines. They refer to the scientists and not people in in-
dustry. If there is any movement at this tune, I beUeve it wiU not be 
against the scientists, it wiU be against the industry. 
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BERNARD: My initial role is to estabUsh the background and the scenario for 
other speakers and then cover other areas of topical interest. 
Since some thougihts have been raised about how to deal with 
changes resulting from a new technology, I wiU provide an overview of our 
system to help clarify some points already raised. Everything starts with 
the Constitution, Article I, Section 8. Its purpose is to promote and 
advance the arts and sciences and to provide the right to exclude others 
from the use of your invention for Umited tunes. 
Starting with that charter, we then arrive at the legislative branch, 
which is one of our three branches. In the legislative branch, the patent 
law we have been dealing with primarUy is the Patent Act of 1952. Judge 
Rich is the author of that act and his personal involvement in that act, of 
course, represents a number of years of effort, and is based upon his 
experience in private practice. 
Anotiier law that I wiU discuss involves govemment patent poUcy 
and was enacted in the last session of Congress. By govemment patent 
poUcy, we are referring to the government's participation in the sponsor-
ship of contract research. EssentiaUy, we are aU talking about one thing: 
the government's attitude toward the right to exclude in connection with 
what it does in government-sponsored research. 
The focal point of the executive is generaUy in the Office of Science 
and Technology PoUcy. With the enactment of the law, the executive is 
responsible for implementing it. Frequentiy, there are differences between, 
perhaps, the executive and the legislative branches, or more generaUy with 
people Uke us who are dealing with the law. It requues interpretation, so 
we generaUy go to the court system, namely the judicial branch, for that. 
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Sometimes, we beUeve the court system and the court have not 
interpreted the law properly. Or, we contend that present needs dictate 
revisions in the law. In these instances, we request the legislative or execu-
tive branches to review the law, consider changes in certain provisions, and 
possibly to uiitiate new legislation. In this process, differences often arise 
among the competing branches of govemment and nongovernment groups 
as different positions are expressed in the fomiulation of new poUcy. 
Thus, the legislative branch acts as an information-gathering conduit for 
determining what form legislation should take. 
In the government patent poUcy area, as I have just described it, we 
have had a tremendous amount of activity since World War II. In that ac-
tivity, the attitude of Congress has influenced the shape and content of the 
law. That attitude varies from time to time. As it was initiaUy conceived, 
the concept was that if the govemment sponsored research, it should take 
title back. That attitude has prevaUed untU just recentiy. 
What has caused it to change? WeU, about 5 or 6 years ago, you 
started reading about the tremendous deficit in the balance of payments. 
Suddenly Congress became acutely aware that the United States had de-
veloped a considerable amount of technology that had not been com-
mercialized. The government possessed approximately 28,000 patents. Of 
the inventions in those 28,000 patents, only about 4% had been com-
mercialized. 
What happened? Education constituted one area of disagreement 
and debate between the govemment and a competing sector; an examina-
tion of federal grants to imiversities reveals the contradictions inherent in 
government-sponsored research on coUege campuses. As the govemment 
started furnishing fimds for sponsored research, one of the sectors that 
received money was universities. Universities had historicaUy particq>ated 
in research anyway. Now, however, the govemment created a problem, 
because when it approached a university, it said to the people receiving 
grants, "WeU, look, whatever you do belongs to us in titie." 
In the meantime, those at the university who conducted research 
had a conflict. The issue concemed the presupposed aUegiance of re-
searchers under arrangements with the universities for research projects. 
When researchers were dealing with a university, they generaUy secured 
arrangements with that imiversity under which they passed titie to the 
university entity. In other words, the researchers were responsive to the 
university which through some means attempted to Ucense and transfer 
technology in order to acquire revenues. Yet, the issue became cloudy 
when researchers worked on a project supported by federal monies, 
namely a government-sponsored program. In this case, the central 
question remained unanswered: Were coUege researchers involved in 
government-sponsored projects under the auspices of the federal govem-
ment or the local university? 
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About this tune, the so-caUed contamination theory evolved. The 
contamination theory stated that any individual conducting research with 
govemment money must tum over aU fuidmgs and data to the govern-
ment. Proponents of the contamination theory encountered strong opposi-
tion from groups in educational cucles who pubUcly denounced this 
theory. In view of their background in education, the university groups 
carried credibUity with the members of Congress and precipitated revisions 
Ul laws govemuig federaUy-funded research projects. FinaUy, months of 
debate and cajoling culminated in the proposal of an institutional patent 
agreement (IPA) under which university researchers could enjoy exclus-
ivity for government-sponsored programs. 
Years later Senator Birch Bayh (D.-Ind.) introduced the foremnner 
of this govemment poUcy law. In it, he unveUed a startling statistic— 
of 28,000 govemment-owned patents, less than 4% were commercial-
ized. But then Bayh noted that, with respect to the universities, where 
exclusivity had been provided, about one-third of their patents covered 
inventions which were commercialized. Suddenly the right to exclude and 
its significance emerged from the shadows of doubt and came into 
prominence. 
This led to an appreciation of another factor which encouraged 
further refinement of government patent poUcy laws. This was the recogni-
tion of the high risk and costs for commercialization. Burdened by the 
high risk and costs for commercialization, those with nonexclusive rights 
to inventions had an increasingly difficult time attracting potential in-
vestors to assume financial responsibUity for a particular project. 
The increasing costs of govemment regulation added significantly to 
the high risk and costs for commercialization. This can be exemplified 
with the Food and Dmg Law. UntU mid-1960's, one need only show that 
a prospective pharmaceutical was safe to obtam govemment clearance. 
With the 1964 amendments to the Law, one had to also prove the effec-
tiveness of a given product; this added significantiy to the costs and time 
requued for conunercialization. Therefore, I want to emphasize that 
govemment regulation has taken an increasingily active role in the com-
mercialization of inventions. BUl O'NeiU substantiated this statement 
yesterday in his discussion of commercialization of a dmg. As BiU 
mentioned, obtaining governmental clearance may take 8 or 9 years and it 
wiU require about $75 milUon. On top of this cost sales for a successful 
commercial product must exceed $75 mUUon per annum. We are aU weU 
aware that averaging a retum of $75 mUUon a year in revenues is no easy 
task. 
In summary, as we reflect on the low rate of commercialization of 
govemment-owned inventions, the rising costs of research and develop-
ment, and the mcrease m governmental regulations, we must ask ourselves: 
What uicentives exist for mvestors to finance a real high-risk and costly 
288 / E. L. Bernard, N. E. Noonan, and G. M. Karny 
endeavor? The more we ponder this question, the more we may appreciate 
the right-to-exclude provision. Undoubtedly, Congress, in recent years, 
has developed a greater understandmg and appreciation for the right-to-
exclude concept. WhUe Congress would not have initiated major patent 
poUcy reform 4 years ago, it has lately introduced two bUls, the Schmitt 
and Ertel bUls, which comprehend big business, as weU as smaU busmesses, 
universities, and not-for-profit institutions comprehended in PL 96-517. 
With this brief review of patent poUcy, Dr. Norine Noonan wUl 
teU you a Uttle bit about her background and where we stand today on 
govemment patent poUcy. 
NOONAN: As a novice in this whole field I wish to emphasize that science 
poUcy has always been an interest of mine. I got involved in it quite 
recentiy but my background is basicaUy as a scientist. I really am 
associated with one of the subcommittee staffs—the Science Research and 
Technology Subcommittee. Our subcommittee chairman is Doug Walgren 
from Pennsylvania. George Brown from California was his predecessor, 
and is stiU on our subcommittee. Our fuU committee chairman is Don 
Fuqua, who has been very interested in aU areas of science and technology, 
particularly, energy research and appUcations and space science, smce 
Florida has a great investment in space science technology. 
The Science Research and Technology Subcommittee is one of 
seven of the fuU comnuttee. We basicaUy do everything associated with 
science research and the impact of that research on technology. It is a 
rather broad mandate for the subcommittee. In 1981 we touched on four 
areas of relevance to many participants. The hearings that we have had this 
year include 2 days on the commercialization of biotechnology. We have 
also had hearings on human factors in innovation. The area of innovation 
and productivity, particularly as it relates to high-technology fums and 
smaU business is one of our special areas. We also had hearings on altema-
tives to animals in research and testing. Lastiy, our patent hearings, which 
were fuU committee hearings, or, more correctiy, joint hearings with the 
Senate Committee on Commerce, Science and Transportation were chaired 
by Senator Harrison Schmitt. Most of our hearings are joint hearings since 
we act m an advisory capacity to many other committees and subcom-
mittees as they carry out theu legislative mandate. Our investigations and 
oversight subcommittee, however, has no legislative authority. 
In any case, the Schmitt and Ertel bUls, which are currently under 
consideration-Mr. Ertel is a member of our fuU committee, and Senator 
Schmitt is, of course, the head of our counterpart comnuttee over on the 
Senate side-my perception of this is that these bUls have come out of a 
feeUng that the patent poUcy, with respect to the Federal agencies, has 
been so diverse that many tunes it has been unpossible for projects jointiy 
funded between two Federal agencies to come to any kind of an agree-
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ment when the time comes to Ucense an invention. The Department 
of Energy (DOE) and the Department of Defense (DOD) have marked-
ly different poUcies on who retains titie. The National Institutes of Health 
(NIH) of course, and the National Science Foundation (NSF) have been 
very Uberal for some tune on retummg title to mventions to theu re-
spective grantees. BasicaUy, the Schmitt and Ertel bUls repeal part of 
PL96-517. In both bUls is a specific statement that repeals the portion 
of PL96-517 that specifies retum of patent title to universities, not-for-
profit institutions, and smaU businesses. The biUs don't repeal aU of 
PL96-517, only that specific section of it. Both biUs deal with the favored 
position now granted only to universities, not-for-profit institutions, 
and smaU business. SmaU businesses are anything less than $25 miUion 
in sales. I think that probably encompasses a few participants at this 
meeting. 
In any case, in repealing this portion of PL96-517, the bUls sub-
stitute the provision that all Federal contractors, grantees, whoever re-
ceives Federal money, wiU be treated exactly the same way. That is, the 
bUls just substitute the word "contractor" for the words "university," 
"not-for-profit institution," and "small business," such that McDonneU-
Douglas is now on the same footing with Litton Bionetics or anyone else. 
I thmk primarily this language came about due to the fact that the 
big defense contractors, since they could not retain title to theu inventions 
that they came up with, or rather title to the patents, were very reluctant 
to make the large investment necessary to commercialize any of these 
patents. Many of those 28,000 Federal patents not conunercialized I 
think, are probably defense-associated. Moreover, the DOD has been very 
reluctant to sign over any of theu rights. They have also been reluctant to 
give up any of the money in their budget. 
In any case, the two biUs are basicaUy the same. There are some 
differences, but the differences are probably not ureconcUable. The two 
biUs have the same major provisions, i.e., aU Federal contractors wiU re-
tain titie to any patents developed within whoUy-operated Federal re-
search faciUties or laboratories, lUce LASL (Los Alamos Scientific Labs) 
or Lawrence Livermore Laboratory; Federal contractors wiU also retain 
title if national security interests must be protected, or in exceptional cir-
cumstances where the health, safety, or welfare of the general public is at 
stake. 
Other than that, the contractor has the first option on title to any 
patents. The House bUl (Ertel) specificaUy states that the Govemment 
retains titie if the contractor elects not to fUe for it. In other words, if 
Stanford University elects not to fUe a patent on a specific invention or 
discovery, the Federal Government (NIH probably) would retam title 
specificaUy. The Senate bUl (Schmitt) provides no specific statement that 
the Government would retain title if the contractor elects not to file. 
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Probably the most disparate provisions of the biUs concern who 
wiU implement this legislation. In the Ertel biU, implementation faUs 
to the Office of Science and Technology Policy, which, of course, is 
the executive arm for science and technology poUcy in this Govemment. 
Within that office, it is the Federal Coordmating CouncU for Science, 
Engineering and Technology. Mr. Schmitt's biU gives aU of the imple-
mentmg authority to the Department of Commerce, specificaUy, the 
Secretary of Commerce. 
JOHNSON: Do these two bUls retain the sort of language that is about the in-
ventor having to notify within a certain period of time? 
NOONAN: There is no specified period of time in which the contractor must 
notify unless it is already in the contract. That question may be covered in 
the implementing regulations. Both do retain the provision that was in 96-
517 of nondisclosure of proprietary mformation under the Freedom of 
Information Act (FOIA), so that the companies have an mcentive to fUe a 
patent and not risk disclosure to their competitors under FOIA. 
To retum to the differences in the two bflls: The Ertel biU aUows for 
judicial review of disagreements between contractors and their respective 
agencies. In other words, if McDonneU-Douglas and the DOD can't come 
to an agreement on who owns the patent or who wishes to own the patent, 
or have a disagreement over it, there is a provision for judicial review. Mr. 
Schmitt's bUl provides that the Secretary of Commerce wUl mediate those 
problems and come to some sort of consensus. In addition, HR 4564 man-
dates royalty payments by the contractor to the Govemment-in other 
words, recoupment for the cost of the development-with the exception of 
universities, not-for-profit institutions, and smaU businesses. They do not 
have to pay the Government back. Mr. Schmitt's bUl has no such provision. 
Judging from the hearings, the Administration does not support the 
recoupment provision. So when the committees come to some sort of a 
consensus, Mr. Ertel's recoupment provision may drop out, as might the 
provision for judicial review. 
Other than that, the two bUls are basicaUy the same. Both bUls have 
the same provision with respect to how one defmes a contractor, and both 
bUls contain simUar provisions for march-m rights, although the Senate bUl 
provides for a formal hearing before any march-in rights are exercised. 
However, this provision has been rarely, if ever, used-I can't think of a 
case where it has reaUy been used-1 don't tiunk anybody has to worry 
too much about it. The government basicaUy writes nice letters and asks 
if you want tiie patent, and if you don't, asks you to retum it to them. 
We had one day of hearings on September 30th and I got the feeUng 
that tiie Admmistration supports tiiis legislation. Dr. Keywortii testified 
tiiat botii pieces of legislation are consistent witii tiie Administration's 
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economic recovery program. He does think the recoupment provision 
should be left out, and his position was supported by the General Counsel 
of the Department of Commerce, who also testified as did Mr. Mossing-
hoff, the Commissioner of Patents. Mr. Mossinghoff explained that there 
is a backlog of 200,000 appUcations from 1980 that have not been 
processed and that the backlog is growing by 10% annuaUy. Perhaps 
they wUl squeeze some additional money out of the budget to unprove 
theu system. 
Mr. Ertel's bUl goes to fuU committee markup on October 29,1981. 
Mr. Schmitt's bUl is in the Senate. No formal date has been set for it, but 
I suspect that it might be done before the end of the session. The com-
mittees probably won't come to any sort of a resolution on the differ-
ences. I was told the language wUl be cleaned up and some amendments 
are expected in Mr. Ertel's bUl. Schmitt's bUl is the shorter, cleaner version 
of the two. It wUl be ptobably be used as model for the Ertel biU. I suspect 
by spring 1982 this legislation wiU replace PL96-517 as the uniform 
Federal patent poUcy. 
KARNY: How much is RusseU Long going to have to say about the passage? 
NOONAN: Both Senator Long and Admiral Rickover (who also testified at the 
hearings) are in agreement. They both feel that the Government should 
retain titie to aU patents developed with Federal money, no matter who 
develops them. I am sure that would include universities, not-for-profit in-
stitutions, and smaU businesses as weU. I don't know how much Senator 
Long wiU have to say about this. He was critical about it then, but not 
reaUy vehement. 
KARNY: Can he block it in committee or on the floor, if he reaUy wants to? 
NOONAN: The Democrats don't have a majority m the Senate anymore so I 
don't think he wUl be able to block it. I thmk there are enough people 
who cross party lines on this kind of issue. 
JUDGE RICH: I thuik I can predict what he is gomg to say, that it is a $50 
bUUon giveaway of taxpayers' money. 
NOONAN: Right. However, I think Mr. Schmitt's answer to that wUl be that 
we are gomg to get aU that back from taxes on mventions that have been 
processed and put on the market, and we have to give Federal contractors 
some incentive to develop theu patentable inventions. 
Included m PL96-517 is a provision for "limited exclusivity"-uni-
versities and smaU businesses are prohibited from exclusively Ucensmg 
theu mventions for greater than a period of 5 or 8 years dependmg on the 
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regulatory agencies. If the invention must be approved by FDA, for ex-
ample, the patentee can license for 8 years. 
JOHNSON: That is one of the things wrong with this bUl. 
NOONAN: Correct, 8 years is not enough time for big dmg companies to 
recoup theu mvestment and development costs. However, that provision 
drops out in both biUs. The elimination of this provision, in fact, should 
help in situations where limited exclusivity has been a blocking factor to 
the marketing of certain products. 
UDRY: Can't you go beyond the eight-year Umit under certain circumstances? 
I think Niels has done that, haven't you? 
REIMERS: We have petitioned for an extension to that and gotten it. 
UDRY: For how long? 
REIMERS: It depends on the circumstances. The clock starts tolling from the 
date of first commercial sale, and I think we have had them 8 years from 
first commercial sale. 
DITZEL: Yes, but PL96-517 provides for extension of that 5- and 8-year 
period for the time required for regulatory review. You reaUy can get 
more than that to meet the concems. 
How many cosponsors were there for the Schnutt and Ertel bUls? 
In the Dole-Bayh bUl there were a lot of cosponsors. 
NOONAN: Schmitt had about six. 
KARNY: It looks lUce for Ertel there were ten cosponsors, as of October 15, 
and five on Schmitt. 
BERNARD: I might mention tiiat both of tiiose biUs were introduced on 
September 23,1981. 
NOONAN: This has moved fauly rapidly. 
BERNARD: Noruie, would you care to comment upon tiie implemenUtion of 
regulations for 517? 
NOONAN: I think tiie universities are probably not too happy about tiie cur-
rent state of tiie implementing regulations. The regulations tiiat were 
promulgated-at least tiie one tiiat I know about tiiat is making people 
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fairly unhappy—requue that the contractor, i.e., university or smaU 
business, notify the Govemment 3 months before the date of pubUcation 
if the university . . . 
DITZEL: Submission for consideration. 
NOONAN: Submission for publication, yes. WhUe the paper is being thought 
about they have to notify the Govemment and aUow the funduig agency 
to decide whether or not they wish to fUe a patent appUcation. 
BRENNER: That is SO that the foreign rights can be picked up. 
NOONAN: Exactly. This regulation, however, is optional with individual 
agencies. For example, if NIH does not wish to force that regulation on 
theu grantees, it doesn't have to. The DOD, on the other hand, wiU 
probably do it posthaste. 
UDRY: NIH has announced that they are opting for the altemative. 
NOONAN: Yes, in fact, this is not gomg to present a problem. They wiU opt 
for some alternative method. 
As for DOE—aU I know is what I read in the papers-apparently a lot 
of people may be lookuig for new jobs by January 1,1982. 
GOULD: Who wUl take over theu patent functions? 
NOONAN: I reaUy don't know. Things seem to be m such turmoU, quite 
frankly, at those agencies. I don't thiiUc a lot of determinations have been 
made with regard to specific functions. 
HALLUIN: Do you know the status of some outstanding contracts that are stiU 
being worked on at DOE? Is there any indication of what is going to hap-
pen to the remainder of those contracts that go beyond January 1? 
NOONAN: WeU, I don't thmk this new legislation wUl be in effect by then. The 
Congress has so much else to do. Moreover, there has been no real action 
on the Schmitt bUl. My guess is that the effective date won't be January 1, 
but rather sometime in the Spring, during the second session. PL 96-517 is 
StiU the law right now. 
JUDGE RICH: You admitted you are kind of new at this business on Capitol 
HiU. Anybody can mtroduce a bUl. There is no problem about bUls. I have 
seen thousands of biUs. And you have your hearings. I have seen many 
hearings on many bUls, and that is the last you ever hear of them. So what 
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can you say about the prospects of either one of these bills moving in 
either committee? Who is going to have the next move on them? Are they 
in subcommittees? 
NOONAN: No, they are both in fuU committee. 
JUDGE RICH: Have the fuU committees acted on them in executive session? 
NOONAN: The fuU committee takes Mr. Ertel's bUl to markup at the end of 
October. I think that there is enough support m the Administration. The 
Administration is very concemed about iimovation and productivity, and 
they see this legislation as a way to improve the U.S. position worldwide. 
Keyworth, although he has not been extremely effective yet, does speak 
for the Administration on science and technology poUcy. I thiiUc the Com-
merce Department is behind this, and Keyworth is behind it, as the Office 
of Science and Technology PoUcy, the patent people, and the GAO. The 
ComptroUer General testified, as did the general coimsel for 3M, and they 
were behind it. So, you know, one industry representative supports it—big 
industry. It is my personal opinion that, barring some catastrophe, these 
wiU go through. However, you are right in your assessment. Look at the 
recombinant DNA act. That legislation sort of sUd into obUvion after 
much debate and pubUcity. 
JUDGE RICH: WeU, it was kind of a muacle that 96-517 got enacted as fast as 
it did. Maybe there is some hope. 
KARNY: WeU, "mnovation" is a real buzz word in the Congress right now, and 
Ertel is pushing his bUl pretty strongly. So there may be a steamroUer 
effect. 
NOONAN: Yes. The Members would Uke to be able to say they did something, 
other than argue over the budget, this session. 
DITZEL: What provisions are tiiere for effective date in the Senate and House 
biUs? Are tiiey gomg to be lUce 96-517, effective essentiaUy 6 months after 
they are passed? 
NOONAN: Yes. 
DITZEL: We have a real interim problem at universities. There wUl be two sets 
of regulations under 96-517. There wUl be overlapping inventions. Is tiiere 
gomg to be wordmg to give tiie agencies flexibUity in deaUng witii tiiose 
problems? 
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NOONAN: Both of these repeal those provisions of 96-517. As soon as they are 
passed, 96-517 is repealed and this act would take effect on the first day 
of the seventh month after date of enactment. 
DITZEL: Where does that leave me for the invention that arises today, with no 
law at aU? 
NOONAN: Accept that regulations implementing these biUs may be issued 
themselves prior to that date. Even though the act may not take effect 
for 7 months, the implementing regulations may be in effect before 
that time. Amendments may be introduced that would take care of this 
problem. 
DITZEL: But it would repeal 96-517 as of the effective date of the new law. 
It would not repeal it retroactively. 
KARNY: I think the procedures are going to carry forward pretty much. Con-
ceptuaUy, you are just applying 517 to large companies, in addition to 
smaU businesses. The regulations wUl probably continue to develop. 0MB 
published a bulletin (81-22) on proposed regs implementing that. I think 
they wUl be modified if the bUls are passed, but not m substantial ways. 
The NIH advisory committee to the duector has pubUshed an uiterim re-
port on some of the issues. It is bemg revised. 
DITZEL: Okay, but that agam gives rise to another problem. With 96-517 we 
tried to stay away from 26 different agency regs and mterpretations. If 
NIH and other agencies pubUsh theu interpretation of the OMB regs, we 
wUl be right back where we started. What you are saymg scares me a littie 
bit. 
NOONAN: But you had that same problem with 96-517. With 96-517 not only 
were the unplementmg regulations dtfferent, but the overaU patent poUcy 
differed from agency to agency as weU. 
UDRY: Is there any oversight legislation going on concurrently with this? 
NOONAN: Not as far as I know. Investigations and Oversight is looking at some 
of the things that are happening in industrial genetic screenmg. 
BERNARD: Geoff Karny, an attorney with the Congressional Office of Tech-
nology Assessment handled the legal work on OTA's recent report on 
genetic engmeering. He wiU update us on the status of legislation in the 
plant varieties area. 
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KARNY: I would Uke to use plant varieties as a springboard for taUcing about 
legislation duected toward patenting Uving organisms in general. This topic 
wUl be broken into three parts: the outlook for that type of legislation, 
what kinds of problems and issues need to be addressed, and if they were 
addressed by a statute, what that statute might look Uke. I should note 
that the views to be expressed are my own and not necessarily those of the 
Office of Technology Assessment. 
As far as the outiook, I think I can put it fairly succinctly by re-
lating a discussion I had earUer. One of the participants referred to the fact 
that I was a speaker this morning. He said, "Are you going to teU us 
whether or not the Govemment is going to put it to us?" The short 
answer to the question is no, the Govemment is not going to put it to you, 
unless you ask for it. 
What I mean by that is that there is reaUy nothing happening, and 
Congress presentiy has Uttle interest in specific legislation on patenting 
Uving organisms. However, if there is outside pressure in the form of 
"the pubUc" getting concemed about patents on organisms other than 
microorganisms, or if it tums out that Chakrabarty either raises questions 
not readUy resolved on a case-by-case basis or leads to substantial Utiga-
tion, and if the patent bar pushes for legislation or drafts bSls, then 
Congressional activity is likely. But right now there is no real interest. 
I would like to address some of the problems and questions that 
have been raised by this new technology and ask whether or not a case-by-
case approach by the Patent Office and the courts would be the best way 
to resolve them, or whether a statutory approach might be better. 
The first major problem or issue that I see being raised is, how 
broadly wUl the Chakrabarty case be interpreted by other courts? I 
thmk the Chakrabarty case is authority for the patenting of any living 
organism, assuming the other requuements of the patent law are met. 
Of course, I am not talking about humans. 
For complex, multiceUular organisms, however, there might be a 
real problem with enablement, a problem we have taUced a lot about at 
this meeting. 
JUDGE RICH: We know that Chakrabarty decided that the microorganisms in-
vented by Mr. Chakrabarty were within Section 101 that says that any 
person who has mvented a new and useful process, machine, manufacture, 
or composition of matter may be patented. The issue was, is the miao-
organism of Chakrabarty either, or both, a manufacture or a composition 
of matter? The question, for example, is going to be, as a practical mat-
ter, is a cow a manufacture or is a cow a composition of matter? Or is 
a human, or a dog, or a monkey, a composition of matter or a manu-
facture? That is the real issue witii respect to Chakrabarty. Why do you 
tiiink Chakrabarty changes tiie situation tiiat preexisted in any way? 
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The patent that Stanford University is now commercializing would 
have issued without regard to CMkrabarty. It did issue without regard to 
Chakrabarty, and now they are commercializing it. 
It is a process patent. Chakrabarty had a process claim, a process of 
makmg the organism, the process of using the organism. Without regard to 
that case, with which I had a Uttie to do, the patent would have issued 
anyway if they had dropped the product claim specific to the organism 
itself. 
KARNY: I understand that, but what I am talking about is patenting the Uvmg 
organism. That is what I want to duect this discussion toward. 
JUDGE RICH: The real issue wasn't whether the orgaiusm is patentable under 
the statute in complying with the novelty and nonobvious provisions. The 
real issue was: do you get through the first door by getting through 101? 
Is it within the categories of subject matter which may be patentable? 
Once we said yes, and the Supreme Court agreed, the Patent Office had 
nothing to show that it was not new or not unobvious, the patent came 
out forthwith. I think it is important to realize what reaUy happened. 
KARNY: I think that Judge Rich has stated the issue more narrowly than I 
had. Essentially, I was trymg to address the patenting of living organisms 
and what types of issue might arise therefrom. 
OTA is charged with looking at the broad unpacts of technology. I 
am trymg to look towards the future and move away from a case-by-case 
approach of patent lawyers in order to deal with broader pubUc policy 
issues. I want to discuss whether or not we should be specifically pro-
tecting other forms of Uving organisms besides plants or besides microor-
ganisms; whether or not Chakrabarty has resolved that issue; or whether or 
not we need to provide specificaUy for patenting, for example, animal 
breeds, like the Hungarian patent law provides for, by statute. 
BERNARD: I gather that the suggestion you are addressing, Geoff, is whether 
we should take overt action now or whether we should exercise patience 
and restraint. If we act now, I assume our goal is to initiate something ui 
the form of a broad-ranging statute; conversely, if we wait, I presume our 
objective is to study selected cases on an individual basis, namely in a 
piecemeal fashion. Then, if we are not pleased with the results, we can 
seek legislative reforms. 
KARNY: Yes. For example, in another 5 years, it may be possible to deal with 
the problem of enablement in patenting cows by depositing embryos or by 
using tissue culture. Alternatively, we can deal with the problem of enable-
ment by statute, taking the approach in the Plant Patent Act of 1930, 
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which simply requues the description for making the mvention as "com-
plete as is reasonably possible." 
DITZEL: Would you require asexual reproduction for anything patented, to 
ensure constancy of Une, or hope to? I bring that in only because the Plant 
Patent Act Umits it to asexual. 
KARNY: At the time the Plant Patent Act was passed in 1930, it was beUeved 
that sexuaUy reproduced varieties could not be produced tme-to-type. 
Therefore, to deal with this problem. Congress permitted patents on 
asexuaUy reproduced plants only. As the technology progressed, or per-
haps as Congress leamed more about the technology, it became clear that 
sexuaUy produced varieties of plants could be reproduced tme-to-type. 
Therefore, in 1970 Congress passed the Plant Variety Protection Act, 
which provides patent-like protection to sexuaUy reproduced plants. 
There are particular problems associated with patenting Uving or-
ganisms that we may not want to deal with on a case-by-case basis. We 
could draw on the concepts embodied in the Plant Variety Protection Act 
to draft a statute. My thesis is that Uving organisms are sufficientiy differ-
ent from machines that we must ask whether current patent law is ade-
quate to the task of securing property rights in geneticaUy engineered 
organisms, theu components, or products. 
Living organisms reproduce themselves and occasionaUy change in 
the process. In addition, they are extraordinarUy complex. Nobody knows 
or understands every component or every metaboUc pathway in the 
simplest bacteria. FinaUy, Uvuig systems embody a tremendous amount of 
redundancy. That is, a product can be made by many different biochem-
ical processes or even different organisms. 
The fact that organisms reproduce may require a change in the 
statutory definition of mfringement. The current law defines infringement 
as the unauthorized making, usmg, or seUing of the patented invention. If 
someone took a patented organism from a pubUc depository, reproduced 
it, and gave it away to many users, would this be infringement? One could 
argue that the aUeged mfringer did not "make" the mvention. Perhaps 
there is a need for statutory clarification of the definition of infringement 
to mclude "reproducing" the mvention. 
What happens if a patented organism mutates? Does the patent cover 
the new organism? Should it? What if tiie organism mutates m a significant 
way after it has been deposited for the purposes of enablement? If tiie 
deposited organism is the standard against which mfringement is measured, 
the patent holder may be out of luck. 
The complexity of Uvmg inventions wUl make it difficult to fuUy 
describe tiie invention. WhUe depositing a nucroorganism in a culture col-
lection may circumvent tiiese difficulties witii regard to enablement, it 
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does not help in estabUshing novelty and the bounds of patent protection. 
Microbial taxonomy is an imprecise art. Microorganisms have different 
taxonomic features in different environments, and taxonomists often dis-
agree on the classification and description of microorganisms. Even after a 
series of expensive tests, uncertainty can stiU exist about whether a given 
microorganism is distinct from other strains. Thus, it may be virtuaUy un-
possible to distinguish it from others that may be existing, but unknown, 
in nature or from simUar ones created by other inventors. 
FinaUy, there is the problem of redundancy. How does one ade-
quately protect a product that can be made many different ways, only 
some of which may be known at the tune the patent appUcation is 
drafted? Because of the degeneracy of the genetic code, for example, a 
particular protein can be made by various base sequences. Claiming a 
particular sequence of bases wiU provide msufficient protection, and 
claiming the protem wiU be no solution if the protein is not novel. 
Claiming the novel organism may be one solution, but then others can 
easUy constmct different organisms to produce the same product. 
Whether current patent law can adequately address the problems 
outlined above remains to be seen. It may be sufficiently flexible to adapt, 
but there is likely to be a long sorting out period marked by uncertainty 
and plenty of Utigation. On the other hand, we should at least discuss an 
altemative—a statute specificaUy designed for Uving organisms. I would 
Uke to propose one without necessarUy advocating this approach. I wiU 
discuss how such a statute would apply some traditional patent law 
concepts—patentable subject matter, novelty, enablement, and infringe-
ment—to the living invention. 
BasicaUy I would lUce to hybridize the Plant Variety Protection Act 
(7 U.S.C. §§ 2321-2583) and tiie Plant Patent Act (35 U.S.C. §§ 161-
164) and come up with, hopefuUy, the best of both. Let's start with the 
issue of what subject matter should be patentable. This lends itself quite 
weU to a statutory approach. Obviously Congress can draw lines and state 
specificaUy what organisms should or should not be patentable. They may 
wish to limit it to microorganisms and plants and, for whatever poUcy 
reasons, not permit patents on new breeds of animals. That is somethmg 
Congress is weU quaUfied to deal with. In other words, the legislative 
process is designed to make those kinds of value decisions. 
As to novelty, if you look at the Plant Variety Protection Act, you 
wiU see that it embodies two types. One is the Section 102 type of prior 
art. {See 7 U.S.C. § 2402.) But also to deal with some of the problems 
that Roger [Ditzel] raised, such as uniformity of reproduction, the Plant 
Variety Protection Act has a term caUed "novel variety." Section 2401(a) 
states that a plant is a novel variety if it has the characteristics of "distinct-
ness, uniformity, and stabiUty." These three terms are defined in that 
section. 
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I would Uke to paraphrase those definitions so you can get an idea 
of how a statute could address some of the problems associated with 
patenting Uving inventions. "Distinctness" is defined in terms of a variety 
clearly differing in one or more identifiable morphological, physiological, 
or other characteristics from aU prior pubUcly known varieties. "Uiu-
formity" is defined in terms of any variations being describable, pre-
dictable, and commerciaUy acceptable. "StabiUty" is defined in terms of 
the variety bemg basicaUy imdianged in its essential and distinctive charac-
teristics when sexuaUy reproduced. Thus, this section of the statute 
addresses the problems of mutabiUty and complexity by recognizing that 
it is necessary only to know the unportant characteristics of a new plant 
variety in order to distinguish it from others and that only these character-
istics need to be stable through succeeding generations. 
How would this new statute deal with the enablement requirement 
for geneticaUy enguieered inventions? As I mentioned before. Section 162 
of the Plant Patent Act states that the description of the new plant need 
only be as complete as is reasonably possible. I think we could take that 
approach and apply it to microorganisms or any other organisms that we 
care to patent, pursuant to new legislation. 
It is interesting to note, thou^, the Plant Variety Protection Act has 
a depository requirement for seeds. That is a different way to approach 
the problem, but it might Umit the types of organisms that could be 
patented, if you have a strict requirement for enablement. 
DAHLING: Don't you think, even if a statute is passed, that we wUI stiU have 
case-by-case Utigation on various points? 
KARNY: Oh, sure. 
DAHLING: I am never convinced that passing a new statute is going to save any 
tune or court costs. It seems Uke what is distinctiveness, the various 
criteria you are mentionmg, would have to be Utigated and settied, and 
you are stUl gomg to have your series of cases and tiie time and the effort. 
Rather than settUng certain questions without a statute, you are now 
quibbluig over meanings and shades of differences between tiie terms used 
Ul the statute. 
UDRY: But you could exclude large classes, lUce human ceUs. 
KARNY: I agree tiiat tiiere is stiU going to be Utigation. I am not advocating 
a statute. I should mention tiiat my agency provkies nonpartisan advice to 
Congress, and we don't advocate any particular positions. My reason for 
putting fortii tills statute is to get discussion Uke tiiis. I can't guarantee 
tiiat a statute would lessen Utigation. However, I tiunk by defming 
Discussion / 301 
"novelty" for Uving organisms with reference to the terms "distmctness, 
StabiUty, and uniformity," it could save a lot of Utigation. I suspect that 
a case-by-case approach would eventuaUy result m the evolution of a 
definition similar to the one I am proposing. So why not draft a satis-
factory definition right now? 
At this point, I would Uke to address another issue. Infringement is 
the unauthorized making, using, or seUing of the patented invention. But 
the two plant protection acts also mclude "reproduction" within the defi-
nition of infringement because they were drafted specifically to deal with 
Uvmg organisms. In Section 2541 of the Plant Variety Protection Act, 
there is a series of subparagraphs that protect the owner of the new organ-
ism much better than Section 271 of the Patent Act because they cover 
such thmgs as reproduction of the organism, the importation or exporta-
tion of the organism into the United States, and the use of the novel 
variety m producmg, as distinguished from developmg, a hybrid or differ-
ent variety. As an aside, I should note that this distinction between pro-
ducing and developing means that the protected variety can be used for re-
search purposes, but not commercial purposes. This distinction is also sup-
ported by Section 2544, which exempts research from the definition of 
infringement. 
UDRY: Does it exempt commerce in research, the seUing of seeds to research 
organizations? 
KARNY: I would think not. I read these sections to mean that scientists, in-
cluding scientists who work for commercial entities, may take the novel 
and protected organism and work with it to try to develop a new one, 
which could also be patented or, under this act, protected via the certifi-
cate. But if it were being produced and sold to others to do research on it, 
I would see that as a commercial activity, which would be an mfringe-
ment. I think any statute that we would want to draft, should protect 
against the unauthorized commercialization of the invention, yet aUow 
research on it to develop new organisms. 
There is one other subject I want to touch on briefly before ending 
my presentation. Chakrabarty raises a question about the continumg 
vaUdity of the two plant protection acts and how they wiU interact in the 
future with Section 101. For example, tuber propagated plants are not 
patentable under the Plant Patent Act of 1930. Presumably they can now 
be patented under 101. First-generation hybrids are not protectable under 
tKe Plant Variety Protection Act. If somebody wanted to protect a hybrid, 
presumably it is now patentable under 101. In fact, I understand that the 
Patent Office has taken this position, teUing people to consider 101 for 
patenting plants and plant tissue culture. 
JUDGE RICH: Is a microorganism a plant? 
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BRENNER: Some are. The classic definition, if you want the textbook defi-
nition, a plant is something that has chlorophyU. That is one of its dis-
tinguishing features. 
JUDGE RICH: One of the problems that the judiciary gets is carrying out the 
supposed intent of the Congress, which is not always easy to come by. 
When the Congress taUcs about plants, I doubt they are talking about 
microorganisms and vice versa. They didn't know what they were taUcing 
about. When the potato producers came in and said, "You have to exclude 
potatoes," they put in "other than tuber propagated." 
BERNARD: I guess One of the general advantages to this case-by-case versus 
statutory approach is that, in the statutory approach, you are often re-
duced to speculation; conversely, in a case-by-case study, you are pre-
sented with facts which assist you in determining appropriate legislation. 
Obviously, this approach—the luxuiy of dealing in facts rather than 
speculation—transcends purely legal cases and enjoys wide-ranging 
acceptance in most fields. 
NOONAN: Right, and I might add for the subcommittee, and the fiiU com-
mittee as weU, that we certainly have no plans in this area. Patent law is 
reaUy within the purview of the judiciary committee. As far as Uving 
organisms are concemed, we have no plans for legislation. 
BERNARD: If you wUl, I would just like to run down the remaining pieces of 
legislation, both enacted and pending, that may be of interest to you. One 
significant bUl, directed to the restoration of the patent term, has already 
cleared one hurdle on Capitol HiU. Known as S-255 ui the Senate, the bUl 
was accorded Senate approval earUer this year; labeled HR 1937 in the 
House, this legislation was debated in committee hearings two months ago 
and now awaits fmal passage. The purpose of this bUl is to restore part of 
the patent term lost as a resuh of delay due to obtaining govemment 
clearance. The bUl would encourage more commercialization. 
Another piece of legislation of interest concems the replacement of 
cucuit courts of appeals witii a smgle appeUate court. Referred to as S-
1700 and HR 4482 ui tiie Senate and House respectively, it awaits 
Judiciary Committee action in tiie former House and ahready has won 
approval of tiie Judiciary Committee in tiie latter House. To understand 
the vital unpact tiiis bUl would have on the appeal process, I wUl outUne 
the court system in the United States. 
As Judge Rich pomted out, our judicial system is comprised of 
various district courts, whose decisions may be appealed to circuit courts 
of appeals. Each district court comes under tiie jurisdiction of a specified 
cucuit court of appeals and may be held accountable for any decisions 
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rendered. WhUe this system provides adequate opportunity for appeal by 
disgruntied parties, one problem which develops is that different circuit 
courts frequentiy offer different interpretations on patent statutes. Hence, 
some circuit courts would overtum a given lower court mling whUe other 
circuit courts would affirm the lower court decision. This lack of uni-
formity leads to what we caU fomm shopping. In order to increase 
uniformity in decisions, S-1700/HR 4482 proposes to retain district 
courts; however, a complainant, rather than appealing to the circuit court 
of appeals, would go to a single appeUate court. 
One of the advantages here is that this appeUate court, as the bUl 
stands, wiU be a combination of the present Court of Customs and Patent 
Appeals and the Court of Claims. As Judge Rich noted, when you put 
them together, with 12 judges, there wUl be two patent lawyers, two 
judges with patent law backgrounds, m that group of 12. 
JUDGE RICH: For a little whUe. 
BERNARD: What Judge Rich refers to is the possibUity that retuements may 
upset the balance of the court. 
The next item is reexamination. This is law. Attached to the govern-
ment patent poUcy statute, 96-517, the concept of reexamination basical-
ly states that any individual who has a pruited pubUcation or a patent as 
prior art, and limited solely to that as prior art, can petition the Patent 
Office to reexamine the patent. There is a long history m this area, datuig 
back to the mid-sixties or so. 
There was an attempt at a general revision of the Patent Act of 
1952, involving many issues. As the discussion developed, the Department 
of Justice was very vocal and determined. The Department articulated its 
differences with the patent bar and carried the battle into the haUs of 
Congress. As it turned out, when you exammed what attomeys, namely 
members of the patent bar, and the users of the patent system were 
seeking, the goal was clearly defined: a way of simplifying the high cost of 
Utigation and the tune that it takes to resolve disputes. 
The high cost of Utigation started in 1936, with the adoption and 
unplementation of the mles of discovery. The rules of discovery vutuaUy 
eliminated the element of surprise when an individual went to court. 
Patent lawyers, having technical backgrounds, were somewhat accustomed 
to detaU and very ingenious in deciding what information they required. 
As a result, the discovery area expanded immensely. It reached the point, I 
would probably say, in the 1960's and 1970's, when the advances m 
technology precipitated new demands for patent protection. In late 1940 
and early 1950, the Department of Justice paid little attention to the field 
of patent law. For example, the Justice Department debated the estabUsh-
ment of a patent unit, but never formalized their plans. However, the 
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explosion m technology, for example as shown by developments m the 
pharmaceutical industry, focused greater attention on the patent laws. One 
need only recaU the involvement of the Federal Trade Commission ui the 
tetracycline area in the late fifties. 
JOHNSON: Is that reexamination excluded in the repeal of 96-517? 
BERNARD: No. It continues to exist. 
NOONAN: Reexamination wUl continue. It is not repealed. 
BERNARD: Revertuig to the sixties, we had the tremendous development of 
the pharmaceutical industry and other related industries concemed with 
patents and technology. In 1966 the Department of Justice actuaUy es-
tabUshed what it caUed an InteUectual Property Unit. This organization 
felt a responsibUity and an obligation to review patent protection for in-
dustrial properties. In an overt fashion, it took an active role in attempting 
to revise the patent statutes with the permission and support of the Justice 
Department. This fiurry of activity culminated in a discussion of msgor 
revisions and improvements in the Patent Act of 1952. 
In 1977, a major objective was achieved by then Commissioner 
MarshaU Dann, who took the reissue provision of this patent law and 
unplemented it with a greater degree of authority. The result: patents 
could be reexamined under the reissue provisions. In effect, this act 
negated the necessity of undertaking a general revision of the Patent Act 
of 1952. As it tumed out, when members of the bar reaUy analyzed where 
theu interests were, they recognized the importance and relevance of re-
examination; simultaneously, they noted the paraUels between the right to 
reissue and the right to reexamine. Hence, the broadening use of the re-
issue provisions dissipated the drive toward general revision of the patent 
law. 
The concept of reexamination, as I defined it before, is very limited 
in scope. The purpose of petitioning the Patent Office for reexanunation is 
to reduce both the costs and time involved in court Utigation. Prior to 
enactment of reexamination laws, an mdividual, not an appUcant, had to 
resort to the courts to have prior art reevaluated. At present, the Patent 
Office can expedite the process of reevaluation whUe Umituig the costs to 
any individual. 
Let me be candid in describing the progress achieved in the area of 
patent laws over the years. The contrasts between the 1930s and the 
present are astounduig. One need only review the Sinclair decision to sub-
stantiate this view. Sinclair was one of the parties. At that time the court 
was considering a patent. The patent owner adopted the position that 
there was infringement and his patent was valid. Tlie defendant countered 
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by argumg that the patent was invalid and there was no infrmgement. 
Finally, the two parties agreed that there was no infringement, and were 
ready to settle their differences out of court. The court said, "No, you 
can't forget about it. You have raised the matter of validity. It is in the 
public interest to have that validity evaluated so that you don't have bad 
patents hanging around." 
As I regard that case now, the decision of the court acted as a be-
ginnmg for what became the modern pubUc interest in the patent law. 
Twenty years later, during the height of the tetracycline Utigation, the 
demand for patent protection became more pronounced. As you know, 
actuaUy the beginnmg of the dmg industry, probably started with sulfa 
dmgs in 1938. When World War II arrived, the need for penicUUn grew, but 
it wasn't avaUable in large quantities. The big question was, as it probably 
is with Interferon now, how do you make penicillin in large quantities? 
This question led to major developments in the fermentation area, such as 
deep-tank fermentation, where the techniques were developed to produce 
these antibiotics in large quantities. 
At about this tune, one particular scientist by the name of Dr. 
Dugger of Lederle Labs came up with chlorotetracydine. In investigating 
the chemical properties of chlorotetracydine, one discovered that a Uttle 
chlorine atom was present. Patients usmg chlorotetracycluie enjoyed good 
results, but theu teeth tumed purple and their hau feU out. FinaUy, after 
more advanced study and analysis^ the stmcture of this dmg became 
known. Scientists studied particular components of chlorotetracydine and 
devised an experiment to remove the chlorine atom. Among others, Pfizer, 
Cyanamid, and Bristol-Myers, deserve mention for theu contributions to 
experiments on chlorotetracycUne and related dmgs. Their efforts helped 
to produce a real expansion of the dmg industry. 
During this period, various parties initiated Utigation in this area and 
brought close to 150 lawsuits of different types. Approximately 60% of 
these cases resulted in settlements at the outset, whUe the remaining 40% 
required court action to some degree. The important statistic here is the 
tremendous increase in cases involving the question of conduct in the en-
forcement of patents. Judge Wyatt in New York decided to take the 
settling cases (60%). He invited a judge from MUwaukee by the name of 
MUes Lord to handle the nonsettling cases (40%). Lord agreed to take over 
the cases and the cases were handled in Minneapolis. 
Next came the advent of the Judicial Panel of Multidistrict Litiga-
tion, which developed out of the General Electric price fixing cases of the 
fifties. The panel was charged with the responsibUity of consoUdating aU 
these cases for discovery purposes. So the panel assumed an important role 
m the resolution of discovery in multiple but related cases. 
ActuaUy, the whole thesis of tetracycline Utigation started out on a 
price fixing theory. Appended to that was the aUeged nature of conduct 
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before the Patent Office theory. As the Utigation developed over the years, 
price fixing diminished in stature and conduct (aUeged fraud) became 
more prominent in stature. In other words, this concept of fraud on the 
Patent Office reaUy came into focus during this period. 
Today the concept, as the judges have held in -many decisions, 
states that if you deal with the Patent Office, you are not dealing in an 
adversary relationship. Since the Patent Office is a governmental unit 
charged with the implementation of the Patent Law, you must reveal aU 
that you know about the relevant and material facts conceming an appUca-
tion for a patent. BasicaUy, you must display candor and fraiUcness in aU 
your dealings with the Patent Office. The personal integrity you exhibit 
before the Patent Office is important; only after you have presented aU the 
relevant and material facts should it decide whether you are entitied to a 
patent or not entitied to a patent. 
One pomt the courts frequentiy reiterate is that the Patent Office 
doesn't have faciUties for'testing. Therefore, you must fiimish evidence of 
experiments you have conducted and provide itemized results before the 
Patent Office can issue you a patent. In other words, for the Patent 
Office to appropriately judge, m the pubUc mterest, whether you should 
have a patent or not, it must have the benefit of relevant test results. Then 
may it decide on the appropriateness of a patent and the scope of that 
patent. 
This is the basis for our uncompromising duty in dealing with the 
Patent Office. 
Another case that came up in discussions is Dawson Chemical Co. v. 
Rohm iSc Haas Co., 448 U.S. 176, 206 USPQ 385 (1980). Contributory in-
fringement represented the real issue in this case. I had the privUege and 
honor of arguing this case on behalf of a number of parties before the 
Supreme Court. Two of tiie principal parties of interest are represented 
here. One, tiie Society of University Patent Administrators and the other, 
the Council on Government Relations which constitutes an organization 
comprised of those universities involved in a great deal of basic research. 
Various parties associated with industry such as the National 
Agricultural Chemicals Association and the National Association Manu-
facturers (NAM) took an active mterest in tiie case. But the universities 
had tiieu own interests, as weU. The universities expressed concem over 
tiie pubUshing of results of expermiental work conducted at universities. 
They argued that frequentiy tiie pubUcations were released with only tiie 
naming of a number of compounds, but witii no known utUity for tiiose 
compounds. As tiiey correctiy stated, witiiout utilities for tiie compounds, 
one could not patent tiie compounds themselves. 
WeU, tiie pomt of Dawson v. Rohm and Haas was tiiat old com-
pounds, technicaUy compounds unpatentable per se, could be protected 
witii exdusivity witii respect to a nonstaple use, once tiiat use was found. 
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This case had far-reaching impUcations for a number of pesticides and 
pharmaceuticals. A multitude of pesticides and pharmaceuticals are pro-
tected only by what we caU "use" patents. Use patents mean that the 
compound per se may be old, but when you employ it for that use, you 
are entitied to a right to exclude, as long as it is a nonstaple. Thus, from 
the standpoint of pubUcation, Dawson v. Rohm and Haas at the very least 
ensured the exclusive protection, with respect to a nonstaple use, of 
various older compounds. 
There are other issues I want to touch upon quickly. The category of 
"scientific advances" involves patentabUity. Professor Beier at the Max-
Planck-Institute is mvolved m caUing for protection for "scientific ad-
vances." What he means by scientific advances, as an example, is a chem-
ical compound the identity of which may be pubUshed someplace but at 
that pomt may have no known utiUty. Professor Beier suggests that the 
discovery of this chemical compound could be protected as a scientific 
advance. 
The second thing that he was advocatuig was a grace period in 
Europe. I mention that to our practicing coUeagues here from Europe. 
DITZEL: For those scientists here, I think it is important to point out that that 
duty mns to them also, just as weU as the attomeys. 
BERNARD: Yes, both attorneys and mventors have a legal responsibiUty and 
moral obligation to be candid in aU matters uivolving patents. To reiterate, 
the concept is quite sunple: anyone attemptmg to secure patent protection 
through the Patent Office must wUUngly and ethicaUy provide any relevant 
material to the Patent Office. 
REIMERS: That is unique to the United States. 
BERNARD: As I understand from our friends abroad, our relationship with the 
U.S. Patent Office is unique. I must state that we wUl continue to en-
courage open and honest dealings between U.S. attomeys and the Patent 
Office. 
VOSSIUS: Could you explain, at least to me, what the term means, "as long as 
it is a nonstaple use," in connection with a use patent? What does it mean? 
BERNARD: For your information, the drafter of that particular provision in 
our statute is Judge Rich who remains the foremost authority on the 
concept of patentabUity of a chemical compound for a nonstaple use. We 
refer, VoUcer, to chemicals that are staple and chemicals that are non-
staple. A staple item, to offer an example, might be salt. It can be used for 
many purposes. A nonstaple item, for example in the Rohm and Haas case. 
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was propanU. In this case, propanU, has use only as an herbicide. It has no 
other substantial noninfringing use. If it had another use, it would sUp mto 
the category of a staple compound. 
VOSSIUS: Aspirin would be a nonstaple then. 
BERNARD: No. It has many uses, I would think. 
VOSSIUS: But if you discover a third use, is it stiU a staple product? 
BERNARD: The key is uncovering a second use for any particular compound. 
In other words, you have a nonstaple use, which in the case of propanU is 
an herbicide; if you fmd, for example, propaml is also useful as an anti-
inflammatory agent, it then possesses a second use, deeming it no longer a 
member of the category of nonstaples as defined in the Patent Act. 
JUDGE RICH: Gene, let's be a Uttie clearer and use the term "staple" in its 
statutory sense, which doesn't taUc of staple uses, but simply says having 
no other substantial known noninfringing use and is not a staple com-
modity. A staple commodity is a Uttie different concept from staple use. 
PropanU, of course, is a trade name. The only known commercial use for 
the product—excluding research use—was as an herbicide used on rice 
crops. Therefore, it could not be put into the statutory category of being a 
staple commodity, with respect to which they could not have rendered the 
decision they did, which was that the sale of the propanU, the instructions 
as to how to use it as an herbicide on rice crops, constituted contributory 
infringement. 
Yesterday we discussed antitmst/patent right to exclude dichotomy. 
The patent right is the right to exclude that which is covered by the claims 
of the patent. That is aU that the patent right is. TheoreticaUy you are 
within your patent when you are within the claims. But there is an 
exception to that. The exception is this ancient doctrine of contributory 
infringement—a situation in which the court wiU give you a remedy against 
someone who is doing something not within the scope of the chums. There 
is your dichotomy. You are limited to what is within your claims except 
when there is a contributory infringement situation. This is an ancient 
doctrine that was developed in the courts. It was, in effect, abolished by 
the 1944 decision by tiie Supreme Court ui Merchoid cases. The patent 
bar went to work to revive it, because it was a useful doctrine, useful 
primarUy ui a situation Uke this propanU situation, where it just isn't 
feasible, it isn't practical as a business matter to sue the actual infringers, 
the farmers who put the propanU on the rice. The only practical way to 
enforce that patent is against the suppUer of the propanU, and tiie suppUer 
is not usmg the process himself, so he has to be hooked under the doctrine 
of contributory infringement. 
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This was the thing that was so hard to get across to the Supreme 
Court, which finaUy bougjit the statute that was written into the 1952 act, 
Section 271(c) and (d). 
BERNARD: You heard it from the dean of that section, the dean, the drafter, 
and the individual who was in the courtroom there the day I was arguing. 
FLYNN: I was wondering what your speculation might be on the impUcations 
of Dawson v. Rohm and Haas if you had a simUar fact situation on pro-
panU, but it mvolved an induced infringement, not a contributory one. 
That is to say, the propanU had a number of noninfringmg uses, but it also 
had a use which was patented. 
JUDGE RICH: The statutory basis of that is 271(b), which taUcs about active 
inducement. It has never gotten to the Supreme Court. 
COMMENTS 
REIMERS: To contuiue with the discussion, we must cover some additional 
points. There are several questions left unanswered: First, do patents "con-
trol" research? We talked about whether patents control research or not 
and yesterday I mentioned there is sort of a visceral reaction among 
scientists that bothered them with respect to, particularly, a patent Uke 
the Cohen-Boyer case. We talked briefly about whether it engendered se-
cret research, but I thuik the opposite should occur, as PhU Sharp thought. 
Secondly, do patents cause a delay of pubUcation. It can cause 
pubUcation delay, as occurred in the case described by Jun Hicks, but that 
is not something that either UC or Stanford would permit, nor Cold Spring 
Harbor Laboratory, nor, I understand from Tom Kiley, that even Genen-
tech would aUow, which leads me to my rule number one: "A pa:tent is 
not a valid excuse for not disclosing your research to coUeagues or delay-
ing a publication." The thud question: Is the exclusive feature of patents 
contrary to the public interest? I thmk that the public interest is in en-
abling the appUcation of a new technology to useful products and 
processes. GeneraUy, the right to exclude is necessary to encourage the 
investment in an undeveloped basic scientific discovery. This Cohen-
Boyer case where initial Ucensing can be nonexclusive is quite unusual. 
McELHENY: Perhaps these propositions should be put before the participants 
and then kind of open up to discussion. 
PHILLIPS: I keep hearuig about causing a suppression of exchange of informa-
tion within the scientific conununity by trying to abide with the system 
of laws and avoiding loss of rights by conunercial mterests. There is not 
that much novel that is being spiUed from one to the other. There has to 
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be a balance of interests somewhere. The bottom line, of course, is that 
corporations wish to make profit for the stockholders. They, in tum, help 
maintam the universities. There needs to be a Uttle cooperation, not 
feeling like industry is suppressing science. 
REIMERS: That leads to my mle number four. "An industry research contract 
is not a vaUd excuse for not disclosing your research to your coUeagues or 
delaying pubUcation." 
PHILLIPS: I don't think you get too much supported research like that. 
REIMERS: We do. GeneraUy, we easUy can get an appUcation on fUe before 
the pubUcation occurs. 
PHILLIPS: WeU, this is what I was going to observe. I don't think it is that 
difficult to prepare an appUcation to fUe and that is why I don't reaUy 
think there is a problem as the scientific community seems to feel. 
DITZEL: Certain segments of our faculty object to the patent system or 
stmcture we have, to try to respond to the balance of needs. Niels and I 
get criticisms from faculty members who just want to criticize industry 
generaUy. 
REIMERS: Jun Hicks gave the example in England. But I hear of individuals 
not disclosing theu research to coUeagues with the reason attributed to 
either a patent or industry research contract. 
JOHNSON: WeU, the view they take is that the traditional role of the university 
is dissemination of information as weU as education and furthering 
knowledge. If this mformation is not disseminated quickly, then you are 
dismptmg tiie function of the university. I think that is the view many 
take. 
KILEY: The scientist's job is to create new knowledge. What drives him to do 
it? If he is in industry, money, and perhaps tiiat is enough. In tiie academic 
community what drives him is tiie opportunity to announce before his 
competitors do. That is tiie most efficient and effective motivation for 
science, not money. If you tiueaten his priority by postponing his pubUca-
tion, then you take away his mcentive to do good science. 
REIMERS: It is scientific immortaUty, which is probably more important 
than money. 
DAVIES: I think tiiere are a lot of components to tius whole question. You 
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asked, is there a desperate need to pubUsh? In fact, we were trying to work 
on how many scientific journals are presently avaUable on the market. 
There must be approximately 250 coming out monthly packed with 
useless material. But, there is a lot of novel unpubUshed material available. 
I thmk the major problem at the moment on university campuses is 
that a lot of research people are finaUy realizing that they are doing 
somethmg that they might be able to seU. They don't know how to seU 
it and the universities don't know how to seU it, and so there is this 
question of, **We've got something. Could we seU it to Genentech or 
Biogen? If so, how do we do it, and how do we cover ourselves, and how 
do we publish it as weU?" In my experience this is where the real problem 
is on the campuses at the moment. 
O'NEILL: In addition to stressing priority in scientific pubUcations, the other 
word you ought to take into account is "reciprocity." The exchange of 
information is the life blood of science. Scientists are interested in havmg 
theu own contributions to give m exchange for what they can get from 
theu scientific coUeagues and advance the general front of knowledge. This 
is a very excituig area to work in, and it is entirely buUt on collaboration. 
EISEN: On a different aspect, Niels, does your university, or any universities 
that you know of, exercise any restramts on pubUcation from the stand-
point of quaUty? Can any researcher on your faculty pubUsh his associa-
tion with Stanford, even if you don't think that particular pubUcation has 
merit, in terms of protecting the university name? Is there any permission 
needed at aU? 
REIMERS: No, it is between the scientist and the joumal, which has a peer 
review. Sydney can explam that process better than I. 
ZINDER: I think that is what divides the scientist's loyalty today. On the one 
hand . . . his shoulder as to whether a particular vector or clone that was 
made is conunerciaUy useful. In addition, the universities . . . something 
has commercial potential. This area has also a bit of tuUpmania now. That 
has to calm down. We face a number of problems. I think the science wiU 
remain tremendously interesting. I thmk its commercial appUcations wiU 
also grow, and I think it is a situation we are just going to have to Uve 
with. 
NOONAN: Many of the issues we are discussing, at least in a superficial way, 
were discussed at the hearings that we had on commercialization of bio-
technology in June 1981. I can send the hearings record to you. It has 
gone to the printer. At those hearings I don't thmk these questions were 
not answered—they were simply put forth. 
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Another point addressed m the Senate hearings was on what we caU 
engineering manpower and the crisis thereof. Many of the best university 
people Ul engmeering schools are leaving to go to industry. In fact, at 
many of the engineering departments at universities, students are being 
told that it may take them as long as 5 years to get through the program, 
because there aren't enough faculty to teach the sections for the numbers 
of students that are enroUing, particularly in basic computer sdence 
courses. 
This has presented a major problem, not only to the universities, but 
to the industries as weU. Where are they going to get the next generation 
of engineers if there is nobody there to teach them? 
I would not lUce to see this happen ui biological sciences. Biological 
science is not going to have the time to adjust to the Midas factor that 
engineering and computer science has had. Universities are losing people. 
KILEY: Universities might consider fiilfUIing the teaching needs and at the 
same time pemtitting more direct industry interaction and cross-fertUiza-
tion. 
JOHNSON: That is certainly a convenient solution, but a controversial one. 
REIMERS: Rule number three: if you want to work for a company and a 
university at the same time, at least consider a joint appointment! 
OSTRACH: Niels, aren't there restrictions actuaUy at Stanford as to the 
amount of tune a faculty member can devote? 
REIMERS: Faculty members can consult. In engineering, we have people who 
are teaching, but who are also associated with a company. One particuhu 
professor has a 50% appomtment with Stanford and 50% with the 
company. 
JOHNSON: In many parts of the world, people very frequentiy wear two hats-
it is not aU that uncommon in parts of Europe and Japan. I thuik it would 
be more of a problem m this country in pubUc universities versus private. 
At pubUc universities, many people have had great difficulty with that. It 
is a solution, but it is, agam, a very controversial one to some people. I 
think it is a mechanism that needs to be worked on. 
DITZEL: It does exist in pubUc universities, but its acceptance varies widely 
from department to department. 
JOHNSON: But a life form could evolve here which is simUar to some which 
exist in other countries. 
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DITZEL: GeneraUy, the part-time appointments are only teaching appoint-
ments, as opposed to research appomtments. When you mn out of slave-
labor graduate students to teach the underclassmen, then you try to use 
that technique. 
DAHLING: One additional pomt I think needs mentioning is that a professor's 
job is more than teaching. Part of the job involves being avaUable so that 
students can informaUy discuss theu research or just talk. It seems to me 
that combining a professorship with a position in private industry would 
ahnost certainly Umit this type of interaction. In time I think this could 
have a very detrimental effect on higher education. 
JOHNSON: One of the factors that frequently comes up in discussion, of 
course, is unproper use of graduate students or postdocs m situations 
where someone is working for industry and stUl maintaining an academic 
appointment. Some kmd of safeguard has to be established. 
For example, we have had our own medical facUities at LiUy, since 
the 1920s. Our physicians, who are part of a large county hospital on the 
edge of the largest medical school in the United States—not necessarUy 
the best but the largest—have jomt appointments in the medical school and 
teachmg responsibiUty, make rounds and things of that sort. 
BRENNER: I bet they don't eam equity in EU LUly. They don't have stock 
options, do they? 
JOHNSON: Sure, some of them do. What they teach is not LiUy; they teach 
pharmacology or obstetrics, and they are a part of the faculty and have 
been for 40 or 50 years. 
WILLIAMS: Let me point out that that is a lot easier to handle with a phy-
sician teaching in medical school than it is with, for instance, a chemist or 
a pharmacologist, who may weU be an inventor and be maintaining his 
company ties. 
JOHNSON: We have mdividuals in basic sciences who also have joint appoint-
ments. That doesn't mean that they have a 6-hour teaching course. They 
lecture once in a whUe. 
WILLIAMS: Do they mn a research group at the university? 
JOHNSON: No, they do not. 
WILLIAMS: How about the situation where one does run a research group at 
the university? 
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JOHNSON: That is one of the areas, as I pointed out, that is a controversial 
and difficult one to handle, particularly ui regard to improper use of grad-
uate students and postdocs. 
WILLIAMS: And conflict of interest. 
JOHNSON: Conect. 
WILLIAMS: 1 mean, it is a great way to get scientific exchange and more 
mUeage for company dollars in research, but the problems are there. 
DAVIES: What do you mean by improper use of postdocs and graduate 
students? 
JOHNSON: By that point we mean whether someone who is not an employee 
of the company is being asked by professor who has a role in the company 
to do something in a university lab that may be related to the company's 
activities rather than the university's. 
DAVIES: That is improper use. 
JOHNSON: In theu view, that is improper use, and it would be my view also. 
KARNY: EspeciaUy if it doesn't further the education of the graduate student. 
JOHNSON: Right. 
NOONAN: Or if that graduate student is paid from Federal grant money. 
REIMERS: Norton [Zinder], ui molecular biology is there a problem of losing 
postdocs who do research in industry? 
ZINDER: I don't know. I don't know whether any data that has been coUected 
on this. 
JOHNSON: I don't know about data eitiier, but it is certainly a perception. 
ZINDER: I have no idea whetiier anyone has done a survey. Today, in a sense, 
the postdocs in molecular biology feel much more comfortable than tiiey 
did a few years ago. There aren't many academic jobs, as we aU know: the 
university system has certainly tightened up. Graduate students seem to be 
happier and comforted by the idea that tiiey can get into tiie industry and 
seem to look at mdustry ui a different way tiian graduate students in tiie 
last few years. This area of molecular genetics or the application of 
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molecular genetics is so close to the basic research laboratory. One just 
leads durectly to the other. There is no large R&D area in between. 
McELHENY: Presumably you are also gaiiung methods of support. What we 
have been talking about is a gradual alteration of the method of sup-
porting fundamental research in fundaniental biology. There are aU sorts 
of other arrangements, other than a phUanthropic subvention of what is 
going on in universities, that occur as byproducts of some of these ar-
rangements that we are discussing. We are just havmg an inevitable change 
of the relationship between the university and various large and smaU 
corporate entities. 
ZINDER: It is not gouig to be taken over by industry, but industry probably 
is now providing 5% of our annual budget. That is a significant figure. It 
doesn't have to be 100% to help. 
JOHNSON: My personal view of some of these problems is that this is a short-
term effect, and it is exacerbated by the entrepreneurial role of professors 
who are creating companies, and due to these various syndromes. I don't 
thmk there wiU be the same problems 5 years from now but it is going to 
be an acute exacerbation in the next five years. 
McELHENY: But everybody seems to be quite confident that they can live 
with it. 
JOHNSON: I don't think it is beyond the realm of possibiUty also that in 
another five or six years many of these people wUl be available for faculty 
appointments again. 
DITZEL: WeU, I think they wUl be, and I think we wiU have better faculty 
members in some cases, frankly. 
JOHNSON: Yes, I do, too. 
KILEY: I can think of only one professor who has left the safe haven of the 
university. Taking risks, on the part of faculty members, leads to conflict 
of interest problems that otherwise might not arise. 
REIMERS: Rule number three, yes. I would like to hear comments on the 
problem of the communication between the academic scientist and the 
industry scientist. 
ZINDER: It seems to me that we are extrapolating without any data, from a 
few instances, which excited us and shocked us. If you try to take an 
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overview of the field and add up how many molecular biologists reaUy left 
molecular biology to go to mdustiy, it reaUy is a very smaU number. How 
many instances do we hear about negative interactions or secrets or 
stealing? WeU, we hear of one or two, and now we blame it on the in-
dustry. But years ago, we heard the same kind of thing, and that was just 
in molecular biology. 
I don't want to be PoUyannish about this, but I do think that this 
is a transition state and that aU transition states are, almost by definition, 
metastable. Something wUl be worked out since universities, which are 
problem-solving institutions a priori, should be able to figure out a reason-
able way to live with industry and with the science. 
JOHNSON: You have to be careful of what you define as industry. The 
problems are with the faculty members becoming members of industry. 
Entrepreneurial faculty members cause the problem. It is a start-up 
phenomenon. 
WATSON: I am not reaUy worried as long as the universities themselves stay 
healthy. The problem is that the academic salaries are getting worse and 
worse. People wUl have to consult just to survive as academics. It is putting 
a greater strain on people. 
JOHNSON: In the pharmaceutical and chemical industry, that has been going 
on for years. 
WATSON: I think we would be m a much more serious position if mdustry 
didn't want our products, because we would reaUy be turning out grad-
uate students who wouldn't know where to go. I think our best people 
wUl stay with the universities because they have greater freedom to pro-
mote their own ideas. 
JOHNSON: One of tiie factors tiiat is new is tiiat tiiese are biologists rather 
than chemists and computer people, and it is biology which is at a very 
fundamental level. But the fmits of tiiat biology are of equal interest to 
botii mdustry and academia. In many ways, we are aU reaUy interested in 
gene function, which can go m a variety of dtfferent kinds of appUcations 
and advancement of knowledge. 
I participated m a workshop for the National Science Foundation 
last December, in which we were trymg to develop 5-year projections for 
the Congress. It was a widely mixed group-psychiatirists, attorneys, sociol-
ogists, chemists, biologists-aU addressmg various case studies to come up 
with this technological projection for tiie Congress. One such case study 
on recombmant DNA technology by Werner, as a scientific historian, was 
presented. Most of tiie otiier scientific discipUnes Ustened to it and said. 
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"WeU, we would lUce to welcome the biologists to the club." They had 
gone through simUar experiences in the past m theu particular discipUnes, 
and saw no problem with it. 
BRENNER: I raised some of these points in my taUc at the beginning, and per-
haps I can just go through a number of the pouits again. 
It is very clear that there is a way of selling consultation which is 
fairly standard. There have been guidelines worked out for industry. I 
don't think there is a problem about university professors consulting and 
sharing theu expertise. The scientist should have no further mterest in the 
company surviving or its stock quotation or the like. That is just a sale of 
information and experience. Those thmgs have been worked out, and are 
conditions which are easy to manage. It becomes very difficult when an 
individual is playing two roles because when you have an idea, the ques-
tion now becomes, which hat are you wearing? If you are gomg to a 
seminar, the question becomes, whose ears are you wearing? I think that 
perhaps the best way to mediate between the university or the research 
institute and mdustry is not by co-participation, but through an office 
such as yours, Niels, in other words, through the sale of rights. One may 
view, in this concept, that a patent is a cunency of exchange between an 
academic institution and an outside institution. Therefore, in order for the 
mstitution to offer something to industry, it offers no promises, but 
offers a patent and the exclusivity along with it. 
That would then mean that the institution would have to ensure, 
for itself and for its members, that there is active prosecution of patenting, 
which in itself, as we have seen, can bring strains within the institution. 
But I think that could be worked out. 
Now, that, I think, is a proper, practical, and busuiessUke way of 
mediating this, so that no one is hiring anybody else and there is no 
coparticipation. I do strongly believe that the objectives of organizations, 
however much they may say they agree at this stage, are bound to diverge, 
and there are bound to be problems. It is much better that they have a 
currency for this exchange that is workable and manageable. It is much 
more difficult to do this in Europe, because it does place constraints upon 
pubUcation, because you cannot achieve this currency if you have pre-
mature disclosures. That automaticaUy invaUdates everything. This would 
be a serious disadvantage with respect to simUar institutions in America. 
If we are to pursue this we must ensure that the research products reach 
the public domain through this method because it must benefit our own 
national economy. It just may be that patenting may be one of the 
vehicles. 
As to what one patents—those are decisions which wiU be subject to 
market forces. Clearly, you can't patent everything; you would spend too 
much money. I am sure that every industrial organization has within it 
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some assessment procedure as to what is worth the investment. I think 
that that is a business decision and part of the strategic and technical 
poUcy of the company. Institutions wiU simply have to work that out. 
Your expenses of patenting would become so large it would become an 
uneconomic activity. I think that that is reaUy what one wiU have to face, 
to have some technology assessment within the institution as to what is 
worth doing. 
I think that that is perfectiy workable. As I said, I come from an 
organization which is indeed a govemment agency, and not a private in-
stitution or a uruversity. We are enjoined not to make money for the insti-
tution, but to prove to poUticians that our results can make money for the 
economy of the country. At least it is my opmion that that is exactiy the 
correct attitude that we should adopt. That is, our activities should be de-
signed strictly for a political end, namely that the state should give us 
money to do basic and fundamental research and that we should prove 
that we have not neglected any actions to ensure that the results of that 
research work for the benefit of the economy of my country. That is the 
only guideline under which we can operate. 
WATSON: I thuik I probably totaUy disagree. 
BRENNER: You probably do, yes. 
WATSON: In the sense that you seem to be giving an old-fashioned Fabian 
speech. I think you wUl work very hard to get members of MRC to parti-
cipate and see that things are patented. I just have a feeUng it won't work 
as weU as it does at Stanford. 
Niels [Reimers], some professors on the faculty do have 50/50 
appointments. Are they actuaUy owners of the companies in which they 
are participatmg? Is tiiat good or bad for Stanford? We know tiiat botii 
Stanford and Cambridge are very good universities-both highly success-
ful. ReaUy, has Stanford been harmed in an academic sense by these 
relationships? 
REIMERS: No, it certamly hasn't harmed thmgs ui engineering. Yes, people 
do have equity in companies. We have people Uke Carl Djerassi, who is 
president of Zoecon, and stUl is an exceUent teacher with some very good 
graduate students. 
KARNY: He also segregates his research. 
WATSON: We have examples where it works. 
JOHNSON: Witii some individuals it won't work, and witii some it wUl. 
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WATSON: I am afraid of formal rules. We are not trying to come up with 
universal mles, or I hope not. 
JOHNSON: WeU, there has been a caU for a meeting like that, but I hope it 
won't happen. I completely agree with Dr. Watson. 
DITZEL: May I address Syd's [Brenner] question about his concern on what 
you shoiUd or should not patent with a question: What do you publish? 
Obviously, you make a judgment on what is worthy of publishing and at 
what point in tune. 
BRENNER: That's right. 
DITZEL: Okay, the same type of judgment is made on an ad hoc basis on the 
fact situation ui a patent or anything that is a new invention. 
BRENNER: Yes, but what I am saying is that we haven't made that judgment 
inside research institutes with respect to patenting. If you agree with the 
proposition—that one way of doing this is via patents, then somehow, 
inside the organization you have to get the knowledge to make that 
judgment. 
O'NEILL: I would like to reiterate the position I took yesterday--to try to 
buUd up the technology assessment capabUity within the mstitution is 
costly and kind of a hopeless undertaking. PubUcation wUl be within a 
very short period of time. Why not make a confidential disclosure to a few 
people in industry who have the perspective to judge and advise you—no 
obligation involved, other than the obligation to keep it secret untU pubU-
cation. There are very good ways to handle that so that a company doesn't 
have to feel it is getting contammated with information that is damagmg 
to its own position. I don't know how to do it m a university setting. 
REIMERS: WeU, what you describe is somewhat our procedure. Another 
university procedure is that to fUe on just about everything, the postulated 
reason is you have to do that so you don't miss the important invention 
that comes along to pay for everything else. At Stanford, we occasionaUy 
fUe unmediately on an invention's disclosure without extemal evaluation 
because of our knowledge about the particular field of technology and the 
market. But in most cases, we don't know very much about the field. We 
do contact companies as part of our evaluation process. Some companies 
have set up barriers to that sort of uiterchange, so we don't go back to 
them. 
JOHNSON: The suggestion that Dr. Watson had would stiU be a problem with 
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the State university versus the private university. I don't know whether 
it is equaUy fair for both groups or not, but I think some pubUc people 
wiU have problems with it. 
WATSON: I think there are problems, but the salary levels at some institutions 
are so low that they wUl not be able to attract someone in a highly 
competitive field uiUess they let some industrial participation in. This 
has already happened in some areas. My real concem is, how do we keep 
the salary levels high enough in universities so our best people are not 
tempted out of need—not just tempted out of the desire to be rich, but 
tempted for practical reasons? 
DITZEL: I am aU for raising the salaries at the University of Califonua and also 
providing 4% interest real estate loans! The problem we have with this goes 
even beyond what you have described, if someone is doing research, be-
cause we wUl get mdustrial grants for research, and we don't reaUy want 
scientists from a competitor of that company sitting right there in the 
middle of that research; yet we do want it. That type of dichotomy occurs 
but companies get very upset about it. 
WATSON: WeU, tiiey don't have to fund it. 
McELHENY: WeU, it seems that we have at least touched on a wide range of 
issues that cannot be resolved at this meetmg. It remains for me to thank 
not only tiie organizers of tiie meeting, David Plant, Niels Reimers, Norton 
Zuider, but also those who have served as chairpeople of the sessions, 
and also everyone who has attended. I think in my experience at Banbury, 
of tiuee-and-a-half years' duration, I have never seen an audience of 
participants who have been more mtent, more alert, more participatory at 
every moment of the meeting. 
Afterword 
To our minds, what should have been obvious emerged from our conference. 
It comprises two elements. 
Fust, the language barriers, the cultural differences, and the disconcerting 
suspicions which are manifest when lawyers, businessmen, and research scientists 
are thrown into the same room wiU inevitably evaporate given an atmosphere 
conducive to an unfettered exchange of ideas. This atmosphere was provided 
on a 24-hour per day basis by Jim Watson and his coUeagues. The inevitable 
occurred. Understandmg and trust replaced misunderstanding and distmst. 
This phenomenon led to the second obvious element. 
The role of patents in enabUng the public to benefit from practical appU-
cations of genetic engineering was better understood. Although not aU partici-
pants at the conference may be in specific accord, it seemed to us that the 
consensus was that there is every reason to, and littie reason not to, attempt to 
apply the traditional criteria for patentabUity to the fmits of genetic engineering 
and to expect that this technology wUl fit into and benefit from the patent sys-
tems of the world. Nothing about the technology itself should inhibit the 
innovator from applying for appropriate patent protection. Just as in any other 
technological development, a recombinant DNA invention should be assayed for 
patentabiUty in light of the facts peculiar to that invention. In sum, the patent 
systems of the world have a useful function ui this field just as they do in other 
fields. 
And so new lines of communication and a soUd basis for consensus were 
spawned by this conference. Its hosts and each of its participants are to be 
commended. 
David W. Plant 
Niels J. Reimers 
Norton D. Zinder 
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